<SEC-DOCUMENT>0001493152-23-028488.txt : 20231114
<SEC-HEADER>0001493152-23-028488.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20230814161843
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-23-028488
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20230814
<PUBLIC-REL-DATE>20231114
DATE AS OF CHANGE:		20230814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Telomir Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001971532
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				872606031
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06821
		FILM NUMBER:		231170539

	BUSINESS ADDRESS:	
		STREET 1:		900 WEST PLATT STREET, SUITE 200
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33606
		BUSINESS PHONE:		(813) 864-2562

	MAIL ADDRESS:	
		STREET 1:		900 WEST PLATT STREET, SUITE 200
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33606
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>As
confidentially submitted to the Securities and Exchange Commission on August 14, 2023<BR>
This draft registration statement has not been publicly filed with the Securities and Exchange Commission<BR>
and all information herein remains strictly confidential.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Registration
No. 333-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>REGISTRATION
STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><B>TELOMIR
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Florida</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(State
    or other jurisdiction of</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">incorporation
    or organization)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>2834</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Primary
    Standard Industrial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Classification
    Code Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>87-2606031</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(I.R.S.
    Employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Identification
    No.)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>855
N Wolfe Street, Suite 601<BR>
Baltimore, Maryland 21205<BR>
(737) 289-0835</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Dr.
Christopher Chapman, Jr.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Chief
Executive Officer<BR>
Telomir Pharmaceuticals, Inc.<BR>
900 West Platt Street, Suite 200<BR>
Tampa, Florida 33606<BR>
(737) 289-0835</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Name,
address, including zip code, and telephone number including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Copies
of all communications, including communications sent to agent for service, should be sent to:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Curt
                                            P. Creely</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Neda
    Sharifi</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Foley
    &amp; Lardner LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>100
    North Tampa Street, Suite 2700</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Tampa,
    Florida 33602</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>(813)
    229-2300</B></FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Joseph
                                            M. Lucosky, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Lucosky
    Brookman LLP<BR>
    101 Wood Avenue South, 5<SUP>th</SUP> Floor<BR>
    Woodbridge, New Jersey 08830<BR>
    (732) 395-4402</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Approximate
date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Large
    accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accelerated
    filer &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Non-accelerated
    filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Smaller
    reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Emerging
    growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>EXPLANATORY
NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.3pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
Registration Statement contains two prospectuses as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.3pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Public
    Offering Prospectus</I></B>: A prospectus to be used for the initial public offering by the Company of <B>[&#9679;]</B> shares of
    its common stock through the underwriters named on the cover page, which we refer to as the &ldquo;Public Offering Prospectus&rdquo;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Resale
    Prospectus: </I></B>A prospectus to be used for the potential resale by selling stockholders of up to <B>[&#9679;] </B>shares of
    common stock of the Company, which we refer to as the &ldquo;Resale Prospectus&rdquo;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.3pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Resale Prospectus is substantively identical to the Public Offering Prospectus, except for the following principal points:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.3pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">they
    contain different outside and inside front covers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">they
    contain different Offering sections in the Prospectus Summary section;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">they
    contain different Use of Proceeds sections;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    Capitalization and Dilution sections are deleted from the Resale Prospectus;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a
    Selling Stockholders section is included in the Resale Prospectus;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    Underwriting section from the Public Offering Prospectus is deleted from the Resale Prospectus and a Plan of Distribution is inserted
    in its place; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    Legal Matters section in the Resale Prospectus deletes the reference to counsel for the underwriters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have included in this Registration Statement, after the financial statements, a set of alternate pages after the back cover page of the
Public Offering Prospectus, which we refer to as the &ldquo;Alternate Pages&rdquo;, to reflect the foregoing differences in the Resale
Prospectus as compared to the Public Offering Prospectus. The Public Offering Prospectus will exclude the Alternate Pages and will be
used for the public offering by the registrant. The Resale Prospectus will be substantively identical to the Public Offering Prospectus
except for the addition or substitution of the Alternate Pages and will be used for the resale offering by the selling stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ADDITIONAL
EXPLANATORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pursuant
to the applicable provisions of the Fixing America&rsquo;s Surface Transportation Act, we are omitting our financial statements as of
and for the three months ended March 30, 2023 and 2022. While this financial information is otherwise required by Regulation S-X, we
reasonably believe that it will not be required to be included in the prospectus at the time of the contemplated offering. We intend
to amend this registration statement to include all financial information required by Regulation S-X at the date of such amendment before
distributing a preliminary prospectus to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell, and it
is not soliciting an offer to buy, these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0; font-size: 10pt; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to completion, dated [&#9679;], 2023</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>[&#9679;]
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><IMG SRC="formdrs_001.jpg" ALT="" STYLE="height: 73px; width: 250px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
is the initial public offering of [&#9679;] shares of common stock, no par value, of Telomir Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Prior
to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price
will be between $[&#9679;] and $[&#9679;] per share. We intend to apply to have shares our common stock listed on the Nasdaq Capital
Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;TELO&rdquo;. If shares of our common stock are not approved for listing on Nasdaq,
we will not consummate this offering. No assurance can be given that our application will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are an &ldquo;emerging growth company&rdquo; as defined in the federal securities laws, and, as such, are subject to reduced public company
reporting requirements. See &ldquo;Prospectus Summary&thinsp;&mdash;&thinsp;Implications of Being an Emerging Growth Company&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Investing
in shares of our common stock involves risks. See &ldquo;Risk Factors&rdquo; beginning on page 10 to read about factors you should
consider before buying shares of our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Neither
the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; color: Black">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; color: Black; text-align: left">Initial public offering price</TD><TD STYLE="width: 2%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">$</TD><TD STYLE="width: 12%; color: Black; text-align: right"></TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">$</TD><TD STYLE="width: 12%; color: Black; text-align: right"></TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">$</TD><TD STYLE="color: Black; text-align: right"></TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">$</TD><TD STYLE="color: Black; text-align: right"></TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">$</TD><TD STYLE="color: Black; text-align: right"></TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">$</TD><TD STYLE="color: Black; text-align: right"></TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
    &ldquo;Underwriting&rdquo; for a description of the compensation payable to the underwriters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
underwriters have the option for a period of 45 days from the date of this prospectus to purchase up to [&#9679;] additional shares of
our common stock from us at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise
the option in full, the total underwriting discounts and commissions payable by us will be $[&#9679;], and the total proceeds, before
expenses, to us will be $[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
underwriters expect to deliver the shares to investors on or about [&#9679;], 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><B>Kingswood
Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">division
of Kingswood Capital Partners, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
date of this prospectus is [&#9679;], 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48px; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#ak_001">INDUSTRY AND MARKET DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#ak_002">TRADEMARKS AND COPYRIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#ak_003">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#ak_004">GLOSSARY OF CERTAIN SCIENTIFIC TERMS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">iv</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#ak_005">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#ak_006">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_001">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">37</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_002">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">38</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_003">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">39</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_004">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">40</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_005">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_006">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">46</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#bs_007">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">62</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_001">EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_002">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">76</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_003">PRINCIPAL SHAREHOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">77</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_004">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">79</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_005">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">85</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_006">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_007">UNDERWRITING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">90</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_008">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_009">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_010">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">97</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="#as_011">INDEX TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Please
read this prospectus carefully. It describes our business, financial condition, results of operations and prospects, among other things.
We are responsible for the information contained in this prospectus and in any free-writing prospectus we have authorized. Neither we
nor the underwriters have authorized anyone to provide you with different information, and neither we nor the underwriters take responsibility
for any other information others may give you. Neither we nor the underwriters are making an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date on the front of
this prospectus, regardless of the time of delivery of this prospectus or any sale of securities. You should not assume that the information
contained in this prospectus is accurate as of any date other than its date.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><A NAME="ak_001"></A>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from internal
surveys, market research, publicly available information, and industry publications. We did not fund and are not otherwise affiliated
with any of the sources cited in this prospectus. The market research, publicly available information, and industry publications that
we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information
therein represents the most recently available data from the relevant sources and publications, and we believe remains reliable. However,
this data involves a number of assumptions and limitations regarding our industry which are necessarily subject to a high degree of uncertainty
and risk due to a variety of factors, including those described in the section titled &ldquo;<I>Risk Factors</I>.&rdquo; Forward-looking
information obtained from these sources is also subject to the same qualifications and additional uncertainties regarding the other forward-looking
statements in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><A NAME="ak_002"></A>TRADEMARKS
AND COPYRIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business.
This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective
owners. Our use or display of third parties&rsquo; trademarks, service marks and trade names or products in this prospectus is not intended
to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks
and trade names referred to in this prospectus may appear without the &reg;, trademark (&trade;) or servicemark (<SUP>SM</SUP>) symbols,
but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><A NAME="ak_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
prospectus contains forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
&ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential&rdquo;, or &ldquo;continue&rdquo; or the negative of these terms or other similar expressions. In particular, statements
about the markets in which we operate, including growth of our various markets, and our expectations, beliefs, plans, strategies, objectives,
prospects, assumptions, or future events or performance contained in this prospectus under the headings &ldquo;Prospectus Summary,&rdquo;
&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and &ldquo;Business&rdquo; are forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these
expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed
in this prospectus under the headings &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Business,&rdquo; may cause our actual results, performance,
or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking
statements, or could affect our share price. Important factors that could cause actual results or events to differ materially from those
expressed in forward-looking statements include, but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    use of the net proceeds from this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to obtain and maintain regulatory approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to successfully commercialize and market our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    potential market size, opportunity, and growth potential for our product candidates, if approved;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to obtain additional funding for our operations and development activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    timing of anticipated regulatory filings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    timing of availability of data from our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    future expenses, capital requirements, need for additional financing, and the period over which we believe that the net proceeds
    from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital
    expenditure requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to advance product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to recruit and enroll suitable patients in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    pricing and reimbursement of our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    rate and degree of market acceptance of our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    implementation of our business model and strategic plans for our business, product candidates, and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">developments
    relating to our competitors and our industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the
    future impact of it and COVID-19 on our clinical trials, business operations and funding requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">other
    risks and factors listed under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Given
the risks and uncertainties set forth in this prospectus, you are cautioned not to place undue reliance on such forward-looking statements.
The forward-looking statements contained in this prospectus are not guarantees of future performance and our actual results of operations,
financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking
statements contained in this prospectus. In addition, even if our results of operations, financial condition and liquidity, and events
in the industry in which we operate, are consistent with the forward-looking statements contained in this prospectus, they may not be
predictive of results or developments in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
forward-looking statement that we make in this prospectus speaks only as of the date of such statement. Except as required by federal
securities laws, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><A NAME="ak_004"></A>GLOSSARY
OF CERTAIN SCIENTIFIC TERMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following medical and scientific terms used in this prospectus have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;Antineoplastic
drugs&rdquo; are medications used to treat cancer, also known as chemotherapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;API&rdquo;
stands for Active Pharmaceutical Ingredient, which is the main ingredient in a medicine that causes the desired effect of the medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;AMES
test&rdquo; is a biological assay to assess the mutagenic potential of chemical compounds. It utilizes bacteria to test whether a given
chemical can cause mutations in the DNA of the test organism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;C282Y&rdquo;
is a gene mutation associated with hereditary hemochromatosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;CDMO&rdquo;
stands for Contract Development and Manufacturing Organization, a specialized type of supplier of development and production services
to the pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;cGMP&rdquo;
is the current Good Manufacturing Practices under the US Food and Drug Administration&rsquo;s standards. cGMP contains the minimum requirements
for the methods, facilities, and controls used in the manufacturing, processing, and packing of a drug product. The regulations make
sure that a product is manufactured under conditions and tested to ensure that it meets standards of identity, strength, quality, and
purity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;CYP&rdquo;
stands for cytochrome P450 enzymes, which are a complex and important component of drug metabolism. It is the root of many drug interactions
due to inhibition, induction, and competition for common enzymatic pathways by different drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;DNA&rdquo;
is the molecule that carries genetic information for the development and functioning of an organism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;FDA&rdquo;
is the U.S. Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;GMP&rdquo;
is good manufacturing practice &ndash; a standard that is observed in regulated pharmaceutical-manufacturing facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;H63D&rdquo;
is a gene mutation associated with hereditary hemochromatosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;HFE
gene&rdquo; is a gene that provides instructions for producing a protein that is located on the surface of cells, primarily liver and
intestinal cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;Hereditary
Hemochromatosis&rdquo; a genetic disorder that can cause severe liver disease and other health problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;Iron
Overload&rdquo; is a condition in which your body stores too much iron.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;Maximum
tolerated dose&rdquo; is the highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated
dose is determined in clinical trials by testing increasing doses on different subjects until the highest dose with acceptable side effects
is found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;Metabolite&rdquo;
is a substance made or used when the body breaks down food, drugs or chemicals, or its own tissue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><A NAME="ak_005"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>The
following summary highlights selected information about our company and this offering that is included elsewhere in this prospectus in
greater detail. It does not contain all of the information that you should consider before investing in our common stock. Before investing
in our common stock, you should read this entire prospectus carefully, including the information presented under the heading &ldquo;Risk
Factors&rdquo; and in our financial statements and notes thereto.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>In
this prospectus, unless we indicate otherwise or the context requires, &ldquo;Telomir,&rdquo; &ldquo;the company,&rdquo; &ldquo;our company,&rdquo;
&ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;ours&rdquo; and &ldquo;us&rdquo; refer to Telomir Pharmaceuticals, Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Business
Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Overview</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule
being developed to function as a metal enzyme inhibitor. Our initial focus is to advance the clinical development of TELOMIR-1 in the
United States for the treatment of hemochromatosis and the treatment of the side effects associated with post-chemotherapy recovery in
cancer patients. We also intend to explore TELOMIR-1&rsquo;s broader potential, as we believe TELOMIR-1 may have potential in several
diseases associated with a range of metabolic and geriatric related conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Based
on pre-clinical studies, we believe that TELOMIR-1 has the potential to protect and lengthen telomeres in the human chromosome by reducing
the overload of iron and other metals that accompanies diseases like hemochromatosis and certain cancers. Telomeres are repetitive DNA
sequences at the end of chromosomes that protect the chromosomes from becoming frayed or tangled. Each time a cell divides, the telomeres
become slightly shorter, and eventually they become so short that the cell can no longer divide, with the result being that the cell
dies. Effectively, telomeres protect the ends of our chromosomes by forming a cap, much like the plastic tip on shoelaces, thereby allowing
the chromosome to be replaced properly during cell division.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">TELOMIR-1
is under investigation to potentially provide a therapeutic intervention against hemochromatosis and cancer treatment side effects by
interrupting and preventing the enzymatic actions that create the systemic imbalance of cellular metals that allows elevated reactive
oxygen species to oxidize and erode the protective DNA telomere caps. Our preclinical studies suggest that TELOMIR-1 may selectively
affect the key processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis
and cancer. Our studies suggest that TELOMIR-1 may achieve this outcome by selectively binding to metal ions in a dose dependent manner,
slowing enzyme reactivity, and protecting and lengthening telomeres in the human chromosome. We believe that TELOMIR-1 has potential
as a non-toxic oral enzyme inhibitor that may regulate the overactivity of the enzymes caused by excessive metal reactivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
were organized as a Florida corporation in August 2021 for the purpose of pursuing the development and commercialization of TELOMIR-1
in the United States in human applications. We were originally incorporated under the name &ldquo;Metallo Therapies Inc.&rdquo; and changed
our name to &ldquo;Telomir Pharmaceuticals, Inc.&rdquo; in October 2022. We are an early-stage company that had net losses of $0.14 million
for the year ended December 31, 2021, and $0.85 million for year ended December 31, 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Hemochromatosis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">According
to the CDC, hemochromatosis is a disorder in which the body builds up too much iron in the skin, heart, liver, pancreas, pituitary glands,
and joints. This overload of iron is toxic to the body, and over time, the high levels of iron can damage tissues and organs and lead
to conditions such as liver damage, liver cancer, heart problems, arthritis, and diabetes. Other conditions associated with high iron
levels include inflammatory conditions, chronic kidney disease, and autoimmune disorders. Hemochromatosis is a life-long condition requiring
regular treatment to avoid long-term serious effects with poor pharmacologic options. The most used treatment for hemochromatosis is
phlebotomy, a procedure to remove some of the patient&rsquo;s blood. Phlebotomy is relatively inexpensive, well accepted, and well tolerated,
but it requires regular visits to health care professionals and blood draws and may not be appropriate for all patients. Additionally,
iron chelators are sometimes used, but they have limited use due to gastrointestinal and kidney toxicity issues. Despite the presence
of these potential treatment options, we believe significant unmet need remains such that an innovative therapy achieving reduction in
iron overload with a new profile could be subject to widespread use.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 8; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>




<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are pursuing TELOMIR-1 as a metal enzyme inhibitor that may selectively bind metal ions to inhibit enzymes and protect telomeres and
that aims to increase the average telomere length, or ATL, by selectively binding iron and reducing blood iron levels, therefore supporting
the ability to treat hemochromatosis. There is a sizeable patient population that requires management to avoid significant long-term
damage. Additionally, the current standard of care for the treatment of hemochromatosis is phlebotomy, and certain sub-groups may benefit
from TELOMIR-1 if contraindicated for this treatment method. Lastly, iron chelation is used off-label, poorly tolerated and has toxic
long-term effects. In preclinical stage testing, TELOMIR-1 is shown to have better metal complexing than Doxycycline, an FDA-approved
metalloproteinases (MMP) inhibitor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Post-Chemotherapy
Recovery</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Post-chemotherapy
recovery from adverse effects of antineoplastic treatments is often important for cancer therapy success. While chemotherapy treatment
can be highly effective for cancer, it can also come with many side effects, as chemotherapy drugs destroy both cancerous and healthy
cells. We are investigating the use of TELOMIR-1 as a complementary treatment for patients receiving chemotherapy in the form of a twice
daily, oral regimen to reduce blood iron levels and inhibit metal enzyme activity, enabling better adherence and improved outcomes. In
exploratory early discovery studies, proof of concept was demonstrated, and the animal studies are pending. Post-chemotherapy recovery
space contains several treatments that are used symptomatically based on the nature or severity of side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
believe that post-chemotherapy recovery presents several potential unmet commercial needs for TELOMIR-1. There is potential to enable
a more rapid recovery of patients receiving chemotherapy, improving adherence with chemotherapy regimens. Additionally, as current recovery
management is based on severity and treated as needed, we believe that TELOMIR-1 could potentially be used as a preventative measure.
As a complementary treatment, side effect reduction in post-chemotherapy is important to minimize patient burden while improving treatment
outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Our
Strategy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
goal is to develop and commercialize new treatment options for hemochromatosis and post-chemotherapy recovery as our initial clinical
focus and to thereafter expand the development of TELOMIR-1 to a broad range of other diseases and conditions. The key elements of our
strategy to achieve this goal include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Advancing
    TELOMIR-1 through clinical development and approval for hemochromatosis and post-chemotherapy recovery. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Continuing
    pre-clinical development of TELOMIR-1 across a range of diseases associated with cellular aging. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Exploring
    strategic collaborations to maximize the value of TELOMIR-1.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Pre-Clinical
Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">To
date, we have completed several pre-clinical proof-of-concept studies with respect to TELOMIR-1 that were designed to demonstrate that
TELOMIR-1 is not mutagenic and has good biological and metal binding capabilities. These studies included an Ames test for the TELOMIR-1
compound and several Eurofins BioMap studies. The Eurofins invitro studies showed that TELOMIR-1 was more active against malignant cells,
colorectal cancer cells, and lung cancer cells than rapamycin. Other studies showed that versus Doxycycline TELOMIR-1 was more active
at metal complexing. Extensive analysis is being conducted on the potential of TELOMIR-1 to reprogram stem cells and lower blood ferritin.
We have also completed a variety of toxicology studies, and several others are ongoing or planned. Upon completion of the toxicology
studies, we plan to submit to the FDA two separate Investigational New Drug applications, INDs for TELOMIR-1, with one focused on investigating
TELOMIR-1 for the treatment of hemochromatosis and the second for post-chemotherapy recovery. For a summary of completed, ongoing, and
planned pre-clinical studies and development activities, see the section entitled &ldquo;Business&mdash;Pre-Clinical Studies.&rdquo;&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>




<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Our
Clinical Development Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Following
completion of our pre-clinical development program, we plan to submit to the FDA two Investigational New Drug applications, or INDs,
with one focused on investigating TELOMIR-1 for the treatment of hemochromatosis and the second for post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
first IND application submission investigating TELOMIR-1 for the treatment of hemochromatosis is currently planned for the second quarter
of 2024. If allowed to proceed by the FDA, a Phase I double-blind, randomized, placebo-controlled trial to evaluate the safety, tolerability,
and pharmacokinetics of TELOMIR-1 in 40-60 healthy male and female adult subjects will be initiated approximately 30 days post-IND submission.
We have contracted with Frontage Laboratories Phase I clinic in New Jersey consisting of 160 beds across three units for normal volunteers.
After the Phase I trial is complete, a Phase II trial in the hemochromatosis population is planned to commence after results and guidance
from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
second IND application will focus on investigating TELOMIR-1 for the treatment of post-chemotherapy recovery and is planned for submission
with guidance from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
clinical development plans will depend on FDA acceptance of our IND applications. As appropriate and pursuant to discussions with the
FDA, we may periodically adjust the timeline for certain filings and associated clinical trials. It is important to note that the process
for conducting clinical trials is uncertain and there is no assurance that our clinical development activities will meet the planned
timelines set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Intellectual
Property</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
license the U.S. patent rights for the use of TELOMIR-1 in human applications from MIRALOGX, LLC (&ldquo;MIRALOGX&rdquo;), an intellectual
property development and holding company established by Jonnie R. Williams, Sr., the founder of our company and the inventor of TELOMIR-1.
MIRALOGX has filed two provisional patent applications in the U.S. for the composition of TELOMIR-1 and for its therapeutic uses in hemochromatosis
and various chronic inflammatory diseases. These applications, if granted and subject to payment of patent maintenance fees, would offer
protection extending through at least September 1, 2053 in the U.S. The patent rights for TELOMIR-1 outside of the United States and
in non-human applications are not included in our current license rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
license from MIRALOGX is set forth in an Amended and Restated Exclusive License Agreement, dated August 11, 2023, that we have entered
into with MIRALOGX under which we have the exclusive perpetual right and license under the above-described patent rights to make, have
made, use, and sell &ldquo;Licensed Products&rdquo; in the U.S. for human uses and preclinical studies and activities of any kind conducted
in furtherance of obtaining regulatory approval or commercialization for human uses (the &ldquo;MIRALOGX License Agreement&rdquo;). &ldquo;Licensed
Product&rdquo; is defined in the agreement as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)pyridine
or a pharmaceutically acceptable salt, ester, or solvate thereof. We also have the right to grant corresponding sublicenses under the
licensed patent rights. The MIRALOGX License Agreement provides for the payment to MIRALOGX of an 8% royalty (payable quarterly) on our
net sales of Licensed Products by us or our sublicensees and on non-royalty bearing milestone revenue. For a more detailed description
of the MIRALOGX License Agreement, see the section entitled &ldquo;Business&mdash;Intellectual Property.&rdquo;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Summary
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
are a number of risks that you should understand before making an investment decision regarding this offering. These risks are discussed
more fully in the section entitled &ldquo;Risk Factors&rdquo; following this prospectus summary. If any of these risks actually occur,
our business, financial condition, or results of operations would likely be materially and adversely affected. In such a case, the trading
price of our common stock would likely decline, and you may lose all or part of your investment. These risks include, but are not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    are an early development-stage company with no revenues.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Management
    has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included
    an explanatory paragraph relating to its ability to continue as a going concern in their audit report for the year ended December
    31, 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Because
    we have a limited operating history, you may not be able to accurately evaluate our operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    are dependent on additional financing for the continuation of our operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
    operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable
    revenues and succeed overall.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    have yet to achieve a profit and may not achieve a profit in the near future, if at all.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Certain
    of our executive officers will not be employed by us on a full-time basis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
    future success will largely depend on the success of TELOMIR-1 and any future product candidates, which development will require
    significant capital resources and years of clinical development effort.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    are dependent on the success of our current and future product candidates, some of which may not receive regulatory approval or be
    successfully commercialized.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
    business may be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic as a result of the
    current and potential future impacts on our commercialization efforts, supply chain, regulatory and clinical development activities,
    and other business operations, in addition to the impact of a global economic slowdown.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Results
    of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Should
    we later determine it is in our best interest to develop a sales force we may be unable to effectively train and equip our sales
    force, therefore our ability to successfully commercialize our products may be harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
    product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to
    generate revenue from new products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
    the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate
    reimbursement levels, our revenue and prospects for profitability will suffer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    expect to face intense competition, often from companies with greater resources and experience than we have.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>




<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Business
    interruptions could delay us in the process of developing our product candidates and could disrupt our product sales.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    have significant and increasing liquidity needs and may require additional funding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Operating
    results may vary significantly in future periods.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
    product liability lawsuits are successfully brought against us, we will incur substantial liabilities and may be required to limit
    the commercialization of TELOMIR-1 and our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    depend upon our key personnel and our ability to attract and retain employees.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Failure
    of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
    the operation of our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Security
    breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing
    critical information or expose us to liability, which could adversely affect our business and our reputation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Legislative
    or regulatory reform of the health care system in the U.S. may affect our ability to profitably sell our products, if approved.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    expect additional federal and state legislative proposals for health care reform, which could limit the prices that can be charged
    for the products we develop and may limit our commercial opportunity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    may acquire other companies which could divert our management&rsquo;s attention, result in additional dilution to our shareholders
    and otherwise disrupt our operations and harm our operating results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Clinical
    trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The
    results of clinical trials are open to differing interpretations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
    failure by us to comply with existing regulations could harm our reputation and operating results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
    regulatory approval processes with the FDA are lengthy and inherently unpredictable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
    is a high rate of failure for drug candidates proceeding through clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
    existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
    our ability to develop and commercialize our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    maintain our cash at financial institutions, at times in balances that exceed federally insured limits. The failure of financial
    institutions could adversely affect our ability to pay operational expenses or make other payments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
    third parties claim that the Company&rsquo;s intellectual property, products, processes, or anything else used by us infringes upon
    their intellectual property, our operating profits could be adversely affected.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Because
    of the speculative nature of investment risk, you may lose your entire investment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B></B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a company with less than $1.235 billion in annual gross revenue during our last fiscal year, we qualify as an &ldquo;emerging growth
company&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). An emerging growth
company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    are required to present only two years of audited financial statements and related management&rsquo;s discussion and analysis of
    financial condition and results of operations in the registration statement of which this prospectus is a part;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    are exempt from compliance with the requirement that our independent registered public accounting firm provide an attestation report
    on the effectiveness of our internal control over financial reporting;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    are exempt from compliance with any requirement that the Public Company Accounting Oversight Board (the &ldquo;PCAOB&rdquo;) has
    adopted regarding communication of critical accounting matters and may adopt regarding mandatory audit firm rotation or a supplement
    to the auditor&rsquo;s report providing additional information about the audit and the financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    are exempt from the &ldquo;say on pay,&rdquo; &ldquo;say when on pay,&rdquo; and &ldquo;say on golden parachute&rdquo; non-binding
    advisory vote requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    can provide reduced disclosures about our executive compensation arrangements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
currently intend to take advantage of each of the exemptions described above. It is possible, therefore, that some investors will find
our common stock less attractive, which may result in a less active trading market for our common stock and higher volatility in our
stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this
offering or such an earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon
the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues are $1.235 billion or more; (ii) the date
on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt securities; or (iii) the
date on which we are deemed to be a &ldquo;large accelerated filer,&rdquo; which will occur as of the end of any fiscal year in which
we (x) have an aggregate market value of our common stock held by non-affiliates of $700 million or more as of the last business day
of our most recently completed second fiscal quarter, (y) have been required to file annual and quarterly reports under the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), for a period of at least 12 months and (z) have filed at least one
annual report pursuant to the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, emerging growth companies may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of
this extended transition period. For risks related to our status as an emerging growth company, see &ldquo;Risk Factors&thinsp;&mdash;&thinsp;Risks
Related to Ownership of Our Common Stock&thinsp;&mdash;&thinsp;Taking advantage of the reduced disclosure requirements applicable to
&ldquo;emerging growth companies&rdquo; may make our common stock less attractive to investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are a &ldquo;smaller reporting company&rdquo; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30<SUP>th</SUP>; or (ii) our annual
revenues did not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure
obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205. Our telephone number is (737) 289-0835.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
website address is www.telomirpharma.com. The information contained on, or that can be accessed through, our website is deemed not to
be incorporated in this prospectus or to be part of this prospectus. You should not consider information contained on our website to
be part of this prospectus.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Common
    stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">[&#9679;]
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Initial
    public offering price</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">It
    is currently estimated that the initial public offering price will be between $[&#9679;] and $[&#9679;] per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Shares
    of common stock outstanding before this offering (1)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">[&#9679;]
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Shares
    of common stock to be outstanding immediately after this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">[&#9679;]
    shares (or [&#9679;] shares if the underwriters exercise the option to purchase additional shares from us in full. See &ldquo;Over-allotment
    Option&rdquo; below).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Over-allotment
    Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    have granted the underwriters an option exercisable for a period of 45 days from the date of this prospectus to purchase from us
    in whole or in part and at any time or from time to time up to [&#9679;] additional shares of common stock, solely to cover overallotments,
    if any, at a purchase price equal to the initial public offering price less underwriting discounts and commissions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    estimate that we will receive net proceeds from the sale of shares of our common stock in this offering of approximately $[&#9679;]
    million, assuming an initial public offering price of $[&#9679;] per share (the midpoint of the range set forth on the cover of this
    prospectus), and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend
    to use the net proceeds from this offering to advance the clinical development of our programs, to fund our research and development
    activities, and for working capital and general corporate purposes. In order to advance our clinical development programs, we plan
    to use an estimated [&#9679;]. Our management will have broad discretion in the application of the net proceeds from this offering
    and investors will be relying on the judgment of our management regarding the application of the proceeds. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Lock
    up</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
    directors, officers, and shareholders who beneficially own 5% or more of the outstanding shares of our common stock have agreed with
    not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible
    into common stock for a period of 180 days, commencing on the date of this prospectus, except with the prior written consent of the
    underwriters.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Representative&rsquo;s
    warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
    have agreed to issue to the representative of the underwriters or its designees at the closing of this offering, warrants to purchase
    the number of shares of our common stock equal to 5.0% of the aggregate number of shares sold in this offering (the &ldquo;Representative&rsquo;s
    Warrants&rdquo;). The Representative&rsquo;s Warrants will be exercisable at any time and from time to time, in whole or in part,
    during the four-and-a-half-year period commencing six months after the commencement of sales in this offering. The exercise price
    of the Representative&rsquo;s Warrants will equal 100% of the initial public offering price per share, subject to adjustments. The
    registration statement of which this prospectus is a part also covers the Representative&rsquo;s Warrants and the shares of common
    stock issuable upon the exercise thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Proposed
    Nasdaq Capital Market Symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;TELO&rdquo;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Investing
    in our common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 10 of this prospectus for
    a discussion of factors you should carefully consider before investing in our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
    number of shares of our common stock to be outstanding immediately after this is based on an aggregate of [&#9679;] shares of our
    common stock outstanding as of [&#9679;], 2023, which excludes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">[&#9679;]
    shares of our common stock to be reserved for future issuance under the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan,
    as well as any automatic increases in the number of shares of common stock reserved for future issuance under such plan; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">[&#9679;]
    shares &nbsp;of our common stock to be issued upon the exercise of outstanding warrants at an exercise price of $[____] per share;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unless
    the context otherwise requires, the information presented in this prospectus assumes the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">that
    the shares of our common stock to be sold in this offering are sold at $[&#9679;] per share (the midpoint of the range set forth
    on the cover of this prospectus);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">no
    exercise by the underwriters of their over-allotment option; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">no
    exercise by the Representative of the Representative&rsquo;s Warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Summary
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables summarize our financial data as of the dates and for the periods presented. We have derived the summary statements of
operations data for the years ended December 31, 2022 and 2021, and the balance sheet data as of December 31, 2022 and 2021, from our
audited financial statements included elsewhere in this prospectus. We have derived the summary statement of operations data for the
six months ended June 30, 2023 and 2022, and the balance sheet data as of June 30, 2023 and 2022, from our unaudited financial statements
included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following summary financial and other data should be read in conjunction with the section titled &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and related notes included elsewhere
in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Statement
of Operations data:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="color: Black; font-weight: bold; text-align: center">(Audited)</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; color: Black">Revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&#8239;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Operating costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-left: 10pt">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">20,941</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">11,639</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">833,206</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">126,492</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">854,147</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">138,131</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: right">(854,147</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: right">(138,131</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Balance
Sheet data:</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; color: Black">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B> June 30,</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; color: Black">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2023</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2022</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="color: Black; font-weight: bold; text-align: center">(Audited)</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold">ASSETS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Current assets:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 44%; color: Black">Cash</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="width: 2%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; color: Black; text-align: right">1,419</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">$</TD><TD STYLE="width: 10%; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Deferred offering costs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">47,311</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; color: Black; text-align: left">Total other current assets</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">48,730</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Advances due from affiliates</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">48,730</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Current liabilities:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left">Trade accounts payable</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">$</TD><TD STYLE="color: Black; text-align: right">404,221</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">$</TD><TD STYLE="color: Black; text-align: right">18,735</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left">Due to related party</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">581,787</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">119,396</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Related party line of credit</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; color: Black; text-align: left">Total current liabilities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">986,008</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">138,131</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; color: Black; text-align: left">Total liabilities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">986,008</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">138,131</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Stockholders&rsquo; Deficit</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left">Preferred Stock, no par value, 5,000,000 shares authorized and none issued or outstanding.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left">Common Stock, no par value; 95,000,000 shares authorized, 55,000,000 and 55,000,000 shares issued and outstanding at December 31, 2022, and December 31, 2021, respectively.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left">Additional paid-in capital</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">55,000</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">55,000</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left">Stock subscription receivable</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(55,000</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(992,278</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(138,131</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; color: Black; text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(937,278</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(138,131</TD><TD STYLE="padding-bottom: 1.5pt; color: Black; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; deficit</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">48,730</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><A NAME="ak_006"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Investing
in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
the section of this prospectus entitled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our financial statements and related notes included elsewhere in this prospectus before investing in shares of our common stock.
The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of,
or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur,
our business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline,
and you could lose part or all of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risks
Related to Our Operations and Financial Condition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are an early development-stage company with no revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
an early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, we have generated
no revenue and have an accumulated deficit of $1 million through December 31, 2022. There can be no assurance that sufficient funds required
to pursue our development program will be generated from operations or that funds will be available from external sources, such as debt
or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from
operations, or to raise capital from external sources would force us to substantially curtail or cease operations and would, therefore,
have a material adverse effect on business. Furthermore, there can be no assurance that any such required funds, if available, will be
available on attractive terms or that they will not have a significant dilutive effect on our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
seek to overcome the circumstances that impact our ability to remain a going concern in the future through the growth of revenues with
interim cash flow deficiencies being addressed through additional equity and debt financing. We anticipate raising additional funds through
public or private financing, strategic relationships, or other arrangements in the near future to support our business operations; however,
we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing
will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue operations.
Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional financing
in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and
stock price and require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy
proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing,
if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require
that we relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Management
has concluded that factors raise substantial doubt about our ability to continue as a going concern and our </I><FONT>auditor
</FONT><I>has included an explanatory paragraph relating to its ability to continue as a going concern in their audit report for the
year ended December 31, 2022.</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
anticipate that we will continue to report losses and negative cash flow for the foreseeable future. We have concluded that our historical
recurring losses from operations and negative cash flows from operations as well as our dependence on debt and other financings raise
substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to
our ability to continue as a going concern in its audit report for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
consolidated financial statements of the Company do not include any adjustments that might result from the outcome of this uncertainty.
These adjustments would likely include substantial impairment of the carrying amount of our assets and potential contingent liabilities
that may arise if we are unable to fulfill various operational commitments. In addition, the value of our securities, including the subordinate
voting shares included in this offering, would be greatly impaired. Our ability to continue as a going concern is dependent upon generating
sufficient cash flow from operations and obtaining additional capital and financing. If our ability to generate cash flow from operations
is delayed or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Because
we have a limited operating history, you may not be able to accurately evaluate our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have had limited operations to date. Therefore, we have a limited operating history upon which to evaluate the merits of investing in
our company. Potential investors should be aware of the difficulties normally encountered by new companies and the high rate of failure
of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and
delays encountered in connection with the operations that we plan to undertake. These potential problems include, but are not limited
to, unanticipated problems relating to the ability to generate sufficient cash flow to operate our business, and additional costs and
expenses that may exceed current estimates. We expect to continue to incur significant losses into the foreseeable future. We recognize
that if the effectiveness of our business plan is not forthcoming, we will not be able to continue business operations. There is no history
upon which to base any assumption as to the likelihood that we will prove successful, and it is doubtful that we will generate any operating
revenues or ever achieve profitable operations. If we are unsuccessful in addressing these risks, our business will most likely fail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are dependent on additional financing for the continuation of our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Because
we have generated no revenues and currently operate at a loss, we are completely dependent on the continued availability of financing
in order to continue our business operations. There can be no assurance that financing sufficient to enable us to continue our operations
will be available to us in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
will need additional funds to complete further development of our business plan to achieve a sustainable level where ongoing operations
can be funded out of revenues. We expect that the proceeds from this Offering will provide adequate resources to fund our operations
and initial clinical development programs through [&#9679;]. We will require further funding to fully implement our business plan to
its fullest potential and achieve our growth plans. There is no assurance that any additional financing will be available or if available,
on terms that will be acceptable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
failure to obtain future financing or to produce levels of revenue to meet our financial needs could result in our inability to continue
as a going concern in the future and, as a result, our investors could lose their entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues
and succeed overall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
results of operations may fluctuate as a result of a number of factors, some of which are beyond our control including but not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">general
    economic conditions in the geographies and industries where we sell our services and conduct operations; legislative policies where
    we sell our services and conduct operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    budgetary constraints of our customers; seasonality;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">success
    of our strategic growth initiatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">costs
    associated with the launching or integration of new or acquired businesses; timing of new product introductions by us, our suppliers
    and our competitors; product and service mix, availability, utilization and pricing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    mix, by state and country, of our revenues, personnel, and assets; movements in interest rates or tax rates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">changes
    in, and application of, accounting rules; changes in the regulations applicable to us; and litigation matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a result of these factors, we may not succeed in our business, and we could go out of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
have yet to achieve a profit and may not achieve a profit in the near future, if at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have not yet produced any revenues or profit and may not in the near future, if at all. We cannot be certain that we will be able to
realize sufficient revenue to achieve profitability. Further, many of our competitors have a significantly larger industry presence and
revenue stream but have yet to achieve profitability. Our ability to continue as a going concern in the future is dependent upon raising
capital from financing transactions, increasing revenue and keeping operating expenses below our revenue levels in order to achieve positive
cash flows, none of which can be assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Certain
of our executive officers will not be employed by us on a full-time basis.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Dr.
Christopher Chapman, our Chief Executive Officer, Chief Medical Officer, President, and Chairman, and Erez Aminov, our President, will
not be employed by our company on a full-time basis. As provided in their employment agreements with our company, they are expected to
work on a part-time and as-needed basis. Because they will not work full time for our company, instances may occur where they may not
be immediately available to provide solutions to problems or address concerns that arise in the course of us conducting our business
and thus adversely affect our business. In addition, they can each become subject to conflicts of interest because they devote part of
their working time to other business endeavors and have responsibilities to these other entities. Although each of Dr. Chapman and Mr.
Aminov is aware of his duties and accountability to our company and to applicable laws and policies relating to corporate opportunity
and conflicts of interest, such conflicts of interest may include deciding how much time to devote to our affairs, as well as what business
opportunities should be presented to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risks
Relating to Our Business and Our Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
future success will largely depend on the success of TELOMIR-1 and any future product candidates, which development will require significant
capital resources and years of clinical development effort.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
currently have no drug products on the market, and all of our drug development projects are in a pre-clinical stage of development. Our
business depends almost entirely on the successful pre-clinical and clinical development, FDA regulatory approval, and commercialization
of our product candidates, principally TELOMIR-1. Investors need to be aware that substantial additional investments including pre-clinical
and clinical development and FDA regulatory submission and approval efforts will be required before we are permitted to undertake clinical
studies and market and commercialize our product candidates, if ever. It may be several years before we can commence clinical trials,
if ever. Any clinical trial will be subject to extensive and rigorous review and regulation by numerous government authorities in the
United States and other jurisdictions where we intend, if approved, to market our product candidates. Before obtaining regulatory approvals
for any of our product candidates, we must demonstrate through pre-clinical testing and clinical trials that the product candidate is
safe and effective for its specific application. This process can take many years and may include post- marketing studies and surveillance,
which would require the expenditure of substantial resources. Of the large number of drugs in development for approval in the United
States (and the rest of the world), only a small percentage will successfully complete the FDA regulatory approval financing to fund
our planned research, development, and clinical programs, we cannot assure you that any of our product candidates will be successfully
developed or commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
may be unable to formulate or scale up any or all of our product candidates. There is no guarantee that any of the product candidates
will be or are able to be manufactured or produced in a manner to meet the FDA&rsquo;s criteria for product stability, content uniformity
and all other criteria necessary for product approval in the United States and other markets. Any of our product candidates may fail
to achieve their specified endpoints in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Furthermore,
product candidates may not be approved even if they achieve their specified endpoints in clinical trials. The FDA may disagree with our
trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed
and commented on the design for our clinical trials. The FDA may also approve a drug for fewer or more limited indications than we request
or may grant approval contingent on the performance of costly post-approval clinical trials (i.e., Phase IV trials). In addition, the
FDA may not approve the labeling claims that we believe are necessary or desirable for the successful commercialization of our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
we are unable to expand our pipeline and obtain regulatory approval for our product candidates within the timelines we anticipate, we
will not be able to execute our business strategy effectively and our ability to substantially grow our revenues will be limited, which
would have a material adverse impact on our long-term business, results of operations, financial condition, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are dependent on the success of our current and future product candidates, some of which may not receive regulatory approval or be successfully
commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
success will depend on our ability to successfully commercialize our product candidates. Our ability to successfully commercialize our
product candidates will depend on, among other things, our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">successfully
    complete pre-clinical and other nonclinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">receive
    regulatory approvals from the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">produce,
    through a validated process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently
    large quantities of product candidates to permit successful commercialization;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">obtain
    reimbursement from payers such as government health care programs and insurance companies and achieve commercially attractive levels
    of pricing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">secure
    acceptance of our product candidates from physicians, health care payers, patients, and the medical community;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">create
    positive publicity surrounding our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">manage
    our spending as costs and expenses increase due to clinical trials and commercialization; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">obtain
    and enforce sufficient intellectual property for our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
failure or delay with respect to any of the factors above could have a material adverse effect on our business, results of operations
and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
business may be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic as a result of the current
and potential future impacts on our commercialization efforts, supply chain, regulatory and clinical development activities, and other
business operations, in addition to the impact of a global economic slowdown.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
business could be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic. If we are unable
to obtain adequate supplies of personal protective equipment due to shortages or encounter other challenges related to the evolving COVID-19
pandemic, we may have to place or may experience additional limitations on our in-person activities. In addition, our increased reliance
on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. This
could also increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions,
any of which could adversely impact our business operations. Impacts related to the COVID-19 pandemic could materially and adversely
affect our business, our ability to generate sales of and revenues from our approved products, and our ability to advance the development
of our products and product candidates, as described elsewhere in this &ldquo;Risk Factors&rdquo; section. The magnitude of such impacts
will depend, in large part, on the ultimate duration and severity of the evolving effects of the COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
effects of the COVID-19 pandemic continue to rapidly evolve. These effects have increased market volatility and could result in a significant
long-term disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect
our liquidity. In addition, market corrections resulting from the effects of the COVID-19 pandemic could materially affect our business
and the value of our common stock. The extent to which the evolving effects of the COVID-19 pandemic impact our business, our ability
to generate sales of and revenues from our approved products, and our clinical development and regulatory efforts will depend on future
developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate duration and severity of the pandemic,
government actions, such as travel restrictions, quarantines and social distancing requirements in the U.S. and in other countries, business
closures or business disruptions and the effectiveness of actions taken in the U.S. and in other countries to contain and treat the disease.
Accordingly, we do not yet know the full extent of potential delays or impacts on our business, sales of our products, our clinical and
regulatory activities, our research programs, healthcare systems or the global economy as a whole. However, these effects could materially
and adversely affect our business, financial condition, results of operations and growth prospects. In addition, to the extent the evolving
effects of the COVID-19 pandemic adversely affect our business, financial condition, results of operations and growth prospects, they
may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &ldquo;Risk Factors&rdquo;
section. It is also possible that future global pandemics could also occur and materially and adversely affect our business, financial
condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Results
of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
positive results from future pre-clinical testing of our product candidates and potential future clinical trials may not necessarily
be predictive of the results from Phase I, Phase II or Phase III clinical trials. In addition, our interpretation of results derived
from clinical data or our conclusions based on our pre-clinical data may prove inaccurate. Frequently, pharmaceutical and biotechnology
companies have suffered significant setbacks in clinical trials after achieving positive results in pre-clinical testing and early phase
clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks may be caused by the fact that pre-clinical
and clinical data can be susceptible to varying interpretations and analyses. Furthermore, certain product candidates may perform satisfactorily
in pre-clinical studies and clinical trials, but nonetheless fail to obtain FDA approval or appropriate approvals by the appropriate
regulatory authorities in other countries. If we fail to produce positive results in our clinical trials for our product candidates,
the development timeline and regulatory approval and commercialization prospects for them and as a result our business and financial
prospects, would be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement
capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
ability to generate revenues ultimately depends on our ability to sell our approved products and secure adequate third-party reimbursement.
We currently have limited experience in marketing and selling our products. We currently do not have any products approved for sale in
the United States or in any other country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
commercial success of our product candidates will depend on a number of factors beyond our control, including the willingness of physicians
to prescribe our products to patients, payers&rsquo; willingness and ability to pay for the drugs, the level of pricing achieved, patients&rsquo;
response to our drugs and the ability of our marketing partners to generate sales. There can be no guarantee that we will be able to
establish or maintain the personnel, systems, arrangements and capabilities necessary to successfully commercialize TELOMIR-1 or any
product candidate approved by the FDA in the future. If we fail to establish or maintain successful marketing, sales and reimbursement
capabilities or fail to enter into successful marketing arrangements with third parties, our product revenues may suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Should
we later determine it is in our best interest to develop a sales force we may be unable to effectively train and equip our sales force,
therefore our ability to successfully commercialize our products may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
will be required to expend significant time and resources to train our sales force to be credible, persuasive, and compliant with applicable
laws in marketing TELOMIR-1 or our other product candidates to physicians for their approved uses. In addition, we must continue to train
our sales force to ensure that a consistent and appropriate message about TELOMIR-1 or our other product candidates is being delivered
to our potential customers. If we are unable to effectively train our sales force and equip them with effective materials, including
medical and sales literature to help them inform and educate potential customers about the benefits of TELOMIR-1 and our product candidates
and its proper administration, our efforts to successfully commercialize TELOMIR-1 and our product candidates could be jeopardized, which
would negatively impact our ability to generate product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing
our growth and executing our growth strategy.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
management and personnel, systems, and facilities currently in place may not be adequate to support our business plan and future growth.
As a result, we may need to further expand certain areas of our organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
need to effectively manage our operations, growth and various projects requires that we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">continue
    to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">attract
    and retain enough talented employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">manage
    our clinical trials effectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">manage
    our external manufacturing operations with contract research organizations effectively and in a cost-effective manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">manage
    our development efforts effectively while carrying out our contractual obligations to contractors and other third parties; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, we may utilize the services of part-time outside consultants and contractors to perform several tasks for us, including tasks
related to compliance programs, clinical trial management, regulatory affairs, formulation development and other drug development functions.
Our growth strategy may entail expanding our use of consultants and contractors to implement these and other tasks going forward. If
we are not able to effectively expand our organization by hiring new employees and expanding our use of consultants and contractors,
we may be unable to successfully implement the tasks necessary to effectively execute on our planned research, development, manufacturing,
and commercialization activities and, accordingly, may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate
revenue from new products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Even
when product development is successful and regulatory approval has been obtained, our ability to generate sufficient revenue depends
on the acceptance of our products by physicians and patients. We cannot assure you that our product candidates will achieve the expected
level of market acceptance and revenue if and when they obtain the requisite regulatory approvals. The market acceptance of any product
depends on a number of factors, including the indication statement and warnings required by regulatory authorities in the product label.
Market acceptance can also be influenced by continued demonstration of efficacy and safety in commercial use, physicians&rsquo; willingness
to prescribe the product, reimbursement from third-party payers such as government health care programs and private third-party payers,
the price of the product, the nature of any post-approval risk, management activities mandated by regulatory authorities, competition,
and marketing and distribution support. Further, an ineffective or inefficient distribution model at launch may lead to the inability
to fulfill demand, and consequently a loss of revenue. Any factors preventing or limiting the market acceptance of our products could
have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If
the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate
reimbursement levels, our revenue and prospects for profitability will suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patients
who are prescribed medicine for the treatment of their conditions generally rely on third-party payers to reimburse all or part of the
costs associated with their prescription drugs. Reimbursement systems in international markets vary significantly by country and by region,
and reimbursement approvals generally must be obtained on a country-by-country basis. Coverage and adequate reimbursement from governmental
healthcare programs, such as Medicare and Medicaid, and commercial payers is critical to new product acceptance. Coverage decisions may
depend upon clinical and economic standards that disfavor new drug products when more established or lower-cost therapeutic alternatives
are already available or subsequently become available. Even if we obtain coverage for products we may market, the resulting reimbursement
payment rates may require co-payments that patients find unacceptably high. Patients may not use our products if coverage is not provided,
or reimbursement is inadequate to cover a significant portion of its cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, the market for our products will depend significantly on access to third-party payers&rsquo; drug formularies or lists of medications
for which third-party payers provide coverage and reimbursement. The industry competition to be included in such formularies often leads
to downward pricing pressures on pharmaceutical companies. Also, third-party payers may refuse to include a particular branded drug in
their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is
available, even if not approved for the indications for which our products are approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Third-party
payers or governmental or commercial entities are developing increasingly sophisticated methods of controlling healthcare costs. The
current environment is putting pressure on companies to price products below what they may feel is appropriate. Selling our products
at less than an optimized price could impact our revenues and overall success as a company. It will be difficult to determine the optimized
price for our products. In addition, in the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party
payers. Therefore, coverage and reimbursement for our products may differ significantly from payer to payer. As a result, the coverage
determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for
the use of our products to each payer separately, with no assurance that coverage will be obtained. If we are unable to obtain coverage
of, and adequate payment levels for, products we may market to third-party payers, physicians may limit how much or under what circumstances
they will prescribe or administer them, and patients may decline to purchase them. This in turn could affect our ability to successfully
commercialize products we may market, and thereby adversely impact our profitability, results of operations, financial condition, and
future success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, where we have chosen to collaborate with a third party on product candidate development and commercialization, our partner
may elect to reduce the price of our products in order to increase the likelihood of obtaining reimbursement approvals. In many countries,
products cannot be commercially launched until reimbursement is approved and the negotiation process in some countries can exceed 12
months. In addition, pricing and reimbursement decisions in certain countries can be affected by decisions taken in other countries,
which can lead to mandatory price reductions and/or additional reimbursement restrictions across a number of other countries, which may
thereby adversely affect our sales and profitability. If countries impose prices that are not sufficient to allow us or our partners
to generate a profit, our partners may refuse to launch the product in such countries or withdraw the product from the market, which
would adversely affect sales and profitability. Events, such as price decreases, government mandated rebates or unfavorable reimbursement
decisions, could affect the pricing and reimbursement of TELOMIR-1 and our other product candidates and could have a material adverse
effect on our business, reputation, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
expect to face intense competition, often from companies with greater resources and experience than we have.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
development and commercialization of drugs and medicines is highly competitive. We compete with a variety of multinational pharmaceutical
companies and specialized biotechnology companies, as well as products and processes being developed by universities and other research
institutions. Many of our competitors have developed, are developing, or will develop drugs and processes which may be competitive with
our drug candidates. Competitive products include those that have already been approved by medicines regulators and accepted by the medical
community and any new products that may enter the market. For some of our drug development programs / areas of interest, other treatment
options or products are currently available, under development, and may become commercially available in the future. If any of our product
candidates are approved for the diseases and conditions we are currently pursuing, they may compete with a range of medicines or therapeutic
treatments that are either in development, will be developed in the future or currently marketed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Established
companies may have a competitive advantage over us due to their size and experiences, financial resources, and institutional networks.
Many of our competitors may have significantly greater financial, technical, and human resources than we do. Due to these factors, our
competitors may have an advantage in marketing their approved drugs and may obtain regulatory approval of their drug candidates before
we are able to, which may limit our ability to develop or commercialize our drug candidates. Our competitors may also develop drugs or
medicines that are safer, more effective, more widely used and less expensive than ours. These advantages could materially impact our
ability to develop and, if approved, commercialize our product candidates successfully. Furthermore, some of these competitors may make
acquisitions or establish collaborative relationships among themselves or with third parties to increase their ability to rapidly gain
market share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Moreover,
as generic versions of drug products enter the market, the price for such medicines may be expected to decline rapidly and substantially.
Even if we are the first to obtain FDA approval of one of our product candidates, the future potential approval of generics could adversely
affect the price we are able to charge, and the profitability of our product(s) will likely decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in more resources being concentrated among a smaller number
of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These
companies may compete with us in recruiting and retaining qualified scientific, management and commercial personnel, utilizing contract
manufacturing facilities or contract research organizations (CROs), or establishing clinical trial sites and subject registration for
clinical trials, as well as in acquiring technologies complementary to our research projects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Problems
in our manufacturing process, failure to comply with manufacturing regulations or unexpected increases in our manufacturing costs could
harm our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
manufacturing of our product candidates necessitates compliance with cGMP and other regulatory requirements in jurisdictions internationally.
We must ensure chemical consistency among our batches of products, including clinical batches and, if approved, marketing batches. Demonstrating
such consistency may require typical manufacturing controls as well as clinical data. We must also ensure that our batches conform to
complex release specifications. If we are unable to manufacture our product candidates in accordance with regulatory specifications,
including cGMP, or if there are disruptions in our manufacturing process due to damage, loss or otherwise, or failure to pass regulatory
inspections of our manufacturing facilities, we may not be able to meet current demand or supply sufficient product for use in clinical
trials, and this may also harm our ability to commercialize our product candidates on a timely or cost-competitive basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
may fail to expand our manufacturing capability in time to meet market demand for our products and product candidates, and the FDA may
refuse to accept our facilities or those of our contract manufacturers as being suitable for the production of our products and product
candidates. Any problems in our manufacturing process could have a material adverse effect on our business, results of operations and
financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, before we can begin commercial manufacture of any product candidates for sale in the U.S., we must obtain FDA regulatory approval
for the product, which requires a successful FDA inspection of our manufacturing facilities and those of our contract manufacturers,
processes, and quality systems in addition to other product-related approvals. Although we may successfully navigate this pre-approval
inspection process as it relates in the U.S., pharmaceutical manufacturing facilities are continuously subject to post-approval inspection
by the FDA and foreign regulatory authorities. Due to the complexity of the processes used to manufacture our product candidates, we
may be unable to initially or continue to pass federal, state or international regulatory inspections in a cost-effective manner. If
we are unable to comply with manufacturing regulations, we may be subject to fines, unanticipated compliance expenses, recall or seizure
of any approved products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or
civil prosecution. These possible sanctions would adversely affect our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Business
interruptions could delay us in the process of developing our product candidates and could disrupt our product sales.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
research and development activities are conducted through outside contractors and manufacturers. Loss of our contracted manufacturing
facilities, stored inventory or laboratory facilities through fire, theft or other causes, or loss of our raw material, could have an
adverse effect on our ability to continue product development activities and to conduct our business. Failure to supply our partners
with commercial product may lead to adverse consequences, including the right of partners to take over responsibility for product supply.
We currently do not have insurance coverage to compensate us for such business interruptions. Our contract manufacturers and suppliers
provide that in their separate operations; however, such coverage may prove insufficient to fully compensate us for the damage to our
business resulting from any significant property or casualty loss to those facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
have significant and increasing liquidity needs and may require additional funding.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
operations have consumed substantial amounts of cash since inception. For the year ended December 31, 2022, we reported a net operating
cash outflow of $0.5 million and a net cash inflow from investing activities of $0.5 million. For the year ended December
31, 2021, we reported a net operating cash outflow of $0.1 million and a net cash inflow from investing activities of $0.1
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
and development, and general and administrative expenses, and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new research and development initiatives and continued product commercialization efforts.
We may need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications and to fund commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    timing of FDA approval, if any, and approvals in international markets of our product candidates, if at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    timing and amount of revenue from sales of our products, or revenue from grants or other sources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    rate of progress and cost of our clinical trials and other product development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">costs
    of establishing or outsourcing sales, marketing, and distribution capabilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">costs
    and timing of completion of expanded in-house manufacturing facilities as well as any outsourced commercial manufacturing supply
    arrangements for our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">costs
    of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights associated with our product
    candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    effect of competing technological and market developments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">personnel,
    facilities, and equipment requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    terms and timing of any additional collaborative, licensing, co-promotion, or other arrangements that we may establish.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">While
we expect to fund our future capital requirements from several sources including existing cash balances, future cash flows from
operations and the proceeds from equity offerings, we cannot assure you that any of these funding sources will be available to us on
favorable terms, or at all. Further, even if we can raise funds from all of the above sources, the amounts raised may not be sufficient
to meet our future capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Operating
results may vary significantly in future periods.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
expenses and operating results have fluctuated in the past and our revenues, expenses, and operating results are likely to fluctuate
significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">commercial
    sales of our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    achievement of product development objectives and milestones;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">clinical
    trial enrollment and expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">research
    and development expenses; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    timing and nature of contract manufacturing and contract research payments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter. Because of these factors, our financial results
in one or more future quarters may fail to meet the expectations of securities analysts or investors, which could cause our share price
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If
product liability lawsuits are successfully brought against us, we will incur substantial liabilities and may be required to limit the
commercialization of TELOMIR-1 and our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Although
we have never had any product liability claims or lawsuits brought against us, we face potential product liability exposure related to
the testing of our product candidates in human clinical trials. We may face exposure to claims by an even greater number of persons when
we begin to market and distribute our products commercially in the U.S., Europe and elsewhere. Now, and in the future, an individual
may bring a liability claim against us alleging that TELOMIR-1 or one of our product candidates caused an injury. While we continue to
take what we believe are appropriate precautions, we may be unable to avoid significant liability if any product liability lawsuit is
brought against us. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side
effects. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities. Regardless
of merit or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">decreased
    demand for TELOMIR-1 and our product candidates if such product candidates are approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">injury
    to our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">withdrawal
    of clinical trial participants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">costs
    of related litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">substantial
    monetary awards to patients and others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">increased
    cost of liability insurance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">loss
    of revenue; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    inability to successfully commercialize our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Counterfeit
versions of our products could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Counterfeiting
activities and the presence of counterfeit products in a number of markets and over the Internet continue to be a challenge for maintaining
a safe drug supply for the pharmaceutical industry. Counterfeit products are frequently unsafe or ineffective and can be life-threatening.
To distributors and users, counterfeit products may be visually indistinguishable from the authentic version. Reports of adverse reactions
to counterfeit drugs along with increased levels of counterfeiting could be mistakenly attributed to the authentic product, affect patient
confidence in the authentic product and harm the business of companies such as ours. If our products were to be the subject of counterfeits,
we could incur reputational and financial harm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
depend upon our key personnel and our ability to attract and retain employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
future growth and success depend on our ability to recruit, retain, manage, and motivate our employees. The inability to hire or retain
experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results. Due
to the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific,
technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to continue to attract and retain the qualified personnel necessary for the development of our business
or to recruit suitable replacement personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA or foreign regulations, provide accurate information to FDA or other regulatory authorities, comply with applicable manufacturing
standards, comply with other foreign, federal, and state laws and regulations, report information or data accurately or disclose unauthorized
activities to us. Employee misconduct could also involve the improper use of information, including information obtained during clinical
trials, or illegal appropriation of drug products, which could result in government investigations and serious harm to our reputation.
The precautions we take to detect and prevent these prohibited activities may not be effective in controlling unknown or unmanaged risks
or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such
laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions
laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties,
other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;FCPA&rdquo;),
and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and
our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons
to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions
that pose a high risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions
could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope,
or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws
might be administered or interpreted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are also subject to other laws and regulations governing our international operations, including regulations administered by the government
of the U.S. and other countries in which we operate or plan to operate, including applicable export control regulations, economic sanctions
on countries and persons, customs requirements, and currency exchange regulations, (collectively referred to as the &ldquo;Trade Control
laws&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">However,
there is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including
the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption
laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures,
and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity, as
well as our reputation. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control
laws by the U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
proprietary information, or that of our customers, suppliers, and business partners, may be lost or we may suffer security breaches.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the ordinary course of our business, we will collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our customers, suppliers and business partners, and personally
identifiable information of our customers, clinical trial subjects and employees, and patients, on our networks,
and with our third-party cloud service providers. The secure processing, maintenance and transmission of this information is critical
to our operations. Despite our security measures, our information technology and infrastructure, and that of our third parties, may be
vulnerable to attacks by hackers or breached due to employee error, malfeasance, or other disruptions. Any breach could compromise our
networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure or other
loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in our products and our ability to
conduct clinical trials, which could adversely affect our business and reputation and lead to delays in gaining regulatory approvals
for TELOMIR-1 or other product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
business is increasingly dependent on critical, complex, and interdependent information technology (&ldquo;IT&rdquo;) systems, including
internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external
communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion,
and computer viruses, which may result in the impairment of our ability to operate our business effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our
planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems,
including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures,
additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced
systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could
harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity
improvements at a level that outweighs the costs of implementation, or at all. In addition, our systems and the systems of our third-party
providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons
or to the public. Such data security breaches could lead to the loss of confidential information, trade secrets or other intellectual
property, could lead to the public exposure of personal information (including personally identifiable information or individually identifiable
health information) of our employees, clinical trial patients, customers, business partners, and others, could lead to potential identity
theft, or could lead to reputational harm. Data security breaches could also result in loss of clinical trial data or damage to the integrity
of that data. In addition, the increased use of social media by our employees and contractors could result in inadvertent disclosure
of sensitive data or personal information, including but not limited to, confidential information, trade secrets and other intellectual
property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly
evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business,
could result in enforcement actions by U.S. states, the U.S. federal government or foreign governments, liability or sanctions under
data privacy laws, including healthcare laws such as HIPAA, that protect certain types of sensitive information, regulatory penalties,
other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to
our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which
could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity
threats, our measures to prevent, respond to and minimize such risks may be unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing
critical information or expose us to liability, which could adversely affect our business and our reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the ordinary course of our business, we, our vendors, and our third-party cloud service providers may collect and store sensitive data,
including legally protected patient health information, credit card information, personally identifiable information about our employees
and patients, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing
cloud-based and on-site systems. These applications and data encompass a wide variety of business-critical information including research
and development information, commercial information and business and financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy,
and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized
access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches, or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. We have measures in place that are designed to prevent, and if necessary to detect and respond to
such security incidents, breaches of privacy, and security mandates. However, in the future, any such access, disclosure or other loss
of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such
as HIPAA in the United States and the General Data Protection Regulation in the European Union, or GDPR, government enforcement actions
and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process
samples, provide test results, share and monitor safety data, bill payers or patients, provide customer support services, conduct research
and development activities, process and prepare company financial information, manage various general and administrative aspects of our
business and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Legislative
or regulatory reform of the health care system in the U.S. may affect our ability to profitably sell our products, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
ability to commercialize our future products successfully, alone or with collaborators, will depend in part on the extent to which coverage
and reimbursement for the products will be available from government and health administration authorities, private health insurers and
other third-party payers. The continuing efforts of the U.S., European, and foreign governments, insurance companies, managed care organizations
and other payers for health care services to contain or reduce health care costs may adversely affect our ability to set prices for our
products which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Specifically,
in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health
care system in ways that could affect our ability to sell our products profitably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
expect additional federal and state legislative proposals for health care reform, which could limit the prices that can be charged for
the products we develop and may limit our commercial opportunity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
continuing efforts of government and other third-party payers to contain or reduce the costs of health care through various means may
limit our commercial opportunity. It will be time-consuming and expensive for us to go through the process of seeking coverage and reimbursement
from Medicare, Medicaid, and other governmental health programs and from private payers. Our products may not be considered cost-effective,
and government and third-party private health insurance coverage and reimbursement may not be available to patients for any of our future
products or sufficient to allow us to sell our products on a competitive and profitable basis. Our results of operations could be adversely
affected by the Patient Protection and Affordable Care Act (the &ldquo;ACA&rdquo;), changes to the ACA, and by other health care reforms
that may be enacted or adopted in the future. In addition, increasing emphasis on managed care in the U.S. will continue to put downward
pressure on the pricing of pharmaceutical products. Cost-control initiatives could decrease the price that we or any potential collaborators
could receive for any of our future products and could adversely affect our ability to generate revenue in the U.S. market and maintain
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
may acquire other companies which could divert our management&rsquo;s attention, result in additional dilution to our shareholders and
otherwise disrupt our operations and harm our operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
may in the future seek to acquire businesses, products, or technologies that we believe could complement or expand our product offerings,
enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention
of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not
they are consummated. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies
successfully, effectively manage the combined business following the acquisition or realize anticipated cost savings or synergies. We
also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">incurrence
    of acquisition-related costs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">diversion
    of management&rsquo;s attention from other business concerns;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">unanticipated
    costs or liabilities associated with the acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">harm
    to our existing business relationships with collaboration partners as a result of the acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">harm
    to our brand and reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    potential loss of key employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">use
    of resources that are needed in other parts of our business; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">use
    of substantial portions of our available cash to consummate the acquisition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results arising from
the impairment assessment process. Acquisitions may also result in dilutive issuances of equity securities or the incurrence of debt,
which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business,
results of operations and financial condition may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risks
Related to Development and Regulatory Approval of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results
of clinical trials are open to differing interpretations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Clinical
trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results
differently than us. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates
are expected to continue for several years and may take significantly longer to complete. In addition, we, the FDA, or other regulatory
authorities, including state and local authorities, or an Institutional Review Board, or IRB, with respect to a trial at its institution,
may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular
clinical trial to continue for a longer duration than originally planned, require a change to our development plans such that we conduct
clinical trials for a product candidate in a different order, e.g., in a step-wise fashion rather than running two trials of the same
product candidate in parallel, or the DEA could suspend or terminate the registrations and quota allotments we require in order to procure
and handle controlled substances, for various reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness of any product candidate during clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy,
    insufficient efficacy, fatigue with the clinical trial process or for any other reason;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    evolving effects of the COVID-19 pandemic;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">inadequacy
    of or changes in our manufacturing process or product formulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">delays
    in obtaining regulatory authorization to commence a trial, including &ldquo;clinical holds&rdquo; or delays requiring suspension
    or termination of a trial by a regulatory agency, such as the FDA, before or after a trial is commenced;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature, or timing of studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">uncertainty
    regarding proper dosing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">unfavorable
    results from ongoing pre-clinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">failure
    of our contract research organizations, or CROs, or other third-party contractors to comply with all contractual requirements or
    to perform their services in a timely or acceptable manner;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials or the handling, storage, security, and recordkeeping;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">scheduling
    conflicts with participating clinicians and clinical institutions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">failure
    to design appropriate clinical trial protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">insufficient
    data to support regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">inability
    or unwillingness of medical investigators to follow our clinical protocols; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
of the foregoing could have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are subject to extensive regulation by U.S. federal and state governments in each of the markets where we have product candidates progressing
through the approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
must also adhere to all regulatory requirements including FDA&rsquo;s Good Laboratory Practice, Good Clinical Practice, and current Good
Manufacturing Practices requirements (&ldquo;cGMP&rdquo;) pharmacovigilance requirements, advertising, and promotion restrictions, reporting
and recordkeeping requirements. If we or our suppliers fail to comply with applicable regulations, including FDA pre-or post-approval
cGMP requirements, then FDA could sanction us. Even if a drug is FDA-approved, regulatory authorities may impose significant restrictions
on a product&rsquo;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing trials. TELOMIR-1,
and any of our product candidates that may be approved in the U.S. in the future, will be subject to ongoing regulatory requirements
for manufacturing, labeling, packaging, storage, distribution, import, export, advertising, promotion, sampling, recordkeeping and submission
of safety and other post-market information, including both federal and state requirements in the U.S. In addition, manufacturers and
manufacturers&rsquo; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing
procedures conform to GMP. As such, we, and our contract manufacturers (in the event contract manufacturers are appointed in the future)
are subject to continual review and periodic inspections to assess compliance with GMP. Accordingly, we and others with whom we work
must continue to spend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, quality control
and quality assurance. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and
to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription
drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&rsquo;s
approved label.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product,
it may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply
with applicable regulatory requirements, a regulatory agency or enforcement authority may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">issue
    untitled or warning letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">seek
    to enjoin our activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">impose
    civil or criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">suspend
    regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">suspend
    any of our ongoing clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">refuse
    to approve pending applications or supplements to approved applications submitted by us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">impose
    restrictions on our operations, including by requiring us to enter into a Corporate Integrity Agreement or closing our contract manufacturers&rsquo;
    facilities, if any; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">seize
    or detain products or require a product recall.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, any government investigation of alleged violations of law could require us to expend significant time and resources in response
and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect
our ability to commercialize and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval
is withdrawn, the value of our business and our operating results may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&rsquo;s attention from the operation of our business and damage our reputation. We expend significant resources
on compliance efforts and such expenses are unpredictable and might adversely affect our results. Changing laws, regulations and standards
might also create uncertainty, higher expenses and increase insurance costs. As a result, we intend to invest all reasonably necessary
resources to comply with evolving standards, and this investment might result in increased management and administrative expenses and
a diversion of management time and attention from revenue-generating activities to compliance activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are subject to federal and state healthcare laws and regulations and implementation of or changes to such healthcare laws and regulations
could adversely affect our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the United States, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could
impact our ability to sell our product candidates. If we are found to be in violation of any of these laws or any other federal or state
regulations, we may be subject to administrative, civil and/or criminal penalties, damages, fines, individual imprisonment, exclusion
from federal health care programs and the restructuring of our operations. Any of these could have a material adverse effect on our business
and financial results. Since many of these laws have not been fully interpreted by the courts, there is an increased risk that we may
be found in violation of one or more of their provisions. Any action against us for violation of these laws, even if we ultimately are
successful in our defense, will cause us to incur significant legal expenses and divert our management&rsquo;s attention away from the
operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we may receive for any approved product. There have been judicial challenges
to certain aspects of the ACA and numerous legislative attempts to repeal and/or replace the ACA in whole or in part, and we expect there
will be additional challenges and amendments to the ACA in the future. At this time, the full effect that the ACA will have on our business
in the future remains unclear. An expansion in the government&rsquo;s role in the U.S. healthcare industry may cause general downward
pressure on the prices of prescription drug products, lower reimbursements, or any other product for which we obtain regulatory approval,
reduce product utilization, and adversely affect our business and results of operations. Any reduction in reimbursement from Medicare
or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize products
for which we may receive regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>The
regulatory approval processes with the FDA are lengthy and inherently unpredictable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are not permitted to market our drug candidates as medicines in the United States or other countries until we receive approval of a New
Drug Application (&ldquo;NDA&rdquo;) from the FDA or in any foreign countries until we receive the approval from the regulatory authorities
of such countries. Prior to submitting an NDA to the FDA for approval of our drug candidates we will need to have completed our pre-clinical
studies and clinical trials and demonstrate that our products meet all applicable standards of identity, strength, quality, and purity
throughout their expiration date. Successfully completing any clinical program and obtaining approval of an NDA is a complex, lengthy,
expensive, and uncertain process, and the FDA (or other country medicines regulatory body) may delay, limit, or deny approval of product
candidates for many reasons, including, among others, because:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">an
    inability to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction of the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">results
    of clinical trials that may not meet the level of statistical or clinical significance required by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">disagreements
    with the FDA with respect to the number, design, size, conduct or implementation of clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">requirements
    by the FDA to conduct additional clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">disapproval
    by the FDA of certain formulations, labeling or specifications of product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">findings
    by the FDA that the data from pre-clinical studies and clinical trials are insufficient;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">findings
    by the FDA that our API or finished products do not meet all applicable standards of identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    FDA may disagree with the interpretation of data from pre-clinical studies and clinical trials; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    FDA may change their approval policies or adopt new regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
of these factors, many of which are beyond our control, could increase development time and / or costs or jeopardize our ability to obtain
regulatory approval for our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>There
is a high rate of failure for drug candidates proceeding through clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Generally,
there is a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, FDA may disagree with our
interpretation of the data. In the event that we obtain negative results from clinical trials for product candidates or other problems
related to potential chemistry, manufacturing and control issues or other hurdles occur and our product candidates are not approved,
we may not be able to generate sufficient revenue or obtain financing to continue our operations, our ability to execute on our current
business plan may be materially impaired, our reputation in the industry and in the investment community might be significantly damaged
and the price of our common stock could decrease significantly. In addition, our inability to properly design, commence and complete
clinical trials may negatively impact the timing and results of our clinical trials and ability to seek approvals for our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If
we are found in violation of federal or state &ldquo;fraud and abuse&rdquo; laws, we may be required to pay a penalty and/or be suspended
from participation in federal or state health care programs, which may adversely affect our business, financial condition, and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the United States, we are subject to various federal and state health care &ldquo;fraud and abuse&rdquo; laws, including anti-kickback
laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect
us particularly upon successful commercialization of our products in the U.S. The Medicare and Medicaid Patient Protection Act of 1987,
or federal Anti-Kickback Statute, makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its
behalf), to knowingly and wilfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of
business, including the purchase, order or prescription of a particular drug for which payment may be made under a federal health care
program, such as Medicare or Medicaid. Under federal law, some arrangements, known as safe harbors, are deemed not to violate the federal
Anti-Kickback Statute. Although we seek to structure our business arrangements in compliance with all applicable requirements, it is
often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices
may be challenged under the federal Anti-Kickback Statute and Federal False Claims Act. Violations of fraud and abuse laws may be punishable
by criminal and/or civil sanctions, including fines and/or exclusion or suspension from federal and state health care programs such as
Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring
actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Many
states have adopted laws similar to the federal anti-kickback statute, some of which apply to the referral of patients for health care
services reimbursed by any source, not just governmental payers. There are ambiguities as to what is required to comply with these state
requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Neither
the government nor the courts have provided definitive guidance on the application of fraud and abuse laws to our business. Law enforcement
authorities are increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these
laws. While we believe we have structured our business arrangements to comply with these laws, it is possible that the government could
allege violations of, or convict us of violating, these laws. If we are found in violation of one of these laws, we could be required
to pay a penalty and could be suspended or excluded from participation in federal or state health care programs, and our business, results
of operations and financial condition may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Serious
adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates,
limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already
marketed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
any of our product candidates prior to or after any approval for commercial sale, cause serious or unexpected side effects, or are associated
with other safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">regulatory
    authorities may interrupt, delay or halt clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">regulatory
    authorities may deny regulatory approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) in
    connection with approval or post-approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require us
    to recall any product that is approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    may be required to change the way the product is administered or conduct additional clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    relationships with our collaboration partners may suffer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    could be sued and held liable for harm caused to patients; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    reputation may suffer. The reputational risk is heightened with respect to those of our product candidates that are being developed
    for pediatric indications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants
or if preliminary data demonstrate that our product candidates are unlikely to receive regulatory approval or unlikely to be successfully
commercialized. Following receipt of approval for commercial sale of a product we may voluntarily withdraw or recall that product from
the market if at any time we believe that its use, or a person&rsquo;s exposure to it, may cause adverse health consequences or death.
To date we have not withdrawn, recalled, or taken any other action, voluntary or mandatory, to remove an approved product from the market.
In addition, regulatory agencies, IRBs, or data safety monitoring boards may at any time recommend the temporary or permanent discontinuation
of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are
not being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to participants.
Although we have never been asked by a regulatory agency, IRB, or data safety monitoring board to discontinue a clinical trial temporarily
or permanently, if we elect or are forced to suspend or terminate a clinical trial of any of our product candidates, the commercial prospects
for that product will be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore,
any of these events may result in labeling statements such as warnings or contraindications. In addition, such events or labeling
could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase
the costs of commercializing our product candidates and impair our ability to generate revenue from the commercialization of these products
either by us or by our collaboration partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risks
Related to Our Reliance Upon Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
may seek additional collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization
of our product candidates. We may, with respect to our product candidates, enter into new arrangements on a selective basis depending
on the merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration arrangements with
leading pharmaceutical or biotechnology companies for each product candidate, both in the U.S. and internationally. To the extent that
we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators and the terms
of any collaboration or other arrangements that we may establish may not be favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
existing or future collaboration that we enter may not be successful. The success of our collaboration arrangements will depend heavily
on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and
resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding development,
intellectual property, regulatory or commercialization matters can lead to delays in the development process or commercialization of
the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult
to resolve if neither of the parties has final decision-making authority. Any such termination or expiration could harm our business
reputation and may adversely affect us financially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
depend on a limited number of suppliers for materials and components required to manufacture our product candidates. The loss of these
suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely affect
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
depend on a limited number of suppliers for the materials and components required to manufacture our product candidates. As a result,
we may not be able to obtain sufficient quantities of critical materials and components in the future. A delay or interruption by our
suppliers may also harm our business, results of operations and financial condition. In addition, the lead time needed to establish a
relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new
supplier. The time and effort to qualify for and, in some cases, obtain regulatory approval for a new supplier could result in additional
costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Our dependence
on single-source suppliers exposes us to numerous risks, including the following: our suppliers may cease or reduce production or deliveries,
raise prices or renegotiate terms; our suppliers may become insolvent or cease trading; we may be unable to locate a suitable replacement
supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our
customers and cause them to turn to our competitors for future needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
maintain our cash at financial institutions, at times in balances that exceed federally insured limits. The failure of financial institutions
could adversely affect our ability to pay operational expenses or make other payments.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
cash held in non-interest-bearing and interest-bearing accounts can at times exceed the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;)
insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance
limitations. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&rsquo;
access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in
the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability
to pay our operational expenses or make other payments, which could adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary
rights of others. We may rely upon a combination of patents, trade secret protection (i.e., know-how), trademarks, licenses, and confidentiality
agreements to protect the intellectual property of our product candidates. The strengths of patents in the pharmaceutical field involve
complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects of our
products and technology. However, patent protection for naturally occurring compounds is exceedingly difficult to obtain, defend and
enforce. Filing, prosecuting and defending patents throughout the world would be prohibitively expensive, so our policy is to look to
patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection
may not be available for some of the products or technology we are developing. If we must spend significant time and money protecting,
defending, or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other
proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may not develop additional
proprietary products that are patentable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
patent positions of pharmaceutical products are complex and uncertain. Although we have sought and expect to continue to seek patent
protection for our product candidates, their methods of use, and methods of manufacture, any, or all of them may not be subject to effective
patent protection. If any of our products are approved and marketed for an indication for which we do not have an issued patent, our
ability to use our patents to prevent a competitor from commercializing a non-branded version of our commercial products for that non-patented
indication could be significantly impaired or even eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Publication
of information related to our product candidates by us, or others may prevent us from obtaining or enforcing patents relating to these
products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or may design
around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable. If we fail
to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product to compete
with our product candidates. We may also face competition from companies who develop a substantially similar product to one of our product
candidates that is not covered by any of our patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Currently,
we do not own the rights to the technology used to commercially develop our lead product candidate, TELOMIR-1. MIRALOGX, which is a separate
intellectual property development company owned by a trust established by the Company&rsquo;s founder and largest stockholders and affiliates
thereof, holds the patent rights to TELOMIR-1, which are currently comprised of a pending U.S. provisional patent application. We have
an exclusive, license from MIRALOGX to develop and commercialize TELOMIR-1 in the U.S. for human applications. The term of the license
will continue through the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration of the
last strategic partnership/sublicensing agreement covering the licensed products. The licensed patent rights are expected to extend through
2043. We expect additional patent terms may b awarded, including additional patent terms based on the time for regulatory review of drug
products. We are also required to pay an 8% royalty on net sales or revenue in exchange for an exclusive, worldwide license to patent
rights, and we may bring suit in our own name to enforce our patent rights under the license agreement. In the event we are unable to
enforce our rights under the agreement or are unable to detect unauthorized use of our intellectual property, we may lose the benefit
of the licensed rights used to commercially develop TELOMIR-1. MIRALOGX will control the prosecution of the patent applications for TELOMIR-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If
third parties claim that the Company&rsquo;s intellectual property, products, processes, or anything else used by us infringes upon their
intellectual property, our operating profits could be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights,
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time consuming to defend and divert management&rsquo;s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disclosure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that our product candidates, or our commercialization thereof, does not and will not infringe any third party&rsquo;s intellectual
property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
have been granted a license to the right to develop TELOMIR-1 in the United States in human application, but we have not been granted
a license to the rights to patents covering TELOMIR-1 in foreign jurisdictions and have not been granted rights in non-human applications.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have been granted a license to the right to develop TELOMIR-1 in the United States but not in countries outside the United States, as
MIRALOGX has retained all rights outside the United States and may license such rights to other parties. Accordingly, MIRALOGX potentially
could develop a competing product for such jurisdictions outside of the United States. Additionally, our license rights to TELOMIR-1
extend only to human applications and do not extend to animal application or other non-human applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Risks
Relating to our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Because
of the speculative nature of investment risk, you may lose your entire investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">An
investment in our securities carries a high degree of risk and should be considered as a speculative investment. We have a limited operating
history, no revenues, have not paid dividends, and are unlikely to pay dividends in the immediate or near future. The likelihood of our
success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection
with the establishment of any business. An investment in our securities may result in the loss of an investor&rsquo;s entire investment.
Only potential investors who are experienced in high-risk investments and who can afford to lose their entire investment should consider
an investment in our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>The
requirements of being a public company may strain our resources, divert management&rsquo;s attention and affect our ability to attract
and retain executive management and qualified board members.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a reporting issuer, we will be subject to the reporting requirements of applicable securities legislation of the jurisdiction in which
it is a reporting issuer, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these
rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or
costly and increase demand on its systems and resources. Applicable securities laws will require us to, among other things, file certain
annual and quarterly reports with respect to its business and results of operations. In addition, applicable securities laws require
us to, among other things, maintain effective disclosure controls and procedures and internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
order to maintain and, if required, improve its disclosure controls and procedures and internal control over financial reporting to meet
this standard, significant resources and management oversight are required. Specifically, due to the increasing complexity of its transactions,
it is anticipated that we will improve our disclosure controls and procedures and internal control over financial reporting primarily
through the continued development and implementation of formal policies, improved processes and documentation procedures, as well as
the continued sourcing of additional finance resources. As a result, management&rsquo;s attention may be diverted from other business
concerns, which could harm our business and results of operations. To comply with these requirements, we may need to hire more employees
in the future or engage outside consultants, which will increase its costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations
and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty
regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to
continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general
and administrative expenses and a diversion of management&rsquo;s time and attention from revenue-generating activities to compliance
activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing
bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us,
which could adversely affect our business and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a public company subject to these rules and regulations, we may find it more expensive for it to obtain director and officer liability
insurance, and it may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could
also make it more difficult for us to attract and retain qualified members of its Board, particularly to serve on its Audit Committee
and Compensation Committee, and qualified executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a result of disclosure of information in filings required of a public company, our business and financial condition will become more
visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful,
our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in its favor,
these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm its business
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are an &ldquo;emerging growth company&rdquo; and any decision on our part to comply only with certain reduced reporting and disclosure
requirements applicable to emerging growth companies could make shares of our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act. For as long as we continue to be an emerging
growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies
that are not emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting
firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth
company until the fifth anniversary of the fiscal year end date following the completion of this offering, however, our status would
change more quickly if we have more than US$1.235 billion in annual revenue, if the market value of our shares of common stock held by
non-affiliates equals or exceeds US$700 million as of June 30 of any year, or we issue more than US$1.0 billion of non-convertible debt
over a three-year period before the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Investors
could find our shares less attractive if we choose to rely on these exemptions. If some investors find shares less attractive as a result
of any choice to reduce future disclosure, there may be a less active trading market for our shares and our share price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
as long as we are an &ldquo;emerging growth company&rdquo;, our independent registered public accounting firm will not be required to
attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We could be an &ldquo;emerging
growth company&rdquo; until the fifth anniversary of the fiscal year end date following the completion of this offering. An independent
assessment of the effectiveness of our internal controls could detect problems that our management&rsquo;s assessment might not. Undetected
material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
we identify material weaknesses in our internal control over financial reporting, or if we are unable to comply with the requirements
of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered
public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting when
required, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities
could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed,
the SEC, or other regulatory authorities, which could require additional financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>We
are a &ldquo;smaller reporting company&rdquo; and, even if we no longer qualify as an emerging growth company, we may still be subject
to reduced reporting requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Additionally,
we are a &ldquo;smaller reporting company&rdquo; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30<SUP>th</SUP>; or (ii) our annual
revenues did not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure
obligations, it may also make the comparison of our financial statements with other public companies difficult or impossible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Our
management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways
that increase the value of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
management will have broad discretion over the use of our net proceeds from this offering and you will be relying on the judgment of
our management regarding the application of these proceeds. Our management might not use our net proceeds in ways that ultimately increase
the value of your investment. We expect to use the net proceeds from this offering to advance the clinical development of our programs,
to fund our research and development activities and to fund working capital and for general corporate purposes. Our management might
not be able to yield a significant return, if any, on any investment or use of these net proceeds. You will not have the opportunity
to influence the decision on how to use the net proceeds from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If
we fail to maintain compliance with Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading
market for our shares and make obtaining future debt or equity financing more difficult for the Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
intend to apply to have shares of our common stock sold in this offering listed on the Nasdaq under the symbol &ldquo;TELO&rdquo;. However,
there is no assurance that we will be able to continue to maintain our compliance with the Nasdaq continued listing requirements. If
we fail to do so, our securities may be de-listed and cease trading on Nasdaq. As a result, selling our securities could be more difficult
because smaller quantities of shares or warrants would likely be bought and sold, transactions could be delayed, and security analysts&rsquo;
coverage of us may be reduced. In addition, in the event our securities are delisted, broker-dealers would face certain regulatory requirements
which may discourage them from effecting transactions in the securities and further limit the liquidity of the securities. These factors
could result in lower prices and larger spreads in the bid and ask prices for the securities. Such delisting from Nasdaq and continued
or further declines in the share price of the securities could also greatly impair our ability to raise additional necessary capital
through equity or debt financing and could significantly increase the ownership dilution to shareholders caused by our issuing equity
in financing or other transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If
our shares were to be delisted from Nasdaq, they may become subject to the SEC&rsquo;s &ldquo;penny stock&rdquo; rules.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Delisting
from Nasdaq may cause the securities of the Company to become subject to the SEC&rsquo;s &ldquo;penny stock&rdquo; rules. The SEC generally
defines a penny stock as an equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00
per share, and that is not listed on a national securities exchange, such as Nasdaq subject to certain exemptions. Therefore, if shares
of our common stock were to be delisted from Nasdaq, the securities of the Company could become subject to the SEC&rsquo;s &ldquo;penny
stock&rdquo; rules. These rules require, among other things, that any broker engaging in a purchase or sale of our securities provide
its customers with: (i) a risk disclosure document, (ii) disclosure of market quotations, if any, (iii) disclosure of the compensation
of the broker and its salespersons in the transaction, and (iv) monthly account statements showing the market values of our securities
held in the customer&rsquo;s accounts. A broker would be required to provide the bid and offer quotations and compensation information
before effecting the transaction. This information must be contained in the customer&rsquo;s confirmation. Generally, brokers are less
willing to effect transactions in penny stocks due to these additional delivery requirements. These requirements may make it more difficult
for shareholders to purchase or sell the shares of our common stock. Since the broker, not us, prepares this information, we would not
be able to assure that such information is accurate, complete or current.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
you purchase shares in this offering, the value of your shares based on our actual book value will immediately be less than the price
you paid. This reduction in the value of your equity is known as dilution. This dilution occurs in large part because our existing stockholders
paid less than the assumed public offering price when they acquired their shares of common stock. Based upon the issuance and sale of
[&#9679;] shares of common stock by us in this offering at an assumed public offering price of $[&#9679;] per share, you will incur immediate
dilution of in the net tangible book value per share. If the underwriters exercise their over-allotment option, or if outstanding options
to purchase shares of our common stock are exercised, investors will experience additional dilution. For more information, see &ldquo;Dilution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>There
is no existing market for our securities and we do not know if one will develop to provide you with adequate liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Prior
to this offering, there has not been a public market for our securities. We cannot assure you that an active trading market for shares
of our common stock will develop following this offering, or if it does develop, it may not be maintained. You may not be able to sell
your shares of our common stock quickly or at the market price if trading in our securities is not active. The initial public offering
price for the shares of common stock offered hereby will be determined by negotiations between us and the underwriter and may not be
indicative of prices that will prevail in the trading market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some
provisions of Florida law and our amended and restated articles of incorporation and amended and restated bylaws that will be in effect
immediately prior to the completion of this offering may have anti-takeover effects that could discourage an acquisition of us by others,
even if an acquisition would be beneficial to our shareholders, and may prevent attempts by our shareholders to replace or remove our
current management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, our status as a Florida corporation and the anti-takeover provisions of the Florida Business Corporation
Act, which we sometimes refer to as the FBCA, may discourage, delay or prevent a change in control even if a change in control would
be beneficial to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control share acquisition statute, Section 607.0902 of the FBCA, generally provides that in the event a person acquires voting shares
of the company in excess of 20% of the voting power of all of our issued and outstanding shares, such acquired shares will not have any
voting rights unless such rights are restored by the holders of a majority of the votes of each class or series entitled to vote separately,
excluding shares held by the person acquiring the control shares or any of our officers or employees who are also directors of the company.
Certain acquisitions of shares are exempt from these rules, such as shares acquired pursuant to the laws of intestate succession or pursuant
to a gift or testamentary transfer, pursuant to a merger or share exchange effected in compliance with the FBCA if we are a party to
the agreement, or pursuant to an acquisition of our shares if the acquisition has been approved by our board of directors before the
acquisition. The control share acquisition statute generally applies to any &ldquo;issuing public corporation,&rdquo; which means a Florida
corporation which has:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    hundred or more shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
    principal place of business, its principal office, or substantial assets within Florida; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    (i) more than 10% of its shareholders are resident in Florida; (ii) more than 10% of its shares are owned by residents of Florida;
    or (iii) one thousand shareholders are resident in Florida.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affiliated transaction (or so-called &ldquo;business combination&rdquo;) statute, Section 607.0901 of the FBCA, provides that we may
not engage in certain mergers, consolidations, sales of assets, issuances of stock, reclassifications, recapitalizations, and other affiliated
transactions with any &ldquo;interested shareholder&rdquo; for a period of three years following the time that such shareholder became
an interested shareholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to the time that such shareholder became an interested shareholder, our board of directors approved either the affiliated transaction
    or the transaction which resulted in the shareholder becoming an interested shareholder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;interested shareholder&rdquo; is generally defined as any person who is the beneficial owner of more than 15% of our outstanding
voting shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
voting requirements set forth above do not apply to a particular affiliated transaction if one or more conditions are met, including,
but not limited to, the following: if the affiliated transaction has been approved by a majority of our disinterested directors; if we
have not had more than 300 shareholders of record at any time during the three years preceding the date the affiliated transaction is
announced; if the interested shareholder has been the beneficial owner of at least 80% of our outstanding voting shares for at least
three years preceding the date the affiliated transaction is announced; or if the consideration to be paid to the holders of each class
or series of voting shares in the affiliated transaction meets certain requirements of the statute with respect to form and amount, among
other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the control share acquisition statute and the affiliated transactions statute may have the effect of discouraging or preventing certain
change of control or takeover transactions involving us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our amended and restated articles of incorporation and amended and restated bylaws that will be in effect immediately prior
to the completion of this offering contain provisions that may make it more difficult for a third party to acquire us or increase the
cost of acquiring us, even if doing so would benefit our shareholders, including transactions in which shareholders might otherwise receive
a premium for their shares. These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nothing
    in our amended and restated articles of incorporation precludes future issuances without shareholder approval of the authorized but
    unissued shares of our common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    notice procedures apply for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting
    of shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    special meeting of shareholders can only be called by our chairman of the board of directors, our chief executive officer, our president
    (in the absence of a chief executive officer), a majority of our board of directors or the holders of 10% or more of all of our votes
    entitled to be cast on any issue proposed to be considered at the special meeting of shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    provision in our amended and restated articles of incorporation or amended and restated bylaws provides for cumulative voting, which
    limits the ability of minority shareholders to elect director candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directors
    will only be able to be removed for cause;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    amended and restated articles of incorporation authorizes undesignated preferred stock, the terms of which may be established and
    shares of which may be issued, without the approval of the holders of our capital stock; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    litigation against us can only be brought in Florida.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also
discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us
to take corporate actions other than those you desire. See &ldquo;Description of Capital Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
amended and restated bylaws that will be in effect immediately prior to the completion of this offering designates the state courts located
within the state of Florida as the exclusive forum for substantially all disputes between us and our shareholders and the federal district
courts as the exclusive forum for Securities Act claims, which could limit our shareholders&rsquo; ability to obtain a favorable judicial
forum for disputes with us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws that will be in effect immediately prior to the completion of this offering provide that, unless we consent
in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought
on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers
or other employees to us or our shareholders, (iii) any action arising pursuant to any provision of the FBCA, our amended and restated
articles of incorporation or our amended and restated bylaws, or (iv) any other action asserting a claim that is governed by the internal
affairs doctrine shall be a state court located within the state of Florida (or, if a state court located within the state of Florida
does not have jurisdiction, the federal district court for the Middle District of Florida); provided that, the exclusive forum provision
will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or to any claim for which the federal courts
have exclusive jurisdiction. Our amended and restated bylaws that will be in effect immediately prior to the completion of this offering
also provide that, unless we consent in writing to the selection of an alternative forum, the U.S. federal district courts shall be the
exclusive forum for the resolution of any claims arising under the Securities Act. Under the Securities Act, federal and state courts
have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot
waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether
a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
becoming a shareholder in our company, you will be deemed to have notice of and have consented to the provisions of our amended and restated
bylaws related to choice of forum. The choice of forum provisions in our amended and restated bylaws may limit our shareholders&rsquo;
ability to obtain a favorable judicial forum for disputes with us. Additionally, the enforceability of choice of forum provisions in
other companies&rsquo; governing documents has been challenged in legal proceedings, and it is possible that, in connection with any
applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated bylaws
to be inapplicable or unenforceable in such action. If so, we may incur additional costs associated with resolving such action in other
jurisdictions, which could harm our business, results of operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Securities
or industry analysts may not regularly publish reports on us, which could cause the price of our securities or trading volumes to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our securities could be influenced by research and reports that industry and/or securities analysts may publish us,
our business, the market or our competitors. We do not have any control over these analysts and cannot be assured that such analysts
will cover us or provide favorable coverage. If any of the analysts who may cover our business change their recommendation regarding
our securities adversely, or provide more favorable relative recommendations about our competitors, the price of our securities would
likely decline. If any analysts who may cover our business were to cease coverage or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which in turn could cause the price of our securities or trading volumes to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will likely conduct further offerings of our equity securities in the future, in which case your proportionate interest may become diluted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will likely be required to conduct equity offerings in the future to finance our current projects or to finance subsequent projects that
we decide to undertake. If our common stock shares are issued in return for additional funds, the price per share could be lower than
that paid by our current shareholders. We anticipate continuing to rely on equity sales of our common stock shares in order to fund our
business operations. If we issue additional common stock shares or securities convertible into shares of our common stock, your percentage
interest in us could become diluted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise
adversely affect holders of our common stock, which could depress the price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes us to issue one or more series of preferred stock. Our board of directors will have the authority
to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting
any series and the designation of such series, without any further vote or action by our shareholders. Our preferred stock could be issued
with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock
may delay or prevent a change in control of us, discouraging bids for our common stock at a premium to the market price, and materially
adversely affect the market price and the voting and other rights of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never declared or paid any cash dividends or distributions on our capital stock. We do not anticipate paying any cash dividends
on our common stock in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain our future earnings,
if any, to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our common stock
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
declaration, payment and amount of any future dividends will be made at the discretion of the board of directors, and will depend upon,
among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other
factors as the board of directors considers relevant. There is no assurance that future dividends will be paid, and, if dividends are
paid, there is no assurance with respect to the amount of any such dividend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_001"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to us from the sale of shares of common stock by us in this offering will be approximately $[&#9679;] million, assuming
an initial public offering price of $[&#9679;] per share (the midpoint of the range set forth on the cover of this prospectus), and after
deducting underwriting discounts and commissions and estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $[&#9679;] million to advance our clinical development programs, including:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $[&#9679;] million to fund our preclinical animal toxicology studies and CMC activities,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $[&#9679;] million for expenses associated with our initial IND application, and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $[&#9679;] million for expenses relating to our Phase I clinical trials for Telomir-1; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    remaining amounts to fund working capital and general corporate purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operating plan, we believe that the net proceeds of this offering, together with our existing cash and cash equivalents,
will be sufficient to fund our development and research activities through [&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot specify with certainty the particular uses of the net proceeds that we will receive from this offering or the amounts we actually
spend on the uses set forth above. Pending the use of proceeds from this offering as described above, we plan to invest the net proceeds
that we receive in this offering in short-term and intermediate-term interest-bearing obligations, investment-grade investments, certificates
of deposit or direct or guaranteed obligations of the U.S. government. Our management will have broad discretion in the application of
the net proceeds from this offering and investors will be relying on the judgment of our management regarding the application of the
proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_002"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid dividends on our capital stock. We currently intend to retain all available funds and future earnings, if
any, for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future.
Investors should not purchase our common stock with the expectation of receiving dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_003"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents, as well as our total capitalization, as of June 30, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an as adjusted basis to give effect to our issuance and sale of [&#9679;] shares of our common stock in this offering (assuming no
    exercise of the underwriters&rsquo; overallotment option) at an assumed initial public offering price of $[&#9679;] per share (the
    midpoint of the range set forth on the cover of this prospectus), and after deducting underwriting discounts and commissions and
    estimated offering expenses payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this table together with our financial statements and related notes and the section titled &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; that are included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    of June 30, 2023</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    Adjusted <SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party line of credit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    deficit:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock, no par value, 5,000,000 shares authorized and none issued or outstanding, actual: [&#9679;] shares authorized and none issued
    or outstanding, as adjusted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, no par value; 95,000,000 shares authorized, 55,549,451 issued and outstanding, actual; shares authorized and [&#9679;]
    shares issued and outstanding, as adjusted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; deficit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    capitalization</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    $1.00 increase or decrease in the assumed initial public offering price per share of our common stock would increase or decrease
    each of cash, additional paid-in-capital and total capitalization on an as adjusted basis by approximately $[&#9679;], assuming the
    number of shares of our common stock offered by us remains the same and after deducting the estimated underwriting discounts and
    commissions and offering expenses payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_004"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the public offering price per share of our common stock and the pro forma net tangible book value per share of our common stock
immediately after this offering. Dilution in pro forma net tangible book value per share to new investors represents the difference between
the amount per share paid by purchasers of shares of our common stock in this offering and the pro forma net tangible book value per
share of our common stock immediately after completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
tangible book value per share is determined by dividing our total tangible assets less our total liabilities and common stock in stockholders&rsquo;
equity (deficit) by the number of shares of our common stock outstanding. Our historical net tangible book value (deficit) as of June
30, 2023, was approximately $[&#9679;], or $[&#9679;] per share. After giving effect to the sale by us of shares of our common stock
in this offering at the assumed public offering price of $[&#9679;] per share, the midpoint of the price range per share, and after deducting
underwriting discounts and commissions, and estimated offering expenses payable by us, our pro forma net tangible book value as of June
30, 2023, would have been $[&#9679;] million, or $[&#9679;] per share. This represents an immediate increase in pro forma net tangible
book value of $[&#9679;] per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of $[&#9679;]
per share to investors purchasing shares of our common stock in this offering. The following table illustrates this dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price per share of common stock</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value (deficit) per share as of June 30, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    per share attributable to new investors purchasing shares of common stock in this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma net tangible book value per share immediately after this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    in pro forma net tangible book value per share to new common stock investors in this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents, on a pro forma basis as of June 30, 2023, after giving effect to the sale by us of shares of our common stock
in this offering at the assumed offering price of $[&#9679;] per share, the difference between the directors, officers and their affiliates
and the new investors purchasing shares of our common stock in this offering with respect to the number of shares of our common stock
purchased from us, the total consideration paid or to be paid to us, and the average price per share paid or to be paid to us by such
persons during the last five years and new investors, before deducting underwriting discounts and commissions and estimated offering
expenses payable by us:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    Purchased</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Consideration</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
    Price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($
    in millions)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
    officers and their affiliates</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the underwriters exercise in full their option to purchase [&#9679;] additional shares of our common stock from us in this offering,
the pro forma net tangible book value (deficit) per share after this offering would be $[&#9679;] per share and the dilution to new investors
in this offering would be $[&#9679;] per share. If the underwriters exercise such option in full, the number of shares held by new investors
will increase to approximately shares of our common stock, or approximately [&#9679;]% of the total number of shares of our common stock
outstanding after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase (decrease) in the assumed public offering price of $[&#9679;] per share would increase (decrease) the as-adjusted net
tangible book value per share by $[&#9679;], and the dilution per share to new investors in this offering by $[&#9679;], assuming the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have
sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity,
as common stock, or other securities that are convertible into our common stock, such as convertible debt securities, the issuance of
these securities could result in further dilution to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_005"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of
our results of operations and financial condition. You should read the following discussion and analysis of our results of operations
and financial condition together with our financial statements and related notes and other information included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations
that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of
various factors, including those set forth under &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;
included elsewhere in this prospectus. Additionally, our historical results are not necessarily indicative of the results that may be
expected for any period in the future.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule
being developed to function as a metal enzyme inhibitor. Our initial focus is to advance the clinical development of TELOMIR-1 in the
United States for the treatment of hemochromatosis and the treatment of the side effects associated with post-chemotherapy recovery in
cancer patients. We also intend to explore TELOMIR-1&rsquo;s broader potential, as we believe TELOMIR-1 may have potential in several
diseases associated with a range of metabolic and geriatric related conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had net losses of $0.9 million and $0.1 million for the years ended December 31, 2022 and December 31, 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supply
Chain Disruption / COVID-19 Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the residual impact of the global COVID-19 pandemic, we have taken measures to secure our research and development activities, while
work in laboratories and facilities has been organized to reduce the risk of COVID-19 transmission. The extent of the impact of the COVID-19
pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments,
including the duration and spread of the outbreak and its impact on our clinical trials, CROs, manufacturing process, supply chain, and
other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel.
While we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global
supply chains and the other risks and uncertainties associated with the pandemic, our business, financial condition, and results of operations
ultimately could be materially adversely affected. Some of our suppliers have experienced delays in securing critical raw materials;
while this has not materially impacted their services, we have observed delays in certain activities. Therefore, we continue to closely
monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of our Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research
and development costs as they are incurred. Research and development expenses consist primarily of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracted
    research and manufacturing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    arrangements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    expenses incurred to advance the Company&rsquo;s research and development activities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses have historically been the costs associated with our initial investment in pre-clinical research and development activities.
We expect research and development expenses will increase in the future as we advance Telomir-1 into and through clinical trials and
pursue regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support, and contract
manufacturing. In addition, we will evaluate opportunities to acquire or in-license additional product candidates and technologies, which
may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development
costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely
development and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be
affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we
are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue
from the commercialization and sale of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of administrative functions, as well as fees paid for legal, consulting fees and facilities costs
not otherwise included in research and development expense. Legal costs include general corporate legal fees and patent costs. We expect
to incur additional expenses as a result of becoming a public company, including expenses related to compliance with the rules and regulations
of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of Operations for years ended December 31, 2022 and 2021</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 11pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year ended December
31,</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 11pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating costs:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">General and administrative expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">20,941</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">11,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">833,206</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">126,492</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total operating costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">854,147</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">138,131</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 20pt; font-weight: bold; text-align: left">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(854,147</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(138,131</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses.</I></B> We incurred general and administrative expenses of $0.02 million during the year ended December
31, 2022, which consisted of consulting fees, office and rent expenses, and expenses related to compared to $0.01 million during the
year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses. </I></B>We incurred research and development expenses of $0.8 million during the year ended December 31, 2022,
compared to $0.1 million during the year ended December 31, 2021, as our contract research organizations (&ldquo;CROs&rdquo;) began substantive
pre-clinical efforts on Telomir-1. The increase in research and development expenses during 2022 compared to 2021 is due to the expansion
of pre-clinical programs during 2022. Major components of research and development expenses during 2022 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>R&amp;D
    Category</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expense</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toxicology</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.2
    million</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
    research</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4
    million</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
    consultants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.2
    million</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sources
of Liquidity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the Company&rsquo;s inception in August 2021, we have financed our operations primarily through an unsecured line of credit with a major
shareholder and an affiliated company and through a private placement of shares of our common stock that occurred during the first quarter
2023. We intend to finance our clinical development programs and working capital needs from existing cash, potential new sources of debt
and equity financing, including the proceeds from our anticipated initial public offering. We may enter into new licensing and commercial
partnership agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by our founder, Jonnie
R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan Agreement (the
&ldquo;Bay Shore Note&rdquo;), we have the right to borrow up to an aggregate of $5 million from the Bay Shore Trust at any time up to
the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of our IPO. Our right to borrow funds
under the Bay Shore Note is subject to the absence of a material adverse change in its assets, operations, or prospects. The Bay Share
Note, together with accrued interest, will become due and payable on the second anniversary of the issuance of the note, provided that
it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at a rate equal 7% per annum, simple interest,
during the first year that the note is outstanding and 10% per annum, simple interest, thereafter. The Bay Shore Note is unsecured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January 1, 2023, MIRALOGX, an intellectual property development and holding company owned by Bay Shore Trust, and The Starwood Trust,
a separate Trust established by our founder, have advanced funds on behalf of Bayshore Trust to our company in order to fund operating
activities. The total cumulative amount of such outstanding advances was $0.3 million as of March 31, 2023. The total amount advanced
and outstanding as of June 30, 2023, was $0.5 million. These advances were consolidated into the Bay Shore Note as of June 30, 2023,
and became payable under the terms of the Bay Shore Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, we issued to the Bay Shore Trust a common stock purchase warrant
on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 5,000,000 shares of common stock at an exercise price of $1.82
per share, which warrant will expire five years after the date of grant. Pursuant to a registration rights agreement, we have granted
to Bay Shore Trust the right to require our Company, at any time after one year following our IPO, to register for resale the shares
issuable upon the exercise of the warrant, with such registration rights being in the form of demand and &ldquo;piggyback&rdquo; registration
rights that are subject to customary limitations and restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we had cash of $0.001 million. In total, we have raised $1.0 million in 2023 through the issuance of equity. Substantially
all our equity capital has been raised at $1.82 per share. We used $0.5 million in operating activities during the year ended December
31, 2022, compared to $0.1 million in operating activities during the year ended December 31, 2021. We expect that our existing cash
and available line of credit, before our anticipated initial public offering, will be sufficient to finance our planned level of operations
through [&#9679;].&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commercializing or monetizing our product candidates, we anticipate that additional capital will be required to support ongoing activities
and further phases of development. Should that be required, our available capital may be consumed more rapidly than currently anticipated,
resulting in the need for additional funding. In addition, there can be no assurance that additional funding, when and if required, will
be available at commercially favorable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we may need to raise additional capital, which may be available to us through a variety of sources, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    equity markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">private
    equity financings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialization
    agreements and collaborative arrangements;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of product royalty;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grants
    and new license revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bank
    loans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    or private debt.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funding, capital, or loans (including, without limitation, milestone, or other payments from potential commercialization agreements)
may be unavailable on favorable terms, if at all. If adequate funds are not available, we may be required to significantly reduce or
refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain technologies and drug
formulations or potential markets, any of which could have a material adverse effect on us, our financial condition, and our results
of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities or exercise
of warrants and options, the issuance of such securities would result in ownership dilution to existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to attract additional funds on commercially acceptable terms, it may adversely affect our ability to achieve our development
and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
Flows</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding our cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from August 2021 (Inception)
    to December 31, 2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by (used in):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 52%; text-align: left">Operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(468,661</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(119,396</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">470,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">119,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Cash Used in Operating Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash used in operating activities resulted primarily from our net losses and changes in components of accounts payable and accrued liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
August 2021 (inception) to December 31, 2021, operating activities used $0.12 million of cash, primarily due to a net loss of $0.14 million,
offset by a $0.02 million in accounts payable and accrued liabilities. Accounts payable and accrued liabilities was composed of research
and development payables and accrued rent expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
year ended December 31, 2022, operating activities used $0.47 million of cash, primarily due to a net loss of $0.85 million, offset
by a $0.38 million change in accounts payable. Accounts payable was composed of research and development payables and rent
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Cash Provided by Financing Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
August 2021 (inception) to December 31, 2021, financing activities provided $0.12 million of cash, resulting from $0.12 million in amounts
due to a related party. Related party advances were used to pay research and development payables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
year ended December 31, 2022, financing activities provided $0.47 million of cash, resulting from $0.46 million in amounts due to a related
party, $0.06 million in collection of stock subscription receivable, offset by a $0.05 million in deferred offering costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
Funding Requirements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until
we successfully complete preclinical and clinical development of, receive regulatory approval for, and commercialize a program and we
do not know when, or if at all, that will occur. We expect our expenses to increase substantially in connection with our ongoing activities,
particularly as we advance the preclinical activities and studies and initiate clinical trials. In addition, if we obtain regulatory
approval for any programs, we expect to incur significant expenses related to product sales, marketing, and distribution to the extent
that such sales, marketing and distribution are not the responsibility of potential collaborators. Further, upon the completion of this
offering, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditure
will depend largely on the factors set out above. For more information, see the section titled &ldquo;Risk Factors-Risks Related to Our
Operations and Financial Condition.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the rate of progress in the development of our TELOMIR-1 program and other development programs&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the scope, progress, results and costs of preclinical studies and clinical trials for any other current and future
programs&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the number and characteristics of programs and technologies that we develop or may in-license&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of
our programs for which we receive marketing approval&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions,
and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is
obtained&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending any intellectual property-related claims&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the continuation of our existing licensing arrangements and entry into new collaborations and licensing
arrangements&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs we incur in maintaining business operations&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs of hiring additional clinical, quality control, manufacturing and other scientific personnel&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs adding operational, financial and management information systems and personnel&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the costs associated with being a public company&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the revenue, if any, received from commercial sales of our programs for which we receive marketing approval&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the effect of competing technological and market developments&#894; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or
collaboration arrangements for programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential programs, product candidates, conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our programs, if approved, may not achieve commercial success. Our commercial revenues, if any, will
be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need
to obtain substantial additional funds to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued and Adopted Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 1, 2022, we adopted
Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 842 ASC Topic 842, which is intended to improve financial reporting about
leasing transactions. Under the standard, organizations that lease assets, referred to as &ldquo;Lessees&rdquo; shall recognize on the
balance sheet the assets and liabilities for the rights and obligations created by those leases. In addition, the standard requires disclosures
including financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. We do not expect that
the adoption of Topic 842 will materially impact our Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under Generally Accepted
Accounting Principles (GAAP) and SEC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risks and inflation risks.
Periodically, we maintain deposits in accredited financial institutions in excess of the FDIC federally insured limits. We deposit our
cash in financial institutions that we believe have high credit quality and have not experienced any losses on such accounts and do not
believe we are exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest
Rate Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash consists of cash in readily available checking accounts. We may also invest in short-term money market fund investments. Such interest-earning
instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inflation
Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had
a material effect on our results of operations during the periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_006"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule
being developed to function as a metal enzyme inhibitor. Our initial focus is to advance the clinical development of TELOMIR-1 in the
United States for the treatment of hemochromatosis and the treatment of the side effects associated with post-chemotherapy recovery in
cancer patients. We also intend to explore TELOMIR-1&rsquo;s broader potential, as we believe TELOMIR-1 may have potential in several
diseases associated with a range of metabolic and geriatric related conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on pre-clinical studies, we believe that TELOMIR-1 has the potential to protect and lengthen telomeres in the human chromosome by reducing
the overload of iron and other metals that accompanies diseases like hemochromatosis and certain cancers. Telomeres are repetitive DNA
sequences at the end of chromosomes that protect the chromosomes from becoming frayed or tangled. Each time a cell divides, the telomeres
become slightly shorter, and eventually they become so short that the cell can no longer divide, with the result being that the cell
dies. Effectively, telomeres protect the ends of our chromosomes by forming a cap, much like the plastic tip on shoelaces, thereby allowing
the chromosome to be replaced properly during cell division.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
is under investigation to potentially provide a therapeutic intervention against hemochromatosis and cancer treatment side effects by
interrupting and preventing the enzymatic actions that create the systemic imbalance of cellular metals that allows elevated reactive
oxygen species to oxidize and erode the protective DNA telomere caps. Our preclinical studies suggest that TELOMIR-1 may selectively
affect the key processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis
and cancer. As illustrated in the graphic below, TELOMIR-1 may achieve this outcome by selectively binding to metal ions in a dose dependent
manner, slowing enzyme reactivity, and protecting and lengthening telomeres in the human chromosome. We believe that TELOMIR-1 has potential
as a non-toxic oral enzyme inhibitor that may regulate the overactivity of the enzymes caused by excessive metal reactivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> To
date, we have completed several pre-clinical proof-of-concept studies with respect to TELOMIR-1 that were designed to demonstrate that
TELOMIR-1 is not mutagenic and has good biological and metal binding capabilities. These studies included an Ames test for the TELOMIR-1
compound and several Eurofins BioMap studies. The Eurofins invitro studies showed that TELOMIR-1 was more active against malignant cells,
colorectal cancer cells, and lung cancer cells than rapamycin. Other studies showed that versus Doxycycline TELOMIR-1 was more active
at metal complexing. Extensive analysis is being conducted on the potential of TELOMIR-1 to reprogram stem cells and lower blood ferritin.
We have also completed a variety of toxicology studies, and several others are ongoing or planned. Upon completion of the toxicology
studies, we plan to submit to the FDA two separate Investigational New Drug applications, INDs for TELOMIR-1, with one focused on investigating
TELOMIR-1 for the treatment of hemochromatosis and the second for post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_002.jpg" ALT="A diagram of telomere formation&#10;&#10;Description automatically generated" STYLE="height: 349px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<U>Source</U>:
Rini, D. John Hopkins School of Medical Arts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporate in Florida in August 2021 for the purpose of pursuing the development and commercialization of TELOMIR-1 in the United
States in human applications. We were originally incorporated under the name &ldquo;Metallo Therapies Inc.&rdquo; and changed our name
to &ldquo;Telomir Pharmaceuticals, Inc.&rdquo; on October 10, 2022. Our rights to develop and commercialize TELOMIR-1 are licensed to
us under a license agreement with MIRALOGX under which we have the exclusive right to develop and commercialize TELOMIR-1 for human applications
in the United States. See &ldquo;&mdash;Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage company that had net losses of $0.1 million for the year ended December 31, 2021, and $0.9 million for year ended
December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hemochromatosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the CDC, hemochromatosis is a disorder in which the body builds up too much iron in the skin, heart, liver, pancreas, pituitary glands,
and joints. This overload of iron is toxic to the body, and over time, the high levels of iron can damage tissues and organs and lead
to conditions such as liver damage, liver cancer, heart problems, arthritis, and diabetes. Hemochromatosis is most commonly hereditary
and caused by certain variants in the HFE gene. In the U.S., about 1 in 300 non-Hispanic white persons have hereditary hemochromatosis,
with lower rates among other races and ethnicities. Hemochromatosis can also result in persons who need multiple blood transfusions,
which can lead to excess iron build up in a condition also referred to as &ldquo;iron overload.&rdquo; Other conditions associated with
high iron levels include inflammatory conditions, chronic kidney disease, and autoimmune disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemochromatosis
is a life-long condition requiring regular treatment to avoid long-term serious effects with poor pharmacologic options. The most used
treatment for hemochromatosis is phlebotomy, a procedure to remove some of the patient&rsquo;s blood. Phlebotomy is relatively inexpensive,
well accepted, and well tolerated, but it requires regular visits to health care professionals and blood draws and may not be appropriate
for all patients. Additionally, iron chelators are sometimes used, but they have limited use due to gastrointestinal and kidney toxicity
issues. Despite the presence of these potential treatment options, we believe significant unmet need remains such that an innovative
therapy achieving reduction in iron overload with a new profile could be subject to widespread use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pursuing TELOMIR-1 as a metal enzyme inhibitor that may selectively bind metal ions to inhibit enzymes and protect telomeres and
that aims to increase the average telomere length, or ATL, by selectively binding iron and reducing blood iron levels, therefore supporting
the ability to treat hemochromatosis. There is a sizeable patient population that requires management to avoid significant long-term
damage. Additionally, the current standard of care for the treatment of hemochromatosis is phlebotomy, and certain sub-groups may benefit
from TELOMIR-1 if contraindicated for this treatment method. Lastly, iron chelation is used off-label, poorly tolerated and has toxic
long-term effects. In preclinical stage testing, TELOMIR-1 is shown to have better metal complexing than Doxycycline, an FDA-approved
metalloproteinases (MMP) inhibitor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post-Chemotherapy
Recovery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-chemotherapy
recovery from adverse effects of antineoplastic treatments is often important for cancer therapy success. While chemotherapy treatment
can be highly effective for cancer, it can also come with many side effects, as chemotherapy drugs destroy both cancerous and healthy
cells. According to a study published in the British Journal of Clinical Pharmacology<SUP>1</SUP>, of approximately 650,000 patients
who use chemotherapy each year, only a fraction use drugs for side effects. Side effects and toxicity of chemotherapy lead to reduced
compliance, and therefore treating chemotherapy side effects can increase compliance. Common barriers center around the complexity of
post-chemotherapy side effects, obtaining reimbursement without significant outcomes, avoiding pauses, and/or delays in treatment due
to side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are investigating the use of TELOMIR-1 as a complementary treatment for patients receiving chemotherapy in the form of a twice daily,
oral regimen to reduce blood iron levels and inhibit metal enzyme activity, enabling better adherence and improved outcomes. In exploratory
early discovery studies, proof of concept was demonstrated, and the animal studies are pending. Post-chemotherapy recovery space contains
several treatments that are used symptomatically based on the nature or severity of side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that post-chemotherapy recovery presents several potential unmet commercial needs for TELOMIR-1. There is potential to enable
a more rapid recovery of patients receiving chemotherapy, improving adherence with chemotherapy regimens. Additionally, as current recovery
management is based on severity and treated as needed, we believe that TELOMIR-1 could potentially be used as a preventative measure.
As a complementary treatment, side effect reduction in post-chemotherapy is important to minimize patient burden while improving treatment
outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP><U>https://www.nih.gov/about-nih/what-we-do/impact-nih-research/improvinghealth/cancer#:~:text=At%20the%20time%20this%20was,oncology%20clinics%20in%20the%20U.S</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to develop and commercialize new treatment options for hemochromatosis and post-chemotherapy recovery as our initial clinical
focus and to thereafter expand the development of TELOMIR-1 to a broad range of other diseases and conditions. The key elements of our
strategy to achieve this goal include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advancing
                                            TELOMIR-1 through clinical development and approval for hemochromatosis and post-chemotherapy
                                            recovery. </I></B>Our product candidate, TELOMIR-1, is in pre-clinical studies. Existing
                                            treatment options for hemochromatosis and post-chemotherapy recovery have significant limitations,
                                            and, if approved, we believe TELOMIR-1 may represent a major therapeutic advancement for
                                            patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continuing
                                            pre-clinical development of TELOMIR-1 across a range of diseases associated with cellular
                                            aging. </I></B>Given the impact of telomere cap regrowth on a variety of age-related diseases,
                                            we intend to explore TELOMIR-1&rsquo;s broader potential, as we believe TELOMIR-1 may have
                                            potential in several diseases associated with a range of metabolic and geriatric related
                                            conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exploring
                                            strategic collaborations to maximize the value of TELOMIR-1.</I></B> We plan to explore collaborations
                                            opportunistically to maximize the value of TELOMIR-1. We intend to retain significant economic
                                            and commercial rights to our programs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Clinical
Studies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mechanism
of Action of TELOMIR-1</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that preclinical studies demonstrate that TELOMIR-1 uniquely and selectively binds critical metals to interrupt enzyme function,
returning cellular metals like iron, copper, and zinc to homeostasis, and turning off the underlying cause of cancer development and
growth. TELOMIR-1 may selectively affect the key processes that drive the concentration and accumulation of iron and copper in the serum
that affects diseases like hemochromatosis and cancer. TELOMIR-1 has the potential to be a therapeutic intervention against hemochromatosis
and cancer by interrupting and preventing the enzymatic actions that create the systemic imbalance of cellular metals that allows elevated
reactive oxygen species to oxidize and erode the protective DNA telomere caps.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1. Insilico Affinity Computations Between TELOMIR-1 and Fe<SUP>2+ </SUP>ions in Water Solution</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_003.jpg" ALT="A close-up of several molecules&#10;&#10;Description automatically generated" STYLE="height: 345px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Source:
</U>Donald R. Burgess (2004), NIST SRD 46. Critically Selected Stability Constants of Metal Complexes: Version 8.0 for Windows, National
Institute of Standards and Technology. https://doi.org/10.18434/M32154.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study aims to investigate the affinity of TELOMIR-1 for Fe2+.The results of the affinity tests show that TELOMIR-1 has a higher affinity
to Fe2+ in comparison to Diethylenetriamine (Dien) but for 1micro molar Fe2+ you will need more 10 micro molar of TELOMIR-1 to form an
effective complex. Additionally, Fe2+ is the bound form of iron in the human body; the majority of biological iron in the free state
occurs in the Fe3+ (Ferric) state, and in the context of Hemochromatosis the excess iron is in the ferric form, hence the chelating agents
currently used primarily target Fe3+.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ongoing
Pre-Clinical Proof-of Concept Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the ongoing pre-clinical proof-of-concept studies that we are conducting with respect to TELOMIR-1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Efficacy
of TELOMIR-1 in reducing ferritin in aged mice:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evotec
will complete a tolerability assessment, ferritin assay optimization, whole blood Methylation assay optimization, efficacy assessment
with ferritin assay, and whole blood DNA methylation assay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Assay
development to detect plasma concentration of rat and dog ferritin</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
assays are performed based on the manufacturer&rsquo;s manual of the commercial ELISA kit. The sample analysis for rat to measure concentrations
of rat ferritin from rat plasma samples will be done by using ELISA assay (LS Bio commercial kit cat# LS-F36491.The sample analysis -for
dog to measure concentrations of dog ferritin from dog plasma samples will be done by using ELISA assay (LS Bio commercial kit cat# LS-F11494).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>In
Vitro stem cell therapy study conducted by Frontage Laboratories</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem
cell therapy will be tested for the potential of TELOMIR-1 to lengthen telomeres and reprogram stem cells. Details regarding Cell line
selection, Telomere length determination, Cell death determination, Cell death determination, and R&amp;D cell bank are outlined below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
line selection:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the literature highlighting their appropriateness for telomere and aging research, we will acquire three vials for each cell line:
Primary human umbilical vein endothelial cell HUVEC (Lonza C2517A), non-immortalized human fibroblast MRC-5 (ATCC CRL-171), and the human
BM-derived mesenchymal stem cell line (ATCC PCS-500-012). The cellular expansion will be carried out, followed by treatment with TELOMIR-1,
a small molecule known for regulating telomere length. The cells will then undergo an evaluation to determine telomere length and their
capacity for cell renewal and proliferation and assess cell death, as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomere
length determination:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
commercially available qPCR kit will be employed to treat and assess the absolute telomere length of the cells. The cells will undergo
treatment with different concentrations of TELOMIR-1, followed by harvesting at distinct time intervals, and subsequently subjected to
telomere length analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Proliferation/renewal determination:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cells will undergo treatment with TELOMIR-1 at various concentrations and time points. Subsequently, they will be harvested and lysed
using a lysis buffer. The resulting lysates will be subjected to the Cell Titer-Glo cell viability assay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
death determination:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellular
apoptosis and necrosis are recognized as distinctive indicators of telomere shortening in stem cells and other cell types. To investigate
this phenomenon, the cells will be treated with TELOMIR-1, administered at multiple concentrations and varying durations. The resulting
cell death, characterized by apoptosis and necrosis, will be quantitatively assessed using flow cytometry techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
cell bank:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
single cell type will be chosen and utilized to establish an R&amp;D cell bank. It is of utmost importance to preserve the original cell
vial to ensure consistent cell line behavior throughout the development of analytical assays and subsequent Good Manufacturing Practice
(GMP) analytical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Completed
Pre-Clinical Toxicology Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the type, species, purpose, and results of our completed pre-clinical toxicology studies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
    of Study </B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Species</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolite
    Identification</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD-1
    mouse, SD-rat, Beagle dog, Cynomolgus monkey and human</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    determine the metabolic pathways of TELOMIR-1 across species </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    showed little/no metabolism by CYP enzymes. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
Reaction Phenotyping Using Liver S9</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mouse,
rat, monkey and human liver</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the Enzymes Involved in the Metabolism of Telomir-1 Using Hepatic S9 Fraction</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    compound does not appear to be a substrate of cytochrome P450 enzymes. There was little/no metabolism of TELOMIR-1 in dog S9, consistent
    with the fact that the dog lacks aldehyde oxidase activity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytochrome
    P450 (CYP) reaction phenotyping</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate the potential of TELOMIR-1 to be a victim of drug-drug interactions</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    was extensively metabolized in mouse, rat, monkey, dog, and human hepatocytes. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytochrome
    P450 (CYP) inhibition</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate the potential of TELOMIR-1 to cause drug-drug interactions as a perpetrator</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    (up to 100 &micro;M) did not inhibit any of the tested CYP enzymes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
    protein binding</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD-1
mouse, SD rat, Beagle dog, Cynomolgus monkey and human</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    know the unbound fraction of TELOMIR-1 in plasma </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    highly Protein Bound</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Rats</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rats</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate and characterize the toxicokinetic and toxicity of TELOMIR-1 and to estimate the MTD of TELOMIR-1 following </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MTD following 7 days of repeated administration of TELOMIR-1 at dose levels of 50, 200, and 750 mg/kg/day in rats was determined
    to be &ge; 750 mg/kg/day </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Dogs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dogs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate and characterize the toxicokinetic and toxicity of TELOMIR-1 and to estimate the MTD of TELOMIR- </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    were no treatment-related clinical observations, body weights, clinical pathology and anatomic gross pathology findings up to 7.5
    mg/kg/day.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SafetyScreen44
    <SUP>TM</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate, in Enzyme, and Radioligand Binding assays, the activity of TELOMIR-1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    significant results noted</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ongoing
Pre-Clinical Toxicology Study</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
only ongoing study is the invitro Metabolic ID Function study in mouse, rat, dog, monkey, and human. The study is designed for identification
of enzymes involved in the metabolism of TELOMIR-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Planned
Pre-Clinical Toxicology Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the type, species, and purpose, of additional planned pre-clinical toxicology designed to demonstrate that TELOMIR-1
will be not toxic before starting human clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
    of Study </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Species</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Vivo Micronucleus Study in Rats Using Bone Marrow</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    assess the potential of TELOMIR-1 and/or its metabolites to induce micronuclei (MN) in bone marrow reticulocytes (RETs) of male and
    female Sprague Dawley </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hERG
(Manual Patch-Clamp)</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    detect the risk of the protein product of the human-Ether-a-go-go -Related Gene (hERG) is an ion channel which plays an integral
    role in the repolarization and relaxation of the myocardium. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardiovascular
Study Dog (Telemetry)</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dog</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardiovascular
analysis: ECG and Blood Pressure will be monitored continuously in conscious animals in their home cage for a minimum 1 hour of baseline
(prior to dosing) and a minimum 24 hours after dosing.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respiratory
Study Rat</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plethysmography:
    Animals will be place in a whole-body plethysmograph and allowed to stabilize for a minimum of 1 hour prior to administration of
    the control or test article.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neurobehavioral
Evaluation Rats</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
                                            observational battery will occur pre-dose and 1 time point (txmax) post-dose.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    activity conducted following functional observational battery using opto-varimax boxes.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Day
Dog Study</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dog</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evaluate the toxicity and toxicokinetic profile following oral gavage administration of TELOMIR-1 to male and female Beagle dogs
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Day
Rat Study</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    objectives of this study are to evaluate the toxicity and toxicokinetic profile following oral gavage administration of TELOMIR-1
    to male and female Sprague Dawley rats. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
are IND enabling studies with the purpose of demonstrating there are no animal toxicity issues before dosing in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>CMC
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below identifies our ongoing chemistry, manufacturing, and controls activities relating to TELOMIR-1. We started the analytical
development and manufacturing of TELOMIR-1 in the first quarter of 2023. By the third quarter of 2023, we anticipate our suppliers will
be developing TELOMIR-1 at scale and manufactured under cGMP conditions, expanding on earlier non-GMP volumes of TELOMIR-1 for use in
our advanced testing programs. We plan to work closely with our suppliers to generate sufficient volumes of cGMP-grade TELOMIR-1 materials
for the planned pre-clinical toxicity programs, expanded animal testing in human clinical trials expected to be performed in 2024, subject
to FDA concurrence with our clinical trial design.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 59%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chemistry,
    Manufacturing, and Controls</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Planned/In
    process Activity</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
    Substance Preparation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Analytical Development</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;
    Method Development</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;Assay/impurity</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
    Dissolution</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;Method
    Validation (cleaning method)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Drug Excipient Compatibility</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Formulation Development and Prototypes</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Lead Formulation Stability</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Scale-up Demo Batch Manufacturing</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    R&amp;D Demo Batch Stability</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Method Validation</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;Assay/impurity</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;Dissolution</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    GMP Manufacturing</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Release Testing</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    GMP Stability Study</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Clinical Development Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regulatory
Submissions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of pre-clinical development program as described above, we plan to submit to the FDA two INDs, with one focused on investigating
TELOMIR-1 for the treatment of hemochromatosis and the second for post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first IND application submission investigating TELOMIR-1 for the treatment of hemochromatosis is currently planned for the second quarter
of 2024. If allowed to proceed by the FDA, a Phase I double-blind, randomized, placebo-controlled trial to evaluate the safety, tolerability,
and pharmacokinetics of TELOMIR-1 in 40-60 healthy male and female adult subjects will be initiated approximately 30 days post-IND submission.
We have contracted with Frontage Laboratories Phase I clinic in New Jersey consisting of 160 beds across three units for normal volunteers.
After the Phase I trial is complete, a Phase II trial in the hemochromatosis population is planned to commence after results and guidance
from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second IND application will focus on investigating TELOMIR-1 for the treatment of post-chemotherapy recovery and is planned for submission
with guidance from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical development plans will depend on FDA acceptance of our IND applications. As appropriate and pursuant to discussions with the
FDA, we may periodically adjust the timeline for certain filings and associated clinical trials. It is important to note that the process
for conducting clinical trials is uncertain and there is no assurance that our clinical development activities will meet the planned
timelines set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Manufacture
of Product for Clinical Development Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthem,
a leading CDMO, has been developing a large-scale synthesis protocol for us and will be supplying quantities of TELOMIR-1 needed for
our pre-clinical and clinical development activities. We are currently in discussions with Frontage to have TELOMIR-1 formulated into
solid oral dosage forms for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1,
if approved, is expected to compete in two markets initially: hemochromatosis and post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disease
Epidemiology &ndash; Patient Targets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
target patient pool for TELOMIR-1 will vary depending on which indication is under review. Hemochromatosis is largely an inherited condition
while the second category, post-treatment recovery, is a derivative of broader oncology epidemiology and treatment seeking behaviors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Market in Hemochromatosis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
with two mutated copies of the <I>HFE</I> gene (C282Y and H63D) are at the greatest risk for developing hemochromatosis, alongside patients
with a family history of hemochromatosis. As a result, ~13M US patients carry mutations for hemochromatosis but only a fraction of them
has symptoms, and not every symptomatic patient develops hemochromatosis. On average, about 750,000 US patients express one or more iron
overload symptoms. There are 2 types of hemochromatosis, with the following patient mix: 150,000 primary hemochromatosis, and 65,000
secondary hemochromatosis confirmed diagnoses in the United States. Today, we estimate that over 150,000 patients have sought treatment
since 2018, with most receiving phlebotomy, which is the withdrawal of blood to bring iron to normal levels. At present, 99% of hemochromatosis
patients receive phlebotomy, with a portion of patients also receiving iron chelators as a co-treatment. Note that ~1% of hemochromatosis
patients received deferasirox or deferoxamine off-label for 12 weeks (1 year for primary). The chart below outlines the epidemiological
flow for hemochromatosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_004.jpg" ALT="" STYLE="height: 352px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Market in Post-Chemotherapy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
undergoing chemotherapy irrespective of type of cancer are at risk. That said, older patients aged 65+ and above, have a higher risk
of developing post-chemotherapy side effects such as digestive issues, sleep and memory issues, fatigue, and body aches. Other risk factors
include the presence of metabolic conditions, dose levels of chemotherapy medication, blood count, and BMI.US CDC health data estimates
that 650,000 patients receive chemotherapy annually in the US, with 45% experiencing severe side effects and 40% having more moderate
side effects. Thus, ~158,000 patients were diagnosed with the adverse effects of chemotherapy (antineoplastic and immunosuppressive drugs.
Today, Neulasta is given to patients undergoing chemotherapy as a &ldquo;catch-all&rdquo; therapeutic to help manage side effects. Neulasta
is typically given to patients after chemotherapy for recovery. 95,000 patients with chemotherapy side effects got Neulasta over the
last 12 months while 5,500 patients with immunosuppressive therapy side effects got Jakafi, also used for myelofibrosis and polycythemia
vera. The FDA will determine TELOMIR-1 can be given as a standalone compound or in conjunction with existing therapies to accelerate
recovery from chemotherapy. Given existing compliance levels around the use of Neulasta (~70%), we believe that adding TELOMIR-1 may
boost overall compliance levels higher especially if levels of side effects are reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_005.jpg" ALT="A diagram of a patient's recovery&#10;&#10;Description automatically generated" STYLE="height: 355px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to competition from pharmaceutical and biotechnology companies and academic and research institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
will face competition in its two initial target indications. Below we discuss the known competitors by target indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hemochromatosi</U>s:
                                            The current standard of care is phlebotomy, which typically costs $80 - $300/visit in community
                                            health facilities or offered for free at blood banks. Based on historical treatment data,
                                            phlebotomy serves more than 95% of hemochromatosis patients, as there are no FDA-approved
                                            indications. Each year, about 70,000 patients receive phlebotomy in healthcare facilities,
                                            excluding the blood banks (that provide the service for free). Patients who use it continue
                                            to embrace it given the lack of clinical options, its broad accessibility and low treatment
                                            cost. However, this option is not available to patients with hemophilia and other blood disorders.
                                            About 5% of patients are treated with iron chelators such as Exjade and Jadenu (and associated
                                            generics). This option is more expensive with pricing for Exjade at $532/day and Jadenu at
                                            $517/day. The last treatment option, deferasirox / deferoxamine was used with only 7,000
                                            patients (2018-2022) based on IQVIA claims and scripts data. Future clinical options for
                                            treating hemochromatosis exist and remain limited. For example, 2 molecules are preclinical,
                                            2 in Phase I, 1 in Phase II, and 1 is in Phase III.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="formdrs_006.jpg" ALT="A table with blue and white text&#10;&#10;Description automatically generated" STYLE="height: 329px; width: 624px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Chemo
                                            Recovery</U>: The current standard of care involves prescribing a small set of compounds
                                            designed to reduce patient discomfort from side effects. Filgrastim, pegfilgrastim, sargramostim
                                            are some examples of prescribed medication. These medications stimulate the growth of healthy
                                            white blood cells and granulocytes by subcutaneous injection. However, prices are high and
                                            can cost around $4,000-6,400 per dose of injection. Jakafi, a tyrosine kinase inhibitor is
                                            used in polycythemia vera and graft-versus-host disease. Pricing for Jakafi is $16,200 per
                                            bottle, with a $270 wholesale acquisition cost (WAC) unit price. Thus, given cost, only a
                                            portion of the high-risk patients are given the script; these are usually patients who are
                                            older than 65, and with a weakened immune system and low white blood cell count. Patients
                                            who use the class of medication do so to reduce post-treatment infection risk, even if they
                                            suffer from fevers and aches because of usage. The development pipeline of competing assets
                                            is robust but targeted at specific side effects such as iron deficiency or thrombotic
                                            constraints.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_007.jpg" ALT="A table with text on it&#10;&#10;Description automatically generated" STYLE="height: 335px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
license the U.S. patent rights for the use of TELOMIR-1 in human applications from MIRALOGX, an intellectual property development and
holding company established by Jonnie R. Williams, Sr., the founder of our company and the inventor of TELOMIR-1. MIRALOGX has filed
two provisional patent applications in the U.S. for the composition of TELOMIR-1 and for its therapeutic uses in hemochromatosis and
various chronic inflammatory diseases. These applications, if granted and subject to payment of patent maintenance fees, would offer
protection extending through at least September 1, 2053 in the U.S. The patent rights for TELOMIR-1 outside of the United States and
in non-human applications are not included in our current patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license from MIRALOGX is set forth in the MIRALOGX License Agreement. Under the MIRALOGX License Agreement, we have the exclusive perpetual
right and license under the above-described patent rights to make, have made, use, and sell &ldquo;Licensed Products&rdquo; in the U.S.
for human uses and preclinical studies and activities of any kind conducted in furtherance of obtaining regulatory approval or commercialization
for human uses. &ldquo;Licensed Product&rdquo; is defined as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)pyridine
or a pharmaceutically acceptable salt, ester, or solvate thereof. We also have the right to grant corresponding sublicenses under the
licensed patent rights. The MIRALOGX License Agreement provides for the payment to MIRALOGX of an 8% royalty (payable quarterly) on our
net sales of Licensed Products by us or our sublicensees and on non-royalty bearing milestone revenue, with the royalty obligation ceasing
upon the later of the expiration of the last-to-expire licensed patent or the expiration of the last strategic partnership/sublicensing
agreement entered into by us. The agreement provides for a perpetual license and does not contain a provision that permits MIRALOGX to
terminate the agreement. The MIRALOGX License Agreement provides that MIRALOGX will have sole control over the filing, prosecution, maintenance,
and management of the licensed patent rights, provided that we will be responsible for the cost of prosecuting, maintaining, and managing
the licensed patents. The agreement grants to us the primary right, but not the obligation, to enforce the licensed patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Besides
relying on patents, we will also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive
position, especially when we do not believe that patent protection is appropriate or can be obtained. We will seek protection of these
trade secrets, proprietary know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements.
However, these agreements may not provide meaningful protection for, or adequate remedies to protect, our technology in the event of
unauthorized use or disclosure of information. Furthermore, our trade secrets may otherwise become known to, or be independently developed
by, our competitors. We may in the future seek appropriate patent protection for technology in our research and development programs
to the extent not licensed from MIRALOGX or another third party, where applicable, and their uses by filing patent applications in the
appropriate jurisdiction. We intend for these patent applications to cover, where possible, claims for compositions of matter, medical
uses, processes for preparation and formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently use TELOMIR and TELOMIR-1 as unregistered trademarks, and we intend to rely on such trademarks and trade names and service
marks, as well as our domain names and logos, as appropriate, to distinguish, build, and market our brand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration (FDA) and comparable regulatory authorities in state and local jurisdictions impose substantial and
burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs. These
agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling and export and import of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Government Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending New Drug Applications (NDAs), withdrawal of an approval, imposition
of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice
    (&ldquo;GLP&rdquo;) regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an Investigational New Drug (&ldquo;IND&rdquo;) application, which must become effective before human clinical trials
    may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board (&ldquo;IRB&rdquo;), at each clinical site before each trial may be initiated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practices (&ldquo;GCP&rdquo;) requirements
    to establish the safety and efficacy of the proposed drug product for each indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    that the API and finished product are manufactured under cGMP conditions and meet all applicable standards of identity, strength,
    quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&rsquo;s identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing or sale of the drug in the United States; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) or to conduct a post-approval study.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pre-clinical
studies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any drug or biological product candidate in humans, the product candidate must undergo rigorous pre-clinical testing. The pre-clinical
developmental stage generally involves laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate
toxicity in animals, to assess the potential for adverse events (&ldquo;AEs&rdquo;) and, in some cases, to establish a rationale for
therapeutic use. The conduct of pre-clinical studies is subject to federal regulations and requirements, including GLP regulations for
safety/toxicology studies. An IND sponsor must submit the results of the pre-clinical studies, together with manufacturing information,
analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from the FDA to ship an investigation product and then administer it to humans and must be allowed
to proceed by the FDA before human clinical trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive
AEs and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the
FDA, unless the FDA raises concerns or questions before that time related to one or more proposed clinical trials and places the trial
on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by, or under control of, the trial sponsor, in accordance with
GCPs, which include the requirement that all research patients provide their informed consent for their participation in any clinical
trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol,
and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must
be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical
trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries. Information about most clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov
website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects
of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years
after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress
of development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, side effect tolerability and safety of the drug.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At
    the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
    risks are identified, and a preliminary evaluation of efficacy is conducted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary
    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk
    relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo
    and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow
up. In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA or a Biologics
License Application (&ldquo;BLA&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if significant
adverse events (&ldquo;SAEs&rdquo;) occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may
impose other sanctions on various grounds, including a finding that the research patients are being exposed to an unacceptable health
risk. Similarly, an IRB can refuse, suspend, or terminate approval of a clinical trial at its institution if the clinical trial is not
being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious harm to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional pre-clinical studies and must also develop additional information about the
physical characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency,
and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must
be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marketing
Approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed
information relating to the product&rsquo;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted
to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of
an NDA is subject to a substantial application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
review process typically takes twelve months from the date the NDA is submitted to the FDA. The FDA conducts a preliminary review of
all NDAs within the first 60 days after submission to determine whether they are sufficiently complete to permit substantive review before
accepting them for &ldquo;filing.&rdquo; The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information and may be subject to an additional application user fee. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins
an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether
the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&rsquo;s continued
safety, quality and purity. Under the current guidelines in effect in the Prescription Drug User Fee Act (PDUFA), the FDA has a goal
to review and act on the submission within ten months from the completion of the preliminary review of a standard NDA for a new molecular
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include
medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution
methods, patient registries, or other risk minimization tools.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect
one or more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding
the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter.
A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of
the NDA and may require additional clinical trials or pre-clinical studies in order for FDA to reconsider the application. Even with
submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA will typically issue an approval letter.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-approval
requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing annual user fee requirements for any
marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative and accounting office is located in Tampa, Florida. We currently share space with MIRA Pharmaceuticals, Inc., another
pharmaceutical development company, under a lease of approximately 2,279 square feet of office space under a lease that is due to expire
on March 31, 2024. We share the office and costs in Tampa with two other companies. Our corporate headquarters and executive offices
are in Baltimore, Maryland. Our Baltimore location, which comprises approximately 150 square feet, is under a lease that is due to expire
on November 30, 2023. We believe that this facility will be sufficient for our current and planned operations, although we may require
additional office and laboratory space in Baltimore for our planned operations as we progress our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees
and Human Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 1, 2023, we had 2 full-time employees and 4 part-time employees, of which one of our part-time employees is engaged in research
and development. None of our employees is represented by a labor union or are covered by a collective bargaining agreement. We consider
our relationship with our employees to be satisfactory. In addition, we utilize the services of contractors and part-time outside consultants
to support our organization&rsquo;s needs. We expect to continue to build our team to ensure we can effectively execute against our development
plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions,
administrative actions, investigations, or claims are pending against us or involve us that, in the opinion of our management, could
reasonably be expected to have a material adverse effect on our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the
future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial
resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporation
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205. Our telephone number is (737) 289-0835.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is www.telomirpharma.com. The information contained on, or that can be accessed through, our website is deemed not to
be incorporated in this prospectus or to be part of this prospectus. You should not consider information contained on our website to
be part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="bs_007"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our current executive officers and directors, including their ages as of August 1, 2023.
With respect to our directors, each biography includes information regarding the experience, qualifications, attributes, or skills that
caused our board of directors to determine that such person should serve as a director of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 54%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Chapman, Jr., MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Chief Medical Officer, and Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    McNulty, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Treasurer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Aminov</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christos
    Nicholoudis, Esq.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
    Vorhoff</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Kroenig</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    Eagle, MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Talhia
    Tuck</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hugh
    McColl III</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief biography of each of our current executive officers and directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christopher
Chapman, Jr., MD</I></B> was appointed to serve as our Chief Executive Officer, Chief Medical Officer, and Chairman effective November
2022. He also currently serves as the Executive Chairman of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), a publicly traded pre-clinical
pharmaceutical development company (&ldquo;MIRA&rdquo;), a position he has held since April 2023. As Executive Chairman of MIRA, Dr.
Chapman&rsquo;s duties include those that are customarily associated with the position of Chairman of the Board, as well as oversight
of the regulatory affairs and drug development activities of the company. Dr. Chapman has also served as one of MIRA&rsquo;s directors
since November 1, 2021, and served as a consultant with respect to regulatory affairs and drug development from November 1, 2021 until
he began serving as MIRA&rsquo;s Executive Chairman in April 2023. Dr. Chapman also serves as the President, Chief Medical Officer, and
a director of MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a publicly traded clinical-stage pharmaceutical development company (&ldquo;MyMD&rdquo;).
Dr. Chapman previously served as President and Chief Medical Officer of MyMD Pharmaceuticals (Florida), Inc. (&ldquo;MyMD Florida&rdquo;)
effective as of November 1, 2020. MyMD Florida is the predecessor by merger of MYMD. Prior to joining MyMD Florida and since 1999, Dr.
Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides
support to pharmaceutical and biotechnology companies in North America, Europe, Japan, India and Africa on issues such as product safety,
pharmacovigilance, medical devices, clinical trials and regulatory issues. Dr. Chapman served as Director, Medical Affairs, Drug Safety
and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995 to 2003, where he grew the division from no employees
to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff.
Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (formerly, Star Scientific, Inc.) from 2007
to 2016, including as a member of the Audit Committee from 2007 to 2014, chairperson of the Compensation Committee from 2007 to 2014,
and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert
and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects.
Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established
to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and
tuberculosis, which was organized in 2006. Dr. Chapman earned an Executive Certificate in Nonprofit Financial Stewardship from the Harvard
Kennedy School in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his
internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown.
We believe Dr. Chapman is qualified to serve as one of our directors due to his executive experience in the pharmaceutical and biotechnology
industries, as well as his medical expertise. Dr. Chapman&rsquo;s recent publications include two poster presentations: 1)British Society
of Immunology, Liverpool, UK, December 5-8, 2022 <I>Pharmacology and clinical profile of MYMD-1<SUP>&reg;</SUP> (isomyosamine), an oral,
selective, next-generation, TNF-alpha inhibitor that crosses the blood brain barrier </I>and 2) Society of Toxicology, Nashville, TN,
March 19-22, 2023, <I>A Naturally Occurring Novel Therapeutic </I>and Oral Selective Inhibitor of TNF-&alpha;, <I>MYMD-1</I><SUP>&reg;
</SUP><I>(Isomyosamine), </I>Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody Induced
Arthritis. Additionally, Dr. Chapman published a manuscript in Drug Research, &ldquo;A Double-blind, Placebo-controlled, Randomized,
Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine
Capsules in Healthy Adult Subjects&rdquo; (Brager, J., <B>Chapman, C</B>., Dunn, L., &amp; Kaplin, A. (2023). A Double-blind, Placebo-controlled,
Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose
Isomyosamine Capsules in Healthy Adult Subjects. <I>Drug research</I>, <I>73</I>(2), 95&ndash;104. https://doi.org/10.1055/a-1962-6834).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Erez
Aminov</I></B> has served as our President since August 11, 2023, and as President, he reports to Dr. Chapman. Mr. Aminov has served
as Chief Executive Officer and a director of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), a preclinical pharmaceutical development company
since April 2023. From April 2022 to March 2023, Mr. Aminov was a consultant to MIRA providing support on fundraising and investor
relations matters. Mr. Aminov is an experienced biotechnology investor and adviser with over 18 years of experience. Since September
2021, Mr. Aminov was the founder of Locate Venture Corp, a strategy and investment consulting firm which has advised multiple, early-stage
life sciences companies including MyMD Pharmaceuticals (Nasdaq: MYMD), Telomir Pharmaceuticals and Tyna Pharmaceuticals on fund raising
and strategic partnerships. Mr. Aminov&rsquo;s work has generally focused on assisting clients with structuring private investment opportunities,
designing new clinical partnerships, and negotiating access to new markets. From February 2015 to September 2020, Mr. Aminov served as
the President of Finds4less Inc., a global distributor of electronics and gaming products. In this role, Mr. Aminov provided strategic
oversight and direction for all aspects of the company&rsquo;s operations, while also spearheading new business development initiatives
to capitalize on emerging market opportunities. Mr. Aminov received his B.A. in accounting in 2004 from Touro University in New York.
We believe that Mr. Aminov is qualified to serve as one of our directors based on his finance and investment experience, particularly
with early-stage life sciences companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>James
A. McNulty, CPA</I></B>, was appointed to serve as our Chief Financial Officer and Treasurer effective November 2022. Mr. McNulty served
as the Chief Financial Officer of MIRA Pharmaceuticals, Inc., (Nasdaq: MIRA) a publicly traded early pre-clinical-stage pharmaceutical
company focused on the development and commercialization of a new molecular synthetic THC analog, from September 2020 through March 2023.
From January 2016 until it became public in November 2020, Mr. McNulty was the Chief Executive Officer of MyMD. Mr. McNulty also serves
as Interim Chief Financial Officer for Inhibitor Therapeutics, Inc. (Nasdaq INTI:OTC), a publicly traded, clinical stage pharmaceutical
development company. After leaving public accounting in 1998 after a 26-year career in Tampa as founder of three public accounting firms,
he served as a Chief Financial Officer in the biopharmaceutical industry, including 15 years with BioDelivery Sciences International,
Inc. (NASDAQ: BDSI). He served five years on the board as Lead Director and Chair of the Audit Committee of CV Sciences, Inc (OTC: CVSI).
He has extensive experience in privately held companies, including five years as a director of Quantum Technology Sciences, Inc. until
its acquisition by a public company, and since 2000 as Chief Financial Officer of Hopkins Capital Group, an affiliation of limited liability
companies which engage in venture activities primarily in the development of pharmaceuticals, and Chief Financial Officer of Defender
Pharmaceuticals, Inc. He is a partner in Perfect Golf Event, LLC, an online organizer of over 4,000 charity golf events. Mr. McNulty&rsquo;s
career in accounting and consulting services includes expert testimony as a Certified Public Accountant, primarily in construction litigation
and personal injury cases. He is a 1972 graduate of the University of South Florida.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christos
Nicholoudis </I></B>joined our company as a director on August 11, 2023. He was initially appointed under an agreement between
our company and our largest stockholder, the Bay Shore Trust, to serve as the designated representative of the Bay Shore Trust on our
board of directors. He has also served as a director of MIRA Pharmaceuticals, Inc., (Nasdaq: MIRA) since April 2023. Mr. Nicholoudis
was also named General Counsel of MIRA in April 2023, although he is not deemed to be an executive officer of that company. Mr. Nicholoudis
is an attorney who has practiced with his own firm, The Law Firm of Christos Nicholoudis PLLC, since February, 2022, where he handles
a wide range of legal matters including contract work, personal injury, real estate, wills trusts and estates and criminal law. Prior
to that, from July of 2019 to February of 2022, Mr. Nicholoudis was employed by the State of Florida as a Public Defender for the 12<SUP>th
</SUP>Judicial Circuit and from July 2012 to February of 2020, Mr. Nicholoudis owned and operated a restaurant franchise under Cortez
Roadhouse, LLC. Mr. Nicholoudis is a 2012 graduate of Cornell University&rsquo;s School of Hotel Administration where he received a B.S.
in hospitality and a 2017 graduate of Stetson College of Law where he received his J.D. degree. He is admitted to the bar in New York,
Florida, Texas, and Washington D.C. We believe that Mr. Nicholoudis is qualified to serve as one of our directors based on his legal
experience and training and his diverse business management experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>David
Vorhoff</I></B> joined our company as a director in November 2022. He has served as a director of MIRA Pharmaceuticals, Inc., (Nasdaq:
MIRA) since May 3, 2022. Since August of 2021, Mr. Vorhoff has served as Chief Executive Officer and co-founder of Creo Valo, a financial
services company, and a Partner of Texas Atlantic Group, a family office and advisory firm, since May of 2019. He is also the Co-founder
and Chairman of the board of directors of Fintag Holdings, Inc., a financial technology company since April 2021. Previously, from August
2015 to March 2019, Mr. Vorhoff served as Senior Vice President of Corporate Development and Strategy for Premier, Inc. (Nasdaq: PINC),
a healthcare improvement company, and as Managing Director, Co-Head Healthcare and Life Sciences at Deloitte, a professional services
company, from 2013 to August 2015. He also previously served as a director of Start Scientific, Inc. Mr. Vorhoff has a B.A. in Interdisciplinary
Studies from University of North Carolina at Chapel Hill, and an MBA degree from UNC Kenan-Flagler Business School. We believe Mr. Vorhoff
is qualified to serve on our board of directors because of his experience in the healthcare and life sciences sectors, as well as his
executive experience in the finance and investment banking industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Brad
Kroenig</I></B> joined our company as director in November 2022. Since November 2021, he has also served as a member of the Board of
Directors of MIRA Pharmaceuticals, Inc., (Nasdaq: MIRA) a publicly traded early pre-clinical-stage pharmaceutical company focused on
the development and commercialization of a new molecular synthetic THC analog. Since 2000, Mr. Kroenig&rsquo;s principal occupation has
been serving as one of the world&rsquo;s leading fashion models. Mr. Kroenig was the face of Ralph Lauren, The Gap, Tommy Hilfiger, Chanel,
Fendi, Peter Millar, and many other top brands. Models.com ranked him the #1 male model in the world from 2004 to 2006, and Vogue magazine
ranked him the #3 male model of all time. Mr. Kroenig also serves as a business and strategy consultant for many private firms and early-stage
companies, where as a part of his consulting business he advises companies regarding building management teams and managing relationships
with investors. Mr. Kroenig is an experienced investor and business executive with significant experience in collaborating with executive-level
and cross-functional teams, analyzing business situations, and developing and implementing practical investor strategies. Mr. Kroenig
attended Florida International University on a NCAA Division I soccer scholarship. We believe that Mr. Kroenig&rsquo;s business experience
in the modeling industry as a business executive qualifies him to serve as one of our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Craig
Eagle, MD </I></B>joined our company as a director in November 2022. He has also served as a director of MyMD since April 16, 2021. Dr.
Eagle is currently the Chief Medical Officer of Guardant Health, Inc. since 2021. Previously, Dr. Eagle was Vice President of Oncology
for Genentech, where he oversaw the medical programs across Genentech&rsquo;s oncology portfolio. Prior to his current role, Dr. Eagle
worked in several positions at Pfizer from 2009 to 2019, including as the oncology business lead in the United Kingdom and Canada, the
global lead for Oncology Strategic Alliances and Partnerships based in New York, and as the head of the Oncology Therapeutic Area Global
Medical and Outcomes Group, including the U.S. oncology medical business. Through his multiple roles at Pfizer, Dr. Eagle delivered significant
business growth and was involved in multiple strategic acquisitions and divestitures. In addition, while at Pfizer, Dr. Eagle oversaw
extensive oncology clinical trial programs, multiple regulatory and payer approvals across Pfizer&rsquo;s oncology portfolio, health
outcomes assessments and scientific collaborations with key global research organizations like the National Cancer Institute (NCI), and
the European Organization for Research and Treatment of Cancer (EORTC), and led worldwide development of several compounds including
celecoxib, aromasin, irinotecan, dalteparin and ozagomicin. Dr. Eagle currently serves as a member of the board of directors and chair
of the Science and Policy Committee of Pierian Biosciences, a privately held life sciences company. Dr. Eagle attended Medical School
at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in
Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney and was granted
Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his
training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets
before moving into the pharmaceutical industry. Dr. Eagle&rsquo;s qualifications to sit on our Board include his long and successful
career in the international pharmaceutical industry, his senior executive experience in areas such as business growth, strategic alliances
and mergers and acquisition transactions, his experience as a member of both public and private company boards in the healthcare and
life science industries, and his wealth of oncology experience, including leading and participating in scientific research, regulatory,
pricing and re-imbursement negotiations for compounds in therapeutic areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Talhia
Tuck</I></B> joined our company as a director in November 2022. She has also served as a director of MIRA since November 1, 2021. She
currently is an Admissions and Recruitment Counselor at Georgetown Law School. From 2019 to 2023, Ms. Tuck was a Project Director with
Georgetown Law School&rsquo;s Center for Innovations in Community Safety, formerly the Innovative Policing Program, which identifies
new approaches to long-standing issues in policing. Ms. Tuck served as an Associate Director of Admissions at Georgetown University from
2016-2019, where she evaluated applications for the undergraduate schools and chaired several admissions committees. Prior to 2016, Ms.
Tuck worked in the investment relations and communications field as Vice President for Communications and Investor Relations at Star
Scientific, Inc. (OTC: STSC) where she was responsible for coordinating communications with shareholders, the financial community, and
the media. She also has experience in the legal industry, as she participated in the Ropes &amp; Gray New Alternatives Program as a Fellow
at the Office of the State&rsquo;s Attorney for Montgomery County, Maryland, and subsequently worked in the Corporate Department at Ropes
&amp; Gray LLP in Washington, D.C. Prior to attending law school, Ms. Tuck was a journalist with MSNBC, NBC News, ABC News, and the CBS
affiliate, WINK-TV, and worked as an admissions officer for Harvard College at Harvard University. She also served as a financial analyst
at Goldman Sachs in the Investment Management Division from July 2000 until April 2001. We believe that Ms. Tuck&rsquo;s experience in
public policy and investment relations qualifies her to serve as one of our directors. She received her A.B. degree from Harvard College,
<I>cum laude</I>, and received her J.D. degree from Harvard Law School. We believe that Ms. Tuck&rsquo;s experience in public policy
and investment relations qualifies her to serve as one of our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hugh
McColl III</I></B> joined our company as a director in November 2022. He has served as a director of MIRA Pharmaceuticals, Inc., (Nasdaq:
MIRA) since November 1, 2021. Mr. McColl has served as Co-Managing Member of Collwick Capital LLC, a fund of funds, since 2010 and Managing
Member of McColl Brothers Lockwood LLC, a family investment office, since 2006. Since June 2015, he has served as a Senior Advisor at
Brown Brothers Harriman Capital Partners where he assists in sourcing, investment evaluation, transaction execution, and providing post-investment,
value-added oversight to portfolio companies. Before co-founding Collwick Capital LLC, Mr. McColl spent 14 years in the hedge fund industry,
where he was a private investments portfolio manager for Round Table Investment Management and McColl Brothers Lockwood LLC, served as
the Chief Operating Officer for M&amp;M Partners LLC and was the Chief Executive Officer for McColl Partners LLC. Mr. McColl has served
on the boards of directors of Heritage Brands Inc. since 2019 and Fintag Holdings Inc. since 2022. Mr. McColl received a B.S. degree
in Business Administration from the University of North Carolina at Chapel Hill in 1982 and an MBA degree from the University of Virginia
Darden School of Business in 1987. We believe that Mr. McColl&rsquo;s investment management and executive experience qualifies him to
serve as a member of our board of directors. We believe that Mr. McColl&rsquo;s investment management and executive experience qualifies
him to serve as a member of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Composition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are managed under the direction of our board of directors, which currently consists of seven members. The number
of directors is determined by our board of directors, subject to the terms of our amended and restated articles of incorporation and
bylaws that will become effective upon the completion of this offering. Upon the completion of this offering, our board of directors
will continue to consist of seven members, and our directors will be elected for one-year terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
his or her background, employment, and affiliations, our board of directors has determined that Dave Vorhoff, Talhia Tuck, Dr. Craig
Eagle, and Hugh McColl III do not have any relationship that would interfere with the exercise of independent judgment in carrying out
the responsibilities of a director and are independent directors under the Nasdaq Listing Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making these determinations, our board of directors considered the current and prior relationships that each non-employee director has
with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including
the transactions described in the section of this prospectus titled &ldquo;Certain Relationships and Related Party Transactions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish an audit committee, a compensation committee, and a nominating and corporate governance committee prior
to the completion of this offering. The functions of these committees are described below. Members will serve on these committees until
their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it
deems necessary or appropriate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish an audit committee, and we anticipate that [&#9679;], [&#9679;], and [&#9679;] will be the members
of the committee, with [&#9679;] serving as the chair of the audit committee. Each member of the committee will meet the requirements
for independence under the listing standards of Nasdaq and SEC rules and regulations, including Rule 10A-3(b)(1) under the Exchange Act.
Each member of our audit committee will also meet the financial literacy requirements of the listing standards of Nasdaq. In addition,
our board of directors has determined that [&#9679;] is an audit committee financial expert within the meaning of Item 407(d) of Regulation
S-K under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee&rsquo;s main purpose is to oversee our corporate accounting and financial reporting process. Our audit committee will
be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
    to ensure the independence and performance of the independent registered public accounting firm;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent registered public accounting firm, our interim and year-end results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our policies on risk assessment and risk management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    related party transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving, as required, all audit and all permissible non-audit services to be performed by the independent registered public
    accounting firm; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
    our board of directors in monitoring the performance of our internal audit function.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee will operate under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards
of Nasdaq, a copy of which will be available on our website at www.telomirpharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish a compensation committee and we anticipate that [&#9679;], [&#9679;], and [&#9679;] will be the members
of this committee, with [&#9679;] serving as the chair of the compensation committee. Each member of the committee will meet the requirements
for independence under the listing standards of Nasdaq and SEC rules and regulations. Each member of our compensation committee will
also be a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act, or Rule 16b-3. In arriving at
these determinations, our board of directors will examine all factors relevant to determining whether any compensation committee member
has a relationship to us that is material to that member&rsquo;s ability to be independent from management in connection with carrying
out such member&rsquo;s duties as a compensation committee member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee&rsquo;s main purpose is to review and recommend policies relating to compensation and benefits of our officers
and employees. Our compensation committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    approving, and determining, or making recommendations to our board of directors regarding, the compensation and compensation arrangements
    of our executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity compensation plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving, or making recommendations to our board of directors regarding, incentive compensation and equity compensation plans;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general policies relating to compensation and benefits of our employees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will operate under a written charter that satisfies the applicable rules and regulations of the SEC and the listing
standards of Nasdaq, a copy of which will be available on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish a nominating and corporate governance committee, and we anticipate that [&#9679;], [&#9679;], and [&#9679;]
will be the members of this committee, with [&#9679;] serving as the chair of the nominating and corporate governance committee. Each
member of the committee will meet the requirements for independence under the listing standards of Nasdaq and SEC rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    evaluating, and selecting, or making recommendations to our board of directors regarding, nominees for election to our board of directors
    and its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and overseeing the annual evaluation of our board of directors and of its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
    and making recommendations to our board of directors regarding the composition of our board of directors and its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our corporate governance practices; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to our board of directors regarding corporate governance guidelines.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will operate under a written charter that satisfies the applicable listing standards of
Nasdaq, a copy of which will be available on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of our compensation committee is a current or former executive officer or employee of our company. None of our executive
officers serves as a member of the compensation committee of any entity that has one or more executive officers serving on our compensation
committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors administers
this oversight function directly through our board of directors as a whole, and through various standing committees of our board of directors
that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring
and assessing strategic risk exposure, including risks associated with cybersecurity and data protection, and our audit committee has
the responsibility to consider our major financial risk exposures and the steps our management has taken to monitor and control these
exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee
will review legal, regulatory, and compliance matters that could have a significant impact on our financial statements. Our nominating
and corporate governance committee will monitor the effectiveness of our corporate governance practices, including whether they are successful
in preventing illegal or improper liability-creating conduct. Our compensation committee will assess and monitor whether any of our compensation
policies and programs has the potential to encourage excessive risk taking. While each committee is responsible for evaluating certain
risks and overseeing the management of such risks, our entire board of directors will be regularly informed through committee reports
about such risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Diversity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the
appropriate characteristics, skills, and experience required for the board of directors as a whole and its individual members. Although
our board of directors does not have a formal written diversity policy with respect to the evaluation of director candidates, in its
evaluation of director candidates, our nominating and corporate governance committee will consider factors including, without limitation,
issues of character, integrity, judgment, potential conflicts of interest, other commitments, and diversity, and with respect to diversity,
such factors as gender, race, ethnicity, experience, and area of expertise, as well as other individual qualities and attributes that
contribute to the total diversity of viewpoints and experience represented on the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee will ensure compliance with the new rule by Nasdaq for board diversity (the &ldquo;Nasdaq
Diversity Rule&rdquo;), on or before the date required under the Nasdaq Diversity Rule. The Nasdaq Diversity Rule requires, assuming
our shares of common stock are listed on the Nasdaq Capital Market and that we are a smaller reporting company, that we will have at
least two directors serving on our board of directors, at least one of which identifies as female and the second of which identifies
as female, underrepresented minority or LGBTQ+, by December 31, 2026, unless our board of directors is comprised of five or less directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, our board of directors will adopt a code of business conduct and ethics applicable to all of our
directors, officers (including our principal executive officer, principal financial officer, and principal accounting officer) and all
global employees in accordance with applicable federal securities laws and corporate governance rules of the Nasdaq Capital Market. Our
code of business conduct and ethics will be available on our website. Any amendments to the code of business conduct and ethics, or waivers
of its requirements, will, if required, be disclosed on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance Guidelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, our board of directors will adopt corporate governance guidelines, a copy of which will be available
on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not provide any cash or equity compensation to any of our directors during the year ended December 31, 2022 in their capacity as
directors, and we have not yet adopted a compensation program for our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_001"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section discusses the material components of the executive compensation program for the following persons: (i) all persons serving as
our principal executive officers during 2022 and (ii) the most highly compensated of our other executive officers who received compensation
during 2022 of at least $100,000 and who were executive officers on December 31, 2022. We refer to these persons as our &ldquo;named
executive officers&rdquo; elsewhere in this prospectus. Our &ldquo;named executive officers&rdquo; and their positions are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Chapman, Jr., MD, Chief Executive Officer, Chief Medical Officer, Former President, and Chairman; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    A. McNulty, CPA, Chief Financial Officer and Treasurer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
August 11, 2023, Mr. Erez Aminov was appointed as President of our company and Dr. Chapman ceased to serve as President. Because Mr.
Aminov did not become an executive officer until after December 31, 2022, he is not identified as a named executive officer in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the compensation paid by us during the 2022 and 2021 fiscal years to our named executive officers. As indicated
below, there was no compensation paid to any named executive officer of our company during 2021 or 2022. For a description of the compensation
program for our named executive officers following 2022, see &ldquo;&mdash;Executive Compensation Arrangements&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name and principal position</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock Awards</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Option Awards </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>All Other Compensation</B></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total ($)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 18%">Christopher Chapman, Jr., MD</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%">2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 8%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 8%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 8%">-</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Executive Officer, Chief Medical Officer, President, and Chairman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">James A. McNulty, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Financial Officer and Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Compensation Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a more detailed summary of the elements of our current executive compensation program as it relates to our named executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christopher
Chapman, Jr., MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
[&#9679;] 2023, we entered into an employment agreement with Dr. Chapman pursuant to which Dr. Chapman will serve as our Chief Executive
Officer, Chief Medical Officer, and Chairman of our Board. Under his employment agreement, Dr. Chapman has agreed to work part-time and
on an as-needed basis with respect to the affairs of our company. Dr. Chapman&rsquo;s employment agreement provides that his employment
will be on an at-will basis and can be terminated by either Dr. Chapman or us at any time for cause. Under the agreement, Dr. Chapman
will receive an initial base salary of $[________] per year. In the event that Dr. Chapman&rsquo;s employment is terminated by our company
without &ldquo;Cause&rdquo; or is terminated by Dr. Chapman for &ldquo;Good Reason&rdquo;, Dr. Chapman will be entitled to severance
compensation in the form of salary continuation for a period of three months (subject to Dr. Chapman executing and delivering a customary
general release in favor of the company). &ldquo;Cause&rdquo; is defined in the agreement to include dishonesty, misappropriation, willful
misconduct, breach of the agreement, and other customary matters. &ldquo;Good Reason&rdquo; is defined to include a material adverse
change in Dr. Chapman&rsquo;s compensation or duties and level of responsibility. The employment agreement also contains customary confidentiality
and invention-assignment covenants to which Dr. Chapman is subject. Beginning in 2023, in lieu of health insurance coverage and 401k
benefits, we have agreed to pay Dr. Chapman&rsquo;s life insurance policy premium in an amount up to 2,215 per quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Erez
Aminov</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
[&#9679;], 2023, we entered into an employment agreement with Mr. Aminov pursuant to which Mr. Aminov will serve as our President. Under
his employment agreement, Mr. Aminov has agreed to work part-time and on an as-needed basis with respect to the affairs of our company.
Mr. Aminov&rsquo;s employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr.
Aminov or our company at any time for cause. Under the agreement, Mr. Aminov will receive an initial base salary of $[_______] per year.
In the event that his employment is terminated by our company without &ldquo;Cause&rdquo; or is terminated by Mr. Aminov for &ldquo;Good
Reason&rdquo;, Mr. Aminov will be entitled to severance compensation in the form of salary continuation for a period of three months
(subject to Mr. Aminov executing and delivering a customary general release in favor of the company). &ldquo;Cause&rdquo; is defined
in the agreement to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. &ldquo;Good
Reason&rdquo; is defined to include a material adverse change in Mr. Aminov&rsquo;s compensation or duties and level of responsibility.
The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Aminov is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>James
A. McNulty, CPA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
[&#9679;], 2023, we entered into an employment agreement with Mr. McNulty pursuant to which Mr. McNulty will serve as our Chief Financial
Officer and Treasurer on a full-time basis. Mr. McNulty&rsquo;s employment agreement provides that his employment will be on an at-will
basis and can be terminated by either Mr. McNulty or our company at any time for cause. Under the agreement, Mr. McNulty will receive
an initial base salary of $[_______] per year. In the event that his employment is terminated by our company without &ldquo;Cause&rdquo;
or is terminated by Mr. McNulty for &ldquo;Good Reason&rdquo;, Mr. McNulty will be entitled to severance compensation in the form of
salary continuation for a period of three months (subject to Mr. McNulty executing and delivering a customary general release in favor
of the company). &ldquo;Cause&rdquo; is defined in the agreement to include dishonesty, misappropriation, willful misconduct, breach
of the agreement, and other customary matters. &ldquo;Good Reason&rdquo; is defined to include a material adverse change in Mr. McNulty&rsquo;s
compensation or duties and level of responsibility. The employment agreement also contains customary confidentiality and invention-assignment
covenants to which Mr. McNulty is subject. Beginning in 2023, in lieu of health insurance coverage and 401k benefits, we have agreed
to pay premiums under Mr. McNulty&rsquo;s life insurance policy in an amount up to [_______] per quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Base
Salaries</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
base salaries of our employed executive officers are specified in their respective employment agreements, as summarized above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bonuses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not pay any bonuses to any of our named executive officers during 2022 or during the first two quarters of 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the date of this prospectus, none of our officers, directors, or employees have received any equity compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Retirement
Plans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently maintain any retirement plans for our employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted and outstanding as of December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023
Omnibus Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to adopt the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (the &ldquo;2023 Omnibus Plan&rdquo;) prior to the completion
of this offering. The 2023 Omnibus Plan will authorize the grant of incentive stock options, within the meaning of Section 422 of the
Internal Revenue Code, to our employees and any of our parent and subsidiary corporations&rsquo; employees, and the grant of non-statutory
stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to our employees,
directors, and consultants and any of our future subsidiary corporations&rsquo; employees and consultants. The following is a summary
of certain terms and conditions of the 2023 Omnibus Plan that we intend to adopt. This summary is qualified in its entirety by reference
to the 2023 Omnibus Plan attached as an exhibit to the registration statement of which this prospectus forms a part, as well as conditioned
upon and subject to the approval of the 2023 Omnibus Plan by our Board and our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Administration</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan is administered by our board of directors or our compensation committee, or any other committee or subcommittee or
one or more of our officers to whom authority has been delegated (collectively, the &ldquo;Administrator&rdquo;). The Administrator has
the authority to interpret the 2023 Omnibus Plan and award agreements entered into with respect to the 2023 Omnibus Plan; to make, change
and rescind rules and regulations relating to the 2023 Omnibus Plan; to make changes to, or reconcile any inconsistency in, the 2023
Omnibus Plan or any award agreement covering an award; and to take any other actions needed to administer the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eligibility</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may designate any of the following as a participant under the 2023 Omnibus Plan: any officer or employee, or individuals
engaged to become an officer or employee, of our company or our affiliates; and consultants of our company or our affiliates, and our
directors, including our non-employee directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Types
of Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan permits the Administrator to grant stock options, stock appreciation rights (&ldquo;SARs&rdquo;), performance shares,
performance units, shares of common stock, restricted stock, restricted stock units (&ldquo;RSUs&rdquo;), cash incentive awards, dividend
equivalent units, or any other type of award permitted under the 2023 Omnibus Plan. The Administrator may grant any type of award to
any participant it selects, but only our employees or our subsidiaries&rsquo; employees may receive grants of incentive stock options
within the meaning of Section 422 of the Internal Revenue Code. Awards may be granted alone or in addition to, in tandem with, or (subject
to the repricing prohibition described below) in substitution for any other award (or any other award granted under another plan of our
company or any affiliate, including the plan of an acquired entity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
Reserved Under the 2023 Omnibus Incentive Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan will provide that 5,000,000 shares of our common stock are reserved for issuance under the 2023 Omnibus Plan, all of
which may be issued pursuant to the exercise of incentive stock options. The number of shares available for issuance under our 2023 Omnibus
Plan will also include an annual increase on the first day of each fiscal year after the completion of this offering equal to the lesser
of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000
    shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0%
    of the outstanding shares of all class of our common stock as of the last day of the immediately preceding fiscal year; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    other amount as our board of directors may determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares reserved for issuance under the 2023 Omnibus Plan will be reduced on the date of the grant of any award by the maximum
number of shares, if any, with respect to which such award is granted. However, an award that may be settled solely in cash will not
deplete the 2023 Omnibus Plan&rsquo;s share reserve at the time the award is granted. If (a) an award expires, is canceled, or terminates
without issuance of shares or is settled in cash, (b) the Administrator determines that the shares granted under an award will not be
issuable because the conditions for issuance will not be satisfied, (c) shares are forfeited under an award, (d) shares are issued under
any award and we reacquire them pursuant to our reserved rights upon the issuance of the shares, (e) shares are tendered or withheld
in payment of the exercise price of an option or as a result of the net settlement of outstanding stock appreciation rights or (f) shares
are tendered or withheld to satisfy federal, state or local tax withholding obligations, then those shares are added back to the reserve
and may again be used for new awards under the 2023 Omnibus Plan. However, shares added back to the reserve pursuant to clauses (d),
(e) or (f) in the preceding sentence may not be issued pursuant to incentive stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant stock options and determine all terms and conditions of each stock option, which include the number of stock
options granted, whether a stock option is to be an incentive stock option or non-qualified stock option, and the grant date for the
stock option. However, the exercise price per share of common stock may never be less than the fair market value of a share of common
stock on the date of grant and the expiration date may not be later than 10 years after the date of grant. Stock options will be exercisable
and vest at such times and be subject to such restrictions and conditions as are determined by the Administrator, including with respect
to the manner of payment of the exercise price of such stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Appreciation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant SARs, which represent the right of a participant to receive cash in an amount, or common stock with a fair market
value, equal to the appreciation of the fair market value of a share of common stock during a specified period of time. The 2023 Omnibus
Plan provides that the Administrator will determine all terms and conditions of each SAR, including, among other things: (a) whether
the SAR is granted independently of a stock option or relates to a stock option, (b) the grant price, which may never be less than the
fair market value of our common stock as determined on the date of grant, (c) a term that must be no later than 10 years after the date
of grant, and (d) whether the SAR will settle in cash, common stock or a combination of the two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Performance
and Stock Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant awards of shares of common stock, restricted stock, RSUs, performance shares or performance units. Restricted
stock means shares of common stock that are subject to a risk of forfeiture or restrictions on transfer, which may lapse upon the achievement
or partial achievement of performance goals (as described below) or upon the completion of a period of service. An RSU grants the participant
the right to receive cash or shares of common stock the value of which is equal to the fair market value of one share of common stock,
to the extent performance goals are achieved or upon the completion of a period of service. Performance shares give the participant the
right to receive shares of common stock to the extent performance goals are achieved. Performance units give the participant the right
to receive cash or shares of common stock valued in relation to a unit that has a designated dollar value or the value of which is equal
to the fair market value of one or more shares of common stock, to the extent performance goals are achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator will determine all terms and conditions of the awards including (a) whether performance goals must be achieved for the
participant to realize any portion of the benefit provided under the award, (b) the length of the vesting or performance period and,
if different, the date that payment of the benefit will be made, (c) with respect to performance units, whether to measure the value
of each unit in relation to a designated dollar value or the fair market value of one or more shares of common stock, and (d) with respect
to performance shares, performance units, and RSUs, whether the awards will settle in cash, in shares of common stock (including restricted
stock), or in a combination of the two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Incentive Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant cash incentive awards. An incentive award is the right to receive a cash payment to the extent one or more performance
goals are achieved. The Administrator will determine all terms and conditions of a cash incentive award, including, but not limited to,
the performance goals (described below), the performance period, the potential amount payable, and the timing of payment. While the 2023
Omnibus Plan permits cash incentive awards to be granted under the 2023 Omnibus Plan, we may also make cash incentive awards outside
of the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Performance
Goals</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the 2023 Omnibus Plan, the Administrator may establish objective or subjective performance goals which may apply to any performance
award. Such performance goals may include, but are not limited to, one or more of the following measures with respect to our company
or any one or more of our subsidiaries, affiliates, or other business units: net sales; cost of sales; gross income; gross revenue; revenue;
operating income; earnings before taxes; earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization;
earnings before interest, taxes, depreciation, amortization and exception items; income from continuing operations; net income; earnings
per share; diluted earnings per share; total stockholder return; fair market value of a share of common stock; cash flow; net cash provided
by operating activities; net cash provided by operating activities less net cash used in investing activities; ratio of debt to debt
plus equity; return on stockholder equity; return on invested capital; return on average total capital employed; return on net capital
employed; return on assets; return on net assets employed before interest and taxes; operating working capital; average accounts receivable
(calculated by taking the average of accounts receivable at the end of each month); average inventories (calculated by taking the average
of inventories at the end of each month); economic value added; succession planning; manufacturing return on assets; manufacturing margin;
and customer satisfaction. Performance goals may also relate to a participant&rsquo;s individual performance. The Administrator reserves
the right to adjust any performance goals or modify the manner of measuring or evaluating a performance goal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Equivalent Units</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant dividend equivalent units. A dividend equivalent unit gives the participant the right to receive a payment, in
cash or shares of common stock, equal to the cash dividends or other distributions that we pay with respect to a share of common stock.
We determine all terms and conditions of a dividend equivalent unit award, except that dividend equivalent units may not be granted in
connection with a stock option or SAR, and dividend equivalent unit awards granted in connection with another award cannot provide for
payment until the date such award vests or is earned, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Stock-Based Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant to any participant shares of unrestricted stock as a replacement for other compensation to which such participant
is entitled, such as in payment of director fees, in lieu of cash compensation, in exchange for cancellation of a compensation right
or as a bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transferability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
are not transferable, including to any financial institution, other than by will or the laws of descent and distribution, unless the
Administrator allows a participant to (a) designate in writing a beneficiary to exercise the award or receive payment under the award
after the participant&rsquo;s death, (b) transfer an award to a former spouse as required by a domestic relations order incident to a
divorce, or (c) transfer an award without receiving any consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adjustments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(a) we are involved in a merger or other transaction in which our shares of common stock are changed or exchanged; (b) we subdivide or
combine shares of common stock or declare a dividend payable in shares of common stock, other securities, or other property (other than
stock purchase rights issued pursuant to a stockholder rights agreement); (c) we effect a cash dividend that exceeds 10% of the fair
market value of a share of common stock or any other dividend or distribution in the form of cash or a repurchase of shares of common
stock that our board of directors determines is special or extraordinary, or that is in connection with a recapitalization or reorganization;
or (d) any other event occurs that in the Administrator&rsquo;s judgment requires an adjustment to prevent dilution or enlargement of
the benefits intended to be made available under the 2023 Omnibus Plan, then the Administrator will, in a manner it deems equitable,
adjust any or all of (1) the number and type of shares subject to the 2023 Omnibus Plan and which may, after the event, be made the subject
of awards; (2) the number and type of shares of common stock subject to outstanding awards; (3) the grant, purchase, or exercise price
with respect to any award; and (4) the performance goals of an award. In any such case, the Administrator may also provide for a cash
payment to the holder of an outstanding award in exchange for the cancellation of all or a portion of the award, subject to the terms
of the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, authorize the issuance
or assumption of awards upon terms and conditions we deem appropriate without affecting the number of shares of common stock otherwise
reserved or available under the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
of Control</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a change of control (as defined in the 2023 Omnibus Plan), the successor or surviving corporation may agree to assume some or all outstanding
awards or replace them with the same type of award with similar terms and conditions, without the consent of any participant, subject
to the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    award that is assumed must be appropriately adjusted, immediately after such change of control, to apply to the number and class
    of securities that would have been issuable to a participant upon the consummation of such change of control had the award been exercised,
    vested, or earned immediately prior to such change of control, and other appropriate adjustment to the terms and conditions of the
    award may be made.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the securities to which the awards relate after the change of control are not listed and traded on a national securities exchange,
    then (a) each participant must be provided the option to elect to receive, in lieu of the issuance of such securities, cash in an
    amount equal to the fair value of the securities that would have otherwise been issued, and (b) no reduction may be taken to reflect
    a discount for lack of marketability, minority, or any similar consideration, for purposes of determining the fair value of such
    securities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a participant is terminated from employment without cause, or due to death or disability, or the participant resigns employment for
    good reason (as defined in any award or other agreement between the participant and our company or an affiliate) within two years
    following the change of control, then upon such termination, all of the participant&rsquo;s awards in effect on the date of such
    termination will vest in full or be deemed earned in full.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the purchaser, successor, or surviving entity does not assume the awards or issue replacement awards, then immediately prior to the change
of control date, unless the Administrator otherwise determines:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    stock option or SAR then held by a participant will become immediately and fully vested, and all stock options and SARs will be cancelled
    on the change of control date in exchange for a cash payment equal to the excess of the change of control price of the shares of
    common stock over the purchase or grant price of such shares under the award.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
    restricted stock and RSUs (that are not performance awards) will vest in full.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    performance shares, performance units and cash incentive awards for which the performance period has expired will be paid based on
    actual performance, and all such awards for which the performance period has not expired will be cancelled in exchange for a cash
    payment equal to the amount that would have been due under such awards, valued assuming achievement of target performance goals at
    the time of the change of control, prorated based on the number of full months elapsed in the performance period.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    unvested dividend equivalent units will vest (to the same extent as the award granted in tandem with such units) and be paid.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other unvested awards will vest and any amounts payable will be paid in cash.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Term
of Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated by our board of directors, the 2023 Omnibus Plan will terminate on, and no further awards may be granted, after the
tenth (10<SUP>th</SUP>) anniversary of its effective date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Termination
and Amendment of Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors or the Administrator may amend, alter, suspend, discontinue, or terminate the 2023 Omnibus Plan at any time, subject
to the following limitations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    board of directors must approve any amendment to the 2023 Omnibus Plan if we determine such approval is required by prior action
    of our board of directors, applicable corporate law, or any other applicable law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    must approve any amendment to the 2023 Omnibus Plan, which may include an amendment to materially increase the number of shares reserved
    under the 2023 Omnibus Plan, if we determine that such approval is required by Section 16 of the Exchange Act, the Code, the listing
    requirements of any principal securities exchange or market on which the shares are then traded, or any other applicable law; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    must approve any amendment to the 2023 Omnibus Plan that would diminish the protections afforded by the participant award limits
    or repricing and backdating prohibitions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment,
Modification, Cancellation and Disgorgement of Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the requirements of the 2023 Omnibus Plan, the Administrator may modify or amend any award or waive any restrictions or conditions
applicable to any award or the exercise of the award, or amend, modify, or cancel any terms and conditions applicable to any award, in
each case, by mutual agreement of the Administrator and the participant or any other person that may have an interest in the award, so
long as any such action does not increase the number of shares of common stock issuable under the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not need to obtain participant (or other interested party) consent for any such action (a) that is permitted pursuant to the adjustment
provisions of the 2023 Omnibus Plan; (b) to the extent we deem the action necessary to comply with any applicable law or the listing
requirements of any principal securities exchange or market on which our common stock is then traded; (c) to the extent we deem the action
is necessary to preserve favorable accounting or tax treatment of any award for us; or (d) to the extent we determine that such action
does not materially and adversely affect the value of an award or that such action is in the best interest of the affected participant
or any other person as may then have an interest in the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator can cause a participant to forfeit any award, and require the participant to disgorge any gains attributable to the award,
if the participant engages in any action constituting, as determined by the Administrator in its discretion, cause for termination, or
a breach of a material company policy, any award agreement or any other agreement between the participant and us or one of our affiliates
concerning noncompetition, nonsolicitation, confidentiality, trade secrets, intellectual property, nondisparagement or similar obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
awards granted under the 2023 Omnibus Plan, and any shares of common stock issued or cash paid under an award, will be subject to any
recoupment or clawback policy that we adopt, or any recoupment or similar requirement otherwise made applicable by law, regulation or
listing standards to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_002"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of transactions within the last three years to which we have been a party, in which the amount involved exceeded
or will exceed $120,000, and in which any of our executive officers, directors or holders of more than 5% of our voting securities, or
an immediate family member thereof, had or will have a direct or indirect material interest. We believe the terms obtained or consideration
that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or amounts
that would be paid or received, as applicable, in arm&rsquo;s-length transactions with unrelated third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Line
of Credit and Promissory Note with the Bay Shore Trust</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, an trust established by our founder, Jonnie
R. Williams, Sr., and under which various of his family members are beneficiaries (the &ldquo;Bay Shore Trust&rdquo;). Under this Promissory
Note and Loan Agreement (the &ldquo;Bay Shore Note&rdquo;), we have the right to borrow up to an aggregate of $5,000,000 from the Bay
Shore Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of our
initial public offering. Our right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in
our assets, operations, or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary
of the issuance of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at
a rate equal to 7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest,
thereafter. The Bay Shore Note is unsecured. As of August 1, 2023, the outstanding principal amount under the Bay Shore Note is $0.8
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January 1, 2023, MIRALOGX and The Starwood Trust, a separate Trust established by our founder, have advanced funds on behalf of Bayshore
Trust to our company in order to fund operating activities. The total cumulative amount of such outstanding advances was $0.3 million
as of March 31, 2023. The total amount advanced and outstanding as of June 30, 2023, was $0.5 million. These advances were consolidated
into the Bay Shore Note as of June 30, 2023, and became payable under the terms of the Bay Shore Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, we issued to the Bay Shore Trust a common stock purchase warrant
on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 5,000,000 shares of common stock at an exercise price of $1.82
per share, which warrant will expire five years after the date of grant. Pursuant to a registration rights agreement, we have granted
to Bay Shore Trust the right to require us, at any time after one year following our initial public offering, to register for resale
the shares issuable upon the exercise of the warrant, with such registration rights being in the form of demand and &ldquo;piggyback&rdquo;
registration rights that are subject to customary limitations and restrictions. Upon issuance, the warrant met the criteria to be classified
as equity based on an analysis under Accounting Standards Codification (480) ASC 480, &ldquo;<I>Distinguishing Liabilities from Equity</I>&rdquo;
and will be measured at fair value, resulting in an initial fair value of approximately $5.95 &nbsp;million upon issuance of the warrant
using Black-Scholes valuation techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with MIRALOGX LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2023, we entered into the MIRALOGX License Agreement with MIRALOGX, which is an intellectual property development and holding
company established by our founder and the inventor of TELOMIR-1, Jonnie R. Williams, Sr. See &ldquo;Business&ndash; Intellectual Property&rdquo;.
MIRALOGX is wholly owned by the Bay Shore Trust.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Review
and Approval of Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, our board of directors will adopt a written policy regarding the review and approval of related party
transactions. Our audit committee charter provides that the audit committee shall review and approve or disapprove any related party
transactions, which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected
to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. Upon the completion of this
offering, our policy regarding transactions between us and related persons will provide that a related person is defined as a director,
executive officer, nominee for director or greater than 5% beneficial owner of our common stock, in each case since the beginning of
the most recently completed year, and any of their immediate family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the foregoing disclosures are summaries of certain provisions of our related party agreements and are qualified in their entirety
by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable agreements,
they do not necessarily contain all of the information that you may find useful. Copies of certain of the agreements have been filed
as exhibits to the registration statement of which this prospectus is a part and are available electronically on the website of the SEC
at <I>www.sec.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_003"></A>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of August 1, 2023 (the &ldquo;Beneficial Ownership Date&rdquo;) with respect to the beneficial
ownership of our common stock (i) immediately prior to this offering and (ii) as adjusted to reflect the sale of [&#9679;] shares of
our common stock in this offering, in each case by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current directors and executive officers as a group; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment
power with respect to our securities. In computing the number of shares beneficially owned by a person and the percentage ownership of
that person, shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable
within 60 days of the Beneficial Ownership Date are deemed outstanding but are not deemed outstanding for computing the percentage ownership
of any other person. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting
and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.
The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and
13(g) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the table below, the applicable percentage ownership relating to shares beneficially owned prior to this offering is based on shares
of our common stock outstanding as of the Beneficial Ownership Date. The applicable percentage ownership relating to shares beneficially
owned after this offering is based on 55,549,451 shares of our common stock outstanding and assumes that the underwriters do not
exercise their option to purchase additional shares of common stock from us. Unless otherwise indicated in the footnotes to the table
below, the address of each beneficial owner listed in the table below is 900 West Platt Street Suite 200, Tampa, Florida 33606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Beneficially Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Beneficially Owned Before this Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Beneficially Owned After this Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of beneficial owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-align: left">Directors and Executive Officers</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Christopher Chapman, Jr., MD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.60</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">James A. McNulty, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Erez Aminov</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Christos Nicholoudis, Esq.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Brad Kroenig</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dave Vorhoff</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Craig Eagle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Talhia Tuck</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Hugh McColl III</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">All current directors and officers as a group (9 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.21</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">5% Stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Cappy<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,672,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37.21</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alton Cates<SUP>(2) </SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.04</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian McNulty<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.04</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan Dearborn<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.04</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William J. Nellis<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,850,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.13</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samuel S. Duffey<SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,850,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.13</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">*Represents beneficial ownership of less than 1%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) 50,000 shares held directly by Mr. Cappy, (ii) 15,622,500 shares held by the Bay Shore Trust, and (iii) 5,000,000 shares issuable
    pursuant to a warrant held by the Bay Shore Trust that is immediately exercisable. As trustee of the Bay Shore Trust, Mr. Cappy has
    sole voting and dispositive power over the shares held by the trust, and, as a result is deemed to have beneficial ownership (as
    determined under Section 13(d) of the Exchange Act) of the securities held by the trust.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 2,800,000 shares held by the Caroline Constance Williams 2020 Irrevocable Trust. As trustee of the Caroline Constance Williams
    2020 Irrevocable Trust, Mr. Cates has sole voting and dispositive power over the shares held by the trust, and, as a result is deemed
    to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities held by the trust.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 2,800,000 shares held by the Celeste J. Williams Lifetime QTIP Trust. As trustee of the Celeste J. Williams Lifetime QTIP Trust,
    Mr. McNulty has sole voting and dispositive power over the shares held by the trust, and, as a result is deemed to have beneficial
    ownership (as determined under Section 13(d) of the Exchange Act) of the securities held by the trust.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 2,800,000 shares held by the Francis Murray Williams 2020 Irrevocable Trust. As trustee of the Francis Murray Williams 2020 Irrevocable
    Trust, Mr. Dearborn has sole voting and dispositive power over the shares held by the trust, and, as a result is deemed to have beneficial
    ownership (as determined under Section 13(d) of the Exchange Act) of the securities held by the trust.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 50,000 shares held directly by Mr. Nellis and (ii) 2,800,000 shares held by the Jonnie Ray Williams, Jr. 2020 Irrevocable
    Trust. As trustee of the Jonnie Ray Williams, Jr. 2020 Irrevocable Trust, Mr. Nellis has sole voting and dispositive power over the
    shares held by the trust, and, as a result is deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange
    Act) of the securities held by the trust.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 50,000 shares held directly by Mr. Duffey and (ii) 2,800,000 shares held by the Rachel Jean Williams 2020 Irrevocable Trust.
    As trustee of the Rachel Jean Williams 2020 Irrevocable Trust, Mr. Duffey has sole voting and dispositive power over the shares held
    by the trust, and, as a result is deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of
    the securities held by the trust.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_004"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the material terms of our amended and restated articles of incorporation and our amended and restated bylaws
to be in effect upon the completion of this offering. The following description is a summary, does not purport to be complete and is
qualified in its entirety by reference to our second amended and restated articles of incorporation and amended and restated bylaws,
which are filed as exhibits to the registration statement of which this prospectus is a part and are incorporated by reference into this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of shares of common stock our company is authorized to issue is presently 95,000,000 shares, no par value. The total number
of shares of preferred stock our company is authorized to issue is 5,000,000 shares, no par value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a corporation organized under the laws of the state of Florida and are governed by the Florida Business Corporation Act, which we
sometimes refer to as the FBCA, our amended and restated articles of incorporation and our amended and restated bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of our common stock are entitled to one vote for each share held on all matters submitted to a vote of shareholders. Accordingly,
holders of a majority of the shares of our common stock entitled to vote in any election of directors may elect all of the directors
standing for election. Holders of shares of our common stock are entitled to receive proportionately any dividends if and when such dividends
are declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. Upon the liquidation,
dissolution or winding up of the company, the holders of our common stock are entitled to receive ratably net assets available after
the payment of all debts and other liabilities and subject to the prior rights of holders of any outstanding preferred stock. The rights,
preferences, and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders
of shares of any series of preferred stock that we may designate and issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of our amended and restated articles of incorporation, which we sometimes refer to as the articles, the board of directors
is authorized to designate and issue up to [&#9679;] shares of preferred stock in one or more series without shareholder approval. Our
board of directors will have discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend
rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of our common
stock until the board of directors determines the specific rights of the holders of the preferred stock. However, these effects might
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricting
    dividends on the common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting
    the voting power of the common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing
    the liquidation rights of the common stock; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying
    or preventing a change in control of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, there will be no shares of preferred stock outstanding and, at present, we have no plans to issue any shares
of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends
and Other Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of our common stock will be entitled to receive proportionately any cash or stock dividends if and when such dividends are declared
by the board of directors, subject to any preferential dividend rights of outstanding preferred stock. In the event of the dissolution
or liquidation of the company, after the full preferential rights, if any, on any outstanding preferred stock has been paid to or set
aside for the holders of such preferred stock, the holders of our common stock will be entitled to receive proportionately all of our
remaining assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
declaration and payment of any dividend will be subject to the discretion of our board of directors, subject to applicable laws. The
time and amount of any dividend will depend on a number of factors, including our financial condition, results of operations, capital
requirements, contractual restrictions, general business conditions, and any other factors that our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to retain all available funds and any future earnings for general corporate purposes, including working capital, operating
expenses, and capital expenditures, and do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable
future. See &ldquo;Dividend Policy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
and Election of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board consists of seven members. The holders of common stock and any other class of stock of our company, to the extent they shall have
the right to vote, shall retain the right to elect and remove all members of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quorum/Voting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
all meetings of our board of directors, a majority of the total number of directors constitutes a quorum. If there is a quorum, a vote
of the majority of the directors present at the meeting is considered an act of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Removal
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles provide that any director may be removed from office, but only for cause by the affirmative vote of not
less than a majority of our shareholders entitled to vote in the election of directors. &ldquo;Cause&rdquo; is construed to exist only
if the director whose removal is proposed has been convicted of a felony or has been adjudged to be liable for willful misconduct in
the performance of his or her duties to us in a matter which has a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vacancies
on the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
vacancy on our board of directors may be filled by a vote of a majority of the remaining members of the board of directors, even if less
than a quorum, at any meeting of the board of directors. A person so elected by the board of directors to fill a vacancy shall hold office
for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&rsquo;s successor
shall have been duly elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
by Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of our common stock is entitled to one vote per share for the election of directors and for all other corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
of Articles</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FBCA allows us to amend our amended and restated articles at any time to add or change a provision that is required or permitted to be
included in the articles of incorporation or to delete a provision that is not required to be included in the articles of incorporation.
Our board of directors can propose one or more amendments for submission to shareholders and may condition its submission of the proposed
amendment on any basis if it provides certain notice and includes certain information regarding the proposed amendment in that notice.
The provisions in our articles that require a greater voting requirement than provided in the FBCA may only be amended by the same vote
required to take action under that voting requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
of Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws may be amended or repealed, and new bylaws may be adopted by our shareholders at any annual or special meetings at which a quorum
is present. The bylaws may also be amended or repealed, and new bylaws may be adopted by our board of directors by affirmative vote of
a majority of the number of directors present at any meeting at which a quorum is in attendance. Notwithstanding the foregoing, pursuant
to our articles, the provisions of our bylaws that require a greater voting requirement than provided in the FBCA may only be amended
by the same vote required to take action under that voting requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Various Provisions of Florida Law, Our Amended and Restated Articles of Incorporation and Our Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of Florida law have certain anti-takeover effects. Our amended and restated articles of incorporation and bylaws also contain provisions
that may have similar effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Florida
Anti-Takeover Statutes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control share acquisition statute, Section 607.0902 of the FBCA, generally provides that in the event a person acquires voting shares
of the company in excess of 20% of the voting power of all of our issued and outstanding shares, such acquired shares will not have any
voting rights unless such rights are restored by the holders of a majority of the votes of each class or series entitled to vote separately,
excluding shares held by the person acquiring the control shares or any of our officers or employees who are also directors of the company.
Certain acquisitions of shares are exempt from these rules, such as shares acquired pursuant to the laws of intestate succession or pursuant
to a gift or testamentary transfer, pursuant to a merger or share exchange effected in compliance with the FBCA if we are a party to
the agreement, or pursuant to an acquisition of our shares if the acquisition has been approved by our board of directors before the
acquisition. The control share acquisition statute generally applies to any &ldquo;issuing public corporation,&rdquo; which means a Florida
corporation which has:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    hundred or more shareholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
    principal place of business, its principal office, or substantial assets within Florida; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    (i) more than 10% of its shareholders are resident in Florida; (ii) more than 10% of its shares are owned by residents of Florida;
    or (iii) one thousand shareholders are resident in Florida.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affiliated transaction (or so-called &ldquo;business combination&rdquo;) statute, Section 607.0901 of the FBCA, provides that we may
not engage in certain mergers, consolidations, sales of assets, issuances of stock, reclassifications, recapitalizations, and other affiliated
transactions with any &ldquo;interested shareholder&rdquo; for a period of three years following the time that such shareholder became
an interested shareholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to the time that such shareholder became an interested shareholder, our board of directors approved either the affiliated transaction
    or the transaction which resulted in the shareholder becoming an interested shareholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;interested shareholder&rdquo; is generally defined as any person who is the beneficial owner of more than 15% of our outstanding
voting shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
voting requirements set forth above do not apply to a particular affiliated transaction if one or more conditions are met, including,
but not limited to, the following: if the affiliated transaction has been approved by a majority of our disinterested directors; if we
have not had more than 300 shareholders of record at any time during the three years preceding the date the affiliated transaction is
announced; if the interested shareholder has been the beneficial owner of at least 80% of our outstanding voting shares for at least
three years preceding the date the affiliated transaction is announced; or if the consideration to be paid to the holders of each class
or series of voting shares in the affiliated transaction meets certain requirements of the statute with respect to form and amount, among
other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Cumulative Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FBCA provides that shareholders do not have the right to cumulate votes in the election of directors unless the articles of incorporation
provide otherwise. Our articles do not provide for cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Shareholder Proposals and Director Nominations; Calling a Special Meeting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that shareholders seeking to bring business before an annual meeting must provide timely notice of
their proposal in writing to the corporate secretary. To be timely, a shareholder&rsquo;s notice must have been received on or before
December 31 of the year immediately preceding the annual meeting; provided, however, that in the event that the date of the annual meeting
is on or after May 1 in any year, notice by the shareholder to be timely must be received not later than the close of business on the
day which is determined by adding to December 31 of the year immediately preceding such annual meeting the number of days starting with
May 1 and ending on the date of the annual meeting in such year. The amended and restated bylaws also specify requirements as to the
form and content of a shareholder&rsquo;s notice. These provisions may impede shareholders&rsquo; ability to bring matters before an
annual meeting of shareholders or make nominations for directors at an annual meeting of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws also provide that a special meeting of shareholders can only be called by our chairman of the board of directors,
our chief executive officer, our president (in the absence of a chief executive officer), a majority of our board of directors or the
holders of 10% or more of all of our votes entitled to be cast on any issue proposed to be considered at the special meeting of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
But Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued shares of common stock and preferred stock will be available for future issuance without shareholder approval.
We could use these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital,
acquisitions of other businesses or entities and issuances under employee benefit plans. Additionally, we could issue a series of preferred
stock that could, depending on its terms, impede the completion of a merger, tender offer or other takeover attempt. Our board of directors
will make any determination to issue such shares based on its judgment as to the best interests of us and our shareholders. The board
of directors, in so acting, could issue preferred stock having terms that could discourage an acquisition attempt through which an acquiror
may be able to change the composition of the board of directors, including a tender offer or other transaction that some, or a majority,
of our shareholders might believe to be in their best interests or in which shareholders might receive a premium over the then-current
market price of the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Jurisdiction</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive
forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty
owed by any of our current or former directors, officers or other employees to us or our shareholders, (iii) any action arising pursuant
to any provision of the FBCA, our amended and restated articles of incorporation or our amended and restated bylaws, or (iv) any other
action asserting a claim that is governed by the internal affairs doctrine shall be a state court located within the state of Florida
(or, if a state court located within the state of Florida does not have jurisdiction, the federal district court for the Middle District
of Florida); provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by
the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Our bylaws also provide that, unless we consent
in writing to the selection of an alternative forum, the U.S. federal district courts shall be the exclusive forum for the resolution
of any claims arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities
shall be deemed to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing increased
consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging
lawsuits against us or our directors and officers. We note that investors cannot waive compliance with the federal securities laws and
the rules and regulations thereunder. Please also see the section titled &ldquo;Risk Factors&mdash;Risks Related to Ownership of our
Common Stock&mdash;Our bylaws that will be in effect immediately prior to the completion of this offering designates the state courts
located within the state of Florida as the exclusive forum for substantially all disputes between us and our shareholders and the federal
district courts as the exclusive forum for Securities Act claims, which could limit our shareholders&rsquo; ability to obtain a favorable
judicial forum for disputes with us.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preemptive
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
holder of our common stock has any preemptive or subscription rights to acquire shares of our capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liability
and Indemnification of Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of incorporation and bylaws provide that we shall indemnify any and all persons whom we shall have power
to indemnify under the FBCA to the fullest extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0831 of the FBCA, provides that a director is not personally liable for monetary damages to the corporation or any other person for
any statement, vote, decision to take or not to take action, or any failure to take any action, as a director, unless (1) the director
breached or failed to perform his or her duties as a director and (2) the director&rsquo;s breach of, or failure to perform, those duties
constitutes (a) a violation of the criminal law, unless the director had reasonable cause to believe his or her conduct was lawful or
had no reasonable cause to believe his or her conduct was unlawful, (b) a transaction from which the director derived an improper personal
benefit, either directly or indirectly, (c) a circumstance under which the liability provisions of Section 607.0834 of the FBCA are applicable,
(d) in a proceeding by or in the right of the corporation to procure a judgment in its favor or by or in the right of a shareholder,
conscious disregard for the best interest of the corporation, or willful or intentional misconduct, or (e) in a proceeding by or in the
right of someone other than the corporation or a shareholder, recklessness or an act or omission which was committed in bad faith or
with malicious purpose or in a manner exhibiting wanton and willful disregard of human rights, safety, or property. A judgment or other
final adjudication against a director in any criminal proceeding for a violation of the criminal law estops that director from contesting
the fact that his or her breach, or failure to perform, constitutes a violation of the criminal law; but does not estop the director
from establishing that he or she had reasonable cause to believe that his or her conduct was lawful or had no reasonable cause to believe
that his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 607.0851 of the FBCA, a corporation has power to indemnify any person who is a party to any proceeding (other than an action
by, or in the right of the corporation), because he or she is or was a director or officer of the corporation against liability incurred
in connection with such proceeding, including any appeal thereof, if he or she acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had
no reasonable cause to believe his or her conduct was unlawful. The termination of any proceeding by judgment, order, settlement or conviction
or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith
and in a manner which he or she reasonably believed to be in, or not opposed to, the best interests of the corporation or, with respect
to any criminal action or proceeding, has reasonable cause to believe that his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the indemnification provisions of the FBCA, &ldquo;director&rdquo; or &ldquo;officer&rdquo; means an individual who is or
was a director or officer, respectively, of a corporation or who, while a director or officer of the corporation, is or was serving at
the corporation&rsquo;s request as a director or officer, manager, partner, trustee, employee, or agent of another domestic or foreign
corporation, limited liability company, partnership, joint venture, trust, employee benefit plan, or another enterprise or entity and
the terms include, unless the context otherwise requires, the estate, heirs, executors, administrators, and personal representatives
of a director or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 607.0851 of the FBCA, a corporation has the power to indemnify any person, who was or is a party to any proceeding
by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director or
officer, against expenses and amounts paid in settlement not exceeding, in the judgment of the board of directors, the estimated expense
of litigating the proceeding to conclusion, actually and reasonably incurred in connection with the defense or settlement of such proceeding,
including any appeal thereof. Such indemnification shall be authorized if such person acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made under this
subsection in respect of any claim, issue, or matter as to which such person shall have been adjudged to be liable unless, and only to
the extent that, the court in which such proceeding was brought, or any other court of competent jurisdiction, shall determine upon application
that, despite the adjudication of liability but in view of all circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses which such court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0852 of the FBCA provides that a corporation must indemnify an individual who is or was a director or officer who was wholly successful,
on the merits or otherwise, in the defense of any proceeding to which the individual was a party because he or she is or was a director
or officer of the corporation against expenses incurred by the individual in connection with the proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0853 of the FBCA provides that a corporation may, before final disposition of a proceeding, advance funds to pay for or reimburse
expenses incurred in connection with the proceeding by an individual who is a party to the proceeding because that individual is or was
a director or an officer if the director or officer delivers to the corporation a signed written undertaking of the director or officer
to repay any funds advanced if (a) the director or officer is not entitled to mandatory indemnification under Section 607.0852; and (b)
it is ultimately determined under Section 607.0854 or Section 607.0855 (as described below) that the director or officer has not met
the relevant standard of conduct described in Section 607.0851 or the director or officer is not entitled to indemnification under Section
607.0859 (as described below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0854 of the FBCA provides that, unless the corporation&rsquo;s articles of incorporation provide otherwise, notwithstanding the failure
of a corporation to provide indemnification, and despite any contrary determination of the board of directors or of the shareholders
in the specific case, a director or officer of the corporation who is a party to a proceeding because he or she is or was a director
or officer may apply for indemnification or an advance for expenses, or both, to a court having jurisdiction over the corporation which
is conducting the proceeding, or to a circuit court of competent jurisdiction. Our amended and restated articles of incorporation do
not provide any such exclusion. After receipt of an application and after giving any notice it considers necessary, the court may order
indemnification or advancement of expenses upon certain determinations of the court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0855 of the FBCA provides that, unless ordered by a court under Section 607.0854, a corporation may not indemnify a director or officer
under Section 607.0851 unless authorized for a specific proceeding after a determination has been made that indemnification is permissible
because the director or officer has met the relevant standard of conduct set forth in Section 607.0851.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0857 of the FBCA also provides that a corporation shall have the power to purchase and maintain insurance on behalf of and for the
benefit of any person who is or was a director or officer of the corporation against any liability asserted against the person and incurred
by him or her in any such capacity or arising out of his or her status as such, whether or not the corporation would have the power to
indemnify or advance expenses to the individual against such liability under the provisions of Section 607.0857.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0858 of the FBCA provides that the indemnification provided pursuant to Section 607.0851 and Section 607.0852, and the advancement
of expenses provided pursuant to Section 607.0853, are not exclusive. A corporation may, by a provision in its articles of incorporation,
bylaws, or any agreement, or by vote of shareholders or disinterested directors, or otherwise, obligate itself in advance of the act
or omission giving rise to a proceeding to provide any other or further indemnification or advancement of expenses to any of its directors
or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0859 of the FBCA provides that, unless ordered by a court under the provisions of Section 607.0854 of the FBCA, a corporation may
not indemnify a director or officer under Section 607.0851 or Section 607.0858, or advance expenses to a director or officer under Section
607.0853 or Section 607.0858, if a judgment or other final adjudication establishes that his or her actions, or omissions to act, were
material to the cause of action so adjudicated and constitute: (a) willful or intentional misconduct or a conscious disregard for the
best interests of the corporation in a proceeding by or in the right of the corporation to procure a judgment in its favor or in a proceeding
by or in the right of a shareholder; (b) a transaction in which a director or officer derived an improper personal benefit; (c) a violation
of the criminal law, unless the director or officer had reasonable cause to believe his or her conduct was lawful or had no reasonable
cause to believe his or her conduct was unlawful; or (d) in the case of a director, a circumstance under which the liability provisions
of Section 607.0834 are applicable (relating to unlawful distributions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may have the practical effect in certain cases of eliminating the ability of shareholders to collect monetary damages from
our directors and officers. We believe that these provisions are necessary to attract and retain qualified persons to serve as our directors
and officers. There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for
which indemnification is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
Stock Transfer (also known as Equiniti) will be the transfer agent and registrar for our common stock. The transfer agent&rsquo;s address
is 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;TELO&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_005"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there was no public market for our common stock, and there can be no assurance that a significant public market for
our common stock will develop or be sustained after this offering. Future sales of substantial amounts of our common stock in the public
market (including securities convertible into or redeemable, exchangeable, or exercisable for shares of common stock) or the perception
that such sales may occur or the availability of such shares for sale in the public market, after this offering could adversely affect
the prevailing market price of our common stock. Furthermore, because all of our common stock outstanding prior to the completion of
this offering (including securities convertible into or redeemable, exchangeable, or exercisable for shares of our common stock) will
be subject to the contractual and legal restrictions on resale described below, the sale of a substantial amount of common stock in the
public market after these restrictions lapse could materially adversely affect the prevailing market price of our common stock and our
ability to raise equity capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after
the lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline.
Based on shares of common stock outstanding as of [&#9679;], 2023, upon the completion of this offering we will have outstanding a total
of [&#9679;] shares of common stock. Of these shares, only the shares of common stock sold in this offering by us, plus any shares sold
upon exercise of the underwriters&rsquo; option to purchase additional shares, will be freely tradable without restriction in the public
market immediately following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lock-up agreements pertaining to this offering will expire [&#9679;] days from the date of this prospectus, subject to earlier release
of all or a portion of the shares subject to such agreements by the representatives of the underwriters in this offering in their sole
discretion. After the lock-up agreements expire, based upon the number of shares of common stock, on an as-converted basis, outstanding
as of [&#9679;], 2023, up to an additional [&#9679;] shares of common stock will be eligible for sale in the public market. Approximately
[&#9679;]% of these additional shares are beneficially held by directors, executive officers and their affiliates and will be subject
to certain limitations of Rule 144 under the Securities Act of 1933, as amended, or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity
compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules,
the lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if
it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. Additionally, the
number of shares of our common stock reserved for issuance under the 2023 Omnibus Plan will automatically increase on January 1 of each
year following our initial public offering by the least of 200,000 shares, 1% of outstanding shares, or such lesser number as is determined
by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the shares of common stock sold in this offering will be freely transferable without restriction or further registration under the
Securities Act by persons other than &ldquo;affiliates,&rdquo; as that term is defined in Rule 144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
the balance of our outstanding shares of common stock will be deemed &ldquo;restricted securities&rdquo; within the meaning of Rule 144
under the Securities Act, subject to the limitations and restrictions that are described below. Common stock purchased by our affiliates
will be &ldquo;restricted securities&rdquo; under Rule 144. Restricted securities may be sold in the public market only if they are registered
under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which
rules are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the lock-up agreements described below and subject to the provisions of Rule 144 or Rule 701, shares of our common stock
will be available for sale in the public market as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning
    on the date of this prospectus, all [&#9679;] shares of our common stock sold in this offering will be immediately available for
    sale in the public market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning
    [&#9679;] days after the date of this prospectus, [&#9679;] additional shares of common stock become eligible for sale in the public
    market, of which [&#9679;] shares would be held by affiliates and subject to the volume and other restrictions of Rule 144, as described
    below.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we, our directors, our executive officers and holders of more than 5% of our issued and outstanding shares
of common stock outstanding as of [&#9679;], 2023 have agreed, subject to certain exceptions, with the underwriters not to dispose of
or hedge any shares of our common stock or securities convertible into or exchangeable for shares of common stock during the period from
the date of the lock-up agreement continuing through the date 180 days after the closing date of this offering, except with the prior
written consent of [&#9679;] the representative of the underwriters and certain other exceptions. The representative of the underwriters
has advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to
the expiration of the lock-up period. See &ldquo;Underwriting&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the lock-up periods set forth in the agreements described above, and assuming that the representative of the underwriters does not release
any parties from these agreements, all of the shares of our common stock that are restricted securities or are held by our affiliates
as of the date of this prospectus will be eligible for sale in the public market in compliance with Rule 144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as in effect on the date of this prospectus, beginning 90 days after completion of this offering, a person (or
persons whose common stock is required to be aggregated) who is an affiliate and who has beneficially owned our common stock for at least
six months is entitled to sell in any three-month period a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
    of the number of shares of our common stock then outstanding, which will equal approximately [&#9679;] shares immediately after completion
    of this offering; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    average weekly trading volume in our common stock [&#9679;] during the four calendar weeks preceding the filing of a notice on Form
    144 with respect to such a sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
by our affiliates under Rule 144 are also subject to manner of sale provisions and notice requirements and to the availability of current
public information about us. An &ldquo;affiliate&rdquo; is a person that directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with, an issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Rule 144, a person (or persons whose shares are aggregated) who is not deemed to have been an affiliate of ours at any time during the
90 days preceding a sale, and who has beneficially owned the shares proposed to be sold for at least six months (including the holding
period of any prior owner other than an affiliate), would be entitled to sell those shares subject only to availability of current public
information about us, and after beneficially owning such shares for at least 12 months, would be entitled to sell an unlimited number
of shares without restriction. To the extent that our affiliates sell their shares of common stock, other than pursuant to Rule 144 or
a registration statement, the purchaser&rsquo;s holding period for the purpose of effecting a sale under Rule 144 commences on the date
of transfer from the affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided
that the sale is effected in an &ldquo;offshore transaction&rdquo; and no &ldquo;directed selling efforts&rdquo; are made in the United
States (as these terms are defined in Regulation S) and subject to certain other conditions. In general, this means that our shares may
be sold in some manner outside the United States without requiring registration in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 701 as in effect on the date of this prospectus, any of our employees, directors, officers, consultants, or advisors
who purchased shares from us in reliance on Rule 701 in connection with a compensatory stock or option plan or other written agreement
before the effective date of this offering, or who purchase shares from us after that date upon the exercise of options granted before
that date, are eligible to resell such shares 90 days after the effective date of this offering in reliance upon Rule 144. If such person
is not an affiliate, such sale may be made subject only to current public information provisions of Rule 144. If such a person is an
affiliate, such sale may be made under Rule 144 without compliance with the holding period requirement, but subject to the other Rule
144 restrictions described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register
all shares of common stock issued or issuable under the 2023 Omnibus Plan, which we intend to adopt prior to the commencement of this
offering. Any such Form S-8 registration statements will automatically become effective upon filing. Accordingly, shares registered under
such registration statements will be available for sale in the open market following the expiration of the lock-up period. We expect
that the initial registration statements on Form S-8 will cover approximately [&#9679;] shares of our common stock. Shares issued under
the 2023 Omnibus Plan after the effective date of the applicable Form S-8 registration statement will be eligible for resale in the public
market without restriction, subject to Rule 144 limitations applicable to affiliates and the lock-up agreements described above. See
&ldquo;Executive Compensation &mdash; Executive Compensation Arrangements &mdash; Equity Compensation&rdquo;, and &ldquo;Executive Compensation
Plan&rdquo; for a description of the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_006"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDERS
OF OUR COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the
ownership and disposition of shares of our common stock issued pursuant to this offering but is not intended to be a complete analysis
of all potential tax consequences. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state,
local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;),
final, temporary, and proposed Treasury Regulations, judicial decisions, and published rulings and administrative pronouncements of the
U.S. Internal Revenue Service (the &ldquo;IRS&rdquo;), in each case as in effect as of the date of this prospectus. These authorities
may change or be subject to differing interpretations, and any such change or differing interpretation may be applied retroactively in
a manner that could adversely affect a non-U.S. holder of our common stock. We have not sought and will not seek any rulings from the
IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed
below regarding the tax consequences of the ownership and disposition of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is limited to a non-U.S. holder that holds our common stock as a &ldquo;capital asset&rdquo; within the meaning of Section
1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences
relevant to a non-U.S. holder&rsquo;s particular circumstance, including the impact of the alternative minimum tax, the special tax accounting
rules in Section 451(b) of the Code or the Medicare surtax on net investment income provided by Section 1411 of the Code. In addition,
it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    expatriates and former citizens or long-term residents of the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    holding shares of our common stock as part of a straddle, or other risk reduction strategy or as part of a conversion transaction
    or other integrated investment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
    insurance companies, and other financial institutions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers,
    dealers, or certain electing traders in securities that use a mark-to-market method of tax accounting for their securities positions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;controlled
    foreign corporations&rdquo;, &ldquo;passive foreign investment companies&rdquo;, as defined in Sections 957 and Section 1297 of
    the Code, respectively, and corporations that accumulate earnings to avoid U.S. federal income tax under Section 531 and 532 of the
    Code;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
    or other entities or arrangements treated as partnerships for U.S. federal income tax purposes and other pass-through entities (and
    investors in such entities);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
    organizations or governmental organizations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    deemed to sell our common stock under the constructive sale provisions of the Code;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-qualified
    retirement plans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;qualified
    foreign pension funds&rdquo; as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified
    foreign pension funds.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the
partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner
level. Partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S.
federal income tax consequences to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP,
AND DISPOSITION OF SHARES OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE,
LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
of a Non-U.S. Holder</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a &ldquo;non-U.S. holder&rdquo; is any beneficial owner of our common stock that is an individual, corporation,
estate or trust and is not a &ldquo;U.S. person.&rdquo; A U.S. person is any person that, for U.S. federal income tax purposes, is or
is treated as any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual who is a citizen or resident of the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate, the income of which is subject to U.S. federal income tax regardless of its source; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more &ldquo;United States persons&rdquo;
    (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person
    for U.S. federal income tax purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in the section entitled &ldquo;Dividend Policy,&rdquo; we do not anticipate declaring or paying dividends to holders of our
common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions
will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits,
as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute
a nontaxable return of capital and first be applied against and reduce a Non-U.S. Holder&rsquo;s adjusted tax basis in its common stock,
but not below zero, and any excess will be treated as capital gain and will be treated as described below under &ldquo;&mdash; Sale or
Other Taxable Disposition&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder of our common stock will be subject to U.S.
federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax
treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification
for the lower treaty rate of withholding). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies
for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the
IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within
the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the
United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described
above. To claim the exemption, the non-U.S. holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying
that the dividends are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the rates applicable to U.S.
persons. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult
their tax advisors regarding any applicable tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sale
or Other Taxable Disposition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below under &ldquo;&mdash; Information Reporting and Backup Withholding&rdquo; and &ldquo;&mdash; Additional Withholding
Tax Under FATCA&rdquo;, a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other
taxable disposition of our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United States (and, if required
    by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which such gain
    is attributable);or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    non-U.S. holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the
    disposition and certain other requirements are met;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the rates applicable
to U.S. persons. A non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower
rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty), which may be offset by U.S. source capital losses of the non-U.S. Holder (even though the individual
is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with
respect to such losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Reporting and Backup Withholding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
returns are required to be filed with the IRS in connection with any dividends on our common stock paid to a non-U.S. holder whether
or not withholding is required. Copies of the information returns reporting such interest, dividends, and withholding may also be made
available to the tax authorities in the country in which a non-U.S. holder resides under the provisions of an applicable income tax treaty.
Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not
have actual knowledge or reason to know the beneficial owner is a United States person and the Non-U.S. Holder either certifies its non-U.S.
status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or other applicable documentation, or otherwise establishes
an exemption. Proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain
U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent
receives the certification described above and does not have actual knowledge or reason to know that such beneficial owner is a United
States person, or otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office
of a non-U.S. broker generally will not be subject to backup withholding or information reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a non-U.S. Holder&rsquo;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Withholding Tax Under FATCA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
1471 to 1474 of the Code (such sections commonly referred to as the Foreign Account Tax Compliance Act, or &ldquo;FATCA&rdquo;) and the
Treasury Regulations and administrative guidance thereunder impose a 30% withholding tax on certain types of payments made to a &ldquo;foreign
financial institution&rdquo; or a &ldquo;non-financial foreign entity&rdquo; (each as defined in the Code), including, in some cases,
when such foreign financial institution or non-financial foreign entity acts as an intermediary, unless (1) the foreign financial institution
has entered into an agreement with the U.S. government to withhold on certain payments and to undertake certain diligence and reporting
obligations regarding U.S. account holders (including certain account holders that are non-U.S. entities with U.S. owners), (2) the non-financial
foreign entity either certifies it does not have any &ldquo;substantial United States owners&rdquo; (as defined in the Code) or furnishes
identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign
entity otherwise qualifies for an exemption from these rules. Foreign financial institutions located in jurisdictions that have an intergovernmental
agreement with the United States governing FATCA may be subject to different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition
of stock on or after January 1, 2019, recently proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds
entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_007"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kingswood
Investments, division of Kingswood Capital Partners LLC is acting as representative of the underwriters (the &ldquo;Representative&rdquo;)
of the offering. We have entered into an underwriting agreement (the &ldquo;underwriting agreement&rdquo;) with the Representative. Subject
to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters named below, and the underwriters
have agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite the underwriter&rsquo;s
name in the following table at the initial public offering price per share less underwriting discounts and commissions, as set forth
on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">Kingswood Investments, <BR>division of Kingswood Capital Partners, LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are committed to purchase all of the shares offered by us other than those shares covered by the over-allotment option described
below, if they purchase any shares. The obligations of the underwriters may be terminated upon the occurrence of certain events specified
in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&rsquo; obligations are subject to
customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of
officers&rsquo; certificates and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, or to contribute
to payments the underwriters may be required to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel and other conditions contained in the underwriting agreement. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters an option to purchase from us up to an additional [&#9679;] shares of our common stock, solely to cover
over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. The underwriters may exercise
this option, in whole or in part, for our common stock, any time during the 45-day period from the date of this prospectus. If this option
is exercised in full, the total price to the public will be $[&#9679;] and the total net proceeds before expenses to us will be $[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting
Discount, Commissions and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the per share of common stock and total underwriting discounts and commissions to be paid to the underwriters.
Such amounts are shown assuming both no exercise and full exercise of the underwriters&rsquo; option to purchase additional shares, assuming
an initial public offering price of $[&#9679;] per share, the midpoint of the estimated price range set forth on the cover page of this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Without</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allotment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P>

</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total With</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise in Full of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allotment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P>

</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 39%">Public offering price (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discount and commissions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
                                            an initial public offering price of $[&#9679;] per share, the midpoint of the range set forth
                                            on the cover of this prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative has advised us that they propose initially to offer the shares to the public at the public offering price set forth on
the cover page of this prospectus and to dealers at that price less a concession not in excess of $[&#9679;] per share. After the initial
public offering, the public offering price, concession and discount may be changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to pay all of the expenses relating to the offering, including, but not limited to, (a) all filing fees and communication
expenses relating to the registration of the shares of common stock to be sold in this offering with the Securities and Exchange Commission;
(b) all fees and expenses relating to the listing of the shares on the Nasdaq Capital Market and such other exchanges as the Company
and Representative together determine, including any fees charged by DTC; (c) all fees, expenses and disbursements relating to the registration
or qualification of the shares under &ldquo;blue sky&rdquo; or securities laws. of such states of the United States of America and other
jurisdictions designated by the Representative, including the reasonable fees and expenses of the Representative&rsquo;s blue sky counsel;
(d) all fees, expenses and disbursements relating to the registration, qualification or exemption of the shares under the securities
laws of such foreign jurisdictions designated by the Representative; (e) the costs of mailing and printing the underwriting documents
(including the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&rsquo;
Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), registration statements, prospectuses and all amendments, supplements
and exhibits thereto and as many preliminary and final prospectuses as the Representative may reasonably deem necessary; (f) transfer
and/or stamp taxes, if any, payable upon our transfer of the shares to the Underwriters; (g) the fees and expenses of the Company&rsquo;s
accountants; (h) all filing fees and communication expenses associated with the review of the offering by FINRA; (i) expenses incurred
by the Underwriters for any roadshow for the offering up to $10,000; (j) the costs associated with bound volumes of the offering materials
in an aggregate amount not to exceed $5,000; (k) the fees of counsel to the underwriters in an amount not to exceed $150,000; (l) fees
and expenses of the transfer agent for our common stock; and (m) the costs of preparing, printing and delivering certificates representing
the common stock issued in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid a $25,000 expense advance to the Representative, which shall be applied against actual out-of-pocket-accountable expenses,
which will be returned to us to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA
Rule 5110(f)(2)(C). We have agreed to pay to the Representative 0.5% of the gross proceeds of the offering for non-accountable expenses,
payable upon the closing of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of the offering payable by us, excluding the total underwriting discount, and including the above-referenced
advance to the Representative, will be approximately $[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the shares offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to the Representative or its designees at the closing of this offering warrants to purchase the number of common
stock equal to 5.0% of the aggregate number of shares sold in this offering. The warrants will be exercisable at any time and from time
to time, in whole or in part, during the four-and-a-half-year period commencing six months from the commencement of sales in this offering.
The warrants will be exercisable at a per share price equal to 100% of the initial public offering price per share in the offering. The
Warrants provide for registration rights (including a one-time demand registration right at our expense and piggyback registration rights
that expire 5 years from the commencement of sales of this offering) and customary anti-dilution provisions as permitted under FINRA
Rule 5110(g)(8).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA.
The Representative (or permitted assignees under Rule 5110(e)(2)(B)) will not sell, transfer, assign, pledge, or hypothecate these warrants
or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the date
of this prospectus. The warrants and shares of common stock issuable upon exercise of the warrants are being registered as a part of
the registration statement of which this prospectus forms a part and will be freely tradable upon the declaration of the effectiveness
of such registration statement by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including
in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the closing of this offering and certain conditions set forth in the underwriting agreement, for a period of twelve (12) months after
the closing of the offering, the Representative shall have a right of first refusal to act as sole investment banker, sole bookrunner
and/or sole placement agent, at the discretion of the Representative, for any and all future public and private equity offerings, including
all equity-linked financings, undertaken during such period by us, or any of our successors or subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tail
Period</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative shall be entitled to a cash fee equal to seven percent (7%) of the gross proceeds received by the Company from the sale
of any equity, debt and/or equity derivative instruments to any investor actually introduced by the Representative to the Company during
the period beginning on July 27, 2023 and ending on the later of (i) July 27, 2024 or (ii) the final closing, if any, of the Offering
(the &ldquo;Engagement Period&rdquo;), in connection with any public or private financing or capital raise (each a &ldquo;Tail Financing&rdquo;),
and such Tail Financing is consummated at any time during the Engagement Period or within the twelve (12) month period following the
expiration or termination of the Engagement Period (the &ldquo;Tail Period&rdquo;), provided that such Tail Financing is by a party actually
introduced to the Company first by the Representative during the Engagement Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers and directors, and holders of more than 5% of the issued and outstanding shares of common stock of the Company have agreed not
to, without the prior written consent of the Representative, directly or indirectly, offer to sell, sell, pledge or otherwise transfer
or dispose of any shares of our common stock (or enter into any transaction or device that is designed to, or could be expected to, result
in the transfer or disposition by any person at any time in the future of shares of our common stock, enter into any swap or other derivatives
transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock,
make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect
to the registration of any of the shares of common stock or securities convertible into or exercisable or exchangeable for shares of
common stock or any other of our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions,
for periods of 180 days from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Sales of Similar Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly,
any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or enter into
any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of shares of our common
stock, whether any such transaction is to be settled by delivery of shares of common stock or such other securities, in cash or otherwise,
without the prior written consent of the Representative, for a period of 180 days from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale, and Distribution of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group
members. The Representative may agree to allocate a number of shares of common stock to underwriters and selling group members for sale
to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that
will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information
on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus
forms a part, has not been approved or endorsed by us, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to have shares of our common stock listed on the Nasdaq Capital Market under the symbol &ldquo;TELO&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
this offering, there has been no public market for shares of our common stock. Accordingly, the public offering price will be negotiated
between us and the underwriter. Among the factors to be considered in these negotiations are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    information set forth in this prospectus and otherwise available to the underwriter;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prospects for our Company and the industry in which we operate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    assessment of our management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    past and present financial and operating performance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    prospects for future earnings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    and operating information and market valuations of publicly traded companies engaged in activities similar to ours;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevailing conditions of United States securities markets at the time of this offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors deemed relevant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriter can assure investors that an active trading market will develop for shares of our common stock, or that the shares
will trade in the public market at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged
    in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
    transactions involve sales by the underwriter of securities in excess of the number of securities the underwriter is obligated to
    purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered
    short position, the number of securities over-allotted by the underwriter is not greater than the number of securities that they
    may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number
    of securities in the over-allotment option. The underwriter may close out any short position by exercising their over-allotment option
    and/or purchasing securities in the open market.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
    covering transactions involves purchases of securities in the open market after the distribution has been completed in order to cover
    syndicate short positions. In determining the source of securities to close out the short position, the underwriter will consider,
    among other things, the price of securities available for purchase in the open market as compared with the price at which they may
    purchase securities through exercise of the over-allotment option. If the underwriter sells more securities than could be covered
    by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying
    securities in the open market. A naked short position is more likely to be created if the underwriter is concerned that after pricing
    there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase
    in the offering.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
    bids permit the underwriter to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate
    member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids may have the effect of raising
or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result,
the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither
we nor the underwriter make any representation or prediction as to the effect that the transactions described above may have on the price
of our securities. These transactions may be affected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and, if
commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, underwriter, and selling group members may engage in passive market making transactions in our securities
on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid
at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging,
market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective
affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships
with us, for which they received or will receive customary fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
RESTRICTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member state),
with effect from and including the date on which the Prospectus Directive is implemented in that relevant member state (the relevant
implementation date), an offer of shares described in this prospectus may not be made to the public in that relevant member state other
than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity which is a qualified investor as defined in the Prospectus Directive;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural
    or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive,
    subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the Prospectus Directive,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
    that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
    Directive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this provision, the expression an &ldquo;offer of securities to the public&rdquo; in any relevant member state means the
communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to
enable an investor to decide to purchase or subscribe for the shares, as the expression may be varied in that member state by any measure
implementing the Prospectus Directive in that member state, and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
(and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the relevant member state) and includes
any relevant implementing measure in the relevant member state. The expression 2010 PD Amending Directive means Directive 2010/73/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sellers of the shares have not authorized and do not authorize the making of any offer of shares through any financial intermediary on
their behalf, other than offers made by the underwriters with a view to the final placement of the shares as contemplated in this prospectus.
Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of the shares on behalf
of the sellers or the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the
meaning of Article 2(1)(e) of the Prospectus Directive that are also (i) investment professionals falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &ldquo;Order&rdquo;) or (ii) high net worth entities, and
other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (each such person being referred
to as a &ldquo;relevant person&rdquo;). This prospectus and its contents are confidential and should not be distributed, published or
reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom
that is not a relevant person should not act or rely on this document or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_008"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered hereby will be passed upon for us by Foley &amp; Lardner LLP, Tampa, Florida. Lucosky
Brookman LLP has acted as counsel for the underwriters with respect of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_009"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Telomir Pharmaceuticals, Inc. as of and for the years ended December 31, 2022 and 2021 included in this prospectus
have been audited by Cherry Bekaert LLP, an independent registered public accounting firm, appearing elsewhere herein, given on the authority
of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_010"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set
forth in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that
is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement, or
other document are summaries of all material information about the documents summarized but are not complete descriptions of all terms
of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself
for a complete description of its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without
charge at the SEC&rsquo;s public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of
the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington,
DC 20549. You may call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet
website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC
are also available to the public through the SEC&rsquo;s website at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will become subject to the information reporting requirements of the Exchange Act, and we will file periodic
reports, proxy statements and other information with the SEC. These periodic reports, and other information are available for inspection
and copying at the website of the SEC referred to above. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q,
reports on Form 8-K and amendments to those reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of
charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The
information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this
prospectus. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference
room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement
may be obtained from that office. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The
SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that
file electronically with the SEC. The address of the website is <I>www.sec.gov.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at www.telomirpharma.com. Information contained in, or that can be accessed through, our website does not
constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and
regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_011"></A>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc. Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
of and For the Years Ended December 31, 2022 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fin_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fin_002">Balance Sheets as of December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fin_003">Statements of Operations for the years ended December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fin_004">Stockholders&rsquo; Deficit for the years ended December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fin_005">Statements of Cash Flows for the years ended December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fin_006">Notes to Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fin_001"></A>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheets
of Telomir Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of December&nbsp;31, 2022 and 2021, and the related statements of operations,
stockholders&rsquo; equity (deficit), and cash flows for the year ended December 31, 2022 and for the period from August 26, 2021 (Inception)
through December 31, 2021, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2022
and 2021, and the results of its operations and its cash flows for the year ended December&nbsp;31, 2022 and for the period from August
26, 2021 (Inception) through December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Substantial Doubt about the Company&rsquo;s
Ability to Continue as a Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been
prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has recurring
losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management&rsquo;s
evaluations of the events and conditions and management&rsquo;s plans regarding those matters are also described in Note 2. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We are required
to be independent with respect to the Company in accordance with the relevant ethical requirements relating to our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">We conducted our audits in accordance with the
auditing standards of the Public Company Accounting Oversight Board (United States) and in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Cherry Bekaert LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
Florida</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">August 14, 2023</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fin_002"></A>Balance
Sheets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>DECEMBER
31, 2022 AND december 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I></I></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 64%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,419</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">47,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,730</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left">Total assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,730</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Trade accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">404,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,735</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">581,787</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">119,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">986,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">986,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Preferred Stock, no par value, 5,000,000 shares authorized and none issued or outstanding.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Common Stock, no par value; 95,000,000 shares authorized, 55,000,000 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(992,278</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(138,131</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional Paid in Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total stockholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(937,278</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,730</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fin_003"></A>Statements
of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>YEAR
ended December 31, 2022 and period ended DECEMBER 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">General and administrative expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">20,941</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">11,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">833,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">126,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total operating costs</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">854,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">138,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: center">Net loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(854,147</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(138,131</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fin_004"></A>Statements
of stockholders&rsquo; DEFICIT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>YEARS
ended DECEMBER 31, 2022, and DECEMBER 31, 2021</I></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid-In </B></FONT></P></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stock Subscription </TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated </TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Stockholders&rsquo; </TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><B>Shares</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><B>Amount</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Capital</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Receivable</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Deficit</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Deficit</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balances, January 1, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%">Issuance of founders&rsquo; shares</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">55,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">55,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">(55,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="text-align: left">)</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balances, December 31, 2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">55,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">55,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(55,000</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(138,131</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(138,131</TD><TD STYLE="font-weight: bold; text-align: left">)</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Collection of stock subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(854,147</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(854,147</TD><TD STYLE="text-align: left">)</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balances, December 31, 2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">55,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">55,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(992,278</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(937,278</TD><TD STYLE="font-weight: bold; text-align: left">)</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fin_005"></A>statements
of cash flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>YEARS
ended DECEMBER 31, 2022, and DECEMBER 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from Operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(854,147</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(138,131</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">385,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,735</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Net cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(468,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(119,396</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Collection of stock subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47,311</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Advances from related party</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,391</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">119,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Net cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Cash, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Cash, end of period</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,419</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fin_006"></A>notes
to the financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>DECEMBER
31, 2022 and december 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I></I></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1. Description of business and summary of significant accounting policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc. (&ldquo;Telomir&rdquo; or the &ldquo;Company&rdquo; and formerly known as Metallo Therapies, Inc.) was formed in
August 2021 and is a Florida-based early pre-clinical stage biopharmaceutical company that is developing its product candidate, Telomir-1,
an advanced metal enzyme inhibitor for the treatment of hemochromatosis and cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantive
operations began in late 2021 and the Company&rsquo;s Investigative New Drug application is anticipated to be filed with the U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;) in fourth quarter 2023 for hemochromatosis and first quarter 2024 for post-chemotherapy recovery.
A U.S. provisional patent application is pending for Telomir-1 as a new molecular entity and its therapeutic uses. See Note 3, regarding
this patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, the Company&rsquo;s Common Stock, no par value per share, is referred to as the &ldquo;Common Stock&rdquo; and the Company&rsquo;s
preferred stock, no par value per share, is referred to as the &ldquo;Preferred Stock&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pending
transactions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is in the process of preparing for an initial public offering (IPO) and expects to be listed under the NASDAQ symbol &ldquo;TELO.&rdquo;
The transaction is expected to be complete in the second half of 2023. The Company incurred $0.05 million of legal costs, as of December
31, 2022, associated with the offering, which have been recorded as deferred offering costs in the accompanying balance sheets. There
were no deferred offering costs during 2021. These deferred offering costs will be derecognized as a reduction in offering proceeds when
the offering closes. However, there can be no guarantees that the Company will be successful in completing the proposed transaction and
ultimately listing on the NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C corporation. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences
between the financial statement carrying amount of existing assets and liabilities and their respective tax bases. Deferred tax assets
are recognized for temporary differences that will result in deductible amounts in future years and for loss carryovers. A valuation
allowance is recognized regarding deferred tax assets, if any, if it is more likely than not that some portion of the deferred tax asset
will not be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and development expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&rsquo;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains cash balances with financial institutions that management believes are of high credit quality. The Company&rsquo;s
cash account at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes
it is not exposed to any significant credit risk from its cash account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-size: 10pt"><I>Income taxes</I></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt">The Company is a C corporation. Deferred tax assets
and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amount
of existing assets and liabilities and their respective tax bases. Deferred tax assets are recognized for temporary differences that
will result in deductible amounts in future years and for loss carryovers. A valuation allowance is recognized regarding deferred tax
assets, if any, if it is more likely than not that some portion of the deferred tax asset will not be realized. At December 31,
2022 deferred tax assets are comprised primarily of net operating loss carryforwards and IRC Section 174 qualified research expenditures
totaling approximately $0.06 million and $0.2 million respectively.&nbsp; At December 31, 2021, deferred tax assets consisted of net
operating loss carryforwards of approximately $0.04 million &nbsp;&nbsp;The Company has recorded a full valuation allowance against its
deferred tax assets generated by net operating loss carryforwards as it has determined that such amounts may not be recognizable, given
the historical losses of the Company to date. &nbsp;As of December 31, 2022, the Company has a cumulative federal net operating loss
carryforward of approximately $0.2 million. The net operating loss carryforwards have no expiry date.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2. Liquidity and capital resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had cash of approximately $0.01 million. The Company used approximately $0.5 million of cash
in operations during the year ended December 31, 2022 and had stockholders&rsquo; deficit of approximately $0.9 million, versus stockholders&rsquo;
deficit of approximately $0.1 million at December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company&rsquo;s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company&rsquo;s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4. Additional sources of financing may be sought by the Company. However, there can be no assurance
that any fundraising will be achieved on commercially reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to be able to fund operations through the anticipated IPO, or through the first quarter of 2024, with available borrowings
from a related party line of credit (Note 7). Should actual cash expenditures exceed management&rsquo;s budget, the Company
may be forced to curtail operations along with implementing other cost-saving measures, such as a reduction in staff, reducing the use
of outside professional service providers, or significantly modifying or delaying the development of our product candidates. Because
of these factors, substantial doubt about the Company&rsquo;s ability to continue as a going concern exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3. License agreement, related party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29 2022, (the &ldquo;Effective Date&rdquo;), the Company and MIRALOGX LLC (&ldquo;MIRALOGX&rdquo;), entered into an exclusive,
worldwide license to commercially develop Telomir-1 in the United States and its territories. MIRALOGX, which is a separate intellectual
property development company owned by a trust established by the Company&rsquo;s founder, holds the patent rights to Telomir-1, which
are currently comprised of two pending U.S. provisional patent application. The term of the license from MIRALOGX will continue
through the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic
partnership/sublicensing agreement covering the licensed products. The patent rights are expected to extend through 2043, and additional
patent terms may be awarded, including additional patent terms based on the time taken for regulatory review of drug products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive license agreement requires that Telomir pay an 8% royalty on net sales or revenue in exchange for an exclusive, worldwide license
to patent rights. The agreement also provides that Telomir may bring suit in its own name to enforce patent rights. MIRALOGX will control
the prosecution of the patent applications for Telomir-1. Telomir is required to be kept informed by MIRALOGX of patent prosecution activities
and may select identified countries for patent protection. Telomir is to reimburse MIRALOGX for patent prosecution and maintenance costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4. Related party transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Due
to related party</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &ndash; During the year ended
December 31, 2022, and period ended December 31, 2021, the Company received working capital advances from companies under common
control. These advances are due on demand and are non-interest bearing. Amounts due to related parties as of December 31, 2022, and 2021,
is $0.6 million and $0.1 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>License
agreement - See Note 3.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shared
management- </I>Historically, the Company has shared management with related parties on an as-needed basis, to collaborate and pool resources
efficiently. This arrangement has resulted in cost savings and expertise-sharing while maintaining distinct operations and identities
for each entity. The Company intends on reducing these shared resources post IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shared
jet use-</I> On April 1, 2023 the Company entered into an Agreement For Shared Lease Costs with MIRALOGX, LLC, (the &ldquo;Shared Agreement&rdquo;)
who is a related party. Under the Shared Agreement, the Company agrees to make monthly contributions or payments in accordance with its
monthly use of shared aircraft toward rent payments. There is no minimum cost requirement under the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5. Lease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 85.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leased an office in Baltimore, Maryland, as its corporate headquarters. This Baltimore office lease began in December 2022
for&nbsp;12&nbsp;months. This space is approximately&nbsp;127&nbsp;square feet and has remaining base rent of $0.01&nbsp;million payable
through November 2023. Rent is payable in monthly installments and is subject to yearly price increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accounting
standards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, the Company adopted Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 842 ASC Topic 842, which is intended to
improve financial reporting about leasing transactions. Under the standard, organizations that lease assets, referred to as &ldquo;Lessees&rdquo;
shall recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. In addition,
the standard requires disclosures including financial statements to assess the amount, timing and uncertainty of cash flows arising from
leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company made an accounting policy election to account for leases with an initial term of 12 months or less similar to existing guidance
for operating leases today. The Company recognized those lease payments in the Condensed Statements of Operations on a straight-line
basis over the lease term. Under the new standard, the Company&rsquo;s lease liability is based on the present value of such payments
and the related right-of-use asset will generally be based on the lease liability.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6. Stockholders&rsquo; equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Capital
stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the authority to issue 100,000,000 shares of capital stock, consisting of 95,000,000 shares of Common Stock and 5,000,000
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Subsequent events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through August 12, 2023, in connection with the preparation of these financial statements,
which is the date the financial statements were available to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Private placement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">During 2023, the Company sold 549,451 shares of
Common Stock at $1.82 per share, net of offering costs of $0.1 million, resulting in net proceeds of $0.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">During
2023, the Company issued to the 2023 private placement investors a common stock warrant for the right to purchase up to 549,451
shares of common stock at an exercise price of $7.52 per share. The Company also issued to the placement agent a common stock
warrant for the right to purchase up to 137,363 shares of common stock at an exercise price of $1.82 per share. Both issuances of
warrants are immediately vested and will be exercisable any time until the day that is one year plus ninety days from the date an
Investigational New Drug filing is made with the Food and Drug Administration.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bay
Shore Line of Credit</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, the Company entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&rsquo;s
founder, Jonnie R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan
Agreement (the &ldquo;Bay Shore Note&rdquo;), the Company has the right to borrow up to an aggregate of $5 million from the Bay Shore
Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&rsquo;s
IPO. The Company&rsquo;s right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in its
assets, operations, or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary
of the issuance of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at
a rate equal 7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest, thereafter.
The Bay Shore Note is unsecured. The Bay Shore Note paid off related party balances owed to The Starwood Trust, a separate trust established
by our founder, in which we had an outstanding balance of $0.5 million as of the date of the Bay Shore Note (which outstanding balance
was retired with an advance under the Bay Shore Note).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 5,000,000 shares of common stock at an exercise price
of $1.82 per share, which warrant will expire five years after the date of grant. Pursuant to a registration rights agreement, the Company
has granted to Bay Shore Trust the right to require the Company, at any time after one year following the Company&rsquo;s IPO, to register
for resale the shares issuable upon the exercise of the warrant, with such registration rights being in the form of demand and &ldquo;piggyback&rdquo;
registration rights that are subject to customary limitations and restrictions. Upon issuance, the warrant met the criteria to be classified
as equity based on an analysis under Accounting Standards Codification (480) ASC 480, &ldquo;Distinguishing Liabilities from Equity&rdquo;
and will be measured at fair value, resulting in an initial fair value of approximately $5.95 million upon issuance of the warrant using
Black-Scholes valuation techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">[</FONT><FONT STYLE="font-family: Symbol; font-size: 16pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">]
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"> Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Common
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><IMG SRC="formdrs_008.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 22pt">Telomir
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Prospectus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Kingswood
Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">division
of Kingswood Capital Partners, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
[&#9679;], 2023 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or
not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#8217; obligation to
deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Alternate
Page for Resale Prospectus]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell, and it
is not soliciting an offer to buy, these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">Subject
to completion, dated [&#9679;], 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[&#9679;]
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TELOMIR
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to up to [&#9679;] shares of common stock, no par value, of Telomir Pharmaceuticals, Inc. that may be sold from time
to time by the selling stockholders named in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may sell shares from time to time in the open market, through privately negotiated transactions or a combination
of these methods, at market prices prevailing at the time of sale or at negotiated prices. The Selling Securityholder may offer shares
to or through underwriters, dealers or other agents, directly to investors or through any other manner permitted by law, on a continued
or delayed basis. We will bear all costs, expenses and fees in connection with the registration of the shares offered by this prospectus,
and the Selling Securityholder will bear all incremental selling expenses, including commissions and discounts, brokerage fees and other
similar selling expenses they incur in sale of the shares. See &ldquo;Plan of Distribution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
separate prospectus (the &ldquo;IPO Prospectus&rdquo;), we have registered an aggregate of [&#9679;] shares of common stock which we
are offering for sale to the public through our underwriters, excluding any shares issuable upon exercise by the underwriters&rsquo;
of their over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
[&#9679;] shares of common stock offered by the selling stockholders is defined herein as the &ldquo;Resale Shares.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list our shares of common stock for trading on the Nasdaq Capital Market, subject to official notice of issuance,
under the symbol &ldquo;TELO&rdquo;. No assurance can be given that our application will be approved. The consummation of this offering
is conditioned on obtaining Nasdaq approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the federal securities laws, and, as such, are subject to reduced public company
reporting requirements. See &ldquo;Prospectus Summary&thinsp;&mdash;&thinsp;Implications of Being an Emerging Growth Company&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities is highly speculative and involves a significant degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on
page 10 of this prospectus for a discussion of information that should be considered before making a decision to purchase our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares of our common stock registered in this prospectus and the IPO Prospectus will result in two offerings taking place concurrently,
which might affect price, demand, and liquidity of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is [&#9679;], 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 116; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any of the proceeds from the sale of the Resale Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders will pay any underwriting discounts and commissions and expenses incurred by them for brokerage, accounting, tax
or legal services or any other expenses incurred by them in disposing of the shares. We will bear all other costs, fees and expenses
incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and
filing fees and fees and expenses of our counsel and our accountants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus covers the possible resale by the selling stockholders identified in the table below of up to [&#9679;] shares of our common
stock (the &ldquo;Resale Shares&rdquo;). The transactions by which the selling stockholders acquired their securities from us were exempt
under the registration provisions of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may sell some, all, or none of the Resale Shares. Unless otherwise indicated in the footnotes to the table below,
no selling stockholder has had any material relationship with us or any of our affiliates within the past three years other than as a
security holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have prepared the following table based on written representations and information furnished to us by or on behalf of the selling stockholders.
Unless otherwise indicated in the footnotes to the table below, we believe that (i) none of the selling stockholders are broker-dealers
or affiliates of broker-dealers, and (ii) no selling stockholder has direct or indirect agreements or understandings with any person
to distribute their Resale Shares. To the extent any selling stockholder identified below is, or is affiliated with, a broker-dealer,
it could be deemed, individually, but not severally, to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act. Information
about the selling stockholders may change over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by
each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder,
based on its ownership of Resale Shares as of [&#9679;], 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third column lists the shares of common stock being offered by this prospectus by the selling stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Selling Stockholder</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beneficially</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Before</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of Shares</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beneficially</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Before this</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering</B></FONT></P></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares Being Offered</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beneficially</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of Shares</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beneficially</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(%)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 42%; padding-bottom: 1.5pt">[&#9679;]</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: right">[&#9679;]</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] </FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">%</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] </FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">[&#9679;]</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">[&#9679;]</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] </FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] </FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">[&#9679;]</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">[&#9679;]</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] </FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] </FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Less
than 1%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
    percentage ownership after to this offering is based on [&#9679;] shares of common stock deemed to be outstanding as of [&#9679;],
    2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the Resale Shares to permit the resale of the Resale Shares by the selling stockholders from time to time after the date
of this prospectus. We will not receive any of the proceeds from the sale of the Resale Shares. We will pay all expenses (other than
discounts, commissions, and transfer taxes, if any) relating to the registration of the Resale Shares in the registration statement of
which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time directly
or through one or more underwriters, broker-dealers, or agents. If the Resale Shares are sold through underwriters or broker-dealers,
the selling stockholders will be responsible for any underwriter discounts or commissions and any applicable transfer taxes. The Resale
Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices
determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block
transactions,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the over-the-counter market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions otherwise than on these exchanges or systems or in the over-the-counter market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short
    sales;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated
    price per security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus. The selling stockholders may also sell securities under Rule 144 or any other exemption from registration
under the Securities Act, if available, rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the common stock covered by this prospectus will be passed upon by Foley &amp; Lardner LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all the costs and expenses, other than underwriting discounts and commissions, to be paid by us in connection
with the sale of the shares of common stock being registered hereby. All amounts shown below are estimates, except the SEC registration
fee, the FINRA filing fee and the Nasdaq listing fee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nasdaq listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Transfer agent and registrar fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc. is incorporated under the laws of the state of Florida. Section 607.0831 of the Florida Business Corporation Act,
as amended (the &ldquo;FBCA&rdquo;), provides that a director is not personally liable for monetary damages to the corporation or any
other person for any statement, vote, decision to take or not to take action, or any failure to take any action, as a director, unless
(1) the director breached or failed to perform his or her duties as a director and (2) the director&rsquo;s breach of, or failure to
perform, those duties constitutes (a) a violation of the criminal law, unless the director had reasonable cause to believe his or her
conduct was lawful or had no reasonable cause to believe his or her conduct was unlawful, (b) a transaction from which the director derived
an improper personal benefit, either directly or indirectly, (c) a circumstance under which the liability provisions of Section 607.0834
of the FBCA are applicable, (d) in a proceeding by or in the right of the corporation to procure a judgment in its favor or by or in
the right of a shareholder, conscious disregard for the best interest of the corporation, or willful or intentional misconduct, or (e)
in a proceeding by or in the right of someone other than the corporation or a shareholder, recklessness or an act or omission which was
committed in bad faith or with malicious purpose or in a manner exhibiting wanton and willful disregard of human rights, safety, or property.
A judgment or other final adjudication against a director in any criminal proceeding for a violation of the criminal law estops that
director from contesting the fact that his or her breach, or failure to perform, constitutes a violation of the criminal law; but does
not estop the director from establishing that he or she had reasonable cause to believe that his or her conduct was lawful or had no
reasonable cause to believe that his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 607.0851 of the FBCA, a corporation has power to indemnify any person who is a party to any proceeding (other than an action
by, or in the right of the corporation), because he or she is or was a director or officer of the corporation against liability incurred
in connection with such proceeding, including any appeal thereof, if he or she acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had
no reasonable cause to believe his or her conduct was unlawful. The termination of any proceeding by judgment, order, settlement or conviction
or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith
and in a manner which he or she reasonably believed to be in, or not opposed to, the best interests of the corporation or, with respect
to any criminal action or proceeding, has reasonable cause to believe that his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the indemnification provisions of the FBCA, &ldquo;director&rdquo; or &ldquo;officer&rdquo; means an individual who is or
was a director or officer, respectively, of a corporation or who, while a director or officer of the corporation, is or was serving at
the corporation&rsquo;s request as a director or officer, manager, partner, trustee, employee, or agent of another domestic or foreign
corporation, limited liability company, partnership, joint venture, trust, employee benefit plan, or another enterprise or entity and
the terms include, unless the context otherwise requires, the estate, heirs, executors, administrators, and personal representatives
of a director or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 607.0851 of the FBCA, a corporation has the power to indemnify any person, who was or is a party to any proceeding
by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director or
officer, against expenses and amounts paid in settlement not exceeding, in the judgment of the board of directors, the estimated expense
of litigating the proceeding to conclusion, actually and reasonably incurred in connection with the defense or settlement of such proceeding,
including any appeal thereof. Such indemnification shall be authorized if such person acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made under this
subsection in respect of any claim, issue, or matter as to which such person shall have been adjudged to be liable unless, and only to
the extent that, the court in which such proceeding was brought, or any other court of competent jurisdiction, shall determine upon application
that, despite the adjudication of liability but in view of all circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses which such court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0852 of the FBCA provides that a corporation must indemnify an individual who is or was a director or officer who was wholly successful,
on the merits or otherwise, in the defense of any proceeding to which the individual was a party because he or she is or was a director
or officer of the corporation against expenses incurred by the individual in connection with the proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0853 of the FBCA provides that a corporation may, before final disposition of a proceeding, advance funds to pay for or reimburse
expenses incurred in connection with the proceeding by an individual who is a party to the proceeding because that individual is or was
a director or an officer if the director or officer delivers to the corporation a signed written undertaking of the director or officer
to repay any funds advanced if (a) the director or officer is not entitled to mandatory indemnification under Section 607.0852; and (b)
it is ultimately determined under Section 607.0854 or Section 607.0855 (as described below) that the director or officer has not met
the relevant standard of conduct described in Section 607.0851 or the director or officer is not entitled to indemnification under Section
607.0859 (as described below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0854 of the FBCA provides that, unless the corporation&rsquo;s articles of incorporation provide otherwise, notwithstanding the failure
of a corporation to provide indemnification, and despite any contrary determination of the board of directors or of the shareholders
in the specific case, a director or officer of the corporation who is a party to a proceeding because he or she is or was a director
or officer may apply for indemnification or an advance for expenses, or both, to a court having jurisdiction over the corporation which
is conducting the proceeding, or to a circuit court of competent jurisdiction. Our amended and restated articles of incorporation do
not provide any such exclusion. After receipt of an application and after giving any notice it considers necessary, the court may order
indemnification or advancement of expenses upon certain determinations of the court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0855 of the FBCA provides that, unless ordered by a court under Section 607.0854, a corporation may not indemnify a director or officer
under Section 607.0851 unless authorized for a specific proceeding after a determination has been made that indemnification is permissible
because the director or officer has met the relevant standard of conduct set forth in Section 607.0851.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0857 of the FBCA also provides that a corporation shall have the power to purchase and maintain insurance on behalf of and for the
benefit of any person who is or was a director or officer of the corporation against any liability asserted against the person and incurred
by him or her in any such capacity or arising out of his or her status as such, whether or not the corporation would have the power to
indemnify or advance expenses to the individual against such liability under the provisions of Section 607.0857.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0858 of the FBCA provides that the indemnification provided pursuant to Section 607.0851 and Section 607.0852, and the advancement
of expenses provided pursuant to Section 607.0853, are not exclusive. A corporation may, by a provision in its articles of incorporation,
bylaws or any agreement, or by vote of shareholders or disinterested directors, or otherwise, obligate itself in advance of the act or
omission giving rise to a proceeding to provide any other or further indemnification or advancement of expenses to any of its directors
or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0859 of the FBCA provides that, unless ordered by a court under the provisions of Section 607.0854 of the FBCA, a corporation may
not indemnify a director or officer under Section 607.0851 or Section 607.0858, or advance expenses to a director or officer under Section
607.0853 or Section 607.0858, if a judgment or other final adjudication establishes that his or her actions, or omissions to act, were
material to the cause of action so adjudicated and constitute: (a) willful or intentional misconduct or a conscious disregard for the
best interests of the corporation in a proceeding by or in the right of the corporation to procure a judgment in its favor or in a proceeding
by or in the right of a shareholder; (b) a transaction in which a director or officer derived an improper personal benefit; (c) a violation
of the criminal law, unless the director or officer had reasonable cause to believe his or her conduct was lawful or had no reasonable
cause to believe his or her conduct was unlawful; or (d) in the case of a director, a circumstance under which the liability provisions
of Section 607.0834 are applicable (relating to unlawful distributions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of incorporation and bylaws provide that we shall indemnify any and all persons whom it shall have power
to indemnify under the FBCA to the fullest extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriting agreement for this offering will provide that the underwriters indemnify us against certain civil liabilities that may be
incurred in connection with this offering, including certain liabilities under the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain director and officer liability insurance against certain claims and liabilities which may be made against our former, current
or future directors and officers. In addition, we have individual indemnification agreements with our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the preceding three years, we have issued and sold the following securities that were not registered under the Securities Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September, 2021, in connection with the incorporation of our company, we issued to
                                            our founders, who were comprised of 35 accredited investors, an aggregate of 55,000,000
                                            shares of our common stock in exchange for initial capital contributions in the aggregate
                                            amount of $55,000.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
    January 2023 to March 2023, we undertook a private placement solely to accredited investors pursuant to which we issued and
    sold an aggregate of 549,451 shares of our common stock at a price of $1.82 per share, for an aggregate purchase price of
    approximately $1.0 million to 10 investors. In addition, each investor received one warrant for each share of common
    stock purchased in the offering, exercisable any time until the day that is one year plus 90 days from the date an IND filing is
    made with the FDA, at an exercise price equal to $7.52 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 15, 2023, we granted to Bay Shore Trust a warrant to purchase up to 5,000,000 shares of our common stock at an exercise price
    of $1.83 per share in consideration of making a credit facility available to the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
claimed exemption from registration under the Securities Act of 1933, as amended, or the Securities Act, for the sale and issuance of
securities in the transactions described in paragraphs 1, 2, and 3 above by virtue of Section 4(a)(2) of the Securities Act and/or Regulation
D promulgated thereunder as a transaction not involving any public offering. All the purchasers of unregistered securities for which
we relied on Section 4(a)(2) and/or Regulation D represented that they were accredited investors as defined in Rule 501(a) under the
Securities Act. We claimed such exemption on the basis that (a) the purchasers in each case represented that they intended to acquire
the securities for investment only and not with a view to the distribution thereof and that they either received adequate information
about the registrant or had access, through employment or other relationships, to such information and (b) appropriate legends were affixed
to the stock certificates issued in such transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exhibits</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>INDEX
TO EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Description</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amended and Restated Articles of Incorporation of Telomir Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Bylaws of Telomir Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen
    certificate evidencing shares of common stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Representative&rsquo;s Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Purchase Warrant, dated June 15, 2023, between Telomir Pharmaceuticals, Inc. and Bay Shore Trust</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Foley &amp; Lardner LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023
    Omnibus Incentive Plan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Stock Option Award under 2023 Omnibus Incentive Plan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated License Agreement, dated [________], 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement, dated April 28, 2023, between Pharmaceuticals, Inc. and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement, dated April 28, 2023, between Pharmaceuticals, Inc. and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    Note and Loan Agreement, dated June 15, 2023, by and between Telomir Pharmaceuticals, Inc. and Bay Shore Trust</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Rights Agreement, dated June 15, 2023, between Telomir Pharmaceuticals, Inc. and Bay Shore Trust</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
    of Business Conduct and Ethics</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries of Registrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Cherry Bekaert LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Foley &amp; Lardner LLP (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Committee Charter</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
    and Corporate Governance Committee Charter</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Committee Charter</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Governance Guidelines</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
    Trading Policy</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Person Transaction Policy and Procedures</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    management contract or compensatory plan or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
<I>Financial Statement Schedules</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned Registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time
it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of
such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Tampa, Florida, on this [&#9679;] day of [&#9679;], 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TELOMIR
    <FONT STYLE="text-transform: uppercase">Pharmaceuticals, Inc.</FONT></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Christopher Chapman, Jr.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><A NAME="poa_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Christopher Chapman and
James McNulty, and each of them individually, his or her true and lawful attorneys-in-fact and agents, with full powers of substitution
and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments
(including post effective amendments) to this registration statement and any subsequent registration statement filed pursuant to Rule
462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to
all intents and purposes as he or she might or could do in person, and hereby ratifying and confirming all that either of the said attorneys-in-fact
and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons
in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Chief Medical Officer, President, and Chairman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Christopher Chapman, Jr.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    A. McNulty, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Craig Eagle</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christos
    Nicholoudis, Esq.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
    Vorhoff</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Kroenig</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2023 </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Talhia
    Tuck</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;[&#9679;],
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hugh
    McColl III</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>











































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formdrs_001.jpg
<TEXT>
begin 644 formdrs_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !7 2P# 2(  A$! Q$!_\0
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MBS/X4\=:':Z5>ZGHB?#OXH>(DMK;6]/@U73'&J>&O!FKZ-.;FPN89RMM?RM
M7,,XCF5XU^2O^"8G_!._XR_L3^.?BQXE^)_BKX:>([#Q]X4\-Z%I47@/4?%5
M]=6EYHFL:GJ%Q+J*>(?"7AR&.VFAO46!K:>ZE,J,)(8TVM7XE_\ !8[_ )2
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MOZVG/0\$C(]3V/T[<YKX7^+O_!2/]C;X#?$7Q'\)?BO\6;GPO\0/"?\ 8_\
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MXH,NOZEIVJ:G:6+:?X1T77=2A66QT;49#=S6B6B- (I9TEEA23Y#_P"'O_\
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M"\%>#-!M<R3RLT&B^'M)FOKZ:9H;J>;H_P!JG]L+XS_MC^)O!VO?%>_MIO\
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M^RLE4CJW)6_MLWKZ_H?\*BDVL5/S':>BDCJ5P?7C&<^F:_"(?\%]_P!G3O\
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M3E3GDF56G2FDI4J]*:A6P]:+C.C7I4JD))IJ?\U7_!*S_@F'XST#XCW'Q_\
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MYP/Z_?V,G'_#'G[* P3C]FGX$YP.F/A;X7/\CU]1SBOW[QO:7A5X/)M)_4\
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M[X_?M1>-?''A']G'X%W7Q)T]]9^&_P )H].^&.@:[\0/'OQ/\;^'8[OQ(O\
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M$7PKI/A?Q;IGB+3M*U71O#VJ/+?:9JWBZ3P\UP(!IA\1^"/&^D"^-UI]G%?
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M;S)&WBC0S? 'Z _\%:OV@-)^ UG_ ,$NKWXE_LR?LZ_'[Q3\9?\ @I7^RM\
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MNS^'FJR:K]JNK*W&KZSX9AO[_2=&FU;7-* /NK]E?XD?\%O]<^,GP^;]L?\
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HK?QD^FMXB@TUO-EW6,>I+:MYLF8CO;/H  48 P.>/J<G]3110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>formdrs_002.jpg
<TEXT>
begin 644 formdrs_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %= G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#F:***^H/D
M0HHI"Z@X+J#[D4 +12!E/1E/T.:6@ HJ*6Z@@DCCEF1'D.$5C@M]*EI70[-!
M1113$%%%% !1110 4444 %%%-,D:N$:1 QZ*6 )H =144]S!:H'N)DB4G +G
M S4O44KK8=G:X4444Q!1110 4444 %%%% !13$ECE!,<BN%.#M.<'TI] !11
M10 4444 %%%% !1110 4444 %%%5GU"UBOELY)0DS*&4-P&'L?7BDVEN-)O8
MLT444Q!1110 44A95ZL!]3B@.I. ZD^Q% "T45'/<0VT?F3RI$F<;G.!FANV
MXTF]$244@(8 @Y!&0:6@04444 %%%% !1110 4444 %%-+H#@NH/H6%.H **
M** "BBB@ HHJ**Y@GDDCBF1WC.'53DK]:5T.S):***8@HHZ=:;')'*@>-U=#
MT93D4 .HHHH **** "K6E_\ (8L/^OF+_P!#%5:M:7_R&+#_ *^8O_0Q2ELQ
MQW15HHHIB"N6\4:/"(;C5/,D\TE1LXV]A74UC^*?^1?G_P!Y?YUAB(J5)WZ'
M3A9RC5C9[D6AZ5;:9;"_\Y_WD 9]^,*.":?;>)K6XNHXC!-%'*VV.9QA6-)=
MJS>#2$!)^RH>/3C/Z5BVUM-J%C9QMK-J(T9?+@889&]/6N=SE3Y84UTO_5V=
M*A&KS3J/K;TW[(TM?_Y#NC_]=/\ V85J:IJUOI2(90SR2'"1IU-9GB#_ )#N
MC_\ 73_V84S5W6#Q;IT\Y"P;<!FZ Y/]2*;FX.;7=?D3&"FJ:EV;^YFII>L0
M:IYB(CQ31_?B?J!ZU6O/$UK9SW$#0RM+"VW Q\WJ<]A52Q=+CQK=36Y#Q"+#
MNIR"< ?SHLD5O$VM[E!_=,.1]*?M9N*2>MVK^@O8TU)MK2R=O6Q,_BZQ41%8
MIF#CYR!_J_;W-;%S>06EFUU*^(54-D=\],5R$*K_ ,()<-M&?M .<>ZU?UT2
M'PE9%<[5\LO]-O\ C4PKU.5R>NERIX>GSJ,=/>:-'3]?@O[H6S036\C+NC$@
M^^/:EU#7[73;I[>9)"ZQAP1C#9[5F6=M-=ZG8W4NL6MRT7*(G#;>XQ_C4MS&
MDGCFW#J& AS@C(R :KVE3D\[I=.OHQ>RI<_E9OKT]4:EUJT%GIT5Y*&Q*JE(
MQRQ)&<4W3-8BU)Y8O*D@GCY:*3KCUK*\5>8EQILBR")%<@2$9"'C!Q4VE6DI
MUIKV75+:[D\HJPBZX[$XI^UG[7E6RM^6Y/L:?L>=[N_?OMM8WI&98G9!E@I*
MCU..*XK1].L=961KN\D%\SD[=P!(]>>M=LS!5+$X &2:XS7O['D@%]87"K=%
MP=L9(S[X[&EBDM).S2Z,>#;UBKIOJOU\C3\8#&DP#L)A_(U8T_Q%:7UZ+1(Y
M$8CY&;H^!^E4O%#.^@6;2C]XSH6^NTYI^HJ%\5:1M '[L#@?6IE.4:KE'^[^
M)<81E149;^]^!IZGK%OI?EJZ/+-)]R).II=+U>#54?RE>.2,X>-^HK)OG2W\
M:VDUPP2(Q85FX ."/YT:2RS^+=1G@(:#;@LO0G(_P-7[:7M+=+VM\MS-T(>R
MO;6U[_/8N2>);6.Z:V\J0RB80XXYYQGZ53\0ZO+9ZI:P1M*J(P>4)_RT&1P/
MU_.ET2.-_$6KNR*S*_RDC.,L:/$KK%J>D2N=J)*2S'H!E:B4ZCI.3?7];&D(
M4XUE%+I^ES7EU2W@TM=0F#)&R@A"/FR>@^M0:=KD.H7#6Y@EMY@NX)(/O#U%
M4/%C^;IUG-$X,7G;MXY'(X-)86LT^M6]Y-J]K=NB'"Q_>*X]OKWJW5G[517E
MVZ_/\C.-&G[)S>^O?2W3;\[%R]\1VMC=S6TD4K2Q@$!<8;/I5O2]3AU6V\^$
M,N&VLC=5-95NH/CR?(!Q#QGZ"CPH &U( 8 GX'YT0JS=2S>EVON"I2IJG=+5
M)/[RQX<-F8+K[&DRKYWS>:0>?;':H'\7V:)D6\[-N(9>!M'K2>$/^/>]_P"N
M_P#2L_354^&M:)4$[NN*S52:IQY=-'T[&KI0=2?/K9KKW.K%Y ;$7N_$&SS-
MQ]*Q5\7V9!)MK@9.$X'S5 ZN_@)0F<A 3] _-4-3O;.?0-+@AD4RQD;D'5>,
M'/XTZM>:5T[:7]14L/!MIIO5KTL=O1117>>:4-5U6#2;=9959RYVJB]36-_P
MFMO_ ,^4O_?P?X4>-5)M;-@#M#L"?3@?X5QM>5B<34A4<8O0]C"X6E4I*4EJ
M=E_PFMO_ ,^4O_?P?X4?\)K;_P#/E+_W\'^%<;17/]<K=_P.GZC0[?B=E_PF
MMO\ \^4O_?P?X4?\)K;_ //E+_W\'^%<;11]<K=_P#ZC0[?B=E_PFMO_ ,^4
MO_?P?X5@:YJB:M>I.D31A4"88Y[G_&LRBHJ8FI4CRR>AI3PM*G+FBM3?TKQ1
M<V6V*YS<0#CD_,OT/?\ &NRLK^VU"'S;:4..X[K]17EX!)  R3T KJ-!\.WJ
MS)=S2R6BCD*IP[#W]!]:Z<+7JWY;77Y')C,/1MSWY7^?R.QHHHKUSQ3(US1X
M=2B\^621&@C8J%Q@\9Y_*LKPQHT,L4&IF202I(<(,;3CBNFO/^/&X_ZY/_Z"
M:R?"H)\/*%Z[WQ]:XYTX.NFUT;_([859K#M)]4OON+<>)[6"Y>,03211MMDF
M0?*IJ/Q6ROH"NA#*TB$$=Q@UA:=%-/IUQ:G5+>UCWGS89A@GWS^'Z5K:]";?
MPE;PEP^PH-R]#P>16/M9U*4G+:W]?TS?V,*=6"CO?S_R_(VI+R&PTM+B=B$6
M->G4G'053T_Q%;7UTMLT,L$CC,?F='JCXH5CH5DP!**R[O\ OGBF:M<07NLZ
M.MG(LC@@Y0]%R#C\@:UG6E&5ETMIWN9TZ$)1NUJ^;7M8UM1URVTRY6"=)"S)
MO!49S[?6J/\ PE]G]F\SR)O-W8,7&0/7/I1J0!\9:7D9&S/ZM4.G1H=6\0 H
MN-C#&/K2E4J\[2?5K;RN$*5+D3DM;)[^=C?M+V&\L4NXVQ$RDG=_#CKGZ5F1
M>)[22Y1/)F2!WV)<,/E)JEI2N_@BY6/);$F,?A6?;6\NH:3! VL6L<*M\L#C
M#*V?IGO^M*5>I:/+NU<<,/3O+FV3MU_1,ZK4M5@TMH!<*^V4D;EZ+CUI+75[
M>XTMM08-% I;.[D\5E>*D#/IB.,@RX;/?I5KQ3&1H,JQ* JNI(48&,__ *JU
ME4FI3?1+]#*-*#C!=9/?YCK'Q#;WMVEN8)H#*,Q-(.'K8KD[2VFOKC3II-9M
M9O*93'$!A@.ZX_"NL[U5"<I)\WZ?H1B(0A)<GZ_JD<>NFVNI>(-6%W(T:QDL
M&# 8_.M+PG++)I4BR.62.4K&S>F*S/[*BU77=81V=7CRT97^][UH:%.]SX7G
MB0 2Q*\8"C&>,C\>:Y:.E2]OYOGJ=M?6E:_\ORT_4E/BFS%QM\F8V^_9]IQ\
MF:T=1U&#3+0W$Y)7.%5>K'T%<?90R7NC"W;5[6" -DP2<$'/6M3Q.AAM]+,O
MSQ1.%DQWP!_0&JC7J>SE-^7];F<L/3]I&"\^_P#E^1=L_$MM>74%L+>9)93C
M#8PO&:NR:G%'J\6G%',LB;PPQM Y_P *Q)[NVO/&6GO:R+(H7#,O3.#_ $I^
MHS1VOC.RFG8)%Y.-[=!]X5:K246V[VDE?R)="#DDE:\6[>9L6FIQ7>H7-FB.
MKVY^9CC!YQQ65H'_ "'=9_ZZ?^S&F>'YDG\0ZK+$VY'Y4^HW4_P__P AW6?^
MNG_LQI*;FX-]W^H2@H*I%=H_H3W7B6&UN7C>SN3'&^QY<< T_7M2-IHXEMF?
M=/@1R)V[Y_*N>O;Z?4[*^FGO_*2.0+':#C=S^M;%WSX%7_KA'_,5*K2FII/I
M=?U_3+="$'!M=;/^OZ19TF_6_P!#<RK*?*B*2ENK_+R0:=X?>T71@UMYB0*S
M$F8C/N3BC3IXIO#*B.17,=L4<#^$[>AK-TI7?P3<K&"6(DP!6D9-.+W]U_H9
M2@FI+;WE^I:'BRR,X7R9Q 6V^>1\N?I6EJ.I1:;:K<2*SHS!1LQW[URTMW:'
MP1';B1/.\S_5Y^;.XG./I5[7T>/PC:))G>OEAL^NTU"KSY9.]]+_ / -)8>G
MSQ5K:M?\$O6?B2TO-1%HB2+NXCD;H_X=JV:YG545-;T+:H7A1P.V1735T492
M?,I=/\CEKP@E&4%:Z_6P5:TO_D,6'_7S%_Z&*JU:TO\ Y#%A_P!?,7_H8K:6
MS,([HJT444Q!45S:PWD#07";XVP2N<=*EHI-)JS&FT[H9'$D42Q(H$:KM"^W
MI5!- TN.Y%PEJ%D!W##' /TK2HI.$7:ZV*4Y1O9[E>>RMKF>*::(/)"<QMD_
M*:+RQMK^'RKJ(2*#D=B#[&K%1R7$,3HDDJ(\APBLV"WTH<8ZWZ@I2NK/8BL[
M"UT^(QVL0C4G)[D_4TJ6-M'<S7"1 2S#$C9/S"IDD24,48-M8J<=B.HIU"C&
MRL@<I7=WN4QI5DMBUD( +=FW%,GD_P"15C[/";;[.8U,.W9L/(QZ5)D9QGGT
MHH48K9"<Y/=F?:Z)IUE<>?;V^V09P2Q./I5DV5NUZMX8A]H5=H?)Z5*702+&
M6 =@2JYY('6G4E"*5DANI-N[;(KFVANX&AN(UDC/535>QTFRTYF:UAV,PP6+
M$G'IS5VBFX1;YFM1*<DN5/01E#J58 JPP0>XK.B\/Z7#.)DM%W@Y +$@'Z&M
M*BB4(RU:'&<HZ1=BO=V5O?QB.ZB$B [@"2.:)+&VENHKEX@9H1A&R>*L4CNL
M:,[D!5!))[ 4.,=VA*4EHF5[W3[74(Q'=0B0#D'H1]#2V=E;6$/E6L0C3.3C
MDD^YJ=6#*&4Y4C(/J*1Y$C +L%!(4$G&2>@HY8WYK:CYI6Y+Z=B*"RMK:>:>
M&(+),<R-D_-3;VPMM0A$5U%O4'(YP0?8U9HHY8VM;07/*_-?4@^QVYLQ:&)6
MMPH4(W/ JO9Z-8:?,9K:#9(1C<6)X_&KYX&2<"BCDC=.VP_:32:ON0+96Z7K
M7BQ 7##:7R>126ME;V9D-O$$,C;GP2<FK%%'+'>PG.35KE>ULK:Q5UMHA&';
M<V"3DTR/3+.&VFMXX L4W,BY/S5;J*.Y@EV>7*K;P67'< X-+EBM+#YIN[NR
M)XX['39$M[?>D<9VPCG=[5R30C59X+:RTAK-?,#S.0?YGH.O%=K)*D04R,%#
M,%!/<GH*8]U BAGF4*7\O.?XNF/K656DIV3=DO3^D;T:TH7:5V_7^F2GK14<
M,\5Q'YD+AT)(##H:DKHO<Y6K:,9)%'-&8Y45T/56&0:K?V3IW_/A;?\ ?L5<
MIKR)&C,[!5498D]!ZU+C%ZM%*4EHF5?[)T[_ )\+;_OV*/[)T[_GPMO^_8JX
M.1D=#33(BE 74%SA1GJ?04N2'9?@/GGW?WLJ_P!DZ=_SX6W_ '[%']DZ=_SX
M6W_?L5<HHY(]E]P>TGW?WLI_V3IW_/A;?]^Q7/:QX?DO-7CCL;>.&$1#>X&U
M0<G\S76T5%2A":LT:4\1.G+F3,O2]!L]+ =5\V?O*XZ?0=JU*9%(DT2R1L&1
MAE6'0BGU<(QBK1V,YSE.5YO4**B-S"&*F500XC(_VB,@5+573)::$=5D1D89
M5@01Z@U%:VL%E (;>,1Q@DA0<\U-38Y$E0/&P93T(.1197OU"[M;H4+G0M-N
M[@SS6P,A.258C=]<59N+&VNK9;::(-"N,)DC&.!5BD9E1&=CA5!))["IY(*^
MFY?M)NVKTV&2012VY@DC5XBNTHW(Q56RT>PT^0R6UN%<\;B22![9Z5=5E=%9
M3E6&01W%+3Y8MIV$IR2<;D$EE;RW<=T\0,\0PCY/'^<TD=A;12SRI$ ]P,2G
M)^:K&1G&>:*.6.]A<\K6N0VMI!90"&WC"1@D[<YY-4_^$?TO[3Y_V4!\[L!B
M!GZ5I44G"+236PU4FFVGN5[JRMKQHVN(@YC;<F21@U.ZK(C(ZAE888$9!%+2
M$A5+$X &2?2JLMR;O1&?;Z%IMI<BXAMMLJG*G<3CZ"M&FHZR(KH0RL 5([@T
MZE&,8KW4.4I2?O.Y!#9V\%S+<11A9I?OMD\TEK8VUEYGV:(1^8=S8)Y-6*BC
MN(9MGERJV\%EP>H!P2/QHY8ICYI-/4I2^']+FN#.]HN\G) 8@$_04[6I5ATX
ME[(W<98*T0';UK0IK2+&K,SA0HRQ)Z#UJ73BDU'2Y2J2<DY:V.6TFW:]UN&[
MBL#9V=LIVJ1U//?N>?TKH+[3+/40@NH=^S[IR01^56\Y .<BBIA1C&+B];E5
M*\I24EI8K6VGVEG*\MO L;N K%?0=*6"RMK:>::&()),<R,"?F-6**T48K9&
M3G)[LSGT+3))Y)FM%+R9W<G'/4@=C5L6L M/LOECR-NS8>1CTJ0R(LB1E@'?
M.U?7'6@2(96B##>H#%>X!Z']#24(+9(ISF]VRM::;:6-O)!;Q%8Y,[P6)SQB
MI;6T@LH!#;QA(P2=N<\FIJ*:C%;(ESD[W>YG+H6F+=?:1:+YF<XR=N?7'2K5
MW9V]]#Y5S&)(\[L$D<U/124(I-);C=2;:;>Q7EL;:>:&:2(-)!_JSD_+5BBB
MJ22V);;W"K6E_P#(8L/^OF+_ -#%5:M:7_R&+#_KYB_]#%$MF$=T5:*]#_X5
M!K'_ $$K'\G_ ,*/^%0:Q_T$K'\G_P *P^LT?YCH^J5_Y3SRBO0_^%0:Q_T$
MK'\G_P */^%0:Q_T$K'\G_PH^LT?Y@^J5_Y3SRBO0_\ A4&L?]!*Q_)_\*/^
M%0:Q_P!!*Q_)_P#"CZS1_F#ZI7_E//*R[]_(U*"6%BUPP6,PF,D.F[J#V(Y-
M>K_\*@UC_H)6/Y/_ (4?\*AUC_H)V/Y/_A4RQ%&2MS%PPU:+OR'D=L)XM0<Q
MO(5EFN 8V^YQ@J?S[U7BN+LV%RR37#,(4+,X.4F+?,!QZ=J]D_X5#K'_ $$K
M'\G_ ,*/^%0ZS_T$['\G_P *R]I2Z3-?95MW3_(\FFB>WU4F-YGD%D5BW'(=
M@3U[9Z&H+9[F:SB!NI#YES&A9"VY 1\P)('?\J]@_P"%0ZQ_T$K'\G_PH_X5
M#K/_ $$['\G_ ,*?M:-_C_,2I5[6Y/R\SR2":X,5H6:0MY$^XD<DJ0%)]ZAC
MDO$LIOWUPY,4$C,>64-]_;QZ=NU>P_\ "H=8_P"@G8_D_P#A3)?@YJTT31OJ
M=GM;KMW@_@0*7M:5OC&J5:_P'E^G2R26,[*[RLLLBQF7J0/N@U0AN;O[#<-'
M+</B*,NSK\R.3^\"C'8=NU>NP?!G5+:$11:A8J@R?XR23U)..34O_"H=9_Z"
M=C^3_P"%/VU)I7F+V-5-VAOZ'D_FI]LLT^TW'V0IF)\G]X^[HQQGIV-0PW5P
MUP\3/+NC2XW @XSGY.?ITKU[_A4.L_\ 03L?R?\ PH_X5#K'_03L?R?_  I^
MVI?SA[&M_)^1Y'YD\*:66GFE9\&1,D,Q;'/ Q@<\'M3M<=PJQF29(7AD_P!4
M"=TF/E4X[=:]:_X5#K'_ $$['\G_ ,*/^%0ZP/\ F)V/Y/\ X4G5I<K7."HU
MN92Y-O0\BDNIH98H0THWK;; JG&,X?GMVS3BUP(I9#+*Q-^L84]%0-V_/K7K
M?_"H=9_Z"=C^3_X4?\*AUC_H)6/Y/_A1[6E_.'L:W\AY)"]V+YF$LK[Y+A!&
MWW0%^YBG:/-))+*KS3R8BC9A,""KG=NQD>HKUG_A4&L?]!*Q_)_\*@M_@KJ5
MKO,6HV>7QN9C(Q..G)[4*M24D^<;HU7%KD_(\FNFEFAU>$O++A-RLI.%&?N8
MQUX[=14K33G5;9([AA 5C,9<M^\'.[MR>G7&*];_ .%0ZS_T$['\G_PH_P"%
M0ZS_ -!.Q_)_\*/:TM^?^KW#V5:UN3\NUCQJ5[Q8WF%S<[MDL@7/ *R848QT
MP>G>M35)&CAB.^2.%I0)GB^\JX/ITYQS7J/_  J'6/\ H)V/Y/\ X4?\*AU@
M?\Q*Q_)_\*%5I)-<^XG1K-I\FWH>2K+<'6XD$Y6'Y"@8M^\3;SVP3GN3VIFE
MJP?3\J1B";.1T^<5Z[_PJ'6/^@G8_D_^%'_"H=8_Z"5C^3_X4*K1O?G!T:]K
M<AY!?L[:HL;O,-LT)BC4'85S\S'CKFBXCDN&A#O,N+N<90X(&UL5Z_\ \*AU
MC_H)V/Y/_A1_PJ'6/^@E8_D_^%)U*+O>>XU2KJUH;'CA:ZA@TR*.9HD-NI#.
M6P7R/E. <\<8-3SR72P:C*DDI*W(15R<)'D9(P,]SS7KG_"H=9_Z"=C^3_X4
M?\*AUC_H)6/Y/_A1[2E_/_5K![*M_P ^_P N]SQZ5KMK2$"[ER()I-\)/S%<
M;<DC)_K3[@ND^H2AY1*]BKH.<9P<X'L<?G7KW_"H=9_Z"=C^3_X4?\*AUC_H
M)V/Y/_A1[2C_ #_F'LJ_\GY'DK7$W]MV\2M(J_*K@DX8%"<@8P.0.>N:CL-\
M4=A$C2G%U*LH?/'#<?3H?QKU[_A4.L8Q_:=C^3_X4?\ "H=8_P"@G8_D_P#A
M3]K2O?G_ *T_R%[&M:W)_6O^9XY%<WGV:Z82SF1;9FE# _NY=QP%X].P]JU-
M/$BM<Q2222!)0$:3DX*@]?J37I__  J'6?\ H)V/Y/\ X4?\*@UC_H)6/Y/_
M (4XU:46GSBG1K237)^1XTEY=O:W[)),ORQL@.6:,E\$9(ZX[#BIY))HXO*D
MGN1 EV\;2KDOMQE><=,\9KU[_A4.L_\ 03L?R?\ PH_X5#K'_03L?R?_  J5
M4I?SENE6_P"??Y'DT+3P^%XS"'$RPCHOS#GDX]<9J&\FD"6HL[N00,K;9I&;
M)?(P#QD]^#Q7K_\ PJ'6/^@E8_D_^%'_  J'6?\ H)V/Y/\ X4W5I-6YR51K
M)WY.K?0\DE5OM,IVG_D(Q'IVV"EUNYF@,(@,BO@N&4G!P1\N .3CUXQFO6O^
M%0ZQ_P!!*Q_)_P#"C_A4.L#_ )B=C^3_ .%-U:5FE/<%1K73<-CR22:9=<1&
MEG7-RJ+& ?+,6PG/USFJSR7;6,)6:=&6WGD.SC+*WRYX_2O73\%=2-T+DZC9
MF4=,F0@<8R!T!QWJ?_A4.L?]!.Q_)_\ "I]K2=[S_,KV556M#\CR*[N)UU%-
MTL\>7A$:J#L93]_/'7-2:V[J$0R3)"\<@)B!RSX^53@=#S7J3_!74I;E+A]1
MLV=.5!,FT'L<=,^]3_\ "H=8'_,3L?R?_"G[:DTTY[B]C53BU#;T/()+F:%H
M80TJ[XK;8%4X^]A_IQC-36DMR^LSK++A59QY1)^[QM(&,?CGG->L_P#"H=9_
MZ"=C^3_X4?\ "H=8QC^T['\G_P *%5I7OSB=&LU;V9Y+<>;#>:F\#2F<VZ-&
MO4'&02!ZC^M6-+D9TGQ)++ )/W+RYW,,#/7KSFO4O^%0ZQ_T$K'\G_PH_P"%
M0ZP?^8E8_D_^%4JU%2OSDNA6<;<G8\:BN[N2VO6229<B-D!)+1DOAADCKCTX
MK5L&F%O<(S/(T4TB1F0Y) Z9/>O4/^%0ZS_T$['\G_PH_P"%0:Q_T$K'\G_P
MI1JTHN_.5.C6DK*F>.VTMY)I[EKE][20J=I.^,E@'ZCCZ=!2SRS+9QQRSW(B
M#SQF1<EV(R$!P._ZU[#_ ,*AUG_H)V/Y/_A1_P *AUG_ *"=C^3_ .%3[2E:
MW/\ F5[.M>_L_P CRN,W,>D*5"!%L\C&=X<)^55+A[N)K*-;EU#1!O,D)^:0
ML,@X'/'8XKU__A4.L?\ 02L?R?\ PH_X5#K'_03L?R?_  JG5HM6YR8T:R=^
M0\CBN)6UMHUGF8K<LK1'[@BVYST]<5%:/<Q6ELL*MO%I,RJ1_'NXKUZ/X-ZK
M$9"FHV(\QR[</R3WZ>U/_P"%0ZQ_T$K'\G_PJ55I;N8W2K;*!X]=7)32(C;3
MW+LY8^:Y;*N%S@@#/7H.E/D+B>]FW2B62P5U'.TG!S@>H./SKU[_ (5#K/\
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M^Q@-JJ& *\<'YSUSVJK/X/EN#9RR^(]5:\LY'>"ZVP;U#J%9<>7M(P.XS[T
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M1BA>V%RS3W$%O'&8L,QF3S$;&?N[=Q)[;6]*9J/@+3M1O/M9N[N*<-$RE=C
M>7&T8^5U*G*N>HX.",57TSP)#I?BO2[^%BUGIFEBSAWOF1Y,D!F  'RH6 /^
MV?2@"[?>.M'L/$(T:5I?.$T5N\HV[(Y9!E%(SN.<CD @9&2*RM,^(<4?A^RN
M=2MKJXG%E'=W\UI"#';(Y(#-SG'RDX&3@$UMOX2M?^$CEUF"YFADG=)+B)8X
MF65D 4'+(67@ ':1G%9Q^'.G"U2TBU#48K5K6.SNHDD7%U$A)4/\N1]Y@2N"
M0<4 2-\1-(CN+A)K:_BMX6N4^UM!^ZD> $R*I!R>%)'&#CUXIG_"PK3[)>W#
M:/JB"RD"3JXB&W*"0')DP?E(.,Y)(&*;KG@.&]T"YL["X>.Y,EW/ 96^023J
MX8-@9VC><8Z<=:R-+^&LTUIY&I7!L[:!R;."V:*4H'CV2[F,05BW&#MRN.#S
MB@#33XCV8N=3>>QN4TZUCMG@NAM_?^< 44 D8)+#&>.N2*L7?CNW_P"$*U+Q
M#IUG+=-8NT4EL64%9%(!!8$@@9!R">*;)\.M,>%X!>7JPO;VT)3<A >WQY4O
M*GYA@9'W3W%:C>&()_#%UH5W=33PW2.LDH2.)AN] BA1CMQ]<T 4)/B!I,&K
MPZ9<17,%P\D4,@DV?N)91E$8!LDG(R5! R,FL_3/B'%'X?LKG4K:ZN)Q91W=
M_-:0@QVR.2 S<YQ\I.!DX!-:MOX,AMM8&IKJ5TUQ(8VN2\<+?:'10H8DIE20
M #L*YQ50_#G3A:I:1:AJ,5JUK'9W422+BZB0DJ'^7(^\P)7!(.* %?XB6/VX
MVD&DZO<NT\UM"T-NI6>6(G>JDL.@!.3@<'G/%"_$K0'N;.*-YF2Y6W;S,*!$
M9_\ 5A@2&R<C. <9&<5I6WA*PM;NTN8Y9]UK=W-VBEAC=/NW \=!N./ZU0T[
MP!I^DW5K/8WES'Y,<,<BLD3^<(AA22R$J<<$J1D 4 5V^)NDI:1W+6.HJDS2
M^0)$C0S+'_K'7<X& <#G!)(P#6KHWB_3]?U*2TTZ.>5(XDD:XPH0!T5UX)W<
MJPYVXSD9R*J2^ M/-EID$%U<PRZ<)5@GVQR-MD.65E=2I&0.V1@5;@\)V\?B
M*WUJ6]N9Y[:%H8$=8U"*P /*J"1QG!) ).!0!FVOCX.]]%<:-?+-%J3V%K%$
M%=KEE7=Q\V!A06.< #'/:M"3QGID7AC^WF2X$ F^SM"R!9$E\SRRC9("D-P2
M3@=<XJ"?P/;27EQ=0ZG?VTSWOVZ$Q,G^CS%"CE<J<AE."K9'IBKD?AB"W\.G
M1[6\N8E9VDDN&"2/*S,6<N'4JVXDY&,<\8H C?QA80Q7CS6]U$]FMLTT;(I9
M?/;:@X)!P>O/YUEW?Q"06D5SIVCWMW$^I)8;@47)+E&(&[(((X# =1T!IW_"
MM=,2WAMH-0U*&V2&"*6%)5Q/Y+EXRV5)X)/ P,8&.*FE\ VDTUY<OJ=]]MN)
M8)1<J(E:,PN63 "!6.6()8$D<4 ,U+QW;VRZG:^1<6=Y:V<MTAN(U<,J$!CM
M5\_Q#@[<@Y%6[7QK87.MC2Q:WR$W4EDMT\0$+3HI8H#G/W03G&.,9S6>GPST
MI#> WM\ZW,%Q;D$Q@JLS!W.X)ECD<%B<#BM>+PG8Q7$,RRW!:+4I-24%ACS'
M1D(Z?=PQ]_>@"&\\:Z98ZAJMM.EP$TN'S;N?"[4!4,!C.XY!&"!C/&<UB7?Q
M%69[=M,MY&>*69+NU?8SG%L\R896*\[1W[$=:U]8\#:?K^IRW>IW-U,C020)
M"-BB-77:V&"[CZ@$D \XI8_!5MY4"7-_=7#0O(R/Y<4?WXFB((1%!X8G/7/Y
M4 4=*\:16G@F#5M;N6FOC#'/+:PQH)@)&4+B-6)QEQ@]2",\U8/Q"TF/58=-
MN8+JWN'DBAE$H3]Q+*,HC -DDY'*@@;ADUH3>$M,GT2'3"A411P1"X4*)66)
MD*@MCG[@S3'\)6O_  D<NLP7,T,D[I)<1".)EE9 %!RR%EX !VD9Q0!F0_$S
M17LWNYK;4+6#[/\ :87GA"_:$WK'\GS==[*.<?>!Z<TY/B5H36US-(MS']FA
MGEE4JK8,.PL@*L0S8D0C!((/6I)?AYI$^F6EA++=-%:V9M(CO7<!YB2!^F-P
M:-<=NN0:DN/ MA>VVG17UU<7#6-Z+Q'"11;R/X&5$"E#@9&,G'6@".[^(6EV
M]M/=16M[<VUO''+--$J!45X_,'+,,G:0=HYYXJ_X=UF75[[6@SHUM;W,:6Q5
M<'RV@CDY]\N:Q'^%FB_V?'9Q75[$B/<,6W(Y*S !E^92!A555(&0!UKI=&T&
MUT,7(MGE;[0R,WF$'!2)(QC ]$'XYH U**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH QTA5A]Y_^^S3OLZ?WG_[[-2JH48I<4[L5D0FV3^]
M)_WV:06J_P!Z3_OLT\G#4\.,47861%]G7^\__?9I#;*?XI/^^S4].HNPLBJ;
M5?[\G_?9JO)!L/WY/^^S5]CBJ[@N:+L+(JC /WI/^^S5J.-'7[S_ /?9J,0$
MN*N+'M%%V%D0_9T_O/\ ]]FE^SI_>?\ [[-2D4HHNPLB VR_WI/^^S2?95[O
M)_WV:M;::11=A9$'V5?[\G_?9H6W3^\__?9ITC[:8LU%V%D/-LF/O/\ ]]FF
M"W3/WG_[[-*9N.M1^82>*+L+(G^S)_>?_OLTTVZ_WG_[[-2H20,T\+1=A9%8
MVR_WI/\ OLT?9E_O2?\ ?9JP1BFT7861"+9?[TG_ 'V:7[,@_B?_ +[-2X.:
M"<"B["R(OLZ?WG_[[-+]F3'WG_[[-()/FIWF<47860P6Z _>?_OLT&V4_P 4
MG_?9IP!8U*.*+L+(@%JH_CD_[[-!ME_O/_WV:L9I#R:+L+(@%LO]Y_\ OLT?
M9E_O2?\ ?9JSM(&2"/PJ)Y%0%F8*HY))P!1=A9$?V9?[S_\ ?9I/LJ]GD_[[
M-6.HR.]&*+L+(K"T&?OR?]]FG?95Q]^3_OLU/2%N:+L+(K&S&[.^3'^^:<;9
M,8W2?]]FK&X8J(N,T78614EB$?(>3_OLU&"#_')_WV:T&C$BU ENC'<K*P!Q
MD'/-%V%D)# &Y+2?]]FK MD_O/\ ]]FG*FT<4[-%V%D,^SI_>?\ [Z-'V>/^
M\_\ WT:>31CBB["R&_9TQ]Y_^^C33 GJ_P#WV:ESQ29Q1=A9$#6J'^*0?\#-
M59(0A^_)_P!]FM$G-0R0[Z+L+(IJ!_??_OLTI08^_)_WV:4V[*U*8R!1=A9$
M CR^!))_WV:D>';_ !R?]]FIK>+YLFK$B!A1=A9&=Y6X\22?]]FK4-J"/F>3
M_OLTJPE3GM4@?;Q1=A9"-;HH^\__ 'V:C"ITW/\ ]]FI<,]'V?O1=A9#5A0_
MQ/\ ]]FGF!,?>?\ [[-1;]IQ2F;BB["R PH&^\__ 'V:D\A"/O/_ -]FH Q9
MP!5T+\HHNPLB#R$_O/\ ]]FE\A?[S_\ ?9IS BE5Q1=A9##;K_>?_OLTT0I_
M>?\ [[-2/(*A,F#1=A9"/ O9G_[[-*D"8Y:3_OLTH;)J<(,47861%]G0_P 3
M_P#?9I?LZ_WG_P"^S3L[6IV\8HNPLB$P+G[S_P#?9IWV=?[S_P#?9I5;+4\,
M,T7861&;=?[S_P#?9I/)3.-S_P#?9J1G&*A,GS47861*+=/[S_\ ?9I&@0#J
M_P#WT:<I)&:4\T78617\I2>&?_OLT]8%[L__ 'V:E2/FG$8HNPLB+R4]7_[[
M-*D2;UY?J/XC2MTIJ'$B_447861/@&DVTG-&XBD,:R9IJI@U+NS28H 2G 9%
M,/2@/0 ,M, YIV<TH6@!5P*?D4T+2D4 (>:3% ZT_C% #=QII/<\"E-<WXO\
M20:%IKQ/!-+/=12)#MPJ9VGJQ( ]<=:J,7)V1,I**NSH60./4'I63_:EA%+?
M1W=Q%:?8Y%5VFD55*L 58'T/(^H-><ZMX_U6XL$M=)A^QQQ0*K;6$CM\N,$X
M^7CT_.O/;]3.;@B, EAY2-)R!@YZ^_\ 6NR.#E:\M#AEC8WM'4^D[<PWD*7%
MM/'/ _W9(G#*?H15M(0M?-FC^(]:\/,TNE7TD,$Q+&V^5DS@#)4\9]Q7K_@S
MXA1>)))8+N*&SN(E7Y#)S(3U*Y[=.,DUC4H2AKT.BEB(STZG;XQ2AJ3>&&15
M>[NXK*W>XF)\M.H49)/0 #N2> *YS<LL:B:15W%F4!?O$GI]?2O*;[QUJ.FV
MEUI4-Y').L; .\1$MO\ ,?EW;OWA5>IQP?6N$/FA)-ERUP)VS(X)_>D]=QSD
MX]*[*>$E)7;L<53&0@[6N?15KJUE>W%Q;VTXEDMSMD"] ?0'OCOCID5*S@FO
MF.%[E)FFMM2DBN$D)AVR%"3P3R#[#KZ"N\\+?%&ZAEBLM>C:Y#,JB[0!2N>"
M7'<<YR*53#2CK'4NEBHRTEH>QK&#S4@C%0PSQ31*\4BNA&0RMD$>QJ4/VKD.
ML=@+3>IH)I%;F@!^WBH;B!+FVEMY03'*C(X!(.",'D=*EW9IK4 >4:%I>B^%
M-5\9:UY=XR:#-M@4W4CXC,"L5PQ())8\GIFEO/&4GB7P-XPM+E-/%S;:69MV
MGW7VB(I(IP"W9U(((KL6\'17$/BJWNKDO!X@?<P1<-"/+"=>YRN:I6W@S4F\
M*:QHNH:AICR7MK]FBN+33Q 5&"-S@'YCT..,?C0 S5O%FIZ:UOIVB:3#?S6F
MDIJ-X9YC&%A P%3 .7.UL9XXIFL^/-0B&F'P_I$-^-0TI]34SS&/RT7:2#@<
M\-CZX[58USP;J%[=K=Z1K*:?-+IHTN],D'F"2'LR#(VN,MCMS5H^#XH[O3VM
M+CRK:RT>72HXV7<2'V@.3GMMZ=\T 4?#GCJXU6\G&IZ6FGVK:6NKVDBS>8S6
M^2#OXX;H<#UJCX=^(S:]<W43P6"M_9S:C;+:W?G%44X\N;'W).5.!ZGTK8TO
MP4MA)9_:+Q;B&'0!HLD8C*^8-P)?.>,CC'ZU4\.^%+_1+&YTZXO=/N+7[*;6
MVDBL!%.%Q@&1P?F(&![XS0!G+\0K]?!UCK5YIME93ZG<)#81W%WMBV,N3)*_
M\*C#''7&WUK>\*^(1XGT6*_"1I)YKP2K%)O3>C;25;NIX(/H:S[SP1)<>$-$
MTB*]B6]T?RFM[F2 21NR+M.Z,]58$\5T>@Z;<V&FQ17KVCW*DL[6EN(8B2>,
M)VXQ]: .9T;XD1ZCXP@TH16/V.YN9K2W9+L-<AX@3NDB_A1MK!3UZ>M4M!UZ
M70?!KFTM5NK^^\175G:0N^Q&D>9^6;LH )/TK5T/PG=>'O$$LT-U82:29Y;A
M(7L1]IC+DDJ)<_=#$D<9QQ43^#9%\/)90:DL=_;:M)JUI<^3E4D9V8*RYY&&
M(//O0 Y_'MY!X7O+V72(SJUCJ::9<V:3_(TC,H#(Y'0A@1G\:1/'=W;^&-9O
M-2TE(]6TN\%BUG!-N265]OE[6/0'>,_0T0^"9Y=!GL[C4EDO[O5(]4N[KR<*
M[JZMM5<\+A0HYI?$'AFTAT'Q7<:AJ,D,%_=QWZSP0%WM60(%.T9+X9 3CMF@
M"UH_B76+L>(;;4-,L;74='6,%1=GR9&9"X)<CY5QCG''-<]<^/M2U?X=^*;O
M3S8IJ>E81KFQN&>$JP!\R-B,D@9&#W%0^&]'NO%^C>-O/U.2:/6)(8H=2-J8
M%E*1@%EC/.P'"^XS6];>!;MM&\3VFI:K!-<:[$B-);VOE) 5CV#"YY'3TZ4
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MA>@!S-35YD7ZBF%J6 YE7ZT 6J0TF#36)% #J*16%#,* %J-Q3U8$4UCGB@
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MB_\ WST%:6HWB NFGDR3E#*CJ_  "LR@8ZE0,CWJE D1OX64;1<0H[_+_JT
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M!/>IW IFXJ: ') %YJ3&*:KYI_6@!I533#&*<W I%?/6@ 5=M2+3&84*W&:
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MB6@";:,U(IQ5=9,T_?0!(2#31PZ_44W?2%_G3ZB@![.*53D52#,3@U85L#%
M#97VM0LW%)-&67-5AD'!H M--2*V]:K')XJRHV1T )&QW8JRM4D8;LU8644
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M,N=IZH>ZGW!K26  4 0C*T;ZE:.D-OD<4 1AZ>N6=?\ >%1%"K8JW H!7ZT
M0*RMSWIXP.<U$MNPI_D-W- #FE'05"Z@G-2^3@5'L8MB@!% %*[Y6I/(.*KN
MC9Q0 W!VY%"N:0[D&"*6,;SQ0 XDTT(685(4(.#4ZQ@*".M #2I04W?4P!8\
M]*7RE- '!>(Q]IUE!?JL<+9AM8Y.1*>=Q(Z'(SC/:LR1(HM:EA:1F-S&@\H@
M!%"C[V?Q_2NF\66]N+BTDD3]YAEC;9NP?Z=ZYJVNXYC<I(8T=YV2-F )D0*"
M3^ SB@"ELE.MO!YG[F1?.BD/&,':5.?]X?-CM61-N'VUI'4PR(T<F^7#'RR
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MOTJ9-P?<!0 \[EXJ(A@:MJ-QR:E$:GJ* * W&I8H2QR:L^4H[4]<"@!-N!2
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M>+2_%L4>FWS';%>)_P >UP?K_ ?8\?2N(D?6-3\02:QK5Y;W%PULMNOD0^6
MH;(X_$U+<6\-W T%Q$LL3=589%=<<'S4]=)''/&\M7W=8GO#1D $<@C(([BF
MG(%>(:!XDU[P1MBM-^K:&.NGS/\ O8!_TR;_ -E/'\Z]=\.^)M&\7Z>;K1[H
M2%>)8'&V6$^CKV^O3WK@J4I4W:2/0IU85%>+-**3Y^35H3"JIMW4Y%+L8#)K
M,U+,FTC)J HIZ4PEL<TW<5Z4 4]9L1=Z9,I^T[D4R1_9I6C?< <8((S]#Q7'
M&66UCC6* I!LR"!@[^<@_P \^M>A(Q;BN-F<K<3X4G]ZRHN<]^"?2@#&M[><
M:;&CK&URQ+RR9! <C<6"]">M9<_E7>J2KM\ZUM06W-QO8#_5D=AG&?KBMBZE
M74&6S</#+<ELR1D%D(&",]CTQVX-9%S);P3W?VM=JR(KM"G"NB [3GJ0Q!_+
MO0!CWI5IY;V5\7$B[3&L88 %MI./X>.@K*8/'-)&6EPT8&YURK-VQCD# KH-
M1AN8+4M=QI&;N;S&Y!9<*2@V^G&*P[VXEG6%6E=HX8\A85"A<CITZ_C0!;\,
MF=;LLA7RV1"P<Y(]ACI^->Q:;&;G2_*$TD6X#+QG#8[@'M]:\8\/@17VU&!Z
M@Y8Y;IS[FO9-!D"Z>TCYV(I9L#/ H YV6VM[35+N*TMA]GW\1F0N 0/F/)]>
MW'/UJA:W:L8C<"+?,V'3[KJS $ \<G'IVJU'<LSI=*[1PR%YV1E!8KVR/:LN
M>"2:&>6\9FCB?S8U?C:W4,J]6/.!V]* *-W'%;:C</: _;/M!#.X7&UP2NT'
MW'/ZUFZBTL/E*#]J\U 50D>9YB\'=@^^?;I5NZA$7VV%8"-09_M*$GB ')XP
M<+QG/J6K+NB(+=;BV5S;%_W;C&XNH)9AGL>/UH SII(Y)5,<;1LZ\A!E4/'K
MZXK2TBU6344;A6A&Y6VCK_DUG-ND!:,84C<3*, #..#GG_Z]:_A\;;J5<$AA
MP?3VH ]4\-28 KKXYAO3ZBN1\/QXB!J+X@Z(_B#P+J=E%N^T)'Y\&TX.]/F
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M:T;5-O[XV@(CS^/?UQQZ5>D8;L4R'(/-$@RQKS3U!V$-'DH12)&2,YIQ5EH
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MAXMY2@^E="0RX(&:S=*MQ' I [5K*V>#0!SGA'PI;>%;*]MK7!6YO9;DD#&
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M>:YVXF9/(F>53(ZA!$0%"HP))R?4GJ/3M0!GW P6\KS9@B+%YD8PN[C(STX
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M.<G/M6>@?RH#,I$LC$LP??UZDGTZT >H:'9I/LD4A@1P1T(KM;*#RE'%>9>
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M'' 'OUZ]JZ+QA;"XT6*W787:=6VNS*& YZCGT^M<SY4J:?!;75W$\BE468C
MR,?-@^] %347C6&3=&9UM R$*PC"Y7YF)/0Y.*YN634+A8[>;> $" *W0A,$
M#TX."Q]^E;,BVU^%#A6MH[EI9$8G]X>B[B" !DY_"L2ZN))I;F+>;B0OC$1Q
M&'7/'3+ +[CD4 9<D4<12&%&GW@AGBSD=CANF,C_ .O6?/ O[P,L2.3CSDX;
M)]23Z>M:2V_FVA>X1FB50$7&W=NYQ@]\X^F:I0)&;E#)&DL654HO)*^_J0:
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MCVZY_.O4/"MSYL,+;U<E1EE/&:\F**>'#'>N-@/S _AVKL_ DRPB0^60V_\
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MKS5Z<I+&V)6V !F.-J]/S)QC%9L92[$IM4:*%%R[RMPOJP XYSWJ)%1U(8P
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MI.*1F% "=J;CFE!S3@* &[:3'-28IIXH 0TL7^M3_>'\Z87STI;?)F7/]X4
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,"GK@.@']X?SH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>formdrs_003.jpg
<TEXT>
begin 644 formdrs_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 G # 2(  A$! Q$!_\0
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M 'W117PO_P )5XB_Z#VI_P#@7)_C1_PE7B+_ *#VI_\ @7)_C0!]T45\+_\
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MI_\ @7)_C0!]T45\+_\ "5>(O^@]J?\ X%R?XT?\)5XB_P"@]J?_ (%R?XT
M?=%%?"__  E7B+_H/:G_ .!<G^-'_"5>(O\ H/:G_P"!<G^- 'W117PO_P )
M5XB_Z#VI_P#@7)_C1_PE7B+_ *#VI_\ @7)_C0!]T45\+_\ "5>(O^@]J?\
MX%R?XT?\)5XB_P"@]J?_ (%R?XT ?=%%?"__  E7B+_H/:G_ .!<G^-'_"5>
M(O\ H/:G_P"!<G^- 'W117PO_P )5XB_Z#VI_P#@7)_C1_PE7B+_ *#VI_\
M@7)_C0!]T45\+_\ "5>(O^@]J?\ X%R?XT?\)5XB_P"@]J?_ (%R?XT ?=%%
M?"__  E7B+_H/:G_ .!<G^-'_"5>(O\ H/:G_P"!<G^- 'W117PO_P )5XB_
MZ#VI_P#@7)_C1_PE7B+_ *#VI_\ @7)_C0!]T45\+_\ "5>(O^@]J?\ X%R?
MXT?\)5XB_P"@]J?_ (%R?XT ?=%%?"__  E7B+_H/:G_ .!<G^-'_"5>(O\
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MX\1_[D'\WKZ#H *^<_VEO^0UH'_7O+_Z$M?1E?.?[2W_ "&M _Z]Y?\ T):
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MU=42X91$ARJ(,"LN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFFM&Z@N>] 'CGC:6[F\1327,3(I_U>>A7VKG*]*\8+#=Z1,3C=&=Z'T->:T
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MUO'EC-H6MMIL?FK;&-75G&"V1SS0!S>I7 NM1GF!R&;BJE%% !1110 4444
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M&<^QKUN'6$"?>JAJ.K(4;YJ\><Y3?-)W9NDEL?)-%:?B*.*+Q%J"0 ",3MM
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M*/':6^E3%S\SH512>6)&.*\)1VC8,C%6'0@X-+)-),VZ61W;U9B30 RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /?/V:/^/CQ'_N0?S>OH.OGS]FC
M_CX\1_[D'\WKZ#H *^<_VEO^0UH'_7O+_P"A+7T97SG^TM_R&M _Z]Y?_0EH
M \,HHI<<4 )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'OG[-'_'QXC_W(/YO7T'7SY^S1_P ?'B/_ '(/
MYO7T'0 5\Y_M+?\ (:T#_KWE_P#0EKZ,KYS_ &EO^0UH'_7O+_Z$M 'AE:G^
MC-X>4K"WGI-AI"W'(]/PK+K2L98C83VTA +NK#)QTH5-U)1C'NOZ9G43=K=T
M9V*2KLEI&9"1/$JD\#=FJ\\2Q2%4D#CU%.7*I.*=SIE1G&/-)?BO\R*BBBD9
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 48H'6M2[LK>WL( 7Q=N [#/ 4T*[DHI7;-
M84^=2E=*ROJ_R[LRZ*D\K@G>OYU'6DZ4H?$C&X4445F,**** "BBB@ HHHH
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M8462-JL-S$!,?-16ZMD[NF>GS=>M=I87%Q=6BRW5E)9RDD&&1U<CWRI(Y^M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>formdrs_004.jpg
<TEXT>
begin 644 formdrs_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +N!9(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;SB[M))M/G!0%>/-CSE64]-P[CZ_6KOC7XA'QU:0:!X?TV[(GD#.)%&]R.0
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M_DG\'_7Q+_.O/?"*2O\ &#54A;;*SWH0^C?-BM&[5'Z/\C*UZ:]5^9T.I/\
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M><7=I)-I\X* KQYL><JRGIN'<?7ZU=\:_$(^.K2#0/#^FW9$\@9Q(HWN1R
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M@GP597%[IEK>7%Y'YLDD\8<@-T"D_=P,=*P/B_J4.L>#O#^HVZR+#<RF1%D
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M$8@O(R3M8,0003CO5O>:ZW_ 2V@^ECN?"OPVLO"FM2ZE:ZC=.7#IY. $V$Y
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MQNBFC#J<<C(/%3T4 8W_  B/AG_H7=)_\ H__B:/^$1\,_\ 0NZ3_P" 4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'\J=2DH*ZDGZ?\,9T<1*HVG3E'UM^C98HHHK$Z@HHHH **** "BBB@ HHHH
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M7L6I27]DUI<1Q6B,3<JPRSCL!P?YBE%7=KV*E+E5[7+]%%%24%%%% !1110
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M)<2RZ=91J^'.2K8)QQQZUTFA6RZ9X;LXG&WRX S^Q(R?U)KG=$L)-8\+:Q<
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MHN_WK;YM?<==7FIUE"GO*-EUM9[OT3^;L=1H.E+HVDQ6N=TOWYG_ +SGJ?\
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MQ_\ QRC_ (7GX9_Y\=7_ ._,?_QRCV-3L'UBE_,>FT5YE_PO/PS_ ,^.K_\
M?F/_ ..4?\+S\,_\^.K_ /?F/_XY1[&IV#ZQ2_F/3:*\R_X7GX9_Y\=7_P"_
M,?\ \<H_X7GX9_Y\=7_[\Q__ !RCV-3L'UBE_,>FT5YE_P +S\,_\^.K_P#?
MF/\ ^.4?\+S\,_\ /CJ__?F/_P".4>QJ=@^L4OYCTVBO,O\ A>?AG_GQU?\
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M Q__ !ZC_A*?#/\ S\:O_P" ,?\ \>H^K0\P_M#-/^?<?O\ ^">V?\)IX?\
M^@A_Y!D_^)H_X33P_P#]!#_R#)_\37B?_"4^&?\ GXU?_P  8_\ X]1_PE/A
MG_GXU?\ \ 8__CU'U:'F']H9I_S[C]__  3VS_A-/#__ $$/_(,G_P 31_PF
MGA__ *"'_D&3_P")KQ/_ (2GPS_S\:O_ . ,?_QZC_A*?#/_ #\:O_X Q_\
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MUYG\._\ D8)_^O5O_0TKTRN6K!0E9'KY7BYXO#JK423NUIY!11161Z84444
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M35$-CR\'_O%?U_S"BBBK/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "MKP?_ ,CMH/\ V$;?_P!&+6+6UX/_ .1VT'_L(V__ *,6IE\+
M*A\2/:/AW_R,$_\ UZM_Z&E>F5YG\._^1@G_ .O5O_0TKTRO,Q/\0OA__<EZ
MO] HHHKG/>"BBB@ HHHH **** *3_P"L;ZFFTY_]8WU--/3BF(**X+5-8\=Z
M9>6-NZ>&V:^N/(A51.2."<MR. !SBMVPU'5=-BEE\6WNA6L9($#6\C("><Y,
MA^F,>].VEQ7UL=!14#7UHED;UKF$6H7>9S(-FWUW=,5D^'_$]IK6B/JCSVT,
M2NP8><#Y2@D#>>Q(&?QI#-VBJUEJ-CJ41EL;RWNHP<%H)5< _4&J&C:M/J>I
M:Q&R1BUL[D6\+*#N8A07SSZGVH V**Q-?UBXTVYTBVM$C>:^O%A(D4G$>"7(
MP1R *F\2ZLVA^'+[4HU5I88\QJXR"Y.%!P1QDBCI?^OZU#K8U:*Y_6-<O]-L
M],A@M(I]5OV$2(S%(E;;N8D\G P>.M5K34?%ME?VT>MZ=87%M<2"/SM+\PF$
MGH75A]WW[4[:BOI<ZFBD9E12S,%51DDG  JHFKZ;+-##'J-H\LZ;XD692TB^
MJC/(]Q2&7**BN;JWLX&GNIXH(5^])*X51]2:;:7MK?P">SN8;F$G DAD#J?Q
M'% $]%4CK.E@Q ZE9@RN4C!G7YV!P0.>2#QBK$]U;VOE_:)XHO-<1Q^8X7>Q
MZ*,]2?2@"6BHGNK>.XBMWGB6>4$QQLX#.!UP.IQ69IFK3ZAKFL6Q2,6EB\<2
M. =S.5W/GG&!D=J -BBJ5OK&F7ET]K;:C:3W"9W113JSKCU .16=J'BBTLO$
MMAHOGVHEN-QE,DP4QX VKC^\Q(P/KUH\@-ZBL_3;N:X2[FGN;&6!9V6%[5RP
M5!QAR>-P.<XX%2V>JZ=J+.MC?VMT8_OB"97V_7!XH MT55GU/3[4RBXOK:$P
MJ&D$DJKL!Z$Y/ .#^52V]S!=P)/;31S0N,K)&P96'L1P: ):*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.X_X]I?\ </\
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MW"2&Z=ERQSP-JGIC]:Y.1#%*\;8RK%3CVI\RO8'%I7:&T444R0HHHH ****
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M)O@'Q!-?V-O#=Z9F6WDC!RJX+#D\] 0>Q]*;\*-.\+65W8RQW?VWQ!=6[2%
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M*L9(! 7: !GCCTQ39?#VE3Z&FC2V2/IZ($6%B3@#I@YSGWSFETM_6]V5UO\
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M.7*H_P!;W^?^>IT>UCS<S_K2WR_I'>^#?$NIZYX'\56=Y*IMM/T406\2+A5
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M_P#@;)_\52]C*R2?G\P^L0NW9]O16L>B?#CP&\.F-XHO=-;4+I"?L%AO50S
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M"0A2P^^G\+#V(P:S*]).^IY35G9A1113$%%%% !1110 4444 %%%% !1110
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M ",$_P#UZM_Z&E>F5YF)_B%\/_[DO5_H%%%%<Y[P4444 %%%% !1110!2?\
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ML[^JT 0T4RZGMK%-]W>6\"^LL@7^=8-YXW\/V9*_;Q.P[0(S?KC'ZT =#17
M7?Q/@7(L]-D?T::0+^@S_.J@\1^-=7XL-.:)3T>*W./^^GR*=A71Z55*[U?3
M;'(NKZWA8?PO( ?RZUPH\'^--7YU"_\ )0]4EN"1_P!\ID5>M/A/$H!O-3=_
M40H%_4Y_E1H&I0\87_@;Q) $U"*:ZFCXCFMD*2)]&. 1['(]J\NN?"VC23%+
M#^T<'A?-D1B?P"5[[:?#[0K0AOL:S,.\SLWZ=/TK;MM*@LTVVMO;P+Z1H%_D
M*I3<=F0Z:EJT?.%I\+M3O>8;2]P>A= @/XMBMVT^!E[,0;G4([=>XSO8?@!C
M]:]Y^SOZK1]G?U6G[67<7L8=CQV'X#::%_?:W=N?]B)5_GFI?^%#Z-_T%[__
M +Y3_"O7?L[^JT?9W]5H]K/N/V4.QY%_PH?1O^@O?_\ ?*?X4?\ "A]&_P"@
MO?\ _?*?X5Z[]G?U6C[._JM'M9]P]E#L>1?\*'T;_H+W_P#WRG^%'_"A]&_Z
M"]__ -\I_A7KOV=_5:/L[^JT>UGW#V4.QXCH?P8TG5=(BO)-4O4=V<%5"X^5
MV7T]JT?^%#Z-_P!!>_\ ^^4_PKO_  ; S>%K8@C_ %DW_HUZWOL[^JT>UGW!
M4H=CR+_A0^C?]!>__P"^4_PH_P"%#Z-_T%[_ /[Y3_"O7?L[^JT?9W]5H]K/
MN'LH=CR+_A0^C?\ 07O_ /OE/\*:_P !])*_)K%Z&]61"/Z5Z_\ 9W]5H^SO
MZK1[6?</90['AMW\")DR;35UF]I$V'],UA7?PCU>SR6MKF11WAVOG\!S^E?1
M_P!G?U6C[._JM'M9=Q>QAV/EY/"%E:S!-02_'JH81M^JFO2/!NH>"O#",+2S
MNK>Y==LES< 2.P],CH/8 5ZM+8K.A25(Y$/57&16-=^!]#O/]9IT"'UAS'_Z
M#BDZC>C8U34=4AUIXCT:^Q]GU*W8GHK/M;\C@UI@@C(.0>XKCKOX56,F3:7T
MT!/9P' _D?UK+/P^\3:82VF:HA4<@1S-$3^'3]:G0O4]&HKS8ZAX^T?FYLYK
MA!_>A$H'XIS^M2V_Q,FB?R[_ $K##[QC<J1_P$C^M%@N>B45RUG\0- NL"6:
M6U8\8FB)_5<UT%GJ6G:A@6FHVDS'^%)03^76D,LT5-]G?U6C[._JM $-%3?9
MW]5H^SOZK0!#14WV=_5:/L[^JT 0T5-]G?U6C[._JM $-%3?9W]5H^SOZK0!
M#14WV=_5:/L[^JT 0T5-]G?U6C[._JM $-%3?9W]5H^SOZK0!#14WV=_5:/L
M[^JT 2P_ZE:DIL:E$"GJ*=2&%%%% !6#<:%X5FN99;C1=+DG=RTCO9(S,Q/)
M)V\G/>MZL"X_X^9?]\_SK2FKLSJ.RV&?\(]X/_Z .D?^ "?_ !-'_"/>#_\
MH Z1_P" "?\ Q-)16W)YLQYEV7W"_P#"/>#_ /H Z1_X )_\31_PCW@__H Z
M1_X )_\ $TE%')YL.9=E]PO_  CW@_\ Z .D?^ "?_$T?\(]X/\ ^@#I'_@
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M/_Z .D?^ "?_ !-'_"/>#_\ H Z1_P" "?\ Q-)11R>;#F79?<+_ ,(]X/\
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M/_Z .D?^ "?_ !-'_"/>#_\ H Z1_P" "?\ Q-)11R>;#F79?<+_ ,(]X/\
M^@#I'_@ G_Q-'_"/>#_^@#I'_@ G_P 3244<GFPYEV7W"_\ "/>#_P#H Z1_
MX )_\31_PCW@_P#Z .D?^ "?_$TE%')YL.9=E]PO_"/>#_\ H Z1_P" "?\
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MD?\ @ G_ ,37 ^+/^1DN?]R+_P!%K7>UK-7C'4\#*W;%8G3[7ZL7_A'O!_\
MT =(_P# !/\ XFC_ (1[P?\ ] '2/_ !/_B:2BLN3S9[_,NR^X7_ (1[P?\
M] '2/_ !/_B:/^$>\'_] '2/_ !/_B:2BCD\V',NR^X7_A'O!_\ T =(_P#
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M"#MX.>]15);_ /'S%_OC^=)QTW8U)7V1R7P[_P"1@G_Z]6_]#2O3*\S^'?\
MR,$__7JW_H:5Z92Q/\0\KA__ ')>K_0****YSW@HHHH **** "BBB@ HHHH
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M#::?;0$?Q)$ ?SZU=HHI#"BBB@ HHHH **** "BBB@ HHHH **** .?\%?\
M(J6O_72;_P!&O705S_@K_D5+7_KI-_Z->N@IL2"BBBD,**** "BBB@ HHHH
M**** "J]S8VEZFRZM89U])8PW\ZL44 <U>> ?#EX2WV#R6/>!ROZ=/TKG[SX
M3VS FRU.6/T6:,/G\1C^5>BT4[L5D>5_\(EXVT?G3M1,J#HD5R0/^^7P*/\
MA*O'&C\:AIS3(O5Y;8XQ_O)@5ZI11<5CSFS^+%NV!>Z7*G^U#(&_0X_G6_9_
M$#PY>$+]N,#'M/&5_7I^M;5YH^F:AG[786TY/\4D0)_/K7/WGPW\.W0/EP36
MK'O#*?Y-D4:!J=+:ZA9WR;[2[@G7UBD#?RJQ7FEU\*71_,T_5L$<JLT>"#_O
M _TJC<Z5X\\/VLLR7\LMO$A9V2XWA5 R3A^>GH*+!=GK-%5=,D>;2;.61BSO
M C,QZDE1DU:I%!1110 4444 %%%% !1110 4444 %%%% !1110 5@7'_ !\R
M_P"^?YUOU@7'_'S+_OG^=;4MV95=D8UWK/V7Q%I^D^1N^UQR/YN_&S8.F,<Y
M^M/US5O[&LH[CR/.WSQP[=^W&Y@,]#TS7.>*+>]NO&NA16%_]AN#!/MG\D2X
M&!D;3QS5+Q)I>OVEE:RZAXD^W6XO8 8/L,<63O&#N!S6R>WK^J,'U]/T9Z%1
M7 ^+GO=2\4PZ0FF2:E:I:>>]HEZ+82$MC+'^(#'0>M7/"5EJ^GW=W!/I,NG:
M6T0:&&2]6X"..H4YR 1V]J5]+C:L=E17FF@V$.G> Y/$B*\FJ16\PAE:1B(U
MW,  N<8'7IZU2@T;6C;17UAX9N4U-E5UU(ZTKM(>#EE)P0?2G?6P-'K%95OK
M/VCQ%?:2+?'V6%)?-W_?W9XQCCIZUA:C:CQ%XLATC51(+**P%RULLA422%L'
M)4\@8IGA^PBTSQMK=I!+(\*6D.P2.6*#G"Y/.!V]J3?Z_@'3[OQ-V?6Y-/T-
M-0U.Q>VE+K&UNDBR%2S;1\PP.X-;%>63:?:WGPLTN2XBWO%<@(=Q& TVUNA[
MBM?6M/T5KV/24TS5-46S@4"QMYB(8!G@L=P.X^Y/ IWW_KI<+:_UW:.\HKS;
M0WFB\/>+[!H);:"V1O)MI)O-,(,9^7=^ X[5H6'A"UN/!R7$(?\ M:YM(Y!<
MM(Q.]0&3&3@ $ <#I1?KZ!8[FBN.BU%?$^IZ#$ /+BB-]=)UVNOR*I^C[O\
MOFNQIB"BBB@ HHHH **** "BBB@#:L/^/*/\?YFL6MJP_P"/*/\ '^9K%K*&
M[-)[(****U,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X+Q9_R,ES_N1?\ HM:[VN"\6?\ (R7/^Y%_Z+6N]K27PQ/!RO\ WG$?
MXOU84445F>\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M26__ !\Q?[X_G4=26_\ Q\Q?[X_G2>PUN<E\._\ D8)_^O5O_0TKTRO,_AW_
M ,C!/_UZM_Z&E>F5GB?XAYG#_P#N2]7^@4445SGO!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU7[6-)B6:00FWN!=@"QV@94J.'YSV-=9<>)M,L--L[S4;A;474:NB'+GD ]
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M;+^OZ_KT#1LS?#$6LK?7$NLZ08[B=<R7C72/G!XC5%^ZO)[_ %J'3M#O]/\
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MH'#'9EF)'.,]_2KFK:+<W]MH\<3Q!K*ZAFDW$\J@(...OY577[O^"#_S_P"
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M@_XFJX@^8_+^[*_-QQSZ9JW+H O/",6B74FUEMXXS)'SM=0,,.G<4M;7]/\
M@CT_%_\  ,:\G\3^'+9-5U#5;>_M1(@N;5;81^6K$#*,#DX)[U8OKO7;SQ=<
MZ3IU_':6XLTF\UX5D,9+$9 .,D^YP*9+H7B75TCL=;O]/.G(ZLYM8W$MP%.0
M&SPN<#.*UX=*GC\67.JEH_L\MHD"J"=P96).1C&.?6G;]?R_S%_7X_Y'/6EU
MXIU6RO8X]6MK:73)GA>86P<W++SR#P@P1T'6M[3M5N]2\(0:E"+:.[EM]X\Y
MBL2MW)(YQWHTG1[BP361*\1^VW<D\>TGA6  SQUX]ZICPQ<2> H] EN4CN%B
M"F1,LA(;/<#(/0TM;?)?\$>G-]YSLGBB]TW4;-AXLL=7$UPL4EG%;*H4,<$J
MZYZ=LFK]U#?Q?$R2Y_M79#'8>>R?9U/[D/S'GZ@G=U[4VZ\,>)M1@MH[B;1+
M>.WFCE$-G$Z++M/\3$<8&< #%;>H:+J$GBF#5+.2U,#V_P!ENHI]V?+W9)0C
MO]:-?S_+_,-/Z]?\C*MIO%FJ:6->MM4M8(G0RPZ<;8,K)S@-)G()'I3M9\4W
M1\,Z5J5K)]AAO2/M%V8#-]F&/[O?GCFG1Z!XHL;,Z/8:G8#2\%(YY8W-Q$AS
MP /E./4UJ3:/J-AHUE9Z#>0Q&T79Y=U'NCF&.C$<CGG(H>VGD'77S(/">HW-
M\DXDURRU>$!6CFB3RI1G.0\8X'M52/7M57P_X@O(U^U7-G?2Q0+L'RH"!T7&
M< D^IQ5G0?#M[:ZU-K&I_P!G17+P^2(M.C*1D9R68GECP*EL-#U&RL-6BAO8
M[>YNKV2Y@E1=X4,1@,&'M@_H:;V^7Z_Y OU$\#:]>:A?P1KXNT_5K=U?S;62
MU^S3Q$ D>6/XQGKGM71UD:'X?UZXUO3]5UD:$BV9D9'L8'\Z4LKIAV;H/FS@
M5KU$-V7+9%6?3;2YO[6]FBW7%KN\E]Q&S<,'C.#QZU:(R,'I116AF8<'@[P]
M;:E_:$6EPK<YW!N=H/J%SM!^@J>YT=;CQ'9:KA0UM$Z9R=S;N,8Z8ZGUZ5JT
M4 9&K^&-%UV1)-2L$GD08#[F1L>F5()'/2KMGIUGI]DME:6T<5L 1Y:KQSUS
MZU:HHL!@VO@OPY9Z@+Z#2H4N =RG+%5/J%)P/P%7-7T#2]=B2/4[-+@)]TDE
M67Z$$$=*TJ*5M+!?J4=+T?3]%M?LVG6J6\1.2%R23ZDGD_C5ZBBF 4444 %%
M%% !1110 4444 %%%% !1110!P7BS_D9+G_<B_\ 1:UWM<%XL_Y&2Y_W(O\
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MFFZW!XB!T^QDL;1KGS)I!?B2&52<MB(C(8^V.:[.BE<;7]?UZA1112&%%%%
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MB+6LT-Y)' LIAE&H+Y+,00-L17(SG!R1WYKTVL/6O$L6CW=M:BVEGEFEC0D
MJB!C@$MC&>#Q[=J+W=A6MJ9<FB:E#H.@/!:QRWFF8=[1W"ASMP0&Z9'7-02V
M/B:WTW4KNRLDBU#4IU+01SK_ *.@7!(8X!8^H]<UT>N:Q_8]K"Z6S7-Q/*L,
M,*N%WN>F6/ '%9R>)=1N;%I;+0FFNH)6ANK=[M$\E@ ?O'AAS0W>[_KI_P
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M1D<9]^#BNA\-0ZM#IC+J[,9C(3&CR"1T3C 9@ &/7FMFBE<=@HHHI#"BBB@
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M_P "A_\ $4?\)M!_T"Y/_ H?_$4<DNP?VO@OY_P?^1T]%<Q_PFT'_0+D_P#
MH?\ Q%'_  FT'_0+D_\  H?_ !%')+L']KX+^?\ !_Y'3U);_P#'S%_OC^=<
MI_PFT'_0+D_\"A_\13D\<PHZN-+?*D$9N1_\10X2ML-9O@OY_P '_D1_#O\
MY&"?_KU;_P!#2O3*\S^'?_(P3_\ 7JW_ *&E>F5AB?X@^'_]R7J_T"BBBN<]
MX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )&D_P#BJWJ*/:3[A]0PO_/N/W(P?^$+\/\ _0/_ /(TG_Q5'_"%^'_^@?\
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MO?\ A:7@W_H,_P#DK-_\13=*?9B5:'='<_:$]&H^T)Z-7#?\+2\&_P#09_\
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M4_:$]&KQKP/XM\)Z)9S3WNJ!+R9L%?L\K;4'09"XY//Y5UG_  M+P;_T&?\
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M:$]&KR3P;XS\'Z%H^VXU8+>3MOEQ;2G'HN0O8?S-=%_PM+P;_P!!G_R5F_\
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M $8U8]>S3BHQ21X-63E-MA1115F84444 %%%% !1110 4444 %%%% !1110
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M:]9UF]U[59M1OY3)-*<XSP@[*/0"J%%%>TE961X#;;NPHHHIB"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KLOAOXGN=!\3VUMYK?8+V58IHCTRW"L/0
M@X_#-<;5_0_^1@TW_KZB_P#0Q432<6F73DXS31]84445XQ[Y;A_U*U)4</\
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M #-BBL?_ (2SPY_T,&E?^!D?^-'_  EGAS_H8-*_\#(_\:.279A[2'=?>O\
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M (2SPY_T,&E?^!D?^-'_  EGAS_H8-*_\#(_\:.279A[2'=?>O\ ,V**Q_\
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M  EGAS_H8-*_\#(_\:.279A[2'=?>O\ ,V**Q_\ A+/#G_0P:5_X&1_XT?\
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MXM&N3:G>>#C?3*Y%IOU.%%MX^VU>?F/=NI]A7HM%%PMH0VDDTMI#)<P>1.R
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M>_\ 6UOR#V\[6_K>_P"9Z'KVM^'-,\%7>@>']1EU%M0O?M,TKV[1"-!@A?F
MR>!S]>E>>4454(*)%2HZCN_ZZA1115F84444 ?3/P\_Y$'1_^N)_]"-=%<?\
M>TO^X?Y5SOP\_P"1!T?_ *XG_P!"-=%<?\>TO^X?Y5XT_B9[\/A7H?(E%%%>
MR> %%%% !7H^C>(/#NK^"+#P_KVHS:9)IMUY\4R0-*LJY)V_+R#\Q&3['GI7
MG%%3*/,OQ*A)Q=_E]YZ9>7.A?$;QWJEQ<2W=M:PV+-:M& "YC&<OE2%&-W7'
M89SQ5KP5K/A/0/"4JQ^($T_Q!>*1+=-82S&!<\*H  Z<]>OK@5Y;%<30+(L4
MTD:RKLD",0'7.<'U&0./:HZR]BN7DOII^OYFWMWS<]M=?T_(ZN"S\)-XEN(-
M4U^^N[*5-R:E! 4/FGD[T8,Q'TYK3\0:[H%GX+L/"ND7DVIPI<_:;B[,)ASU
M^50V2#S^G?-<#15^SO:[V_0E56KV6]_Q/4- U+P+X1OGU[2]8O[J?[,R1:=/
M;D.';^]( %Q]/UKF_P"S].3P;'XGAN)QJZZD$:$@"(=6&/EY/ Z'BN3J1KB=
M[>.!YI&AC)*1EB54GJ0.@S2]G9\R>NGW7N'M;KE:5M?OM:YZ]-XU\*1:K?\
MBZVO[AM6NK#[.NG-;,/+DP!N+_=(X'?U^E<_H6M^'=4\%6WA[Q#J$NGFQO?M
M,4JV[2B5"22GRYP>6YZ=.O2O/:*2HQ6WE\K:K\RGB)2W\_G=6_0]0B^(FFR_
M$N_U2X65=(N[4V.X)\RI@8;'U!_ UE>)]:T.U\%V/A?0;^34(TN6N9[IX#$"
M>< !N>_Z5PE%"HQ5K=+?A?\ S!XB3OYW_'1_@@HHHK8YPHHHH ^MM/\ ^0;:
M_P#7%/Y"LSQG_P B3K?_ %Y2_P#H)K3T_P#Y!MK_ -<4_D*S/&?_ ").M_\
M7E+_ .@FO%C\2/H)?"_0^7****]H^?"BBB@ KUG3_%OA?5;/PQ>:QJ4]A?Z
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M)SJO_;'_ -')7SA7L8'^&_4\+,?XJ] HHHKO/-"BBB@ HHHH **** "BBB@
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M *.>NOKD/A=_R3G2O^VW_HYZZ^OG:W\27JSZFA_"CZ(****R-@HHHH ****
M"BBB@"D_^L;ZFF$A5)/0#)I[_P"L;ZFLKQ%+/#X<U%[6*66X^SN(DB4LQ8C
MP!SUH;LM 2NS@_"?CSPUIUMJ$NH:F8KN\OI;AT,,C84G"C*J1T [UJZ!J]EK
MWB_6-?MI3+86=G';Q2E64'J[\$ CH.U=-X<L/[+\-Z=9%2&AMT5@1SNQS^N:
MQ/#NEW%UH>NO=12V\^JW5PP$RE65#\B9!]A52TO;HO\ @$1UM?J_^"<6NH:1
MX@1]8\0QZNYGD86]U!'(+;3ESA/F! W=">M>D7FCW=_X>MM.?5Y5(""YNHDV
MO.@^\ 0?E+>O/>N36?69_"\?@^'PW>6]WY M9KJ11]E5.C.KY^8XYQUR:Z74
MK_4O#OV(6^F3:CI<<'E2BU3?<*XP%(7(#*1UP.*<K6LMNG]?U?J"O>[W_K^O
M(YSPC'I'_"59\'M.-)CA87X=I/+,AQLVASG=P<GIBGV/AG1_&'B#Q!J6K6;7
M*QWGV6 F5T"B-0&QM(SS6GHRWM_XAO?$DNESZ? ;06\4$RXFF(.[<ZCICH!U
MK'\)^([C1]&CL[GPOXDDO))I)9G2PPA=V)ZDCCD=:/SM^;_R#\K_ *&MHUH/
M#?C(Z)923-IES9&XC@DD+B!E8*0I/.T@CBM[Q#K":!H-WJCQ>:+=-PCW;=Q)
M  S@XY/I5'0K"^GU2ZU[581!<SQB&WMMP8P0@YP2."Q/)Q[4SQA:S:C%I6GQ
MV\LL4U_$9RB$JD:98ECV&0!S2=W9/^M?\AJRN_ZV_P R@_CJZMKNT%YX;OH+
M2]!6VE#JTDLF,A?+'(SV)Q[@<XTM$\1W>HZQ<Z7J.C2:;<Q1"= TZRAXR2 2
M5X!XZ<TE[:SWGCS3'-N_V6QM)9?-*G9YCD* #TS@$_C2:+;3R>+-?U&>&:-6
M:*V@,B%0R(N25SU&YCS35OS_ . )W_(O6&L_;];U33T@PE@8U:;?G>S+N(QC
MC QW[UCWOBVX/A76-6L]/W_8YI8(_P!^!N53@R<CC!SQSG%9=AJ&LZ0^OVT?
MA_49]1GNYKE)S&/L^W "8?.6X ^4#/:B?3KVP^%UA9_8+NYED>*2\AAC)EVL
M^^0;>I/;%3:Z^[\=RKV?W_@7=(U77-+\+Z=;R>';RZU-U(""X5E;')DDE/RJ
M6)/!R:U-'\1W6H-?6EWH\MEJ=I&)&M3,D@<-G;M<<<X[]*YO7OM%SKJ7&IZ/
MK]YI4UM']EMK LOEL1\ZRJK#!Y'.<4GA'2+G1[/Q/<6VA36$SX%K:EBQ($9*
MX<DY))YP< \4Y.Z;]25NEZ%;3=<O;S0-3N=9T9I;;5;U8(5:^_U@=_+\L;1E
M0N"<]^:ZK4O$4FGWJZ/HFCRZG>0Q*SQ1RK%'"G10SMP"1T%86F6UQ?6G@^R&
MEWUO;V<C2W'VJ H0\:8!/7&68D9ZXJT+R^\+>(-8>30]2U&'49UF@GLHQ)_"
M%VOR-N,=:;23M_6EDOU!/K_6M_\ @&WH_B1-3L+R6>TDLKJQ)6ZMI&!,; ;N
M&'!!'0U@+\0[U]&AUD>&+K^S, SW!N$&S)Q\BD9<>^!3+G3]7B\(^(;^>R;^
MU=8('V6 %S$A 15X')"Y)-:?B339&T#2=#M+:1X)+FWAEV1EECB0AB6]!\H'
M/K0M]?+_ ((=/O\ ^ =4K!E##H1FEHZ45)04444 %%%% !1110!\M^,89(/&
MNMI*A5C?3. ?1G+ _B"#6)7OOQ!^''_"32C4],>.+40H619.%F Z<]F X]^*
M\KD^''BZ-RAT68D=U="/S!KU:=:#BKL\:K0G&;LKHY:BNG_X5WXM_P"@)<?F
MO^-'_"N_%O\ T!+C\U_QK3VD.YE[*?\ *SF**Z?_ (5WXM_Z EQ^:_XT?\*[
M\6_] 2X_-?\ &CVD.X>RG_*SF**Z?_A7?BW_ * EQ^:_XT?\*[\6_P#0$N/S
M7_&CVD.X>RG_ "LYBBNG_P"%=^+?^@)<?FO^-'_"N_%O_0$N/S7_ !H]I#N'
MLI_RLYBBNA@\"^)KHS"'2)W,,ABDP5^5AC(Z^XJ;_A7?BW_H"7'YK_C1[2'<
M/93[,YBBNG_X5WXM_P"@)<?FO^-'_"N_%O\ T!+C\U_QH]I#N'LI_P K.8HK
MI_\ A7?BW_H"7'YK_C1_PKOQ;_T!+C\U_P :/:0[A[*?\K.8HKI_^%=^+?\
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MT?\ "N_%O_0$N/S7_&CVD.X>RG_*SF* "2 !DFNH'PZ\6D@#1)^?5E_QKN?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \(^"O_(Y7G_8/?\ ]&1U[O7A'P5_Y'*\_P"P>_\ Z,CKW>NS&_Q?DC@R
M_P#@?-A1117&=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45S7BMM3LK674K;738VT,8'D"T24N^>,%CWR!5&2_\01VNAZ5)>I%J
MNH%WEN3"K>4JC=C;@ G! _"FE<3=CLZ*XR+Q#J,FA'SIUBGM]1^Q75VB* B
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MAS)!?W,">$K/4_.F=XM2DU.2%4#$D"2,$$XSCY>N*]6L+5;'3K:T1558(EC
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M%CYCNX!!XW&MN?PA>2VNGL/$-TVHVET;K[7/$L@8E=K*$R JX/ '2B+M9O\
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MC!K8O(HIMK65KI;-:[=^T@W#8/&>HXS707$&H+\6ENAJFRV73#,8/LZG]V&
M,>[KRWS;NO:F7'PXU&XTI]';Q9=#24_X]K46J#R\'*AV!RX'IQ71W/AZ:7Q-
M9:U#J!B,-N;:X@,(99T)SC.<KSSWZ4:)*WG^7^8GN_ZZ_P"1RW]K>+F\/'QB
MNIVGV'8;C^R3:C'D@_\ /7.[?MY],TOC#Q1J=AJT 75FT32W@26*[.G?:5F<
MYRC'^#''09YJ_P#\(!<^6=-_X2.['AXMG^S1"F<9SL\W[VSMCTK3UGP]JMY>
M"XTCQ'<:8K1B.6!H%N(F Z;5?A3ZD=:-.G]:?Y_UT#77^NO^7]=3$\,:U?WD
M'B:\@%A?7D2Q-%]B4!)I/)!^]@,V3_>Y'2J_@SQ3?:AKJVEYXC@NY9$)FL+F
MP-I- V,@)V<=<Y.<#-;GAWP1!X>L]5M8;^X>._(8NO[N2,[<$A@>I.3P!BF6
M'A#4%U:TO-9\13:HEDQ>TB:U2(H<$99UY?@^W/-.ZO\ +_,5G;Y_Y">)+W76
M\4Z7I&CWT5HMW;3/+))")-FTKA@#U(R0!D#GGI4=GK>KV%GKUAJ=[9RWVEQK
M)'?RQF*)U=25+JN<$$'('MBHO%%A<:AX[T6*TU"6PN5LKEXKB-0VULIU4\,.
M>AJ]'X+CDT'4;&_U*XN[S42'N+YE"MN7&W:HX4# P*E?#]_Y_P##_P!;5]K[
MOR_K^M^9T+Q9K/\ PE6FVD^K3ZG9Z@[H3+I)M$B(4L-CGEOH1TJLD6J:?IOC
MVZFU..Z2.5QY4EG&5:38A#D'(/RX7:1CC-=+;^"]6;5]-U/5?%,^H36$I:-#
M:)%&5*D$;5/WN?O<_2I[OP9-<?\ "0Q)JQ2TUE<F%K<-Y,F "P;()&!T_6F[
M?G^:_P"")7Z^7Z_\ S?&/B]M&;3-.358=(^TP&:2^>U,Y0# "K&!C))/7@ 5
M3L?'%U>^#?$4MMJ<=[=Z7&#%J$=L8A*",@F-A@,""",8KJ]8\-S7_P!DN=/U
M273=2M(S%'=1QK("AQE61N". ?8U _A6[N?#6I:9?:Y<WEU?IMDNI4&U.,?)
M&" H]@>?6C2S_KK_ ) D]/ZZ&;;7GB;2_$&CC5-5M[ZTU9F0P1VHC%LP0N-K
M9RPX[UE:3_PD&DGQI?6UY_:,\-R0EM]E4;Y-J'?P<G"G&T=<>IKMK[0_MMYH
MUQ]IV?V;*9-NS/F90ICKQUSWJBOA2=+[6I(]9N8;;4R)/+A4))!* !O60')&
M%'RD8H;_ %_-6_4$MK^7ZW_0Q_ WB.YU/4Y[2?Q+;ZKMC+-%+9&TN(7! P%
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MLZBJ]A GZS,T?MD7J?RH^V1>I_*LZBCV$ ^LS-'[9%ZG\J/MD7J?RK.HH]A
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MI#"BBB@#SCXU?\B;9_\ 803_ -%R5L?"[_DG.E?]MO\ T<]8_P :O^1-L_\
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MZNH]3T)KLVJ++8Z]$5C"XX,3D8R?]D]<\UV7P\O8;[P592V]B;*%=Z)#YK2
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MS<NZPQ'D[WVD$J,=.E+[,>[_ ,[%?:?E_E<ZJQU33]4C:33[ZUNT0X9K>99
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MA73_ *[G3SZ/IES>I>SZ=9RW28V3R0*SKCIAB,BIGL[62[CNWMH6N8U*QS%
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M+%VT[["3G[2H7!89EV^H/R8Z]^E2:/XDBLO UKJ4B7UR\LKPPPR3>=-+(9&
M7=@9Z>G 'M2M>/\ 7>Q6S_KM<Q&\">)-0 L-3N-!%BURL]Q=VEJ8[FYVMD!P
M %_'^=>@7NE:=J2HM_86MV$.4$\*R;3[9!Q6/H_B6\NK]M/UK19=(O#$TT2-
M.LR2HN Q#+W&1D>]4M&\;7>LWD31>'KC^R;B3RXKZ.X20CK@O&OS(.#R>E5K
MM_78G1:_UW.HGT^RNEA6XM()E@</$)(PPC8="N1P1ZBECL;2&ZFNHK6!+B8
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M"H>023*I13T)R> :;+K&EP00SS:E9QPS_P"ID>=0LG^Z2>?PHW'L7  J@
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M8&XMT(P50@<Y]S5S4_#$IL])_LB:**[TK'V<S@E'&W!#8YY]12C%I:^7Z_\
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M+[>^GQV37+1+(5#ONP"<'M53_A"=9_L\:!]OL_[#$_F[]C?:,;MVW^[U[_\
MZJV]:T/47U:UU?19[6.]AA,#)=*Q1T//5>0141C:*37]6_S_ ,RY23DVGW_/
M_+[MCE_[6OK3X>:I EQ)YMM?M8QS%R6";AW^A(K4TW3X?#7CBTT[3S(MG>V;
M/+$TA8&13]_GN:N1^#0?!]SHTUR#<W,AGDN%3CS2V<X]. *DTC0M5_MT:OKE
MQ:27$,'V>!+56"@9R6);N?RJDGS*_E^6OX_YDRDK.WG^:M^!T]%%%:&04444
M %.3[Z_44VG)]]?J*3V&MS6HHHKRSV"W#_J5J2HX?]2M24AA1110!YQ\:O\
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MO4X;XMY_X0"YV]?/AQ_WV*C72_$GB#Q-H]QK&GVUC9Z03+YD5R)?M4A  *C
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M9+XF>M#X48]%!&#@]:*],\D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH UT^XOTID_^H?_ '33U&% ]J;,"87 ]#7F+XCUW\)E4445Z9Y
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M48@=>:DO?!<3Z)IEAIE_/83Z8_F6UT%$C!L$,64\-G))H322^7ZW!I_G_P
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M<]>U4-/\*ZO:W< N?%E]<Z=;,##:B)(V..@>1?F<>W&:(VNK^7_!"2=M//\
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MW_\ 1D=>[UV8W^+\D<&7_P #YL****XSO"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#G_"_^MU[_ +"LO_H*5T%9^EZ9_9KW
M[>=YGVN[:Y^[C9N"C;UY^[U]ZT* "BBB@ HHHH **** "BBB@ HHHH ****
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M<#KL.3G Y[46=["NK7.DHKEO^$]TO^T_LOV34C;^=]G_ +0%J?LOF;MNW?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA(C'DL/F/89P.:ZJBG?6_I^"M^H6T^_\;?Y'GTBZW:OXRM=/L;R.]GF%U:W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH P-7\)VVL:I%J$FH:C;SQ)LC-M,$VCG./E)!.?6G
M3^%K:ZTVWM)[W4'EMW+Q7AG_ 'ZD_P"WC\.E;M%'2P>92TO2[;2+!;.U#A 2
MQ9VW,S'JQ/<U4/ART^P0VJS7"/#,;A+@,OF>82<L<C!SD]JL:7J?]I/?KY/E
M_9+MK;[V=^T*=W3C[W3VK0H8BMI]C!IEA#9VX(BB7"[CDGW-6:**!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 9FNZ)!X@T_[%<SW$46\.?(8
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M60%&QE61N&' JK;^#S'H>KVESJ<MUJ&JQE+F^EC&<[=HP@P HSP,_C4?9?\
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MMXMMM!B\7SZI:26+HD\FE"U "0L1]V3.XL <\\9S781:&J>(-1U1YMZ7MO'
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MJ*Z%Q,2A>V0&*/R20BG!((Q]X8)J'Q#X\=/$5]9)XGM]#CL9!&D3:<]RURP
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M'R HZ 9QWS^E=-]MC_NO^0H=*?8%6AW-+[0GHU'VA/1JS?ML?]U_R%'VV/\
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MY$D&5.:EPDMT.-2,M$RW]H3T:C[0GHU5J*DLO*P=0PZ&EJ.'_4K4E(84444
M><?&K_D3;/\ [""?^BY*V/A=_P DYTK_ +;?^CGK'^-7_(FV?_803_T7)6Q\
M+O\ DG.E?]MO_1SUV/\ W5>IP1_WQ^AOG47&OC3?)B\LVQG\W[0N_.[;CR_O
M8_VNG:E&N:09HH1JED99B5C3[0FYR#@@#/."".*Q6_Y*HG_8&;_T<*XPZ%I4
MGPRUS4WL(#?K<7,BW)0&12LK8PW4=.@KD6RO_6MCO>]E_6ESUMF"J68@ #))
M[5R*^/[*;1;[4;1(;@VMXML8DN5)*F0(). < Y)'KCK74V_[VSBW_-NC&[/?
M(KR8VNF)X&\06]M#:QRC6A'*D(57"?: $!QR!C./QQ32]ZS\OS2);]V_];-G
MJUMJ-C>S30VM[;SRPG;*D4JL8SZ, >/QIKZKIT=^M@]_:K>N,K;M,HD(]ESF
MN4?2-/T7XA:&NEV-O9B:SN4D$$80.%V$;L=>>_6O.=MP^E7HO+CP?!?>?)YL
MUV9O[127>>1@%L@XQM!'3BDE>W]=;#;M_7E<]SN=1LK.6**ZO+>"27/EI+*J
ME\<G )YQ19:C9:E 9[&\M[J('!D@E5USZ9!KSCQ]]A'B#P5_;YB>US)]I,F0
MA.U.3GMNQU_&J*76F6/B'Q;=:%;Q7&AQZ4//BLWV0O+Z*4Z?+G)'O1;1OU_#
M_,+ZKY?B>H6NM:5?73VMIJ=G<7"9WQ13J[KCKD Y%8:>/-,N-6U?3;9X&N-/
MC+)YETB+<,%+%5)/08Y)Z<YZ5YEH_P!E7Q9X.GMKK1@TCY:WTR#:805&%D<D
MLS'D8;G@^M;+VVE6GBWQ[%+#9171L]]FK*@?)A8N8^^3G)Q^--QM]S_"P1=W
M;S7XGI=CK4,V@0:K?O;64<D8=R;I'C3_ +:#Y2/<5:CU"REL3?1WEN]F%+FX
M653'M'4[LXQ7C&I_:?\ A%_ (/V#[%L?=_:6[[+YF/E\S';&<=OPS6EH,4J>
M'?'#I=Z1+:O;,?)TE9?(BD\ML["RA>1C[I/X<425N9]K_A;_ #%!WY5WM^)Z
M?%K>DSW$5O#JEE)/,@>*-+A"SJ>Z@')'N*S--\9Z7JGB:_T.&:(36NU58S+^
M^;!+! #D[<<^E><WFC:;I_P_\'ZG;64,=\U[;,]P%_>-G)(+=2.!QVQ6_P"&
M[;2K3XL^)8I8;**Z)A>S5E0/DH2YC[Y.<G'XU7*KM=K_ (6_S%S/E3]/S:_0
M]"N[VTT^W-Q>W4-M"O!DFD"*/Q/%9VL>(+?3O#%WKEKY5]#!$9%\J4;9/HPR
M*Y/QI]A_X6!X=_M[R?[%\F;'VG'D^=CC=GCICK5*Y;PY_P *\\7)X;,A@#.9
M>OE;R?\ EG_#MQCIVQ63^%O^M[%_:M_6S.^AURR&B6FJ7UQ;V,5Q$DF9Y@JJ
M6 .-QQGK3[O5H8]"N-4LGM[R..)I$(N%2-\#/^L/R@>YX%>8ZW=6DC^$M.N8
MM*A;^RUE6]U4,\*#8 5"9"%C@<M[8YJ+PIM7X7>-(TF66-9;G:R($5AY8P0H
M^Z#Z5<U;F:Z7_.Q$'?EOUM^*N>GVFN6DMC837EQ:6EQ>0^:D!ND?/&6VL#AP
M/4<4_P#X2#1?L:WG]KV'V5GV+/\ :4V%O0-G&?:O,&L+74KWX:6EY"D]N]FY
M:-QE6Q&I ([C('%-M?#VD/=?$(-I]NR6:M]F0QC; 3&Q)0?PG('(]*<TDW\_
MP=AQ;=EWM^-SUB[U*QL+87%[>V]M <8EFE5%.>G).*EM[F"\MTGMIXYX7&5D
MB<,K#V(X->-W-K:77AKP;--JVGV][%9MY,&KPEK68=#N8@J"..OM76_#"\AG
ML]5MH;"TMO(NOGDL)G>VF8CDQ[B=HX' XZ4<N_D)2V\SM;N]M-/MS<7MU#;0
MKP9)I BC\3Q6+IGBJ+4_%&HZ1%"ABLX8YENDF#+*' / QP.>N37.^/19?\)E
MX6.MA/[%W3>9Y_\ J?,VC;OSQ^?OVS7,+>:%8:MXYN-'M8KK35L8U,-LY6)B
M2 VTIT7)YQ[U"VOZ_A8I[V]/Q/7+/6=+U"=X++4K.YEC^_'#.KLOU /%96C^
M,]*UK7-1TNWFB$EFP56,RGS^"6* 'D#')_E7F.@K;1^/_"DEM=Z._F1/OBTN
M (L68SA7;)9V[?-SQ[U;>31=%U+Q\9]/LY;A"HM[8$1N49</M*X8+SEMO;K5
M-6^Y_@TB5*_WK\;GK%GK.EZA.\%EJ5G<S1_?CAG5V7Z@'BGSZKIUK=Q6EQ?V
ML-S+_JX9)E5W^BDY->,Z"MM'X_\ "DEM=Z.WF1/OBTN (L68SA7;)9V[?-SQ
M[UT%L/"9N?$O_"8&Q&H?;Y"?M) F\G \OR\?/C;TV\TW&W]=G8%*_P"'XGHU
M[JFGZ:8Q?7]K:F0XC$\RIO/H,GFI)KRUMA&9[F&(2G;&7<+O.,X&>O )_"O/
M8V\+/XIUQO$WV+<4A-G_ &D /]'\L8V>9SG=NSCG-48+2*_\+>%+6YB,NGRZ
MTRP1RY^:W_>; <\XVXZ]J25_P_&_XC<OZ^5_N/28]:TN:PEOH=2M);2'/F3Q
MSJR)CKE@<"N:T+QW/KHBGBTJ"*TFNUMXY6U*(L00Q)*=0PP/DZ_-GM4%KH^F
MV?CG6=/MK&VBLKC28Y);9(E$;-O<9VXQTK%TBUM[;PKX%>""*)IM21Y"B!2[
M;9!DXZG '-$4F_N_-_Y!)M+[_P D_P!3T>XUC3+27RKG4;2&0,$V23JIW$9
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M&J:AX'M]=MEN7_LZ9I8KA=P+!4QN!ZGZ]ZV_!]I!IVO^*;&TB2&UCNXFCAC
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MP10J]K%(PC0*&8J"2<=2?6MRM)I*32(@VXIL****@H\(^"O_ ".5Y_V#W_\
M1D=>[UX1\%?^1RO/^P>__HR.O=Z[,;_%^2.#+_X'S84445QG>%%%% !1110
M4444 4G_ -8WU-5KZ9K:PN9T7<T<3.!ZD#-67_UC?4TP@$$$9!ZBAJZL@6C.
M=\"VT47A*RN5^:>\3[3<2G[TDC\DD_I^%2ZI=:5HRZOKD2Q27]O;@7"I+\Q
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ML_\ L()_Z+DK8^%W_).=*_[;?^CGK'^-7_(FV?\ V$$_]%R5L?"[_DG.E?\
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MK<Z3%>V@T*YNOM+@HWGK\P)0=L<#GK7<T4<J#G9AW+7X\46=K#,O]F&V?SH
MHR#T!)QP.PY['BL'6/AII4R6O]E6D4#+<*TYDGE.Z+^)1R>>GI]:[JBCE3W!
M3:V.8U/PY>0WUCJ'A^2UAN+2W^RB*Z#,C1]AD<Y'ZU''X-!\'W.C37(-S<R&
M>2X5./-+9SCTX KJZ*.5:_UY_F/G>GD<QI&A:K_;HU?7+BTDN(8/L\"6JL%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"
M/@K_ ,CE>?\ 8/?_ -&1U[O7A'P5_P"1RO/^P>__ *,CKW>NS&_Q?DC@R_\
M@?-A1117&=X4444 %%%% !1110!2?_6-]35>[NH;&SFN[A]D,*&1V] !DU8?
M_6-]369K^FMK&@7VG(X1[B%D5CT!(XS[9H>V@+?4Y'4O$GBA?#UWK3Z791:5
M);L8HO,8W*!AA7;^''()'45<@)TK3/".@FWM9GN"OF+/'O"A$WLR^C!L8/O5
M#4+7QCKND6VDW6C6UG;)-$ERZ72N9XU89*C^%>,X))[8KI)--NY_&]O?M'BQ
MM;%HXFR.9789XSGA5';O6FB?S_!)_J9ZM?+\79%#7]<UVTO)8[(Z%8VL6!Y^
MK7>WS21_"JGY?^!=?2G6_C19/"$6L/:A[F64VT5M#)N$TVXJ K>AQG/I7.Q^
M&=8MY+VU;PKI6H7,TDCKK%Y,CAMQ)&8R"V0#C P.*O'1+RP\'^'+6,VT.L6,
MRSQ6DTRJ)W&XN@(."<,>E2K6U\O^"4[WT\_^ 3W7B#Q?I5Q8Q:CIVEM_:%RD
M$+6SNWDY/(<'&3MW<@XR*MWWB#79O%-YHNB65E-]GMT=I[EV58G;/WMN2>,8
M  /7FLR&[UC7/'VDP:G9PV*64,EVUI'.)F1B-BEV QSG@"N@\/Z?>VEUKM[>
M6X2>[O&>)0RDM$JA4Y!XS@]?6CI=^?\ DOU%Y+R_S?Z%32O%DH\/ZI?:W%!%
M-IEP]O,;4DI(RXQLSSR2!CUJG<>(O%FF6JZQJFEZ;%I.Y?,@CE<W,*L0,D_=
M.,]!3HO"]_=?#^73I]D&J3S-=N'8,HE\S> 2N01P!Q1<6_B?Q0(M.U32X-*T
MY9%:Z=;H3-<!3G:@7[H) Z\XIK?[OTO^H/;[_P#@%OQ5XEO=)N["RL#I\,EV
MK,+K4G98%QCY<K_$<^HI9O$U_HOAV>^U^RMH[E)%BA^SSCRKDMC:5+<H,YSN
MZ 9J/7D\0I?7,<>BVNO:1<*H2UDFCB:%@.<[AA@>OK6:W@W4?^$0L[4Q6<MS
M:WIO(["5B\ 0D_N=S Y&">3WI+;^NX^O]=AVG^-KY=7L[?4;GP]<P7LPA1=,
MO#)+"QSC>#U'09%7_$OB;4K'7;?2--.EV\LL7FB?5'=8Y#G&Q-O5NG?O5?0]
M!N;C5X;^[\,Z1H<%ODK!#%#++(_9MZK\H'7CFGZW#XBDN;RSFT"S\0:9.^Z#
MS)TA-N, 8((YP<D$<^]-VT$KZG2:1/J-Q8!M5LX[6[5BK+%('1@.C*>N#Z'F
MK]9/AG3;G2/#MG87<HDFB0ABI)"\DA03R0 0.?2M:E+<:V"BBBD,**** "BB
MB@ HHHH **** "BBB@#+G!$[@^I-1UI3VZS<YPP[U5^Q2^J_G7="K%K5GG5*
M,U)V17HJQ]BE_P!G\Z/L4O\ L_G5^TAW,_93[%>BK'V*7_9_.C[%+_L_G1[2
M'</93[%>BK'V*7_9_.C[%+_L_G1[2'</93[%>BK'V*7_ &?SH^Q2_P"S^='M
M(=P]E/L5Z*L?8I?]G\Z/L4O^S^='M(=P]E/L5Z*L?8I?]G\Z/L4O^S^='M(=
MP]E/L5Z*L?8I?]G\Z/L4O^S^='M(=P]E/L5Z*L?8I?\ 9_.C[%+_ +/YT>TA
MW#V4^Q7HJQ]BE_V?SJ6*SVL&D(..PI.K!+<I49MVL3VX*P(#UQ4AY&***X&[
MNYZ25E8R""I(/44E:$]J)3N4X;^=5_L4OJOYUWQK1:U9YTJ$T]$5Z*L?8I?]
MG\Z/L4O^S^=/VD.Y'LI]BO15C[%+_L_G1]BE_P!G\Z/:0[A[*?8KT58^Q2_[
M/YT?8I?]G\Z/:0[A[*?8KT58^Q2_[/YT?8I?]G\Z/:0[A[*?8KT58^Q2_P"S
M^='V*7_9_.CVD.X>RGV*]%6/L4O^S^='V*7_ &?SH]I#N'LI]BO15C[%+_L_
MG1]BE_V?SH]I#N'LI]BO15C[%+_L_G1]BE_V?SH]I#N'LI]BO0!DX%6/L4OJ
MOYU/!:"-MSG+#ICH*4JL4MRHT)MV:+"C"@>@ILH+0N!U(-/HK@3UN>DU=6,>
MBKTUGN8M&0">QJ'[%+_L_G7>JL&MSS949IVL5Z*L?8I?]G\Z/L4O^S^=/VD.
MY/LI]BO15C[%+_L_G1]BE_V?SH]I#N'LI]BO15C[%+_L_G1]BE_V?SH]I#N'
MLI]BO15C[%+_ +/YT?8I?]G\Z/:0[A[*?8KT58^Q2_[/YT?8I?\ 9_.CVD.X
M>RGV*]%6/L4O^S^='V*7_9_.CVD.X>RGV*]%6/L4O^S^='V*7_9_.CVD.X>R
MGV*]%6/L4O\ L_G1]BE_V?SH]I#N'LI]BO3X@6E4#UJ7[%+ZK^=68+98>2<M
MZ^E3.K%+1EPHS;U1/1117 >D6X?]2M25'#_J5J2D,**** /./C5_R)MG_P!A
M!/\ T7)6Q\+O^2<Z5_VV_P#1SUC_ !J_Y$VS_P"P@G_HN2MCX7?\DYTK_MM_
MZ.>NQ_[JO4X(_P"^/T.OHHHKC.\**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /"/@K_R.5Y_V#W_]&1U[O7A'P5_Y'*\_
M[![_ /HR.O=Z[,;_ !?DC@R_^!\V%%%%<9WA1110 4444 %%%% %1T8NWRGJ
M>U-V/_<;\JNT4 4MC_W&_*C8_P#<;\JNT4 4MC_W&_*L_5]!L-=M/LNIV*W,
M(.X!@05/J".1^%;M% '/Z-X:TSP_ \6E:>MLKG+$99F^K')/YUI['_N-^57:
M*=[BM8I;'_N-^5&Q_P"XWY5=HI#*6Q_[C?E1L?\ N-^57:* *6Q_[C?E1L?^
MXWY5=HH I;'_ +C?E1L?^XWY5=HH I;'_N-^5&Q_[C?E5VB@"EL?^XWY4;'_
M +C?E5VB@"EL?^XWY4;'_N-^57:* *6Q_P"XWY4;'_N-^57:* *6Q_[C?E1L
M?^XWY5=HH I;'_N-^5&Q_P"XWY5=HH I;'_N-^5&Q_[C?E5VB@"EL?\ N-^5
M&Q_[C?E5VB@"EL?^XWY4;'_N-^57:* *6Q_[C?E1L?\ N-^57:* *6Q_[C?E
M1L?^XWY5=HH I;'_ +C?E1L?^XWY5=HH I;'_N-^5&Q_[C?E5VB@"EL?^XWY
M4;'_ +C?E5VB@"EL?^XWY4;'_N-^57:* *6Q_P"XWY4;'_N-^57:* *6Q_[C
M?E1L?^XWY5=HH I;'_N-^5&Q_P"XWY5=HH I;'_N-^5&Q_[C?E5VB@"EL?\
MN-^5&Q_[C?E5VB@"EL?^XWY4;'_N-^57:* *6Q_[C?E1L?\ N-^57:* *6Q_
M[C?E1L?^XWY5=HH I;'_ +C?E1L?^XWY5=HH I;'_N-^5&Q_[C?E5VB@"EL?
M^XWY4;'_ +C?E5VB@"EL?^XWY4;'_N-^57:* *6Q_P"XWY4;'_N-^57:* *6
MQ_[C?E1L?^XWY5=HH I;'_N-^5&Q_P"XWY5=HH I;'_N-^5&Q_[C?E5VB@"E
ML?\ N-^5&Q_[C?E5VB@"EL?^XWY4;'_N-^57:* *6Q_[C?E1L?\ N-^57:*
M*6Q_[C?E1L?^XWY5=HH I;'_ +C?E1L?^XWY5=HH I;'_N-^5&Q_[C?E5VB@
M"EL?^XWY4;'_ +C?E5VB@"EL?^XWY4;'_N-^57:* &0@B( C!I]%% !1110!
MYQ\:O^1-L_\ L()_Z+DKC_"WQ6_X1KPY::1_8OVG[/O_ 'OVK9NW.S=-AQ][
M'6O9=;T'3/$5FEIJMM]H@202JGF,F& (SE2#T)K"_P"%7>#?^@/_ .34W_Q=
M=M*M25/DJ*^IY]6A6=5U*;2TL<?_ ,+S_P"I<_\ )W_[71_PO/\ ZES_ ,G?
M_M==A_PJ[P;_ - ?_P FIO\ XNC_ (5=X-_Z _\ Y-3?_%U7/A?Y7_7S)]GC
M/YU_7R./_P"%Y_\ 4N?^3O\ ]KH_X7G_ -2Y_P"3O_VNNP_X5=X-_P"@/_Y-
M3?\ Q='_  J[P;_T!_\ R:F_^+HY\+_*_P"OF'L\9_.OZ^1Q_P#PO/\ ZES_
M ,G?_M='_"\_^I<_\G?_ +778?\ "KO!O_0'_P#)J;_XNC_A5W@W_H#_ /DU
M-_\ %T<^%_E?]?,/9XS^=?U\CC_^%Y_]2Y_Y._\ VNC_ (7G_P!2Y_Y._P#V
MNNP_X5=X-_Z _P#Y-3?_ !='_"KO!O\ T!__ ":F_P#BZ.?"_P K_KYA[/&?
MSK^OD<?_ ,+S_P"I<_\ )W_[71_PO/\ ZES_ ,G?_M==A_PJ[P;_ - ?_P F
MIO\ XNC_ (5=X-_Z _\ Y-3?_%T<^%_E?]?,/9XS^=?U\CC_ /A>?_4N?^3O
M_P!KH_X7G_U+G_D[_P#:Z[#_ (5=X-_Z _\ Y-3?_%T?\*N\&_\ 0'_\FIO_
M (NCGPO\K_KYA[/&?SK^OD<?_P +S_ZES_R=_P#M='_"\_\ J7/_ "=_^UUV
M'_"KO!O_ $!__)J;_P"+H_X5=X-_Z __ )-3?_%T<^%_E?\ 7S#V>,_G7]?(
MX_\ X7G_ -2Y_P"3O_VNC_A>?_4N?^3O_P!KKL/^%7>#?^@/_P"34W_Q='_"
MKO!O_0'_ /)J;_XNCGPO\K_KYA[/&?SK^OD<?_PO/_J7/_)W_P"UT?\ "\_^
MI<_\G?\ [778?\*N\&_] ?\ \FIO_BZ/^%7>#?\ H#_^34W_ ,71SX7^5_U\
MP]GC/YU_7R./_P"%Y_\ 4N?^3O\ ]KH_X7G_ -2Y_P"3O_VNNP_X5=X-_P"@
M/_Y-3?\ Q='_  J[P;_T!_\ R:F_^+HY\+_*_P"OF'L\9_.OZ^1Q_P#PO/\
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M='_"KO!O_0'_ /)J;_XNCGPO\K_KYA[/&?SK^OD<?_PO/_J7/_)W_P"UT?\
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M?_4N?^3O_P!KH_X7G_U+G_D[_P#:Z[#_ (5=X-_Z _\ Y-3?_%T?\*N\&_\
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M&_\ 0'_\FIO_ (NCGPO\K_KYA[/&?SK^OD<?_P +S_ZES_R=_P#M='_"\_\
MJ7/_ "=_^UUV'_"KO!O_ $!__)J;_P"+H_X5=X-_Z __ )-3?_%T<^%_E?\
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M6U]'');2&2.1"ZN$;;@'!!., Y['GKQQ5F@ HHH)P,T %%,BD6:%)5#A74,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPHSD'ICK[4KVU_K8=KZ?UO\ U]YE21R3>,-.NXXW:W_L^<>:%.T%GB(!/8D
M\>QKE+@^()=9O)K9-1C 2>3R +C9OC=6C4.[E#O /"*HPQ!S70KXKEFL(I;;
M2G-PSW'^CRRB,K'"V&).#\W3"^IZCK6AJ>NQZ?X>;6(K>:ZC\GS4CB7EAMW<
MG^$8ZD__ %J-@M=V_KL<7J=OKE];6,LL&HR?:(I[AX61SY1;=L0KR 0I Q]:
MU=:T?4]:E@@MG6W6RL RM<6S.K3/TVD,N&79UYQNZ5KW?B3[+?+&;4&U3R5N
M)S+@QM*<( N/FYQDY&,CKSBO;^*+R[54ATC=<3I'-;)YYVM$^[#R,$.S&TY&
M&Z@9.:/02,S5);BZB:YCT[4;:^N[.+:BVIFBN&P?W4Z,A" $X))7@]>*Z^TD
MA>2Y6-G,J2 3*Q8A6V*<+GC&"/N\=>^:R8O%MJ;6TDFMYUDG*JR)AA&QE$6"
M<C(W$\]P"?:MY(TC+E$52YW,0,;CC&3ZG@4WL".(M['5H-97Q R;DNKR6-X!
M:N)XXF 1"6W'Y?W<;8VC&2<U6L+'688[29I]9:58K"1EEFE8%WD*S@@GG"@9
M4\#K@'FO0JQ7URXBUJ*TFT\QV<TS017#289G5"Y.S;]S 8;MW4=,<T1=BGU.
M1DM_$DT^HJ;W5(YW=E816TH5%,RA"CF0H<)S\B=,[JM^3J-KJ,L%Y+X@FM(G
M*VDENSEWD 0 L1\I!&?O_)G=FM6W\737^BRZK8:8);>*68,TMR(QY<?\?0G+
M#D#&/4BK$_B5[2X5KNP,-C+&\D4WG R,%CWDF,#A<9&<YR.0,BDM/Z\B6KG(
MZD?$<^J7'V0ZK;+,[(ZQ)<$0XFC"L&=BARFX_(H4 D'-=7IK7VEZ#JJNM[=/
M:2RBU\[=)+*H *\GELDD5?TC59M0:>&ZM%M;F'8QC67S!L<94YP.>H(QU!Z]
M:U*'M8:=W<\]CTG6=!L[BS,LLPN;6-S/86KJRNC@/NPY)9E;JI!PIVC(I3-J
MHCTJ7[/K> 6 A\V;/^LX)?9D_+T$Z@8ZG/->@T4[ZA;2QY[<?VYYDWD_VQ]J
M\R3[=_K/+\GS1M\G/R[O+SCR^>N>:747U#_1H[&/7/[/D1U:6X%RSQ#>"&VQ
MLLK=, ,0V#D\"O0:*D&KGF]A;ZPL?VF6/5!J+V,$8<B89VW+!@1D@';M/)R0
M2<G)-'V?7;K[';QSZY \C1KJ<I,@VR%^3$6X"[=W*?*!M[UZ113OJ#6ECC+J
MROKSX=W=G<)>RW"R2(@9G\YT68A"3]YOE .>XYJOJJZLE]>I;'5_M:NP@\LR
M&#[-Y/K]TONS_MYQVKNZ*3UO_72P)6=_ZWN<QJ.E7 ^'ES8/-?7MR;1B7=V,
MSL?FQ\N#UXQZ<<UST^GZW;WFH7^D-J:R37FR"%PXC*&T&'8,.3O"C<W0KC@Y
MKTBBG??S!*UO(YGP<E\EM=?:[F\F0LNS[5;2Q$-CYL>;([$9QZ+Z5DBUGFS9
MVUG?Q((+A9K6:$^7;EE.#!/M!.6P,*Q&#T%=Y12EJ"5CSVYGU:UM[:UL+36'
M6:ULEB8+)B$I(?-WEN5.W (/)'L.,U6UFR>YU:9=7$]E9K-.;IBL;RK(K2I&
M3_ 5!P/N],=Z]4J*XM;>[C$=S!%,@8,%D0, P.0<'N#5.5W<5M$C#>'58/!.
MU9)Y-3,(>1E;=)N8[G"9[@$A?H*QM*L;B;Q7978353I\/V@6SW;3!E4K%P^\
M[L%O,QOY./0"NZHI7UN.VECFI;H:=XTNYI[>],4]E!'')#9RS*6#R9!**0,;
MAUQUK$LE\2BXM[1?[0Q)!]L,TS,5$BHR>4Q/3+;&V]^:] HI?U^8SSC3+'7;
MMK*&74M92)KJ,W#^1-"4(BD+C,CN2I;8#@!,XV\UTFL3_8?%.F7LEO=R6ZVM
MQ&S6]K)/M8M&0"$4D9VGKZ5T=%4Y"2L>:W=MK-HL'R:HELP>=X+<S* 7EE8(
MS1992 R9VAN@!&*M$^(3KD<[-J*X2)H;8P2,KIY8+J\BNL2MNW DJ6S@KZ#T
M"BE<+'ED;:Z%GWG66M,Q2A%CO(_F*R!DW%GF !"<J",XRN#FM)U\0RZTCM/J
M=OF.,PQ+;/+\GE#?O<2+"&W;L[ESG&..GH-%#=PL<OX3N+B.RF6\BU(?O41'
MN1,Y8D<D"10ZC/7DH,\-CI8UR;['K^CWCP74D$:SJ[6]M),5)5<9"*2,XKH*
M*&[NX)65CSJ\CUB'RA';W\5K=O/*_EK<'[.'FW*2D+*Q8CL",;CG@&LR2Y\0
MPP:<U[+KD5P9K>*,IN2)H_,VL)<DG<>.Y8C')&ZO6*JOIFGR7Z7[V-LUX@VI
M<-$ID4>@;&1U-""VMSS^RMM=M(;%;VXUV>SFMK>;4&S*948B3<J;?F7!\O(7
MG R>IJWI[:U'JUE]I36) PPFYI%"1_-@O@&-CC;NWE7!'&>E=_10W<+'!^&6
MU=-7LEODU>1G@3S&G:54C'DKPP(,;?-GG*R9/((J;Q%)J_\ PD]LUDEZB136
MX_=)<.DL;/B0DJPB7 )R&5F[\8R.VHIMW=PMOYGF4%KX@M;&T,\^O3Q7%NDM
M_AI#+'A\%8\<JV,9 ^8@$]:V=,MM13X?>3MU"&\>Y<G<"MP%:X)).WOM.21Q
M^%=I12N'6YQ5M;:II]Q++$-4N@JWB+#/<2LK*I!B&6/!/.&ZG/4XK%L;/7KV
M_6T>\UJ*P+F3S46YA)'E$[=TK,X&X =1[ 9KT^BD#1Y<T_BR9K.:"+4(;_R%
M1XVBN"CDVY.]BS>4I\S QLW C)(S4"2:Q-<74%O=Z\EA%(F_[3'/-.A*,1\L
M3K(%+9[_ -W/RUZLZ))&T<BJZ,,,K#((]"*@LM/LM-@\BPL[>UASN\N"((N?
M7 %5?45M#BH-.UBXNHC>76LY>Y6*4K+)"#%]E#$[58A?W@Z@]<@'DU$1XCEN
M](::YU"$_9+8J$M97W2?\M?,*R*BGIGS >.G->AT4-W&UH>8QZ9JXL]/-_)K
M=TLBV]S<!VF)C=9U& %Y&$))'7C)Y&:['Q-YWEV7_']]A\X_:_L'F>;MV-MQ
MY?SXW;<[?Y9K=HI-W"VK9R7A"QO8=1U"[OTNQ--!;C=.['=A6[9V[@,9QWSZ
MUAS:?K]E]LN-.DU(2W-W>#RL,8XX]Q*LJ<#)Y(.<G. :])HI EI8\V^R:W)8
MR&.\UJ1(K:ZEMRL=Q 3(/*V J\CNW._ <\\C&*TIH+^V$L$[ZR^F)J'[QH7F
M><QF!2-K+^\*^83G;TZ= :[>BJ;"QY];KJSQS)J::V]XT.VV6(,8C$8CGS?X
M-V[.<_/G&*AL-(UN.?3--^W:U':D6TLLVYAM/E3;TSC"KE8P5[9'<YKT>BDG
M9@U<\[:/6II$B1M:69Y%746+2J@)N$QY1Z!=F_)3C;][FK5K#K%@)I$75+K-
MM>KY4\\I!V2@0@$G()3."/F;KDUW5%%]+#/---MM7.H)*_\ :4QAEF%G++'<
MHH+0#&Y9&9MN\$?.<9],XITW]J"W#0?\) ;11$9DF-P'>?:^\!E!D5<[.45D
MSVQFO2:*+BL>=ZD^M^9YICUO9M0K#&T@._RDZO$IY!W=5,9.=V.*[NW*&>4@
M3B4JF\2;MHXXVY^7/KM_&K-%%PL<+J[3:[?7RO:WZ/:!DLH?L<JK(5(9W\PK
ML^8+M49Z9_O<6I(+B\T[4[R.UN%6[U.VEBC>%DDV(T*EBA&1]QCR.@S7844)
MV'UN9?E2?\)7YWEOY7V+;OVG;NWYQGUKDK^?5)?%^J16<NKM)#-$(EC9C;(A
MB4R XX#8Y&>^,<YKT&HT@BCDDDCB1'E(,C*H!<@8!)[\ "E_P0/.;Z#7K+3=
M,BAFU>:ZCMHY_.87$KRR,V7C8(RHNT?\] V0< <5/<VUS=Z7<)=1Z_)=K-')
M=#,OE?+<*?W8').S)'E\8'/S8KT.BJYM;DJ-K'#$ZE_PDMZ;P:X;3SE^P"T\
MS;NR-V[^';C'W_E^]CFI_"J:R-:N6U&YO&)5_.BDMI5B#;_EVN\A4\9QY:@8
M^]SBNRHI)V'8\@UE_%*>,KF,7FL(TSW2V\$:.L#((6,>UM^TMP. N0<DGI56
M\/B6Z\3WMS8VOB6SL[FY#R!(I(P8?+168#^_QQ_%TQSFO7X],T^*_DOX[&V2
M\D&'N%B42,/=L9/058DC26-HY$5T<%65AD$'J"*+Z)#>KN>,^%X/$\UNMS/>
M:K''<2%H-L$TN7WX;=LD11ZYD!4\]Q5&WT+Q)'<SBW77[1;:RNFC,/G+OD$K
M,J9[YX.!UKW.&&*WA2&"-(HD 5$10JJ!T  Z"GTV];HGETLSA/!W]O2:F)M6
MN+[S6C<SPRVLJQKR-F':0IG'9$!Z[N:DU.PU677+K7XD!2RN(DBMVM7:62-!
M\YC(;OYLG\)S@5V]%'-K<%&RL<'>:=JDTUW,MQK*ES>D+'/*JC:080H!XYSC
M'WNG(XJ"Z7Q&^K7;FYU%'\H^3%%:RE"GD_WQ((PV_/\ "7SC'%>AT5/2Q76Y
MY[+::K8ZA;07=UK]SIBVD9GEA:4RM*?-/_+/G@E0<>B[N*;?R:ZVLQR6\>JQ
M!1Y;(R3L70P'YV97\D-OP,*N01G/->B44V[B2L<IX4@U*QEGCOI]0N(VL[><
MR799CYS;_,5<],87Y1T_&L[3+#6;&ZBU.3<QU..?S4AM"LT#/F1-Y+$';C8,
MA0"0#7>442=W?^NO]?($K*W]=/Z^9YP'U7^Q,&/7-L=P-WSW6Z7]V>^WSD&[
M!^4.N?5<XM3MKKW :)-5343Y)M58L8!%Y8\P2D?N]^[?UYSC'%=[10W<$CSR
M>74HM+MVL(/$$T@D'VI;EIAEC#('VX._ ;:?E^7.W9S46CVVI_VJDUV-4E$(
MNX[69X[E!AHXF7(=F8 G?C>3R ." !Z110W>X)6L>78\2MHZ!6UM=7*,+EL2
MF,1X'EE,_+O^[G'S?>W5UVC6=W#8:SI]S+?311S-'!+<2,9'0Q(20_4_,6Y'
M3H.E='11)W37<459I]CSJ"UU6RT72[=$U:.5--@%FD)EVK<Y.\38X 'R\/\
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M&6/<FI:**6XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTQU6=6?#@'*.H7 8 <]AQA178CQ;HZS8;4%=9%5XQ';R'8A53N<@$!?F'S'
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M4'WY'AD"GY@N5;;AP&(!*Y SSBI)?$^CP6OVF2\Q#N9=WEN>5C\P]O[@S_\
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M#*<$<CD<&DB\7Z)-:+<1W;RJ6*8BMY';( ).T*3MP0=V,8(.>:+!<W**Q?\
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MCWD IM&[@%0=YSSG'-4XV;78GFT3[G445RFC:\-3\174/]L?-'--%]@^S_*
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MS6>HI#<F6Y;?);[UV3,&9=NX<@@8.>W3M6CH6B1:%:RVT,AD1Y RDK@@!%4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH S[S1-/O[N.ZN8"\J #(D90P!R R@@
M. >0&!P:N0PK!'L0N1N+?.[.<DYZDDXYZ=N@XK,U;76TJZMX/[)OKH7#B.*2
M!H=I<@G;\\BD'"DYQCWK460F$2,C(=NXHV,K['!(S]#1TN'4?4-U:07L/DW"
M;X]ZOC)'*L&!X]P*9I]['J.G6U]"KK%<1+*@<8(##(SCO5D\#IFF]&!4U#3;
M74X%BND9E1@Z,DC1NC>JLI!!P2.#W-5O^$<TD36THM K6P41A78+\I)7<N<,
M022"P)!)(K1B=I(4=HGB9E!,;D94^AP2,_0FLNY\1V=IX?N-9DCG^S0,RNJJ
M"_RN4.!GU'KTI;!N6=/T>QTMI6LX3&92-V79N!G"C).U1DX48 R>*C30--34
M#>K WFES)M,SF,.1@L(\[ QR><9Y-26NK6MY?O:0%G*V\=R)!C8R.6"X.?\
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M)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!SDVCZ^U_-*FO8@9B4B\H#:,\#C
MTIW]DZ[_ -!O_P AUT-%:NK)]ON1C&C&.U_O9QFH>'?%]S,K6GBL6T8&-H@W
M$GUYK=\/6&JZ=IQAU?5?[2N#(6$OE!-J\?+QU[G/O6M14NHVK?H5&FHNZO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>formdrs_005.jpg
<TEXT>
begin 644 formdrs_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )A!'T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<53^(_C'_A'?#0?3KR%=0N@#;G&_*=W7L>"/SKR72==\)W>E1:7XFT86[6Y
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M(['J*YOXF:181?%'2X4MP([X0R7(W']XS2LK'KQD #BM[XNZ59:+X!TRPTZ
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M.\@O[.&[M9!+;S*'C<#AE/0\UXG\1M47Q?K?A73[)S(ES#'*8UXVM*0.>N"
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M-%@N]D:7P3N9[GPSJ#3S22L+P@&1BQ V+ZUT]S\0O"=G=M:S:W;B56VL%#,
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M"3_A&9YI+4RYE2=B71\#J#TXQTXKKZEE(****!A1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ<H-Q:V-:=6%2*E%[[$]%13W-O;*&N)XHE/0R.%'ZTJW$+P&9)4>( G>K C
M]ZFSW-.97M<DHK%\+ZG<ZQH_VVY" O*X3:,?*#@?UINN:Q-I^IZ3:PM&HNIC
MYI?LBXS].M:^QE[1T^J_0P^L0]DJW1V_%V1N45%!=6]T&-O/%*%X/EN&Q^5.
MBFBG3?#*DBYQE&!&?PK)IK<W4D]F/HJ-)X97=(Y4=T.'56!*_7TK(\1ZS<Z6
MMG!90QR7=Y+Y4?F'"K[G\Q50IRG+E6YG4JQIP<Y;(VZ*XZ\N_%NBV[7UT]C>
M6Z8,D<:D, 3CC@?UK:N=0NKFWTZ736@0W+*[+<'#>61D@#N>:UE0:LTTT^IC
M'%1E=.+371K77337]37HJ":]M+9PD]U#$QZ*\@4G\ZR['5I[SQ3J%BIC-I:Q
MI@@<[S@]?SK.-.4DWVU-I5H1DHMZMV_7]#;HJNM_9O/Y"W<!FSCRQ(-WY58J
M&FMS1-/9A17.>)=8U"ROM-L-+$1N;MF&91D #'^)_*H_+\:_\]](_)_\*W5!
MN*DY)7[O_@'++%14W",6[;V7S[HZ>BN0U77=2M6T[2XKNQ749]WVB8_ZN+'U
MZ=^OI4,^N:Q+J%KI%IJ&G"Z$/F3W!Y1FSPH_#';O5K"3:O=?\!==C.6/IQ;5
MGI9=-WTWW[_F=K1507L%LD45Y>6RW&T;@7"Y..< U;R,9SQ7*TT=JDGL%%5X
MK^SFE,45W!)(/X%D!/Y5F6_B&.Y\2SZ8C0>3%$")/,R7<XP!^!-6J<W>RVU(
ME6IQM=[NR]3;HI'8(C.QPJC)-<7I6I^+-<M&O;,Z=% 9&5!,K \?3/T_"JIT
M7-.5TDNY%7$1I24;-MWV5]ON.UHK(TPZU!YTFMSV(B &PPY&#WR3BM%+NVDF
M,*7$32@;BBN"0/7%1*#B[+7T-(5%))M6\GH_S)J*KQW]G-+Y45W \G]Q9 3^
M6:DGN(+9-\\T<2=-TC!1^M3RN]K%<T;7N245$MU;OY>R>)O,!*8<'=CKCUIT
M<T4I81R(Y0[6VL#@^AHLQJ2?4?13(YHI=WER(^T[6VL#@^AJ)+ZSEF\F.[@>
M7^XL@+?E19]A<T>Y8HIC31)(L;R(KOG:I8 MCK@5'#>6MP[)!<PRNOWE20,1
M]<46>X^97M<GHJO-?6ELX2>Z@B<]%>0*3^=2-<0J8PTT8,GW,L/F^GK1ROL+
MFCW)**9+-%"H:61(U)P"[ 9/I3Z15PHHHH **** "BBN<\5ZU>Z5_9\-AY7V
MB[F\L>8,CL/YD5I3INI)1B95JL:,'.6R.CHKD[J;QC86LMW(VE31PJ79$#Y(
M')ZXK<TW58K[1;;492D"RH&;<V IZ'D^]5.BXQYDTUMH9T\3&<N1IIVOJK:?
M>:%%0P7=M= FWN(I@.IC<-C\J;-?6ELX2>Z@B<]%DD"D_G67*[VL;\T;7OH6
M**R/$&NQZ+I+W:^7+*<>7&7QNR<9^@ZUH6<K3V4,KM&SL@+F,Y7=WQ[9S5.G
M)14WL2JL'-TT]4KD]%9.OZY%H5B)F0RSR-LAB7J[?X5E9\:-$;S.GJ<;A9X.
M2/3/K^-:0H2E'F;27F8U,3&$N1)MK>RO;U_JYU=%<V/%*R^#IM96,1S(I3RV
MY DS@#Z9(-:.E:FEQ86?VJYMUO98E=H@X!R1G&W.:4J,XIMK9V*AB:4VE%[J
M_P GH:=%13W5O:J&N)XH5/0R.%'ZTZ*:*XC$D,J2(>C(P(_,5E9VN;\RO:^H
M^BJSZA91H'>\MU4G )E4#/IUI9;ZS@V>;=01[QE-\@&X>WK3Y9=A<\>Z+%%-
M>1(XS([JJ 9+,<#\ZB@O+6Z)%O<PS$=?+<-C\J5G:X^97M<GHK";Q '\4Q:3
M"8#$(B\LI?G/0*/?./7Z5'H>O/>_VA<7T]M#;)<M#;[B$R!ZDGGJ*V=":CS-
M=G]YSK%4G+E3ZM?=J_S.AHIJR(\8D1U9",A@<@CZU#%?V<\GEPW<$DG]U) 3
M^0K&S-^9+J6**CDN(86"RS1HQ!(#, 2!UJ/[=9F#S_M4'DYQYGF#;GZ]*.5]
M@YHKJ6**A@NK>Z!-O<13 =3&X;'Y4Q]1L8QE[RW49V\RJ.?3KUI\KO:P<\;7
MN6:*CDN(8HUDDFC1&. S, #3I)(X8S)*ZH@ZLQP!^-*S'=#J*16#*&4@@C((
M[UREUJ^N7OB:\TS2#:+':HI9[@'!) [CZ_H:TITG4;MI;N8UJ\:23:;N[*VI
MUE%<;J&K^)] A2[U%-.N+7>%<0E@PSZ9Q_6NLDN[>"%99IHXD;HTC!1^M.=&
M44GNGVU%3Q$*C:LTUO?3<FHID4T5Q&)(94D0]&1@1^8J)[^SCF\E[N!9<XV-
M( WY5ERO:QLY12NV6**9++'"A>618T'5F.!3(+NVN@3;W$4P'4QN&Q^5%G:X
M^97M?4FHID<L<REHI$=0<95@1FD2XAD=T2:-FC^^ P)7Z^E%F%T2457AOK2X
MD,<-U!(XZJD@)'X"GR75O$S+)/$C*NY@S@$#U/M1RN]K"YHVO<EHJ&"[MKG/
MD7$4N!D^6X;^5.\^$3>3YJ>:1G9N&['THLQ\R:O<DHHHI#"BLG7]<BT*Q$S(
M99Y&V0Q+U=O\*RL^-&B-YG3U.-PL\')'IGU_&MX4)2CS-I+S.6IB8PER)-M;
MV5[>O]7.KHKEAXM\WP?<ZJL0CNH#Y31,.%DR /PY!K;L[PII-K<:C+%#+)$K
M2%B% 8C)'-*=&<%JNMBJ>)IU'[KZ7^6Q>HJ*"YM[I2UO/%*HZF-PP_2J-K=W
M1O[][F:T%A&56(HX)4]]Q[<U"@W?R-'42MYFG15?[?9B98?M<'FMC:GF#)SZ
M"E%[:FX^SBYA,_\ SS\P;ORZTN5]BN>/<GHJ">]M+5@MQ=0PD]!)(%S^=2HZ
M2('C964\AE.0:5G:XU)-VN.HHHI#"BBB@ HHHH **** "BBB@ KD?!$:-/K5
MP_-RUXROZ@9S_,FNNKF;KPW>V^KS:CH=\EJ]Q_KHI$W(Q]?\^_K731E'EE!N
MU[?@SBQ,)<\*L5?EOIUU5KKT-G4=4L]+2$WDFT32"- %+$M]!7+7-A%XC\?3
MQ7*EK2P@567. ['D _B3_P!\UIV7ANYEU2/4M;OA>SP_ZF-4VQQ^^.YJ[I.D
M2:??ZG=2RK(UY-O&T?=49P#^=:1E"BFX2O*WYOIZ(QJ0JXAQ52-HWO;K9)[^
MKZ?><S:+#I?BG7[RR@6*UL+3F).%9\ C]0:IZ/;M<63W=_X<N-3GNB7:X9QR
M#T"Y/%=;8:!Y#:Q]KD65=1E8L%!&$.0!^M9<?AG6X;!M*BUB)=.)(SY7[P(3
MR,__ %ZZ57@[J^NFNNR7EKO]YQO"U%9\NGO.RMHV]-'I:W7H8.HP7\?A;2]'
MNDDBDFOBD:R')"= /S;]*NZ]X?L[:_T/3+!&CN)I"9+D-^\*C&23Z]3^%;S>
M%U&J:3)'(HL=.0[8B"69SD[L_7:?PJY/I$D_B>UU4RKY5O T:QXYW'.3^1I?
M6DFG%_S/YO8:P$FFI1OK%+T5KO\ K4P)M)LK'QMHEMI\"V^R)Y)"O5A@@9]>
MA'XT[P_IT'B*YOM8U1%N29FAAB<96-%]OQ_SFMN/1Y?^$KEUB696C\@0Q1@<
MKT))/US^=9T?A_6-,EN8]'U.&*TGD,@2:/<T9/7%1[92C;FM*RUU[MM7^XT^
MKN,^9PO'F;LK=DD[;=']]S#'D6EOXNL8?GL(5!CC;D)(>./HP_\ '14E]IL.
MD_#Z+R8E6[O5B1Y /F;<=V"?TK;?PBJ>&+G2X+D_:+EA)+<./OL"#S[<43>'
M]2OK;3(;V]@9;2X$L@2,@,JXV@?AN_.M?K$+IJ6E]?.RW^;1C]4JI-.&KBTM
MM+RNU\D_SL8WB+PY8:/X6@CBA5KUY8XQ<'[Q8]?PXZ5%=S3ZKXMN8Y[&?4K3
M3_D2W1@%#=-S9ZYP:ZO6]&EU:[TUA.J6]K/YTB$9+D8Q_7\ZIW/A[4+?6KC4
M]&OHX'N1^^CF3<I/J*FGB(N/OR][7>^EVONT[%UL')3_ '<;03CHK:I)]'H]
M6MRCHMO/9>([B\329=-TY[4^:C$;=RG.1CV_K57PMH-AJ&F3:QJD?G>=))(J
MN3M09Y.!WR/TK9@\,S1:;J0EO3/J-^A22X8': >, >E:EII4=MH$>ED_((/*
M9E[DC!/YDFHJ8A)/E>KLM+[+UU_X8TI81N4>>.BYG9VW;TVTV5_*YQ=J+.\>
M]OH=$NM8$KEC<W16-1@=%SV%5$FEM_AC.265+F[VPKG.U,@D#\5:NAA\-:VF
ME'23J\*604J#'$1(1UP3V%9VJ:/(5\/>%VF!7,DDKH.PR<C/L6KIC5IRE:]U
M=/J]$F_3[D<,Z%6,'+ELW%KHO>DTNEV^NK;)-9\-:9I?@IY3"/M<:(WGD_,7
M)'Z<XQ4_GM8^+=)O;A]J7>FE)G;L57<2?R%6CX9U/4'MX=:U*.XLK<AA%''M
M,A' W&J'BG[-XCU33-+TZX6256?S7B^81(< YQ].G^-9PGSODE*_Q7?1)K_@
M&]2FZ:]I"'+;E26EVT_+UM][+OA]6US6[GQ#+N\A"8+)6&,+W;^?YFMC5-8?
M39DC73+^[W+NW6T6X#V/O5VRLX;"RAM+==L42A5!J>N"=6,IWMHM$O(]6E0G
M"ER\UI/5O?5[[_=Z(YW_ (2J7_H7M9_\!O\ Z];MM,;FUBF,4D1D4-Y<@PRY
M[$>M2T5G.4&O=C;YMFM.%2+]^5_DE^1P-\VH7?Q&E;2TMWGL[< ?:,[ ".>G
M?YZT+O1O$>O!+?5;JRM['(,D=J&+/@Y'7_'\*T]%T)],U'4KZ>999;R7<"!]
MU<DX_7]*VZZJF)Y6E32T25[:_P!7\CAHX/GC)U6_>;;5]-]+_)+J<!-'IUUK
M\PM],O-6%JHMUAX6"#;Q@$_0]??K4>BM"EWXEEDT]+:UA@ EL]^]=PSQD<=0
M?SK9MO#VL:9-=QZ9J5O%:7$IE_>1;G0GT[&BR\)36NC:K8->*[WK$K,5.?\
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M2S<G2;3[8"+GR5\W=UW8YS^-87_".ZKJ,]N-;U**>U@;<(84V^81TW&NHZ#
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MKP9C\\SC^)SU/]/PK4K@KS4I<L=EHO\ /YGJX:G*,7*?Q2U?Z+Y+3[PHHHK
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MQZ\\UT-_X7-QI>FQ6USY-YIP7R9L9!( SD>Y -)!X>O[O5+>^UJ_2<VQS##
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MI60G&+:;6Q9HJM]H?T6C[0_HM(HLT56^T/Z+1]H?T6@"S15;[0_HM'VA_1:
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M_P#"\=?_ .@;IO\ WS)_\51_PO'7_P#H&Z;_ -\R?_%4?5Z@?6:9[Q17@_\
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M\F_[[_\ K4>PQ'9?>'UNM_*CZ1LO%7@G349;/4;" ,<ML&,_7BK7_">>%O\
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M>>%O^@W:_F?\*/\ A//"W_0;M?S/^%?,GVQ/^>3?]]__ %J/MB?\\F_[[_\
MK4?5\1V7WA];K?RH^F_^$\\+?]!NU_,_X4?\)YX6_P"@W:_F?\*^9/MB?\\F
M_P"^_P#ZU'VQ/^>3?]]__6H^KXCLOO#ZW6_E1]-_\)YX6_Z#=K^9_P */^$\
M\+?]!NU_,_X5\R?;$_YY-_WW_P#6H^V)_P \F_[[_P#K4?5\1V7WA];K?RH^
MF_\ A//"W_0;M?S/^%=%7R-',LN=J%<>K9_I7US6:YE)QGNCIPU>=5R4EL%%
M%%4=@4444 59_P#6?A4=23_ZS\*CIB"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#$\6^(HO"WANZU610[Q@+%&3C>YX _J?8&OG'4/'_ (JU&Z>=
M]<OH=Q)$=O,T2*/0!2*]<^.7_(DV?_813_T7)7S_ %U48JUSFJR=[&U_PE_B
M;_H8M7_\#9/_ (JC_A+_ !-_T,6K_P#@;)_\56+16UD8W9M?\)?XF_Z&+5__
M  -D_P#BJ/\ A+_$W_0Q:O\ ^!LG_P 56+119!=FU_PE_B;_ *&+5_\ P-D_
M^*H_X2_Q-_T,6K_^!LG_ ,56+119!=FU_P )?XF_Z&+5_P#P-D_^*H_X2_Q-
M_P!#%J__ (&R?_%5BT46079M?\)?XF_Z&+5__ V3_P"*H_X2_P 3?]#%J_\
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MRC\)R5?B"BBBM3(**** #.#D4XNQ?>6);.=Q/.:;10 I)9BS$DGDD]Z2BB@
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M9_"PN/\ 7M^'\JCJ2X_U[?A_*HZ*'\*/H@A\*"BBBMB@HHHH **** "BBB@
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MVD?]_I/_ (W7T/\ 9_\ ;_2C[/\ [?Z4>VD'L8GSQ_PHWQ-_S_:1_P!_I/\
MXW1_PHWQ-_S_ &D?]_I/_C=?0_V?_;_2C[/_ +?Z4>VD'L8GSC=?!;Q':0K)
M)>Z45:2.,;99.KN%'\'3+"I_^%&^)O\ G^TC_O\ 2?\ QNO==<@QI\7S?\OE
MKV_Z;QUI?9_]O]*/;2#V,3YX_P"%&^)O^?[2/^_TG_QNC_A1OB;_ )_M(_[_
M $G_ ,;KZ'^S_P"W^E'V?_;_ $H]M(/8Q/GC_A1OB;_G^TC_ +_2?_&Z/^%&
M^)O^?[2/^_TG_P ;KZ'^S_[?Z4?9_P#;_2CVT@]C$^>/^%&^)O\ G^TC_O\
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MP+!)/_"3)_X!_P#VRO9ZYWO6])R5[,PJJ+M='G/_  HL?]#,G_@'_P#;*/\
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M_P!LH_X46/\ H9D_\ __ +97HU%'-4_F#DAV/.?^%%C_ *&9/_ /_P"V4?\
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MBQ_T,R?^ ?\ ]LKT:BCFJ?S!R0['G/\ PHL?]#,G_@'_ /;*/^%%C_H9D_\
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M%3(TW&?E"Y)X(Y]ZFTS5['6+=IK&<2*C%'4@JR,.H93R#]:8%VBBB@ HHHH
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M^G!K:YC8ZNBN-?5;_4]=\*W=J8XK2[ADE:)V8G[HW9QP< \>^:ATS7+R+2=
MM=,L[99-0:Y4"5W*Q[&)SG))'7C^5%QV.W  Z #Z4I (P1D5Q@\:7-OIEY]M
MM;=;^VOEL,B0K"S-T<D\JN,D_3\GP^-!;)J*7\EC=36EL+E'T^7<DBD[=O).
MUMV!WZBBZ"QV%(  , 8%<Y'K&LV.H6$.LV]D(K]S'&;5FS"^W<%;=PW0C(Q5
M&P\3ZS-86>KW5I9IIL]P('"%O,3+[!)D\;=V..OO1<1V1 (P1D45QUKJ5Y86
MVM26MNMQ(VL/'F64)'"I5/G8G^$>@IL?C&[@M=8\]+&^GL8HY4?3W+1L')'S
M<DC;C)]J+A8[.D  Z "N2&L:O>Z'J;13:7,8[8R17=G*2@X.5*YW*P R#TJ"
MQU*2RM]!N=26.1ETN><RHS9"*L1Z$X)(ZD]QQ1<9VN ,\=:0@$$$#!KG]-U/
M7KB:RGN=/MC87J;U\AV+VX(W+OSP<]..A]:Z&F(*, D''2N).NSZ=)J)LK.)
MII=;6SP\C88L@^8\G'..G'M4>IZ_>_V;XATW5K.VDGLK=)=T#NL<JMVZ[@1]
M:5QV.ZHKSZ]N[]+_ ,5FX\F6TAT^)A#O<<%6*@8/'?./:M6]US4K81Q6HTNS
M@2VCD$VH3D"0D?=4 @\8ZDT7"QUE%<7:ZLVLZWX2U#88OM-M=,T8;(! 4?C7
M:47$%%%%, HHHH **** "N:\?_\ (D:C_P!L_P#T8M=+7->/_P#D2-1_[9_^
MC%K.K_#EZ&=7^'+T#P!_R)&G?]M/_1C5G>*M(LK?7M%U-(R;RYU:!'D9B<*%
M;"@=AQGBM'P!_P B1IW_ &T_]&-6MJ6DP:H]DT[R*;.Y6YCV$#+*#@'(/'-*
MG_#CZ(*7P1]!EY%$UU++9?8O[9%OMC:;DA,]P.=N?UKF?#J6N?$5AKZP-<"Z
M22\:1AY#[QE-H.,=!P><UT&J>'H=1OX=0BNKFROH4,:SV[ %EZ[6!!##/.*A
MA\)::FFWUG<&>Z^WMNN9IWR[L.AR  ,=L#BM#4R-3-]9>.=&O=4$+6!EDM;(
MVV08WD&!Y@/7(';@?SO_ !"+#P+J>TX.U 3[>8N?TS4]IX5B@OK6[N]1OK][
M0$6RW3J5CXQG@#+>YI\&BO<)K4&I/--:7TQV122[MJ;0/E_NC.<#M@4@*'B=
M$CU3PMY( 9;\(F.R%#G\,8K/\$I')H?B1I\%WU"X$N?3:.OYFMRQ\*06E_;7
M<]_?7S6BE+5;EP5B!&,@ #)QQDU'=^#K6>YO)+>^OK*.].;J&WD 24]SR"03
MWQUHL!S/A'=)JWADS<[-'E,>>Q\S''_ <5K:!\GQ)\4I'Q$4@9@.F[8/\36S
M>>&+*XBL!;23V,M@NRVFMV 9%P!M.00P.!UJ;1M!M=%6X:)Y9KBY??/<3-N>
M1O?M@>@HL!J44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M-?BS_P P?_MM_P"R5[97B?Q9_P"8/_VV_P#9*]LK@?\ %E\B<-_%G\@HHHJC
MN"BBB@"K/_K/PJ.I)_\ 6?A4=,04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %9]WKND6$OE7FJV-O(/X)KA$/Y$UB_$/Q!-X=\)3W-LQ2ZF<00N/
MX6;))_ !OQQ7SC)(\LC22,SNY+,S'))/4FNBE1YU=LYZM;D=DCZA_P"$K\.?
M]!_2O_ R/_&C_A*_#G_0?TK_ ,#(_P#&OERBMOJJ[F/UI]CZC_X2OPY_T']*
M_P# R/\ QH_X2OPY_P!!_2O_  ,C_P :^7**/JJ[A]:?8^H_^$K\.?\ 0?TK
M_P #(_\ &C_A*_#G_0?TK_P,C_QKY<HH^JKN'UI]CWCQDWA_7UMIK;Q#I*W,
M3!#NO(\%">>_;K^==)9>(/"]A90VD&O:4L<2!%'VR/M^-?,=%'U5=Q?67V/J
M/_A*_#G_ $']*_\  R/_ !H_X2OPY_T']*_\#(_\:^7**/JJ[C^M/L?4?_"5
M^'/^@_I7_@9'_C1_PE?AS_H/Z5_X&1_XU\N44?55W#ZT^Q]1_P#"5^'/^@_I
M7_@9'_C1_P )7X<_Z#^E?^!D?^-?+E%'U5=P^M/L?6EM=VU[")K6XBGB/1XG
M##\Q4U?-?@7Q'=^'O$EJ89&-M<2K%<0Y.UU)QG'J,Y'_ ->OI2N:K3]F['32
MJ>T5PHHHK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )
M[?\ B_"IZ@M_XOPJ>D,*YWO715SO>MJ74QJ]#C;KP/-<0ZG;)J,$4-].T[2_
M9-TXR=VPONY4'VSVXK:BT,QW>M3FYR=3" @1X\O;'L]>?7M6Q16UC$YV#PS+
M:1Z (+Y=^E*T;%H<B9& #<;OE.!QUHT[PM]@_L7_ $SS/[,,Y_U6/,\S/OQC
M/OGVKHJ*+ <O<>#5G&H-]N*RW-\E]$_E ^4ZC@$$_,.OIUJ;_A&9;N#4(]3O
M(Y!=P^2L=M!Y21#KN R26S@Y)[5T5%%@,"/0;^XO=/GU74TN5L&+Q+%;^69'
MQ@,YW')Y/  _I6+X9T+4;SP]IT-Y>[+&.X,YM3;D2,5D)568G[N0&Z9KN:*+
M <GJ7@O[?!(HO5#-J1U!5D@WQD[0-C+GYAQUXZU+'X6O5GO;C^V/)FN8$B3[
M-;B-8-C9&T;C\O)R#UR>173T46 YFS\)E+Z]O;J>W\^ZM6M6%G;>2A!/+D;C
MN;WI\'A=VM[&&_NTN([6SFLRJ0E/,C<(HS\QP0$_'/:NCHHL!@:?HFIVLEC'
M<:R9;2R&V..*'RVE&,#S#N(; ] ,XS6EI?VW[%_I[;I_,DYVA?DWG;P"1]W%
M7:*8'.-X5W7$DOVW[^JIJ./*Z;0!LZ^W7]*;JGA/^TKG6)OMOE_VC;);X\K/
ME[3UZ\_3BNEHI6 YJ^\+2W=SJ;QWZQQ:C:+;2HT&XJ5! 8'</4\8_&HI/",Z
MZO+?V][;!Y8(X2T]IYCQ;%V[HSN&TGKWY]:ZJBBP'.:7X5_LTZ(?MOF?V7%-
M&/W6/,$F.>O&,>^?:NCHHI@%%%% !1110 4444 %<UX__P"1(U'_ +9_^C%K
MI:YKQ_\ \B1J/_;/_P!&+6=7^'+T,ZO\.7H'@#_D2-._[:?^C&KI:YKP!_R)
M&G?]M/\ T8U=+12_AQ] I?PX^@4445H:!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'FOQ9_Y@_P#VV_\ 9*]LKQ/X
ML_\ ,'_[;?\ LE>V5P/^++Y$X;^+/Y!1115'<%%%% %6?_6?A7-^*-5O+,6&
MG:8434-2G\F*5UW+$ -S.1WP!TKI)_\ 6?A7/>(]&O-0FTV_TV6!+[3YC)&)
M\[)%92K*2.1D'KS30F0Q:)K&GWMK<6FN7-XAD O(;]@59#U*;5^5AV'0]ZQ+
M;QG=65_K5Q=65Y=:?'J7V59T*B.$#:F!DY;+$YQ6Y%9>(+[5H+Z_EM[.WMD;
MRK.VG=Q+(1C,C;5R!V&#ZU1C\)WH\*:/I$D\#207D=Q>ODXD <R-MXY))'7%
M,DMZAXN^S7-['9:3=ZA%8?\ 'W-"458B!DJ-Q!8@<D#UJ2^\60P3Z?!8V-SJ
M$]_;FYBC@V@A/EP6+$  [NI]/I6%=>"KTW6IK#9Z3+]MNGN$O;C<TD(8@E3'
MMPQ'./F K:@T"[L]:O+^V:V 738[*Q0Y 4KD_, , 9V],\4:!J4(OB';RQ6%
MP=(ODM+NY6T\]MF$F)(VXSE@,'D<?CQ5R]\9);S7IMM*O+RSL'*7EW%L"1$<
ML "<MM'7 XJNO@^46?A:R,D/V?2I!/<C)S)*%X*\<_.23G%,D\/:[_95[H4,
MEFEA=W$KM>;V,HAD<LR%-N"WS$;MW3M1H&I-/XCO3XVBL([=QI45F;J>?*;6
M4CY7ZY"@AACJ3STYJAX5\77CVFDPZI8WI.I2/Y5Y)M"L3N=5"YW8"X&<8_"I
M=3\,:S*?$,5@UDL6HVT-O;R22L#"B#:4("'@@N<Y[CCTV'T!VU7090T8M-*A
MD 7)W,Y147C&, ;N_<4:!J57\:PAWN$TZZ?28YQ!)J0*B-6W;2=I.XJ&."0*
MGG\4@:]<:3::;=WDMLT7VB2+&R(.,Y))[#G Y//I7/Z=X#N+<6EE/9:0UM!,
M7ENRI>6XCW$A=A7"GU.3[5L:9X<U"ST[Q$)+J);_ %2>:6*:(DB(,N(^< Y6
MC0-1\'B]GO;1+C1;^UL[R;R+>ZF"@,_.,IG<N<'J*KS^.XX?MLPTB^DL+&Y:
MWN;Q=FQ<-M+ 9RPSUP.*RH/"UWI4^G:M<V6EV\.E02RSF*5Y99G$9 <LR XS
MSC/'J>S=#T/7=2\#Z?I%U]CCT^Z"SW%P)&\YHW;S"FW;@,2<;LGCMFGH%V=:
MWB2RBO=3@N-T,>GP1W$DS?=9&!.1WXVU>TV\;4--M[QK>2W,R!Q%(1N4'IG'
M?&*X>[LH/$WQ",5C=1RZ;!;1C4U3E69)&*1$_7DCT6O0N@P*0T%%%%(84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G/QH_
MY$ZT_P"P@G_HN2O"Z]T^-'_(G6G_ &$$_P#1<E>%UZ.'^ \[$?&%%%%=!SA1
M174>!?"B>*]9E@N)98[2VA,\WDKND8 @;5&#R<^E*345=C2;=D<O17IB_#[1
M;GQWIND03:E%:W%JUQ<07$>RX@PIP,E=I!.!QGH>>AJ1OA_H4GB!;81Z[965
MM92WMX;Q4#LJX $9 QW.<YZ5G[6)I[*1Y?173^,O#MCHLFFWFE3SRZ=J5L+B
M 7 'F)ZJV.#U_P XR>ITOX;:1=Z5IUI<ZA<)X@U.R:]ME7'DJH *JW&<D']#
MZ#+=2*5Q*G)NQY?17J$'PUTJ33$L&O;L^)9=,_M)$  A"YP$/&<]NO;/M4>E
M?#S1[S1]/MY[V\77-2L7O;;8%\E5&"%8=22#_/\ %>UB/V4CS.BBBM3(****
M +>E?\ABQ_Z^(_\ T(5]7U\H:5_R&+'_ *^(_P#T(5]7UQ8K=';A=F%%%%<9
MV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $]O_%^%3U!;
M_P 7X5/2&%9VR/\ YY)^5:-9]7$B0FR/_GDGY4;(_P#GDGY4M%60)LC_ .>2
M?E1LC_YY)^5+10 FR/\ YY)^5&R/_GDGY4M% ";(_P#GDGY4;(_^>2?E2T4
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MDU?^SR>WYT?9Y/;\Z+H+,KB&(>9B)/WGW_E'S=N?6F0V=M;QM'#;PQHWWE1
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M3[+YG_+;S-V[;_LC&-OZU]&UG&2E.37D/"S4ZDY1VT"BBBM3O"BBB@ HHHH
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M?2+O3Y-1BMK>&QM?*MFC!:YW*"Q!//'M185SU2BHK;_CUA_W!_*I:104444
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M?B/QI?:_J5E=QQI8I8 "UB@/^J.0<Y]>!V X'%;[_$K3;Z2&[U?PI:7>HPJ
MLXEVAB/4%3_6B-.46FU??3MJ$JD9)J]MM>]D=3K<,;?$?P=?,JK=W,)\]0,=
M%R"?^^B/PKS3QY_R/6L?]?!_D*LS>.KR[\;6WB2[MTD-N<1VR.54* 1@$Y]2
M<^M:EYX]\.W]W+=77@BWEGE.YW:\.6/_ 'Q3A"=-IVOI^H3G"HFKVU_0TO$-
M]=:/\*?#D6F.]O%<@-/+"2I+8W8R/4Y_*C0KRZUGX1^((]3=[A+4DP2S$L00
M V 3Z'_T*L#0_'HL=#_L35]*AU73E;=&DC[6C[X!P<C.<=^>M&O>//[0T/\
ML32-+BTK3BVZ1(WW-)WP3@<9P3]!S1[.7PVZWO\ /[P]I'XK]+6^7W'5>,WN
M;'P[X/TC2[O[!:W:JLDJ.47.$P6([?,S'UZU3\5V/B.+P*IO-=T_4=/M94"O
M#EY"V<#Y_49^M8ND^/XH]#@T;7M&AU:T@/[EG?:\8'0=#T' Z<<5'X@\>1ZI
MH/\ 8FFZ+;:98%P[*C;F)!SV 'UZTHTYII6V>^G_  X2J0:;ONMM?^&._P##
M6M:7KOAFW\1:O$9=1T%'#R$<M\O!]R1CZ-FO'-8U6YUS5KC4;M@9IWW$#HH[
M >P'%:VC>*_[(\+ZMHOV+S?[0&/.\W;Y?&.F#G\Q7-UK2I<DI/[O3_AS*K4Y
MHQ7W^O\ PP4445T& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M1> _^1ZT?_KX'\C7TK7S5X#_ .1ZT?\ Z^!_(U]*UY6-^->AZN"^!^H4445P
MG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% #9)$AB>5SA$4LQ] *9;7$5W:PW,#;X9D$
MB-@C*D9!P?:H]2_Y!=W_ -<7_P#0357PY_R+&D_]>4/_ * * -.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH BGN(K:,23-M4ND8."?F9@JCCU)
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MV>6_\('XI_Z EU^0_P :/^$#\4_] 2Z_(?XU[IKVN7VA>'+6]E@@:\>6"*9
M3L5G8!L=^,G%4M?\6W>D7VIP06<4_P!CM;>=%+$%VDEV%<]N.E'UV?9#^I0[
ML\8_X0/Q3_T!+K\A_C1_P@?BG_H"77Y#_&O8I/%FK:==7VG:A96<NH(L#6HM
MI&5)#-)Y:JVX9&&ZGN.PK)U7Q)JOAOQ-/=ZQ';2.NF*L2VTCK$[-.%!8-RN,
M\GGC\J/KD^R%]3AW9YG_ ,('XI_Z EU^0_QH_P"$#\4_] 2Z_(?XUZ@_Q%NH
M;*^1$L+Z\A6&2)[;S%B=7E6,J=W(8;@>X.1]*UAKOB&?4)M&M8-+;5+. 37;
MLS^3\Q.Q$[Y(&23P/>CZY/LA_4X=V>,_\('XI_Z EU^0_P :/^$#\4_] 2Z_
M(?XU['-XGUZ2#4+RUTNUCM]+0&[AGF)D>01K(Z(5X&T,!DY!-7;;Q.]W::W<
MQ0H([&WCGASG+AH!+\WYXXH^NS[(/J<.[/#_ /A _%/_ $!+K\A_C1_P@?BG
M_H"77Y#_ !KU:+QEK]W:ZE>6MCIWV;3;>&YF$KN&D#0+*RKC@$9."?;CO6EX
M>OM2O/&6OB6:-K!%MS%&2VY-T888'0<$Y]Z/KL^R#ZG#NSQ?_A _%/\ T!+K
M\A_C1_P@?BG_ * EU^0_QKT7QA>ZJEWXRC%T%M8=-MVC578%"6."O. 3SG\*
MU[[QIJ>@R7T&L65F9TMHKBW^SR,%.^3R]C$CL>20.G:CZY/LA?4X=V>1_P#"
M!^*?^@)=?D/\:/\ A _%/_0$NOR'^->S>&O&#ZMK+Z5</9W$GD&=)[(.(P P
M!1@_.[D'/<>E5=1\0:GHGB+7[F417%I!!:+#;AF!+R.ZIC/ R3\Q] /2CZ[/
MLA_4X=V>1_\ "!^*?^@)=?D/\:/^$#\4_P#0$NOR'^->L>)-<\0Z;I&HV5_]
MBBNIM/GGM;JS9U"F,#>N#R& ;(8'\*BU#QCJNCVEI;22:1'<K9)/FXE9FN20
M<*B*=PX'WFX)/'2CZY/LA?4X=V>6?\('XI_Z EU^0_QH_P"$#\4_] 2Z_(?X
MU[+X3U)]5\2ZS=G>L<]EI\Z1%LA-\;L0*KW_ (LUN"77+BWLK%[#1YPDN]W$
MDJ;58[<< @,>3^5'UV?9#^IP[L\B_P"$#\4_] 2Z_(?XT?\ "!^*?^@)=?D/
M\:]LG\4W,6F^*;D6\1;1W=8@<XDQ&K_-^)[5G:AXRUBV&J7,%A9M9Z7'!-.7
M=@\JR1JQ5,< C)Y/MQ1]=GV0?4X=V>2?\('XI_Z EU^0_P :/^$#\4_] 2Z_
M(?XUZ1XJ\0ZU]@O=-NX+>.Z06=W ;61AE7G"[&)[Y&,CCGI6MJ?C6^\-_:K;
M6K:T>\6%)[=K5V$;AI/+PV[D;2021G(/X4?7)]D+ZG#NSR'_ (0/Q3_T!+K\
MA_C1_P ('XI_Z EU^0_QKTY_B+=QQS6\2:??7H:$Q26_F+"RO($*G=R&!(]0
M0?PKO--_M#["G]J?9?M>3O\ LN[R^O&-W/2CZ[/LAK!0?5GA?A;PSK6C>,=%
MN-1TZ:VA:Z"!W P6*DX_('\J]_KG?%7_ !]>'/\ L+Q_^BI:Z*L*U1U+29O1
MIJG>*"BBBN<Z HHHH @ED=7P#@4SSI/[WZ43_P"L_"HZ8B3SI/[WZ4>=)_>_
M2HZ* )/.D_O?I1YTG][]*CHH D\Z3^]^E'G2?WOTJ.B@"3SI/[WZ4>=)_>_2
MHZ* )/.D_O?I1YTG][]*CHH D\Z3^]^E'G2?WOTJ.B@"3SI/[WZ4>=)_>_2H
MZ* )/.D_O?I1YTG][]*CHH D\Z3^]^E'G2?WOTJ.B@"3SI/[WZ4>=)_>_2HZ
M* )/.D_O?I1YTG][]*C)P,GI6;+=2.QVL57L!6D*;GL9U*J@M36\Z3^]^E'G
M2?WOTK%\Z7_GH_\ WT:/.E_YZ/\ ]]&M?J[[F'UI=C:\Z3^]^E'G2?WOTK%\
MZ7_GH_\ WT:/.E_YZ/\ ]]&CZN^X?6EV-KSI/[WZ4>=)_>_2L7SI?^>C_P#?
M1H\Z7_GH_P#WT:/J[[A]:783Q9<:E'X=NI=/EQ*BY<; VY.C#D>AS^%4_ MU
MJ4WAN&2\FS& ([=-@&V-1M';G./TJXTCNI5G8J1@@GJ*2-FBC6.-BB( JJIP
M !T%'U=]P^M+L;GG2?WOTH\Z3^]^E8OG2_\ /1_^^C1YTO\ ST?_ +Z-'U=]
MP^M+L;7G2?WOTH\Z3^]^E8OG2_\ /1_^^C1YTO\ ST?_ +Z-'U=]P^M+L;7G
M2?WOTH\Z3^]^E8OG2_\ /1_^^C1YTO\ ST?_ +Z-'U=]P^M+L;7G2?WOTH\Z
M3^]^E9$=S*C EBP[@FM)6#J&'0C-93IN&YM3JJ>Q+YTG][]*/.D_O?I4$T@B
MC+_D*S6N)6.?,8?0XIPI.>HJE90T9L^=)_>_2CSI/[WZ5B^=+_ST?_OHT>=+
M_P ]'_[Z-:?5WW,OK2[&UYTG][]*/.D_O?I6+YTO_/1_^^C1YTO_ #T?_OHT
M?5WW#ZTNQM>=)_>_2CSI/[WZ5B^=+_ST?_OHT>=+_P ]'_[Z-'U=]P^M+L6-
M<E<V$66_Y?+7M_TWCK2\Z3^]^E>=^,GUE4MYK&XF,)=5>-3G#A@4;\\?D*Z*
MQ-U#90QW%S)+,%&]V;JW>I5!MV*>(25['1>=)_>_2CSI/[WZ5B^=+_ST?_OH
MT>=+_P ]'_[Z-5]7?<GZTNQM>=)_>_2CSI/[WZ5B^=+_ ,]'_P"^C1YTO_/1
M_P#OHT?5WW#ZTNQM>=)_>_2CSI/[WZ5B^=+_ ,]'_P"^C1YTO_/1_P#OHT?5
MWW#ZTNQM>=)_>_2CSI/[WZ5F6]TP<*Y)4\9/:K]8S@X.S-Z=135T2>=)_>_2
MCSI/[WZ53NIS$H"_>/Z52\Z4_P#+1OSJ#0V?.D_O?I1YTG][]*QO.D_YZ/\
M]]&CSI/^>C_]]&D,V?.D_O?I1YTG][]*QO.D_P">C_\ ?1H\Z3_GH_\ WT:
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MGP?ZY2P4!=I/S$L!M.#STHU#0-1\%VVH/J8&I7]M;ZG@W<$+1[78 +D%D)'
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M'XG\OR"BBBH+"BBB@"K/_K/PK \3:Q<:1:6@LHXI+R\NX[6$39V MG)..<
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MT34+VT\71V\!,MS-!+:AB )3''$< _[R$<U;TDWVJ^+7UB;3;FPMH; 6J+=
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M@F6XMXIT#!9$#@,,'!&>13NQ61Y)IOA_Q#=^'_$EI<:?*\,EH!9M>V\27+R
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M=#53[#)V9:YSI*U%6?L4G]Y/S-'V*3^\GYF@"M15G[%)_>3\S1]BD_O)^9H
MK459^Q2?WD_,T?8I/[R?F: *U%6?L4G]Y/S-'V*3^\GYF@"M15G[%)_>3\S1
M]BD_O)^9H K459^Q2?WD_,T?8I/[R?F: *U%6?L4G]Y/S-'V*3^\GYF@!+/_
M %_X&M"HH(!"IYRQZFI:8@HHHH GM_XOPJ>H+?\ B_"IZ0SG?'G_ "(NL?\
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M_ L!CBM[HJA2X::$Y'2(MR%'ID]:X74[G2?/\8F]OKI-8AU&1M,5)I 5?=_
M <9S@'T&*]U "J H  Z 5DZ-X>M]&N=3GBE>5K^[:[<.!\C'L/:G<+'C'B&]
MU=]<NCJMT+:_BM+5K)Y9YD:-BB[C$L8(9BV<@^_IQV'A;3/[6^(FMW6IRS/<
M:>+.2-1(RH)6B^8[>/0]1WKTTJK$$J"1R"1TI:+ARGE_Q48?VII:RW4'D^5(
M3:WKRQP.?[P="!O'8'^M8/\ :5K?VWAD>)7O[;P^]A*<2S.0\RNP4LRX)^4
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M"5K_ -_U_P :Q+NYM=0\;:':6ES'.((KBZE\N0-M&T1KG'J7/Y5M?\(YH?\
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M110 444R6:*WB,LTB1QCJSL !^)H ?12*P90RD%2,@CH:6@ HHI"0.I SQ0
MM%1QSQ3%Q%*C[&*MM8':1V/H:DH **** "BBB@ HHIAFB6983*@E895"PW$>
MH% #Z* 0>AS10!SOBK_CZ\.?]A>/_P!%2UT5<[XJ_P"/KPY_V%X__14M=%5R
M^%?/\R(_$_E^04445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW*-V1[YK@=,TZPOM(\'V31HT,UW<?:$0XW,%8X;'L%_"ERKL'-)]3US[7/\
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M:5[J?<?G208.>,YSP/446CV%>7<]H^US_P!_]!5-->$FK3::LC&XAB69_D&
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M2> O&,^]$WPYGO?#VI:?>:RK75\T9,T=FJ1QJA! 6-2.N.3G_P"N:![Q6O\
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M//I-K)Y5SJ"N L; X;"=6 /4CWHN@LS?M=*TZQADAM+"V@CE_P!8D42J'^H
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MU3\?YUEUJ6G_ !ZI^/\ .L:WPF^'^(FHHHKF.T**** ,C6/^0IX?_P"O]_\
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MELH5<M&RX(8^HR.E8T'PTOO[)U"TGN-(22:U%M"]K8B,YW EW;&XD@= <4]
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M1110 4444 %%%% $%U96M]%Y5W;0W$><[)8PXS]#4D,,5O"L,$211*,*B*%
M^@%/HH **** "BBB@!KHLB,CJ&1@0RL,@CT--@@AMH4A@B2*)!A4C4*JCV J
M2B@!@AB$YG$2><5"&3:-Q4<XSZ<T^BB@ HHHH **** &QQ1Q+MC147);"C R
M3DG\22:=110 4SR8O.\[RT\W;LW[1NVYSC/I3Z* "BBB@ J&>TM[KR_M%O%-
MY;!T\Q VUAT(ST/O4U% #&BC:5)6C4R("%8CE0>N#VS@4^BB@ HHHH ****
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M&?Q7:78U:6?;HK.+MG9%<K(%W%<XQW(Z$\U#H5S?V6HZ0VJ37Q%R3&ES'?\
MVFWNV*D@E2<Q^HP,5V<FBZ;+/:3O90F6S&VW8+@QCI@>WM5>Q\+Z'IM[]LL]
M,MX;@9PZKRN>N/3\*+!S(K>*[B:.#3;:*ZDM$N[Z."6>-MK*A#' /8DJ!GWK
M#U&YATJ6[TR+Q%J4\LUS!'':1MOFB+9.P2N>-V#R3P!7:7UA::E:/:WMO'/
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ME=VMUJ=ILS:ER,Y8*1D<$@$D@'(QS6Q<^+] L]433+K5;>*];'[IB>">@)Z
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M^//^1%UC_KW/\Q715;^!>O\ D0OC?I_F%%<YH=MXGB\1ZQ+JUW!+I4CYL8U
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MY(/!]*-1NR1E^(#XAL+VS:VUY$AOKY;9(S9(?*5@QZY^;&W':H-;U'5=(O\
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M*PU2RNY%7<R6]PDA ]2 >E>;^,Y8]3U7P<NE:/)J>D)&TZ6T$6(W7 "J<C:
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M;A9EMKFT6-8VB=F"G(7U4$9]O:G85ST>RUO2M1N9+:RU*SN9X_OQPS*[+VY
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MJWC&?Q@^D7]M8:?IS06\$L.VXN6Y8X3KCD@>IQ[X]"HHN%CQW1M5NVUM]?\
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M2AT"VT:QN5\.VEG9W4VWYI$)0XZ;L'. "<#/%<UJ/C?5-!$W]J6MI(SZ<MY
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M5C0W+LBNBQMN0*%4+P>>0<T2^"K:[N+RYO\ 4]0NY[NR:QD9VC4",D'Y0J
M@C/XG.:;X=U'5=3\2:VUY%=06EK+]GAA9HC&I"HW\.6+'=G.<8;'7I@ZOXRU
MNUN=;2.VE2*QU&VAB=%C8LC%,I@DDE@20>P(Y!HU%H='<>"[.\2X:ZOKZ2YG
M>"0W(=$=)(@0CKM4 'D]L4J^#K5[T7UW?WMW>">&;SI"B_ZK.U=JJ %Y.<#)
M]:KGQQ'#!=B\TB^M[Z"6*%;/Y'>5I<[-I#;3G:W?C!I)?',5K:79O-*O8+ZU
M>$/9 H[L)6VH5*L5.3QU[4:AH7[[PK:7MS?7/VFYAN+N2WE\R,K^[>$Y0J"I
M'7KG.:M:KHD6L:+_ &;=W,Y_U;>>NT2;T(8-]W;G(!Z8]JQ)?'$L7G+_ ,([
MJ+2VD0FOHU:+-NIS@?>^8D#=A>Q%;\>KVUQH2ZO:K+<6[P>?&L499W&,@!>N
M>V*-1Z&1/X*MIQ>1MJ6H+!?E6O84:,+<,  6)"97<!\P4@'VK9U32X-6TUK"
M8ND+,C?NB 1L8,,9![J*YN?Q^FGBZ74]%OK.:"V%TL3-&YDCWJAQM8X.6'!J
MPWC"XWPVR>'[]M2=&F:S\R)6CB!P'8EL#)S@9SP:-0T+FH>&(KW49[^WU"]L
M+BY@%O<-;,G[Q!G'WE.",G!&#55O!%E&7%C?W]BDMJEI.D+H1+&HVC.Y3AL<
M;A@\UKZ;K-KJNC1ZI;>8870L5V$NI7(9=HY+ @C SR.,UAKXQG>ZCL[G1;[3
MI+J"22UDG,9W%4+?,H8E3@="*-0T)/\ A!=/BBN+>RN[VRL[J)(;FV@==LJJ
MFP<LI925&"01GZ\U:G\(Z9/KVF:OB5)=.B$4,2,!&5 (7(QD[=QQSWKF]"\;
M:AMBEU>"0V4>C0WDUR/+&YVW98 '/)&T #J#V(-:DWCR&QBN/[4TJ\L)TMFN
MH8961C.B_>P58@,.X.#1J+0M77@RTN3>1+?7T-C?3>?=6<3($D?().=N]<D
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M.4?\(W8_\]]4_P#!K=?_ !RC4+R[?C_P#7HK(_X1NQ_Y[ZI_X-;K_P".4?\
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M*R/^$;L?^>^J?^#6Z_\ CE'_  C=C_SWU3_P:W7_ ,<HU"\NWX_\ UZ*R/\
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MB@ HHHH **** .=\>?\ (BZQ_P!>Y_F*Z*N=\>?\B+K'_7N?YBNBJW\"]?\
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MI+7L=S)(HV LN48$$Y!)P#ZBNN_X0^#_ *#.O?\ @SE_QH_X0^#_ *#.O?\
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M.O?^#.7_ !H_X0^#_H,Z]_X,Y?\ &BT>_P" 7EV_$Z*BN=_X0^#_ *#.O?\
M@SE_QH_X0^#_ *#.O?\ @SE_QHM'O^ 7EV_$Z*BN=_X0^#_H,Z]_X,Y?\:/^
M$/@_Z#.O?^#.7_&BT>_X!>7;\0\5?\?7AS_L+Q_^BI:Z*N?A\(6<5Y;7,E_J
MMRUM()8TN;UY4# $9P3C."?SKH*)-62013NVPHHHJ"PHHHH ;(@DC9&) 8$'
M:2#^!'2LCPU$;+1X+-H98R'G*AD;A1*V,D^H((SU'-:TSO'#(\<9E=5)6,$
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MGOK>/<L/*J[84[=W/.'4].F?0U2T[QQ;R*?[5@^P,TSI'RSC:K%0S':,$LK
M#GI0&ADV9UM8;O\ M1]4\O[8H=;..4.O$O"9ZKGRON_)CKU:K5LFIVOB+3HX
M1J;6GVBY$R2"3:,R.0Y;E6&"O#8'3:<Y%:[>,+%&?S+:]C541OG@*MN8L NT
M\YPN?_KUHWVLVFG-;B?S<3\AEC)"+E06;^Z 67D^M(#EIGU7[9J(N#JP3SG^
MT>2LFT0^<OE>3M'WO*W;MG/7/.*:]QJ=O<1W!777:*ZC:=/+=E-OC"X4##/S
ME@N>0V>@K:'BJ*V\/Q:OJEM+;1REB$C5I"J#)#-P,?*,_H,U#/XWT]<+;P74
MS?:4M_\ 5E5.79"P)Z@,C#CV]:8'-V%EK]W82R7TNLK)Y:_NV>0 E;.,XQWS
M(6!]2"*UKM;FT:Z>\N-7%I-=;I/)>0N!ON !'CD#"PY"]N3P2:N0>/-(:VCD
MG\^.1XD?"PL59CY?RHV!N(,J>G7M@X+KQ;X;OK&8W2-<V21^;(9;4M'D*'VG
M(QO"D''7\J T*6IW>J_V1X9DL_MLDCI%)-(@D8G C)WA!@D@M]X[>#U.*Y^X
MTW6-*@6'25U6%I%B>1@LTGSE&QT_V\Y!X^[NXKK3XXTZ&:Y5[>YC@MX8V/[E
MMZDF4,K)CY0!"3GOD8[96Z\<:?''(UI%/<;)6B+;"J959"?FQT!B8''/0XP1
MD#0CEAU:'P]=S/-?/=272><(RQ9(1(!)Y2CD?)N(V\^G.*P)+77K>'4KK2O[
M65[B0C;<JV3&(X,OM ^_@2#(^8D8ZBNN@\0O?B)=/LGGE+)YA?,<80XWLKD8
M;:3C%6M4UVRTB>&*Z,H:6*68%(RP5(P"Q..GW@/<G%(#B8;3Q#<SPB:ZUA8]
ML:9C,L8*E)R2<\Y^6$9/S=,\FK-L-6N2YU$:MYJS)).JK((PHGC,7E@<']WN
M+!>X^;D"M_\ X3"Q+H%M[MT9,@I$6);S#'LP.<Y!_"I;7Q5IUS*D!9EG*1LP
M"DKE]G /?'F)^?L<,-#D[JV\166E6=K8R7ZQ QL6=97=7,0PHV\[ P/!^4'
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MFTI9-1&OK=M%";T)&ZJL9\O/E@#=O^]G9R/GSSMKJ/[%OO\ 7?VS<"[?Y9)
MOR%,8PL><*1U!Y.2<Y'%'_"/N6,7]JWHL0=R0+(0RM_UT^\0#R!GKUR, '/+
M^4/8TO\ GY^#_KT_0;X;-TEO(M]'.)Y2LA:1",@0Q#D]-V?U#>AKE#'!/=W=
MZVAWZQ,[PBV-A)@85Q')@K\S,2^6&<!ER>,UW>GV4UKO>ZO'NIWP"Y&U0HZ
M+G /4D]R?3 %VJ3,)Q2=D[GGGEA[^9[O2;QA:-$DZK92,+E0P,DA.W$AWD$
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MK2F15!5?+RKKM!"@X'F-@DD].<"JMGX)TZRN;>YCFF,T4ID9]D2^:<@@$*@
MP5!^7:3SDG)KI:*=PL8ESX8LKK4KJ^>28/<J ZKL ! 4;@=N<X4#!)'MDYJ&
M3P;ILLT3R/.RIYFY"5Q(&=GY.W(PSMC:1[YKH:*+A8YVX\(Q75O)#<:MJ4OF
MQ^7*TK1OY@!R,@H5X!(P !R3C/-7;[0+:_2TC:6>.*W7RRB,,2Q_*2CY!)!V
M+TP>.O)K5HI7"Q@ZMX2L-9TJUTZXEG6&W4JK)L+$%2ISN4@'!Z@ CL14;>#K
M!K>.(7%VIC<.KAEW ^:TO]W'5B.G3WYKHJ*=PL<P_@32WLK>U,UUBW4B)]R$
M@_N^>5P2/*7J,<G(.:@O_ MO)I=Y;65W<(TT)58Y''E^:4">:<+G=M&../:N
MNHHN%D<G<_#_ $V\9I+B\OI9GV^9*[1EG(\SDY3 .)6&0!C"XP1DR/X%TV1I
MW:ZO3),5S)N3< %=<9V\C$C#G) P!@ 5U%%%V%D9>G:''I;/Y%Y=M&4VI#(X
M*1YZD  <D\\YZG& 2*CN/#T%]#;K?W$UQ+%926;R<#S!)LW.1CALQ@CL,GK6
MQ12'8Q+?PQ:6[VCB>X9K<=3L D._?E@% &#GI@8/TQ"G@[3H_M066X"W%M]G
M(&P%?E5=X(7.["J>20#R!R:Z&BG<5CG9/!NG27$DOFSJ&B5 B[/E95"*X;;N
MR J\9VY&<5:?P^CZ3%8_VA>K)%*THNPR>;N8MN/W=O.]A]WH>*V**5PL9.G^
M';'2Y[62U\Q%M898(H]P*A'9&(Z9X\M0.>F>M0CPO;#S ;V]*;2MLA=2+3D-
MF/Y<\%5QNW8QCIQ6Y10%CG)_!]O<K(LNIZDPE79-F53YJD8<$[<X<!<XQC:-
MNVB?P98W FWW5WEG+PD^6?L^6+%4!0C!+'[P;]*Z.BG<+(S+;0[>STR:PMIK
MF))#N$B28=#@ $''^R.N<]\BFZ?HO]G0R0Q7]RR2(VYGVES*S,S29QC<2W3&
M!@<5JT4AF!:>%(+2"SA_M&^E2U?<OF>4-ZY5MC;4&1N0-GJ3G)()%5T\%Q1V
M"6BZUJ>R.X%RK8@R).3D_NL$Y.[)!.0#FNGHIW%80#  R3CN>]+112&%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>formdrs_006.jpg
<TEXT>
begin 644 formdrs_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) G # 2(  A$! Q$!_\0
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M3)_$^A6TEM'/J]E$]R@DA#SJ-ZGD$<]#5.Z\3+_:.AQZ<;.ZL]2>13/]J52
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M/>DN/#+3)>1B>+RY7ADB#19VF, !6Y^9>.G'4UYK_P )3KO_ $%KG_OH4?\
M"4ZY_P!!:Y_[Z%:+ XA?;1D\TP;_ .7;^]=K'I*>&I(HUFBEM8KQ;A9U\NWV
MQ# (VX!R1@GG.<UIZ3ITM@MRUQ.)Y[B<RNX3:.@  &3T KS$7_BXW%K!]JO/
M,NDWP+N'[Q<9R/PJB?%&NABIU:YR#C&X5F\#6J*W.F:QS3#TFI>SDO\ AOSL
MSTNU\/W5N]E&U[&]I92/)#'Y1#,2&VECGG&X]N:D_L*>&PTN&VNHQ+8L7W21
MDJY*D$X!Z_,3UKR__A*=<_Z"UQ_WT*7_ (2G7/\ H+7/_?0JW@,0W?F7W?UW
M,UFN$2LH2^_T_P D=[/876C36\L3W$UV!.[7"6GFK(9&!VE0<J>!@].*UM,T
MJ1?"ZZ?=L5FGA<3L.2&?)8_7)KRS_A*-=_Z"MS_WT*/^$HUW_H*W/_?0ISP-
M:22YE?YBIYKAH2;496M:VG7?KU/2O^$=NKI774+Y'7[$UI&(8MNS.,MR3R<"
MEM/#7EQW/GFT#RVYMU%O;B, $<L>223]<5YI_P )1KO_ $%;G_OH4J^*-=+J
M#JMSU'\0I/ XBUN=#6:8.]_9O[T>E-X8W:/':M.DMTLZW#RRQ[EE<#&&7/W<
M<8SQ@4ZT\-B":"5Y(04E>5TAA"+DH44+[ $]<GFO/)_$'B"35);:WU"[9C,R
M1QH<D\\ <5+J%]XOTI$>]NKR%'. Q=2,^F1T-3]4K?"ZBU-/[0PVLE2E:.E_
M0[*[T6_MM'6,SBY2QA9;2&&(AG8J45FY/0'M]:L#PY>2VBPW%]&3!:M;6Y2+
M&W<H4LW/)P,<8%>;?\)3KG_06N?^^A1_PE.N?]!:Y_[Z%:?4L1;XE]QC_:>$
MO\$MK;_U\NUCU271&9[AHIP@:Q%G"-G^K'.3UY[?E5"?PDKSMY4EL(I(XT<R
MVX=TV*%^0DX&0.X->=?\)3KF?^0M<_\ ?0H_X2G7/^@M<_\ ?0J8X'$1VFOQ
M*EFN#EO3?WH]1?P_OM+N#SU"W-RDK83I&NW"=?1<9]ZMZ?8RV$M_(\BRI<3F
M=0J$,,@#!YYZ#%>1_P#"4ZY_T%KG_OH4?\)1KO\ T%KG_OH5+RZNU9R7X_UT
M+CG&%BU)0=UZ>?\ F>AZ5HM_/86WVR=8X3,;PP&(A_,+%@K'/0$@],\8IMIH
M^I6VH".TG2(6EFMN)I82RRLY+.R\CD$"O/O^$HUW_H*W/_?0H_X2C7?^@K<_
M]]"M'@J[;]Y:^1BLSPJ2]V5UUNCT27P@JE5MY8"I@6%VN(!(ZD$_.IS@$Y/7
MBK?_  CH%XLJS@1+-"X0)_!$A"K_ -]'->8?\)1KO_05N?\ OH4?\)1KO_05
MN?\ OH4G@L2]YHI9G@UM3?X'J,6@%+6PMWN RV\SSRD+@R,V[WXY;/X55L/#
M3Z84E!MI#:QL(!%;!7D;& 78GD_3%<#!XEUMK2[8ZG<%D5"IW=,L!5FQNO&6
MI6QN+.YO)HMQ7<)%'([<UF\)6BGS321K',,--KDI2;\M=M#TJ>UN[W07M)I4
MCNIH/+DD5<JK$8) S]:KS:(S/<M%<",O9"SA^3/ECG)Z\]1^5>73>(_$-O,\
M,VI7<<J':R,<$'TZ4S_A*==_Z"US_P!]"B.75E\,D$LXPS?O0E=:;KS_ ,V>
MF/X>N(UN+>TO$AM;J-(Y08LNH50AVG..0.XXHN/#LTUY"RW,0@AD1XF,7[Z%
M5Q\BL#]TX[@]37GUAJWBG4YC#97UW,ZC<V' "CU)/ I;C4_%EI/-#/=7R/"G
MF2 D?*OKGIBG]4K*5N>-Q?VAAW'F]E*WX=[?J>@0:3)IDJWMQ-YT=LT\JI#"
M2[&0YSU.2!D<>M.\,:4]C:/<7"NL\Y.U'ZQ19)1/U)/N:\Q'BC7F8*NJW)8G
M  ;DG\J?-XC\0V\SPS:E=QRH<,C$ @^AJI8"M).+DM?4F.:X:,E-0EIZ;O\
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M?AUUM;&$WA!MA,6=5P6DD!&X<\8W&O,?^$HUW_H*W/\ WT*/^$HUW_H*W/\
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M (2C7?\ H*W/_?0H_P"$HUW_ *"MS_WT*/[)J?S+\0_M^C_(_P #VRBO$_\
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MF_N8<F-YKNDOO7G_ ,-Z'%W/E?:YO(&(?,;8,YPN>/TJ*NZ_X0"S_P"@T_\
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MNI3<7!7?FMM?ST7HC@:*[K_A +/_ *#3_P#@/_\ 7H_X0"S_ .@T_P#X#_\
MUZZ_KU#O^#/._LK%_P OXHX6BNZ_X0"S_P"@T_\ X#__ %Z/^$ L_P#H-/\
M^ __ ->CZ]0[_@P_LK%_R_BCC[;_ (\;[_<3_P!#%;UC:G4?"-M;PWMK;S1W
MS2-YTXC*KM SZUKQ>!;1+>XC&L.1(%!/V?IAL^M0_P#"O[(_\QE__ ;_ .O6
M4\51EM*VM]GV.FGE^*AO"]TU\274T8K_ $:^O[ZXA>VDE-Q&LK3&,"2(( 2"
MX^[D'..>E8]O>:.-,GO@EN+C3S-#;PD ^:'/[L\_>VY/-3_\*_LC_P QE_\
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M;^++EW/8K+%-YMLLQL;N*4K)'DG V@[,#/7%<[X5E*V]_ );)C*J9L[SY4G
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M!M_;V-E?">6-%FF@B968#*-N5C]!FM2T\#6D$Q<:N[$QNN/L^.JD9Z^]5_\
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MN8>QQEM*:7S7]7_X!R^OB!?$%^+7R_(\X[/+QMQ[8K.KNO\ A ++_H-/_P"
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M6!872,Y9&:>W6)8MK+Y:@JV\<Y)R*E.M:VZS2%UBDMHO,GM_LV?WGG;3&#W
M7D,.N0?:NPVMZ-^5+A_1ORI6 XQ_$6J0[YP?/$*O+=VJVY#6ZK(%V _Q$J2?
M^ Y'!IUGJOB"\DAMY62U<3&WFD%ON!<([EE![8\L?7-=CA_1ORI-K?W6_*F!
M3TJYEO-(L[F=0LTL*O( ,88CGCM5NEVM_=;\J-K?W3^5,0E%+M;^Z?RHVM_=
M/Y4 )12[6_NG\J-K?W3^5 "5'J)(T^<KG=]F;&.N=IZ5+M;^Z?RI[JWR?*?N
MCM2&<!;:3J<&GZ;=1R+9^:;5"D4DDI9BZDR.&X! R,#U.:FF\2:I!/;Q%MTB
M2*D@-N%$H\YD+#J?NC/& .N>:[;:W]UORI</Z-^5*P'"?\)-K 1E9T($P62Y
M$0$<2D/QDC@DJ!AAD>IR*UKJXO+G3-"N)04GEDW2B(,!_J9.QYQG!YKI</Z-
M^5)M;^ZWY4P.7-_=6?A[0LW)M4E@43W4D1D*$1Y (/=CQSZ8ZFJ4_B+5T29H
MW4W(\T?93:$&-%3*2G//S''!_O8ZBNVP_HWY48?T;\J .+U#6-;TV&\D:[CD
M6&66%2;4 86-7#G!YY)&.A^M0SZSJ:7=Q<6TANHX8C'%<^451T,D6YRO3*Y8
M9]OK7:SVR75N\$\7F1.,,C X(J7#YSAORI6 X,ZYK"%[KSE8M %C 3Y"@FVM
M+TQD*1G''?I1+K6I7=LD=Q=+#EX3$(H"?M8\_!(; QA0,XXYST-=YA_1ORHP
M_HWY4[ (WWC]:=%_K1^/\J;M;^Z?RI\2MY@^4]^WM0]@6YS/BKR]MCYTZQ1!
MW)$ZR>0YV\!V0Y4]P>1G-9UKKUTEE%:%)HY)! L,<RL\AC8,';=@9Z#!.",B
MNT"L.BM^5+A_1ORHL!PFG:WJ"6%E";\&U\J$3WS6QS;,4;*$'J<JHR>F>>HJ
M2Z\0:A/836B3,+QS* 4MF1O*\@NK@'[N6Z?E7;X?T;\J,/Z-^5%@."N/$^I0
MOLM)O.58BHWP=2(=P? Y.6[G /0"K&I:WK>GRRVWFQLL;MB[>$*&/EHRICD=
M6;IR<8ZUVN']&_*C#CLWY4 <5<^(=7B$S)M^TJSA[,6Q/DQJH(EW=2#_ %]1
M2WOB>]%RTEG*K68N62/; 2TJ@1XVYX;EFX!!/;I7:8?T;\J,/Z-^5 '/:K<W
MT?B"WM[-A$)UBC:8Q;]H+OG@\9X%,T#5)KFYF^W%5G98D!"%=[9D'3MD)FNC
MVM_=;\JBBLXH)YYHX2LLY#2OR2Q P/R':@">+[Y_W3_*N8\2W5[9WEK-9%A(
MMM-CY"RABT8!([]3741*V\_*?NGM[4P*W]UORH XZ^UO5[*2ZB2X6:YA:5/(
M-K@A%C)68D>K8XZ<XZBM+[=J=OIFL%B+JYM,&%O)V[@45ONCK@D].N*Z##^C
M?E2;6_NM^5 '$OJ&HF_N;RSU/[5%;6>0_P!D*K/^\'RXZ="?F7^AICZSJUY-
M+!, JK<*6BC4[X=MPH X'0KG.3SU'%=UA_1ORHP_HWY4K < /$&J7D@S<.L*
M302[EA"D9=@4;'0?=R"21GFKEMK6L7DEK!#=)NG,7GR_9/\ CU=MVZ+!ZD;1
MUZ=^M=GA_1ORHP_HWY4[ -'2BEVM_=/Y4;6_NG\J8A**7:W]T_E1M;^Z?RH
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MXGBDE:8GY4"%1R.O.X5IKU_ UD:QH4.LR1-+/)'Y<;1@( <AF1L\_P"X/SH
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M5>7-S7=^YEPV(M]WE6[+NZ\&I?)E_P">;_E5^BA2MLB9)R=V[LH>3+_SS?\
M*CR9?^>;_E5^BGSL7*BAY,O_ #S?\J?%%()!F-N_;VJY3D^\*3FPY49PBE'_
M "S?\J/*E_YYO^51ZKK4.D36HN!B"597DEY/EJB;LX'6J[^*M.1\O(T<:!_-
M$L;K(K+LP-I'.?,7\QBGSL.5%PPR-P8F/U6CRI?^>;_E59?%&EOLV2SNQ)WH
MD#LT6&VG> /EYXYJ.T\5V%Q:V4TRW%N;K;M5XFPA9BJ@MC')%'.PY47?*E_Y
MYO\ E1Y4O_/-_P JRK?QE:3VMC*T;0O.R^:LH9!&A#$NI(^8 H1D5K:;K-EJ
MZR&SE9C'MWJZ%6 894X/8CI1SL.5">5+_P \W_*CRI?^>;_E5^BCG8<J*'E2
M_P#/-_RH\F7_ )YO^57Z*.=ARHIQ12!SF-ONGM[4SRI?^>;_ )5HKU_ UE:G
MJD]K=P6=I!%+<2QO,S3R^7'%&F,LQ )ZL!C%+G8<J)/*E_YYO^5'E2_\\W_*
MJ</B>S%M;27F87E.UC"?.C7Y]@/F+Q@GIWYY K/A\;*\DT<UD8L6C3Q/ORKR
M#>?*SC@D1DCUY]*?.PY4;GE2_P#/-_RH\J7_ )YO^548_$T;:U!8/"$BD@5V
MN"_"2E/,\LC_ ' 3FKEOKMA<V5Q>*\R6\$?FN\L+)F,@D.,CD$ ]*.=ARH=Y
M4O\ SS?\J/*E_P">;_E67?\ BZWM[#[5:H'!0L%N-T71XUST^[^\!S_]?%1O
M&S0QM(]G%<11W20R3V4QECV%&9F4E1DH%Y6CG8<J-_R9?^>;_E1Y,O\ SS?\
MJR;[Q>EI;231VPG"7C0@))]Z%$#O*/HISCOQZUTH8,H96#*PR".A'K1SL.5%
M#R9?^>;_ )4>3+_SS?\ *K]%'.PY44/)E_YYO^5'DR_\\W_*K]%'.PY44/)E
M_P">;_E6\OW1]*H5H#H*SJ.YI!6"J]SU6K%4K^;RFC&W=G/>HBKLJ6QS]QX5
MMKIV$][>R6VZ1X[=G4K$[@@E3C=_$V 3@9J:WT%(WMC<WUS>BV#+&MP$QM9-
MA4A5&1BK7]IP9QOASZ>:*>;Y%^\JCOR^*UY69714TCP[INBQ1);0!GA9S'+*
M TB!F)*ANN.<?2JTGA:$_8/*U"\A%CO,(78PW,Q)8AE(W<D ]A6E_:4.S?F+
M9G&[S1C/UI3J$:H';RPK<!C( #]#1RL+HJVGAS2[#5?[1M+989S$8CLX4Y;<
M3CU)K5JJ;Y X0J@=NBE^3]!0+U22 BDKP0'Z?6GRL.9%JBJPO01D("/4-Q2&
M^4 $JH!Z$OUHY6',BU15;[:,@;!D]!NZT?:_^F?_ (]1RL.9%FCO5;[7_P!,
M_P#QZE%WS_J__'J.5AS(-1LEO[=H3-- P<.DL#[71@<@CM^!R#60/"5D7\V:
MXN9IVD,LDK%09&)0\@  ?ZM1P/6M>6]6-F+JJJ#R6? IHOD8*0JD-]TA\Y^E
M+E871E67A'3[&9'BDFQ%(DD280!-K%@,A06Y/4DG IR>%;2-I!'=7B0SDFXA
M60!9^6.&.,X^<C@C(QFM3[7_ -,__'J/MHSC8,]<;N:.5A=%31M"M]$218)9
M)-X5<NJ+A5& /E S]3R:DCT:VC:%E>3,-W)>+DC[[[L@^WSFIQ>AAE4!![AL
MTAO5!P44'TW\T^5A=&*O@G3$8%9)PNP(Z_(2Y"E0=Q7(X/0$ X%277A&RNKR
M*Z:XN \2PA5^4C,7W>2,@>H! -:_VP9QL&3VW4?:_P#IG_X]1RL+HY^W\%0&
MPM%OKR>>\MXHXXYB$81!0?E52N"IW'[P)Z>E6X_"=G%-"Z75V(XS$S0[EVR-
M&"%9N,]#T&!6K]K_ .F?_CU'VO\ Z9_^/4<K"Z,B'PE;VZH8-0OHIT41B=67
M?LV!-OW<=%7G&<C-6K#P];:?JLNH)-/)*Z%,2$' )!Y(&6Z<%B<5=^U_],__
M !ZC[7_TS_\ 'J.5A=%H=&K'O?#6FZA)>RW47F3704>:P!>$*,+Y9Q\N#S]3
M6@MUE'/E],?Q>]-^V $ H,GH-W6ERL+HS/\ A&8@ HU&^$:2B:&/>NV)]X<D
M#'.6]<X!.,4B^$=+#1EUE<)9O9[6?AD;.2?]H!F /H36I]K_ .F?_CU O PR
M$!![AJ.5A=%;1]&@T:*5(I9)3*069U1>@P!A0!_4UI56^U_],_\ QZC[7_TS
M_P#'J?*PYD6:*K?:_P#IG_X]1]K_ .F?_CU'*PYD6:*K?:_^F?\ X]1]K_Z9
M_P#CU'*PYD6:*K?:_P#IG_X]1]K_ .F?_CU'*PYD6:;<1+/;O"Q(62,H2.N"
M"*@^U_\ 3/\ \>ISW8&W]V/N@_>I<K#F17&D6PT^SLEW+%:/$Z%< DQXVYXY
MZ<UES^#+">Y$QN+H$.'VY4\B0R#!*Y7YB<X(R,9K82_CD!,81P.I63./RIWV
MO_IG_P"/4^5A=&&W@C3F=Y6GN&G+AUE98SMQN'*E=K$ACEF!/3GBM5='MD@T
MV$-)MT]Q)%R,L0I7YN/]H^E3?;5!QL7/IOYI?M@! V#)Z#=UHY6%T6:*K?:_
M^F?_ (]0+P$9" CU#4<K#F19HJM]K_Z9_P#CU'VO_IG_ ./4<K#F19HJM]K_
M .F?_CU'VO\ Z9_^/4<K#F19IR?>%5/M?_3/_P >I\=UEP/+]?XO:ERL.9%3
M5=%MM86,7#RKY:R(-A X==I_2LW4/"L6HZO+-,W^BS(S/\V7\T^7M*@C  \H
M'G.2>E;+7RHA=U55'5F? 'XTHO 0"(P0>00W6GRL+HRX/"UO;,CP7MY%)@K,
M\15/.4MNVD!0%&?[N."158>";$20,;N[80E-BML. CEU .W(&3@XQGC-;OVP
M9QY8SZ;J/M?_ $S_ /'J.5A=&,O@VP*1QW%Q=W*1*(XUE<?+'AODX X.X\]>
M!Z5?T;1(-%CE6&620R;<EU1<!1@#"@#\>IJU]K_Z9_\ CU(;U1U11]7HY6%T
M6J*K?:_^F?\ X]1]K_Z9_P#CU'*PYD6:*K&\ QF,#/3YNM'VO_IG_P"/4<K#
MF1;7K^!K&UC39KV:":VWQ3PJP6>.4*P5L;D(92&!P.H[5HQW66QY?8_Q>U,^
MVC(&P9/0;N32<6RHS2=]SE7\&;O+_=OE>6/VA3O;S-Y893Y26.?EQP,'M5B3
MPJLNFWEA):!XKJ-49OM6&3:S$,IV\'+D_3CK71"]!SA <'!PU!O H)*  =26
MJ?9ON7[:/\J_'_,YYO"T;VY1]/A:=IA-]J,P\T$8 &[;]W QC^Z<=:T--TFX
MM[6>TN)K@PR0B*,FX#-$@! 5<* "!_%R3QZ5H_:_^F?_ (]1]K_Z9_\ CU/D
M8G5BU;E7X_YF-#X,T^&/9YUPQ+%B1M49+1MPJ@ <QKT'<]S5\Z%:_P!J&^1I
M4)F%P85(\LR!&0MC'4AN?7 JU]K_ .F?_CU(;U00"B@MT!?D_2JY69W1DV?@
MO1;.60_9_M$3&0I!<8=(MY!;:"..@'L!BM>PLTT[3[>RCDDDC@01HTARVT=,
MGV''X4?;!G&P9ZXW4?;1S\@XZ_-THY6%T6:*J_;EVEMJX'4[^!2_:_\ IF/^
M^J.5AS(LT56^U_\ 3/\ \>H^U_\ 3/\ \>HY6',BS6@.@K&^U_\ 3/\ \>K8
M'*CZ5G--%P:8M9NJ?>B^AK2K/U*-W:/:I. >E*G\0Y_">?ZMH,4K^(3#I<9\
MZRC6$QP@%F._?M('7D9K*U'2=6NHPLEI.YL[6>PAXW"1=O#X_P!KY1_P$UZ/
MY$O_ #S:CR)?^>;5T:'/J<7=>&+A+VUD0V9:6Z4NL=D/L\2K'( QCW<DEL9S
MZ52.F30V<4=S8SK/$]P'*V0N+8LQ'"Q#E5(P58=.0:]!\B7_ )YM1Y$W_/-J
M- U."DL[H75O,=*E%V5M?W$D!E3Y0OW)P=T6WG().<=\U?\ "MG=6E\PN('#
M^0PN)9(/+/F>82 &_P"6@(R<G./7G%==Y$W_ #S:CR)?^>;4:!J</%%KHT_)
M-VNQ8(Q;",!&5E829&/I]*@N;#64TM+$+=W,0M$QYD88HYMY RKQQ\VP8]_>
MN_\ (E_YYM1Y$O\ SS:C3N&IP%_!JUW:RQH-2EM5C?RI)8@L_P!V,L.F<;@P
M'KR.>*LSS:_()%@DU(3.SB;=$ D:^8HC,9(Y.S.>O?.,5VWD3?\ /-J/(F_Y
MYM1IW#4ACC\J-8_,>3:,;W.6;W)]:<.M2>1+_P \VH\B7/\ JVIW069C^*(?
M.T\*;=[A%O(7DB2/>2@D!;Y>_%<]+;WT=Q<W&E6=S9VDCN85%L-R,(<%PA^[
MENW&<5W;P2F1B(VZFF^1+_SS:EH&IQ=O<:RP@^TG58T4,(C"@<ROY@QOW*"%
MV]-P'?)SBI-6M-2C\4SW]A!(WG6\=D64?* ^_P"?_@!P3]:[#R)O^>;4>1+_
M ,\VHT#4\_L8?$&G16-E:I/%#!&B01F,E7^=MWF<8'&.I&!R,TJ1:RUW]J@B
MOIKKRH0S7<( 64),6"\#Y0Q7GWZUW_D2_P#/-J/(F_YYM1IW#4XF3^UI!$;.
M356^7:9[F!1(A+1;MO&<8W]1V.,@4VZ?Q)#<&&*6\,4<DBP2&,NTA$@V[\#!
M&WUP#SSD5W'D3?\ /-J/(F_YYM1IW#4C/6BI/(E_YYM1Y$O_ #S:G=!9D=%2
M>1+_ ,\VH\B7_GFU%T%F(O\ JY/H/YUR6MV^JW&L_P!H6EL&CTL(859B&E).
M9=@ PV5^3GO78+!+L?\ =MT'\Z;Y$O\ SS:EH%F<5.-1NGC:9]8WI>I)-&D0
M$2()AMV<9/R<X&>^>E%O_P ))#:Q6T$<BDV[7"LR* CJK#R2/]IMC?3-=KY$
MW_/-J/(E_P">;4:=PU,#PV^HO!<?;I)W4,OE&>,JWW?F'(!(S[<<XS6W4GD2
M_P#/-J/(E_YYM3N@LR.BI/(E_P">;4>1+_SS:BZ"S(Z*D\B7_GFU'D2_\\VH
MN@LR.BI/(E_YYM1Y$O\ SS:BZ"S(ZCU!6?3YT4%F:W8 #J3M/%6/(E_YYM3G
MAE.W]VWW11=!9G#6GA^_M+*PN(IA:W#QV]M(MC;")EC+*79\DY8 $9QQS31-
MXE6:=7DN]H=EF"1%BL8D #1DC!;9D\9SST(KN?(E_P">;4>1-_SS:EH&IPES
M'JPGEN;.._D;R\137$(\PX2?:>G7)7T/(SUJ>[37K>XD2!KNX$08QSO&K. R
M1EMIQU!WX'J,<UVGD2_\\VH\B7_GFU&G<-3B+N[UF.:(6']KO&C!HWGBYD'F
M<A@%YPN?O%>.V:Z+089+?1+:*6-HW7?E6&"/G8C]*U?(F_YYM1Y$O_/-J- L
MR.BI/(E_YYM1Y$O_ #S:G=!9D=%2>1+_ ,\VH\B7_GFU%T%F1T^+_6C\?Y4O
MD2_\\VI\4,HD&8V[_P J&T"3.>UN$->Z;/<6DEW81-)YT21^9M<J-CE/X@/F
M'0XR#6)'!J]M'=26D=_;6:I-/:VD2J#RZA5((..-S!>P[=J[D02_\\VH\B7_
M )YM2T#4XW2I[^'4#=ZFETT$"S1QRR1L259H=O4 GG=U&>#5[7'U1-:LUM&N
MS 0JND*X!)?!;=@C@<X;''(.:Z3R)3_RS;\J/(E_YYM1H&IPBW7BS,GFPW6P
M1L1Y:KNS$I7C(_Y:,0P]A4+0:Q>D?:(+N98I2(GD1L["T#=2 2,A^H'0UZ#Y
M$O\ SS:CR)O^>;4:=PU.)^T^(D0SQB_FEB3S+F"6(!6DWXV1<<KM)/&?NCFH
MFD\5+;(MQ)<J(I&MY)(D):38IQ( H)PS$=OX1TKN_(F_YYM1Y$W_ #S:C3N&
MIQENNK7&LZ:VH"],T5R&95BQ;K'Y)&[/9MQ((SUXZ5U]2>1+_P \VH\B7_GF
MU-6"S$B^^?\ =/\ *N6\1V]ZNLZ;J=E;2SO812R;(Q_K,L@*?4J6Q]*ZV.&4
M/S&WW3_*F>1+_P \VI:!9GG1AU[2;6XM[2.]\YII;CS(E)664[#V4YYW=2!B
MK?V/5BNHQ(^H>6OVB41,@*S2-(-HY'(VDG _I7=>1-_SS:CR)O\ GFU&G<-3
MS^675-2L[D1S:E,GF3>> F%4).-@B(')P&R!GIS4SW7B"2YNC&=1BB=7Y>(L
M4(E7&,*,93/W=W'/)KN$M7C7;'!L7).%7 R>33O(F_YYM1IW#4X>WN?$KW=I
MO%U&N(PBNA82#<P<N0H'3'7:0,'!.:LZI%+=ZG:PWFFLLQ*-+>VT4DRHJOE4
MC./E8G[S<8'KVZ_R)O\ GFU'D2_\\VHT[AJ<WJ<.HS>(HTMVN(+67R4EG@4
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MQ"X^Z#\QZC) %8</B'4+2*Y\FZBFTZV6>:*YN4:1YHE=43!!&1EB-QZA?QH
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M0&!%&!G=@(.OK]:\2D^,?B6)(GDT[3E65=T9,;_.,D9'S>H(_"F?\+I\0?\
M/EIG_?#_ /Q5 7/<2B$@E%)4Y!('!]13J\,_X71XA_Y\=-_[X?\ ^*H_X71X
MA_Y\=-_[X?\ ^*H"Y[G17AG_  NCQ#_SXZ;_ -\/_P#%4?\ "Z/$/_/CIO\
MWP__ ,50%SW.CO7AG_"Z/$/_ #XZ;_WP_P#\53D^,_B%I%4V.F\L!]Q__BJ
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M:S?^%T^(./\ 0M,YZ?(__P 53 ]Q"(  $3 & -HX%+M7.=H_*O#?^%U>(/\
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MWQMD^R[XX9-DP5ON*64%HR<KGIUVUQ/]C77_ #VL?_ V+_XJC^QKK_GM8_\
M@;%_\518+LZ__A(="B>VAS9RB1]NHS"R $P\C:64%<J"^.F#D9Q7GZYVC/7%
M:/\ 8UU_SVL?_ V+_P"*H_L:Z_Y[6/\ X&Q?_%4"'Z#_ ,A)_P#KUN/_ $4U
M:OA'5]-TVVN$U!DP]S#*J21;U8(DO48P>67BH=#TBY34')ELS_HTXXNXSUB;
M_:K-&BW6!^^L?_ V+_XJ@#K]/U_0WCLY]2DLV3; 9;7["-ZW E#22E@N"A7/
M /0@8XK'.L:9=:SH-[?Q0NL087PCMPJG$C;,J  V%*_4#%9']C77_/:Q_P#
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M,/@,0ZE:#4-3ACL)YX8DD$;!Y&=B-FWG8<*W)XY'K7(W$:Q74T:YVI(RC/7
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MZP],U>^TI9!9S!4F4++&\:R)(!R,JP(.#TJZ?%>NM%-&VH.PF+ERR(6.[&X
MD9 .!P,#@4AZ&K?^"[>&YO[BWU>#^R;.>6*:X:-RT+*RJ$*XRQ.]>1QUJ*R\
M&^=K-O:S:C UL\<4[30JQW1O,(AMR.N3GD50E\6ZY-<>?)>AF(<,IACV/N(+
M%EV[6)(')&>!Z4-XNU]XRC:D[98,7*)O.'W@;L9P&Y S@4:AH:MOX GOHA-:
MZA%Y;S!$,D+J-AE\L-N(Y.<$@=N_:DL_ ,]^JSVNIV\EDZKLN?*<9=G9-I4\
M@ HQ)Z8YK.'C'7U^[?A3P,K!&#@/O SMZ!N0.@JM:>(M5LHDB@NL11C"1O&C
MJ,,7!PP(R&)(/49HU#0UH/ MS/.+0:A:"^6-9I;?:Q\N)B0&W8PW..!V85%I
MO@RXU+3UNTO8%WVXN$B",[D$N.@YQ\AR1GJ*I1^*M<ABB2/4)%\IE97"KO\
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MOKZS\Z.6:%YK:(*VP&945@23_#\WUK$'B76!')']L)5QCYHT)7Y F5)&5.T
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M-<8W@=T2&%KR-;B60E9&! :/R@X 3KOSD8S6;9>')+G4M0TXNOGV[1QK(VY
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MIGA)M3TV.9+M%NK@Q?9XRIVX9I%8L<=O+)J0>![HM+MO[<A(EE0!&+L#NZH
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M6I:2EO;W,LN;P3I;O#L6WC\O;Y8/?GTX[^M:=WXKTJ6UGC^U3S+(\DD$+6H
MME8(%C'8XVGV_,T7=E[H65_B,&+QCJB"Y\Z2.9IH6C&Z)-JEF5F<KMPQ.T9)
MK/GUS4KGS#/>/(9$>-RP'*NP9AT[D UW/_"8Z%]N>;>_G.%)N# Y7:)&8H%S
MN&01P25XQTJM!XIT&+3XHU,BD/%(L36N\1,LI9L+D+C:>,<GN>E).WV!M7^T
M<L?%&L9)-[E]VX.8T+K\P8@-C(!(!('%0+K6H"VEM_M.895=70HI!#L&;M_>
M .>V.*[5?%VA(\QP[.VPRR/"["<!"I0<@XY'W\]3Z"L;7=8TK5=(L[=+B1)H
M%R ("%&(P-I&3@EAU4[>Y&:<7K\)+6GQ$=OJ'B&;0+5M.MWBL[&,HTR*I9]K
M^83DC<0"5) R. 34%WXHUDVUE-$[6L"(D22(B_O6CZDMC+#+9VG(YHTN\TVS
MT*X)OI(]5D62) \#.L4;#!"8. S]"QZ"K.F>)(]/\,BV2ZFCO88[E(4$>0K2
M%"K!N@(VL/QH:_N]03\S-GUC65G>T>8(S8C,42(JC*E0 %&!PY''K1)K>LV=
MY=137!$K32&XBDC5E:0X#AE(P>@XZ<5U1\5:";>] DFS/YA\LP'&\[=K #C^
M'J<D'I@50U[Q%I>I:%<VT,DIF><R1)Y)3&96;+<D'ANHPW8\"A-MVY1M)*_,
M<S>:I/?(GVC89%E>4RA0&8MCKCL-HP.U7I/%NMS!@]ZI+!E+>2F[#'+#.W(!
M/)]^:Z6P\4Z'9Z98PF29I(!"P5H"VQU#!O\ 9Y+<8&2.IS6?J'B:RO\ PF+2
M3+7SPQK(K1DDRA]S2[L[>1WQGG'2B]W;E%:ROS%:#Q1>:=I<\$]J[7%XDTB3
MR. "LW#,%QQT/W2 >X.*SF\3ZLT@D-VN_#*Q\E/GW !BW'S$@#DY/%=/I7BS
M3+>TM%N9I//BM8(BSPLVP1LQ9!M(R&!4^GRX-0CQE!%&L5K))!"L=NJ1K" $
MQ*6EQ]5P/?I26[]TKI\1@1:[JKSM?O<-*L0"RG<%)5I/,QD<C+C.1R*EUOQ-
M+JMU8RP1FT^Q;FB(<%@Q;<6R% ZX[?7.:Z&#QAIF]9KC>\R2N48VX.$\QV0?
M0*PX[=*71_%FDQ?9Y]1FG:Z$4*71,)83;=X;.,;C@K][@CL2*+O?E"W3F.<N
M?$6NQ2Q&:X,+!$DC5840;<EU8 #'))/XU';ZQK4=I+/%,6MX_*B9FC1A&0I6
M/&1PVT$ CFNJM/%^DQVT0GE=Y5AA5S) S95$*F+@C()^;GY>>>161K6NV5[X
M<DL[:YE'F/;M%9F':EL$1E8!N^2<_P ^::>MN4377F,RWUG68TN+^.;='NB2
M5WC1U#@$1G!!PP"G!'/!J&'Q!JEO.)H[QA(%C7=M!XC/R Y';]:ZL>)]):T\
MA[J<02E%6V^R_+: 0/&Q!S\WS,&X^O6GV_BC0+2P%JF9/+A2-W>V;_20(=FW
M 88^;)^;(YSU%',_Y0Y5_,<U8ZWJ.EZ1/]EC$:W%V'^T^6I"NJGY5!& ?GSD
M8(I8/$>NRA5BNP3"JR$^6F2(QA2Q(RV!D8.>*NZ!KMI9:(+*YNIH9%FE>-EB
M\P1EXPJR#W4@\=?FR.E-;6M./B.:\8O+"UC]G,IA ,TNP*9"O;)&?6GU?NBZ
M+WC*37]3CN!<1WC++OBD#*JC#1C"'&.PR*FM_$&M2RQ01733,Z^0D31JX;<^
M\#!&"=YR/>NGM_&-@^H2SW$[@^?<>4[6Y^6%F0HH*D%>%;IG&<'@FHH?$>AP
M7<=]#/<I(@CB6(VXW!5N?,+EAQDIQ@#VI7_NCM_>*.JW>OV&FI]KB:"5K[[;
M-<&9&,LW*JP0< #!]036-/JFIR7%GJCS;9(&V6SQJJB,H=V%4<#!.>G.:Z>/
MQ?82/$UW)/*ZQQ(LC1!C$P\[+C/7!=#[X]J=;>*-)A\M9KF6ZN1%(AOI+8H0
MY$>&PI#=$89SNYR>M)-K[(VDW\1R[>(-6N"J-?2.<,BCC/SR"0@<=W /X47^
ML:K+=7"7DQ69D:VE3RU7@ON9< <?-D_6NFN_&%B\[+;;X[4Q3$Q) %!F,@9&
MQS@\9SGC-5[+4[:76O$]^FJO;+<1[X;LPYD&9D. O7....P]*I/KRDM=.8P[
M/Q#K$$$-E:71V@JD2B-2W#AE4,1G&[D#.,TZ75]:LVA,ER\;(0R#"Y!3<G(]
MLN,'KFNLC\7:%%%.\/GQEW>18?)^Z_FAPPQ\HR!UY()QP*2U\6Z+#/(6D=Y&
M?>;I[=LNOG2.4(!!Y#+UX.,&IYG_ "%<J_F.2CUG6+V[MH[>9C.DJO;QP1JN
MUP,#:H  XSQ3)/$&I.R'[2J"-TD18XD159"2I   &"Q/XUU-CXRL;>[@RTL5
MK"EOY<:0C]TZNV\C_@+8]^E9&B:_!I,4L<K/<++J,4LX$8_?P+NW Y]20<=Z
MK7^4FR_F,EM:OVNK>Z-S^_MXS'')M7(7G@\<\,>M2V_B/5;6VAMX+TQI#M\L
MJB[@%;<J[L9*@\X)Q767/BK2YF*PWLEM<?(6OHK0LSH'8F(AR2>".O'&.E5U
M\3:7=7427=Q-%9VSV<L"_9@W^J!\Q,#&"Q/7H<4N:ZUB/E[2,:77/$4,:WC3
MF.(K&B.D<81<%G0# PIY8^N"<]:KIXHU:*0O'=1QG "A((U$>,X* +A3\QY&
M#S730>+=.BMT1)IH_*VNL8@RK/Y,B9],AF4Y/I[4VR\8V)E0ZB9)]L<'EEH<
M^7*(6623C!SO(.>IQGL*5W_*%E_,<G9:W?Z;;R06MSY<;$N055BK$;2RDC*G
M'&1BHK]KMKQOMP<7 1%(<8(4* O'^[BNQN?%VGF5(X6;R79Q=%8,"<& ("=Q
M)/S^ISQGK7->(M1CU76#>1SR2J\,0/F+@H0@!7WY!Y]ZN+;>UB9));W,A_\
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MF^9KJ)2#P&4 #/?;N/4?6CVD^[^\/9P[(3_A7WA+_H!6GY'_ !H_X5]X2_Z
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MO^%?>$O^@%:?D?\ &C_A7WA+_H!6GY'_ !KI:*/:3[O[P]G#LCFO^%?>$O\
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M:>,>_?\ *N@HI <R+OQ)YI1;8-#MRDK( S=@",\'O6A82:NRVJWD:JP=UG.
M=P^;:1CIT';G/:M:BF!DWESJ(LXWMD8L9'$A1 S*H) (!/)X%49+WQ&85:*S
M5G( "L .2 V3SQ@$KCU%=)10!B75[JT-U(8+229/EVQE % QG.[.<YR/0=?K
M3FU'Q+"[E=-27."JKP!@<C.<\]<GZ5T]% 6.;EU3Q$F'72488.$4]3[G_/6M
MRQ>>2Q@>Z39.R R+Z'TJQ12&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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9W#(]0<X_WC6I11S.UKARJ][!1114E'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>formdrs_007.jpg
<TEXT>
begin 644 formdrs_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ G # 2(  A$! Q$!_\0
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MJ/3=<CFT;P&=*M%TVVEU9H);93YB\'YMI;)P3S7H&L^!?#6OWOVW4M*BFN2
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MBM+2%(;>%0D<:# 4#L*FJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT:T;V3V+W_"S+_\ Z!]M_P!]M1_PLR__ .@?;?\ ?;5:NO#^G7FH7-U=1;9
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M;?\ ?;5)??$"YCO-C:;:2>20R,Q.5)7J/3J:X1ONGZ5I7%[<:?K,ES:R;)E
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MD.D6D-O>BV\Z."XM+2;RV8,1ODP1G&:KDPFW)_7WD*KF%K^U_+_(=_PLR_\
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MCFM&BBP&9_PCNDAHF^Q+F+&WYFY(;<"W/S'<2<G/)J:VTBPM(YHX;<*LZ;)
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M(''/2BX&WY4?_/-?RH\J/_GFOY5CKXGL6>-5BO"'V9;R.$+_ .K5N>"W&/\
M>&<9J)_%^GQ6LUQ);WR)#*T3[H0,,HRW.[!QTZYSP,FBX&[Y4?\ SS7\J/*C
M_P">:_E6))XOTF(RF4W"0Q[AY[1$1LR@,54]S@BEG\3VW_".W>K6JEQ:N$DC
MDX*MN4$'&>S9XS1<#:\J/_GFOY4>5'_SS7\JYQ_%BSZD]CIL*3R,\44+R[XU
MW.'9BP(S@!,\=<XJ_::C?'5(]/OK6&*1HI)=\4A96"LH! /(!W=#R,47 U/*
MC_YYK^5'E1_\\U_*G44 (8XRJ_NU[]JR8_$&B2V-I>I<1FWNY_L\+;#EI,D;
M<8R.0>M;!Z+^-<1:>"KRW6V1KFW,4#13)&,X$NY?-;IW5!CW+4 =%8:UI6I2
MQQ6^X/+'YL0E@>/S$[LNX#<.1T]:GBOM/FU"YL(WC-S;*K3)C&T-T.>G^%96
MD:/J4+:0-0-HL6EPM'&+=V9I6*A=Q) P,9XYY/M6?<>#]0DMY9DU!6O;M;A+
MM'/[HK,.=N%W<$)C/8&B[$=1<7-C:VDEU-)"L$8)9P01P,G&.IX/ J16MF&0
M8>%#$$C(!Z$^E<EJ/@Z:62\^R0Z<T$\3Q1V\P*I"6C1?,  /S90_7/6H9?!%
MW+/=;YX724N=[.<R!F4[&7;T 4CDGH, 47 [-6M7W;6@;:-S88' ]3[4N;;"
M',/S_<^8?-]/6N1F\'7/]H7LEL+&&UE;>L.#MD&]&"$;<HI"D$ D'(P!TI?^
M$.FD%S+(MDDLBDP(F2MLQF$F$..!@=0!R3QBB[&=6TELEU';%5\Z1&=5V_PK
MC)_45+Y4?_/-?RJLMJYUJXOI"NTPI#"!U R6;/U)'Y5;HN WRH_^>:_E1Y4?
M_/-?RIU% "+''S^[7IZ4GE1_\\U_*GKW^E86O^(X]#N;*)DC<3,6G+2!3%""
M%+@=SN9>/3/I1<#:\J/_ )YK^5'E1_\ /-?RK$O_ !1!:><(;.\N3%.L!=(O
MW9?>JL WJ-WXXP*=%XHL/)=KAVC9)-A 0XP6<!AGL!&V3VVFBX&SY4?_ #S7
M\J/*C_YYK^59^D:[8ZVLILV?,6TLK@ X894\$\$9]_7%:5%P&^5'_P \U_*C
MRH_^>:_E3J* &^5'_P \U_*CRH_^>:_E3J* &^5'_P \U_*CRH_^>:_E3J*
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MWXLDGM($CMEDWW.XM.2Q3:A!SD8SW.2/K6+%XHU>QTZRAN/LTTTT%LXN",!
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MVNNO;VB?:]5@A!B@*%54K&+?+'E<Y\P8S_C3 V(?"T*7Z7TEY-+<^<)Y&*J
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MUS:[Q=QQC8$R"X;]X=Y?IC*XQNY ]Z[0]>*?*@YF6OM?_3/_ ,>H^U_],_\
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MMYBJPQG/\1P?;TI$\76\4;"ZAE\T,2, #?&&D#,!GHHC;/X>M7O^$8T7##[
MF"H7&]N,8Y'/!^5>1SQUJRFCZ<DL,@LXM\*21QL1DJLARXY[$]: *VA:_%KJ
M3-';RP&((V'Y!5AD$'UXY':M:JEAI=EIB.MG#Y8?&[+LQ.!@#))X Z#H*MT
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ML]*T/LT/VS[7Y8^T>7Y7F=]F<X_.@"6BBB@ HHHH **** "E_@_&DI?X/QH
MYBZUC4UM]3U2&2V6ST^Y: VSQ$O*%(#$OGY2<_*,>GK39_&L-M MQ-ITR0L[
MA29DW,B/L+!1SUSQZ#K6Q-H>F7%_]MELT:XW*Y;)PS+]UF7.&([$CM4<_AS2
M+E46:R5E560 .PRK-N(.#R-W.#WH ET>\FO].-Q*JE_.FC 48!"R,H_0"L"V
M\<PQVMH=3M'@N)@&8(P*A"I8/_NY&WZFNCM=-M[*X::W#)N3;L#':/F+DX]2
M6/-53X:T5HC&VG1,AC\K#9/R;]^WKTW<T 4;3Q/)<2/$NG3R2(Q>9<HA@CR
M,Y/S'.>GH:FT;Q3::RTYC@FBCCA\]9'&0\>2,^QXSCT-7)M!TNXF$TUFC2>8
M9"<D;B2"<C/(R <'C(J2STFPT^222UMEC:0;6^8D;<D[0"< 9)X&!0!A#Q=,
MLKR3:>8[=X();9'E0,_F%\,3VX4<8)S42>,S)+%<1P.UFR&1T* .J^6C\'/.
M-Q)^E;"^%M$3.RQ"G*D,LC@KMS@*<Y4 ,PP.,$BE/AW3XK1XK&".UD\MHTD"
M[]@90IX)P?E&* +EA?1ZC;O/"I$0E>-&)XD"G;N'L2#BK506-G#I]A;V5NNV
M&WC6)![ 8J>@!EW(T-G+*N-T<3.,],@$UR&G>)M6%M!=7%K)?0SPQ8VVIM=L
MTC*JHI<X8?,3GMCWKLI462,QN-RNI5AZ@\$56^QVC6L%L(T,$!3RD!X0IC;C
MZ8%(#!@\;6DTK*;.=(U;#29!"@.$<GT )S[@$T+XVLVO%@6TN"I(!?C@,2$;
M'<$#.>P(K5&B:2)+EA:Q$W",DJEB5*O]["YPH8]<8S4;Z9H9O;9&BA$ZP@Q(
M'(!CCX!(!P0N>">F:8&3+XON'CMC#ICQ--Y<A$LBL?)>.1@PP?O?(>/\:D3Q
ME%';":>QN/) *><"OSR"-7VA<Y&=V,],UK2Z'I,L*"2TC,<:(JG<1M5 =O.>
M@#'\ZJS:?HT[R:+$B1W'E-, J%_+#KY>XYRO(&,'J!0!+'KN+#4KBYLI+>33
MWV2Q-*AR=JMPV<8^8=:R9O&C3:==/86#O=01R/(&=2D04@;NVX'<.!CH:NV6
MC:7IME+I5U,EQ_:,KR.&R [*%R!R2, +U.<U8?POH<B&*2Q0Y+.P,K;FW8R6
M.<D':.O&10!3N?&5I:G8UK,9PYB>/<!Y;[RBACVSAF!]!3/^$S1X7FATJ[>*
M.-&D8L%\LNS* 1UQ\I)8#&,&MB32-,N&N6:VB9[ITEE=&(9F085L@Y!&.HJE
M<VOAVR@\B988E=$<;7;<0C85@0<Y#/U!S\U %>#QE9W%_;6L=O*WF^6'=6#"
M-I!E1QG(Z9(/&?K725F1:%I$,UO-%:1(T6!%M<@$KG!QG#$9/)R>:T=Z?WUZ
MX^\.OI]: '44@922 RDCJ,TM %R#_4K4E1P?ZE:DK)[FJV"BBBD,SZ*S+W55
MT^SGO+J41P0J6=MF<#Z#DTR/6H9'VK<I_J5GR0 -C9VG)X[&NCE9S\R-:BLR
M/5DENI+9+A#-&%)3 Y##(QZ\>E*^I!()9_/1HX@S.R8;;@9/2CE8<R-*BLQ=
M4#) XD^6==T;%.,8SSZ<>M/%_E487$6USM5LKACZ ]Z.5AS(T**S8]2\P*1*
MH+,RJK@*6(.#@'KTJ-M:B74TTTSJ+N2(RK'MZJ#C.>GX?6CE8<R-:BLTZE^\
M6,2JS,2OR@$ @9()'3\:2WU5;LS"WG63R7\MRH!&[ /![\$4<K#F1IT53^TR
M_P!X?]\BC[3+_>'_ 'R*.1AS(O= M<1;>%M130WTN6"$;XPC2_VA(ZL!(&/[
MLC"Y /3I75M<2[$^89.>P]:HPZY#.EF\<^5O,^0?+^]@$GMQP#UHY6',C%N/
M!;-(WD16D<;W,K.HR-T+2QNJ<#H C<=!GWIMQX/N(T8V,5DFYI=Z'@.C3JZ+
MR".%! R"!Z8K7D\26T5X;9IGW+(L3N(28T<]%9\8!.1Q[BK4FJK$\:M.A:24
M0*% /SD$@''3H>M'*PYD<W:^%M8M;3[,K6C++Y8=C*W[M4N&E 4!1G*MCM@B
MKVB^';W3M-U:UD^SH+J(I$$;<0VUADMM!(Y&,Y;KDFMD:@"H87$14G:#E<9]
M/K2'40(VD^T0[%.&;*X!],^OM1RL.9'+MX)U QK$MY#&L"LEJRDYA5XVWX_[
M:,,>PI@\&Z@+.1##9S"19$%K--F.,M&JB4%4 W @\!<X/7-=3;ZHMW#%+#.C
M++&)$& &*GH<=:J7/B:UM+J6WGED4Q;1+)]G8QQ[ON[G P,^]'*PYD9:>%;Z
M.X\QXK&[!)"B=VQ =R$2+@9)^7& 0>!SUIFD^%-4M-4ANIVM519(GD6-_O%3
M)E@ HZ[QC.3ZFNF-\0S*9XP4QN&5^7/3/I0M\67<LT97 .001@]*.1AS(OT5
MGG4  Q-Q$ IVL25X/H?>D.I$7:VOF?OFC,H79_""!G/U-'*PYD:2]_I2552Y
ME.[YA]T]A5.[UJ*PEM8[FX6-KJ7R805SN;TZ<?7Z4<K#F1K45EW&K1VB,UQ=
M11A2H;<1D;C@9'N2*?%J)FCWI(,9*_,H!SG'3_.:.5AS(T:*HI>M("4E1P#@
ME<'GTIWVF7^\/^^11RL.9%RBJ?VF7^\/^^11]IE_O#_OD4<C#F1<HJG]IE_O
M#_OD4?:9?[P_[Y%'(PYD7**I_:9?[P_[Y%'VF7^\/^^11R,.9%RE;[QJC]IE
M_O#_ +Y%1ZAJ@T^WFNKB3;#$ 6(3<>PZ#D]:.5AS(T:*P8O$UI+<"W,[0SY*
MF.>$Q,#C/(8#&1T]:O\ VXB0QF:/>!N*\9 ]<>E'*PYD7Z*SQJ&51A<1$.<(
M05PQ]O6F_P!I_P"F_8_,'G^5YNW9_#G&<_6CE8<R-*BJ?VF7^\/^^11]IE_O
M#_OD4<C#F1<HJG]IE_O#_OD4?:9?[P_[Y%'(PYD7**I_:9?[P_[Y%'VF7^\/
M^^11R,.9%RE_@_&J7VF7^\/^^13OM,OE$[AG=CH/2CE8<R+5%84WB6UM[IX)
M)V!C=8Y)!"3'&S8PK/C )R/S%7?[0&[:;B$$MMQN7KZ?7VHY6',C0HK-MM3^
MUP^;!(&3<R9V8Y4E3^H-3?:9?[P_[Y%'*PYD7**I_:9?[P_[Y%'VF7^\/^^1
M1R,.9%RBJ?VF7^\/^^11]IE_O#_OD4<C#F1<HJG]IE_O#_OD4?:9?[P_[Y%'
M(PYD6+N)I[.6%)#$\D3(L@ZH2" ?PKB;7P;J=O8.(;B&WNP8T5A)N4IL*2MP
MJX+*V1P3E1DUUTUW)'$')) 3<0J9)Z]!WK/L_$4-\9!$TT8C8HS3P&(!@<%<
ML!S[4<K#F1@3>"+LSWB121>1()%C9I<%D8KM1@%SA0,<L1P, 58OO!\TEQ<-
M;6]GY$AF$:;S&8T8QL N%..4;CI\W(()%=&=0PC.;B((APS$KA3Z$]JA_MF(
MW36PN$:92 R@ [<J6&3V! HY6',B@-"O!X:L;&1;6:6VN1,]NQVQ3(&8A&(&
M.X/W<9'3%&A^&YM->[DE:!);BU$*O#DF([I#@$\X4,H'^[VK5_M ; _VB'83
MM#;EP3Z9]:<;UE*!IHU+G"@X&X^WK1R,.9'-0^#Y)!;)=6.FI'!"\;+&6;SG
M\K8)6R,9)YZ9'J>*J2>"=4E,PDN8G:2/!F:8Y.8E3RR-N2,@G[V.G&:Z<ZW$
ML<+M.%\YQ'&K)AF8MM''7KWJREX\@)CE1P#@[<'!]*.5AS(YR[\&NS7)L1:V
MQDEF*E<K^Z9%"QG X4LIR!ZYZU!/X.N[B6:3[+I\*7 =?LZ.=MNI:(X4[><[
M&R!@?-]:WK[Q#:Z='')<72!9'*+L ;D D]/0 DU-:ZJMY!'+#*,2()%5E"MM
M/0E3R!1RL.9'.7?@R\?47DMY(5M3,QAB638+92X;<HVG!X/"[>W.*9>^"[Z2
MQAM[5;%9")FEDSM;S&DW*V2I)^7 XP??%=+_ &Q"9A"+R N8S+@%?N X+9Z8
MS3Y]3%M;&XDE'E#'*J&SD@#&.O)%'(PYD<BFA7J:=<7K6:VT\1G>(PJSS7$Q
MGWQ%EQT!4<Y/#=A79Z19M8:5;V\AW3 %YF_O2,=SG_OHFE^TS _>'Y"C[3+_
M 'A_WR*.1AS(V(/]2M25!9L7M49CR<_SJ>L'N;K8****0SC-8TZ74UMH%N##
M DXEF*??.WE0,@C[V"<^E<[)X:OK1K956"_@BN(DA2;/^J5I&_><8XWXX!Z#
MBNS/4_6BNRQR')V_A*:"+=OM?M0EB=)=A/EJH;*#OM^; '<"I=&\.7EA::G%
M-);@WELL2B,\*P5E).%48.1V_.NGHHL*YR6K:1JUWH,<$L%HSVL!C5(79_-R
M@7H5'_ZLT3>%KN1[B01Z</M E008;R[7=L&^/C[WRYZ#D]:ZVBBP[G+VWAJY
MMKB-V^QW0R,R3ABT6)6DW)[D,,\CD=Q4USX>NY]1FU-;\I>?:EDA0']V(U&P
M*>,YVE^AQDUT5%%A'(?\(G=-;) /L%OY<+0F2%6W3?(5W/\ 7/(]SR:V]$TZ
M73TO#+#:PFXN#,L5KG8@VJ,<@?W<].]:E%%@"BBBF ]ON1_C_.N=TW1[^VFT
MZ*X>V-KIOF>4T9;?+N! W C"X!/0G)KHF^Y']#_.O/K37]2L+/3/MT\DNZ&:
MZCG8$K*@C8['QU*MCZ@@^M2,Z2/3]4M;BYBM)K5;2XNC<-*X)DC#8+*%Q@YQ
MP<\9Z<5DKX1NRD2>=:VWE1K$9(-VZ7&_]ZW ^?YO?OS51_$NH7&2UQ#&L1FC
M8(-OFD"-EP5<X(W'H3T/X73XGU!Y42(61DG?:(]K$VI\X1XDYY)!SVY'I1H
M^'PK,;F.>:+3XUC&%@C0M&&$3(LF"!DDD$^P')-5K3PC?V[>;(+"?E,V\A)C
M8B-D).$ 'W@1Q[9[TZ?Q;>6\T4+"U,B2B*<!"-^9C'E<MQP,X ;WQ5HWDQ\/
MZ US>2Q07#*MY<A]K8V$C+_PY8 $_P"-&@$=EX4N[8VJ--;KY31R&[BR)UVQ
M;/+3(QMSSSZ]*LW&B:DS:E;QW$#VVH1QQR3SL3,H"[6^4*%)(Z<BL^\\3?V5
M J6%Y]MB0N^^Y&XLH<+M5R1N R0&&X_EFICXDU)$C>0682YW>6^U@( )Q'N?
MGD8.>W-&@$3>#)VO)6::)X3*7R[$F13*K[6&WL%QR3VZ5<7PLZWD;)+%%;&X
MD>:% 0&CWF2)0.@*L>>V#523Q9?1W8B5;.=$"@O&<"?.[+)N;.!M[!AUYZ&M
M*2\OSH>E74\L:SW%U;L_D JNQSG;R23QP?6C0#-T[P9+;W-JUVUO-% Z%U8E
MA+M5QN(V@9RP/.>_/2NGAMG74[J[D92)%CCB _A5<DY^K$_I7+2>*-6ALX))
M!8[YX8[A2%(V*V_*X9@&/RCN.IZFM?0M4>]N+W[1=Q-OE0V\.W8RJ8E?&"<X
MY)_.A6 WD_C_ -TUS^L^'Y=9NY9)+V2"-;?RK<18R')W%FR/54QCG@UT"?Q_
M[IIM,#DY?#-]<+*9HM,DG>;[29W5B[L61BF<<+\I&>>,<"G_ /"*SLZ W211
M,LAG6,')EW.8F'^Z)#GW5:ZFBBP7,+PUHDVC1SB9H\R"-0L;EA\HQN^Z,$_3
MZDUNT44Q!1110 4444 %%%% !VJGK]@^IZ7=V4;JCS*%#,2 .0>W/:KG:GR_
MZUOP_E2&<]=^%[.:YBDCB611YIE-RS2LY:,HARV>F?PK)/A#4))E:6:T<"-D
M)RPW@P^7@X /4==WX"NTHHLA7.);P9?2+'NN(,89=@;'E N&W A!N;CJ IZ<
MUU/V-_[>^W[U\O[)Y&W^+=OW9^E7:*+ %%%%, HHHH **** "G_\L3_O_P!*
M93_^6)_W_P"E)@<Y<:-?O%?6$4MM]@OIVFDD?=YL88@NH&,-TX.1C/?%9E[X
M.NI;5(;<V2$B4R/C#%VDWAB=I)XP.W(ZUV=%%@N4M*LY+"Q\B5E9O-DDRO3#
M.6'\ZNT44P"BBB@ HHHH **** 'OTC_W?ZFN?D\/FX95G,+QC4)KO!&<!T8+
MP?X@2#^%;=[*T%E),H!:.!G /<@$UQI\77BVB$36,DLB1R++$A,8+1LYC.7
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M;62XBD5DLP\@Q+FU:3<..2&&!_B*ED\':+%<1(&O95PX!4DB<! P<<9QD\[
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M$X\T6CA'\KRW9GBV$$L3LP1W[T:)M'AW3]K*1_:RX*[?7V)%=QY,6,>6F/\
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FCF0I*BNA()5AD<'(_6GU,Y<SN5"/*K!2,"5(!P<<'TI:*@L__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>formdrs_008.jpg
<TEXT>
begin 644 formdrs_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 .$# 2(  A$! Q$!_\0
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M$N"^80V<=.OUJ*,.:C.G=7OW*K3Y:L*EG:W8]FKD?B/9M=>%7D123;R+(?\
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
